0000105770-25-000013.txt : 20250218 0000105770-25-000013.hdr.sgml : 20250218 20250218164456 ACCESSION NUMBER: 0000105770-25-000013 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 139 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250218 DATE AS OF CHANGE: 20250218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 25635789 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-K 1 wst-20241231.htm 10-K wst-20241231
00001057702024FYfalsehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://www.westpharma.com/20241231#OtherIncomeExpensehttp://www.westpharma.com/20241231#OtherIncomeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purewst:instancewst:fiscal_quarterwst:trancheiso4217:SGDiso4217:EURiso4217:JPYutr:bbliso4217:USDwst:bblwst:planwst:facilitywst:segment00001057702024-01-012024-12-3100001057702024-06-3000001057702025-02-0600001057702023-01-012023-12-3100001057702022-01-012022-12-3100001057702024-12-3100001057702023-12-310000105770us-gaap:CommonStockMember2021-12-310000105770us-gaap:AdditionalPaidInCapitalMember2021-12-310000105770us-gaap:TreasuryStockCommonMember2021-12-310000105770us-gaap:RetainedEarningsMember2021-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100001057702021-12-310000105770us-gaap:RetainedEarningsMember2022-01-012022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000105770us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:CommonStockMember2022-12-310000105770us-gaap:AdditionalPaidInCapitalMember2022-12-310000105770us-gaap:TreasuryStockCommonMember2022-12-310000105770us-gaap:RetainedEarningsMember2022-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100001057702022-12-310000105770us-gaap:RetainedEarningsMember2023-01-012023-12-310000105770us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000105770us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:CommonStockMember2023-12-310000105770us-gaap:AdditionalPaidInCapitalMember2023-12-310000105770us-gaap:TreasuryStockCommonMember2023-12-310000105770us-gaap:RetainedEarningsMember2023-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000105770us-gaap:RetainedEarningsMember2024-01-012024-12-310000105770us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000105770us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:CommonStockMember2024-12-310000105770us-gaap:AdditionalPaidInCapitalMember2024-12-310000105770us-gaap:TreasuryStockCommonMember2024-12-310000105770us-gaap:RetainedEarningsMember2024-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000105770srt:MinimumMember2024-12-310000105770srt:MaximumMember2024-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:GenericsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:PharmaCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770wst:ContractManufacturedCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductComponentsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:HighValueProductDeliveryDevicesMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberwst:ContractManufacturedProductsMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2024-01-012024-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2023-01-012023-12-310000105770us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember2022-01-012022-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770srt:AmericasMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770srt:AsiaPacificMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-3100001057702023-02-280000105770us-gaap:LandMember2024-12-310000105770us-gaap:LandMember2023-12-310000105770srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2024-12-310000105770us-gaap:BuildingAndBuildingImprovementsMember2023-12-310000105770srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000105770srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000105770us-gaap:MachineryAndEquipmentMember2024-12-310000105770us-gaap:MachineryAndEquipmentMember2023-12-310000105770srt:MinimumMemberus-gaap:ToolsDiesAndMoldsMember2024-12-310000105770srt:MaximumMemberus-gaap:ToolsDiesAndMoldsMember2024-12-310000105770us-gaap:ToolsDiesAndMoldsMember2024-12-310000105770us-gaap:ToolsDiesAndMoldsMember2023-12-310000105770srt:MinimumMemberwst:ComputerHardwareAndSoftwareMember2024-12-310000105770srt:MaximumMemberwst:ComputerHardwareAndSoftwareMember2024-12-310000105770wst:ComputerHardwareAndSoftwareMember2024-12-310000105770wst:ComputerHardwareAndSoftwareMember2023-12-310000105770us-gaap:ConstructionInProgressMember2024-12-310000105770us-gaap:ConstructionInProgressMember2023-12-310000105770wst:WestCompanyMexicoSADeCVMember2024-12-310000105770wst:AluplastSADeCVMember2024-12-310000105770wst:PharmaTapSADeCVMember2024-12-310000105770wst:PharmaRubberSADeCVMember2024-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2024-12-310000105770srt:AffiliatedEntityMember2024-12-310000105770srt:AffiliatedEntityMember2023-12-310000105770wst:DistributorshipAgreementMember2024-01-012024-12-310000105770wst:DistributorshipAgreementMember2023-01-012023-12-310000105770wst:DistributorshipAgreementMember2022-01-012022-12-310000105770srt:AffiliatedEntityMember2024-01-012024-12-310000105770srt:AffiliatedEntityMember2023-01-012023-12-310000105770srt:AffiliatedEntityMember2022-01-012022-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2023-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2022-12-310000105770wst:ProprietaryProductsMember2022-12-310000105770wst:ContractManufacturedProductsMember2022-12-310000105770wst:ProprietaryProductsMember2023-01-012023-12-310000105770wst:ContractManufacturedProductsMember2023-01-012023-12-310000105770wst:ProprietaryProductsMember2023-12-310000105770wst:ContractManufacturedProductsMember2023-12-310000105770wst:ProprietaryProductsMember2024-01-012024-12-310000105770wst:ContractManufacturedProductsMember2024-01-012024-12-310000105770wst:ProprietaryProductsMember2024-12-310000105770wst:ContractManufacturedProductsMember2024-12-310000105770wst:PatentsAndLicensingMember2024-12-310000105770wst:PatentsAndLicensingMember2023-12-310000105770us-gaap:TechnologyBasedIntangibleAssetsMember2024-12-310000105770us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000105770us-gaap:TrademarksMember2024-12-310000105770us-gaap:TrademarksMember2023-12-310000105770us-gaap:CustomerRelationshipsMember2024-12-310000105770us-gaap:CustomerRelationshipsMember2023-12-310000105770us-gaap:CustomerContractsMember2024-12-310000105770us-gaap:CustomerContractsMember2023-12-310000105770wst:TermLoanDue2027Member2024-12-310000105770wst:TermLoanDue2027Member2023-12-310000105770wst:TermLoanDue2024Member2024-12-310000105770wst:TermLoanDue2024Member2023-12-310000105770wst:SeniorBNotesDue2024Member2024-12-310000105770wst:SeniorBNotesDue2024Member2023-12-310000105770wst:SeniorCNotesDue2027Member2024-12-310000105770wst:SeniorCNotesDue2027Member2023-12-310000105770wst:RevolvingCreditFacilityDue2024Member2022-02-280000105770wst:RevolvingCreditFacilityDue2024Member2022-03-310000105770us-gaap:DomesticLineOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2022-03-310000105770us-gaap:ForeignLineOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2022-03-310000105770wst:RevolvingCreditFacilityDue2024Member2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberwst:ApplicableMarginMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:FederalFundsEffectiveSwapRateMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:BaseRateMembersrt:MinimumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:BaseRateMembersrt:MaximumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Memberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2022-03-012022-03-310000105770wst:RevolvingCreditFacilityDue2024Member2024-01-012024-12-310000105770wst:RevolvingCreditFacilityDue2024Member2023-01-012023-12-310000105770wst:RevolvingCreditFacilityDue2024Member2024-12-310000105770us-gaap:LetterOfCreditMemberwst:RevolvingCreditFacilityDue2024Member2024-12-310000105770wst:TermLoanDue2027Member2024-07-020000105770wst:TermLoanDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2024-07-022024-07-020000105770wst:SeniorBNotesDue2024Member2012-07-050000105770srt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770srt:MaximumMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770srt:MinimumMemberus-gaap:BaseRateMember2024-07-022024-07-020000105770srt:MaximumMemberus-gaap:BaseRateMember2024-07-022024-07-020000105770us-gaap:SecuredOvernightFinancingRateSofrMember2024-07-022024-07-020000105770wst:TermLoanDue2024Member2024-01-012024-12-310000105770wst:TermLoanDue2024Member2023-01-012023-12-310000105770us-gaap:SeniorNotesMember2012-12-3100001057702012-12-310000105770wst:SeniorNotesDue2022Memberus-gaap:SeniorNotesMember2012-12-310000105770wst:SeniorBNotesDue2024Memberus-gaap:SeniorNotesMember2012-12-310000105770wst:SeniorCNotesDue2027Memberus-gaap:SeniorNotesMember2012-12-310000105770us-gaap:SeniorNotesMember2024-12-310000105770us-gaap:SeniorNotesMember2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:SGD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyLoansMembercurrency:USD2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:USD2024-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:EUR2023-12-310000105770us-gaap:ForwardContractsMemberwst:IntercompanyDemandNotesMembercurrency:SGD2023-12-310000105770us-gaap:ForeignExchangeForwardMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPY2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-12-310000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:SGD2024-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-012019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-07-310000105770us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMembercurrency:USD2024-12-310000105770us-gaap:OptionMember2024-12-310000105770wst:OtherExpenseIncomeMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMember2023-01-012023-12-310000105770wst:OtherExpenseIncomeMember2022-01-012022-12-310000105770us-gaap:FairValueHedgingMember2024-01-012024-12-310000105770us-gaap:FairValueHedgingMember2023-01-012023-12-310000105770us-gaap:FairValueHedgingMember2022-01-012022-12-310000105770srt:ScenarioForecastMemberus-gaap:FairValueHedgingMember2025-01-012025-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2023-01-012023-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMember2022-01-012022-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000105770wst:NetSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2024-01-012024-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000105770us-gaap:TreasuryLockMember2024-01-012024-12-310000105770us-gaap:TreasuryLockMember2023-01-012023-12-310000105770us-gaap:TreasuryLockMember2022-01-012022-12-310000105770us-gaap:CurrencySwapMember2024-01-012024-12-310000105770us-gaap:CurrencySwapMember2023-01-012023-12-310000105770us-gaap:CurrencySwapMember2022-01-012022-12-310000105770wst:NetSalesMember2024-01-012024-12-310000105770wst:NetSalesMember2023-01-012023-12-310000105770wst:NetSalesMember2022-01-012022-12-310000105770us-gaap:CostOfSalesMember2024-01-012024-12-310000105770us-gaap:CostOfSalesMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMember2022-01-012022-12-310000105770us-gaap:InterestExpenseMember2024-01-012024-12-310000105770us-gaap:InterestExpenseMember2023-01-012023-12-310000105770us-gaap:InterestExpenseMember2022-01-012022-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:CommodityOptionMemberus-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:NondesignatedMember2024-01-012024-12-310000105770us-gaap:NondesignatedMember2023-01-012023-12-310000105770us-gaap:NondesignatedMember2022-01-012022-12-310000105770us-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:MoneyMarketFundsMember2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:BankTimeDepositsMember2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2024-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2024-12-310000105770us-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2024-12-310000105770us-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2024-12-310000105770us-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2024-12-310000105770us-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:MoneyMarketFundsMember2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:BankTimeDepositsMember2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel1Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000105770us-gaap:BankTimeDepositsMemberus-gaap:FairValueInputsLevel3Member2023-12-310000105770us-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CurrencySwapMember2023-12-310000105770us-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:CommodityMember2023-12-310000105770us-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2021-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2022-01-012022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2023-01-012023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2024-01-012024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000105770us-gaap:AociEquityMethodInvestmentParentMember2024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000105770us-gaap:EmployeeStockOptionMember2024-01-012024-12-310000105770wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember2024-01-012024-12-310000105770wst:StockOptionAndAppreciationRightsMember2024-01-012024-12-310000105770wst:StockOptionAndAppreciationRightsMember2023-01-012023-12-310000105770wst:StockOptionAndAppreciationRightsMember2022-01-012022-12-310000105770us-gaap:PerformanceSharesMember2024-01-012024-12-310000105770us-gaap:PerformanceSharesMember2023-01-012023-12-310000105770us-gaap:PerformanceSharesMember2022-01-012022-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2024-01-012024-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2023-01-012023-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2022-01-012022-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2022-01-012022-12-310000105770us-gaap:EmployeeStockOptionMember2023-01-012023-12-310000105770us-gaap:EmployeeStockOptionMember2022-01-012022-12-310000105770wst:StockSettledPSUAwardsMember2023-12-310000105770wst:StockSettledPSUAwardsMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMember2024-12-310000105770wst:StockSettledPSUAwardsMembersrt:MinimumMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMembersrt:MaximumMember2024-01-012024-12-310000105770wst:StockSettledPSUAwardsMember2023-01-012023-12-310000105770wst:StockSettledPSUAwardsMember2022-01-012022-12-310000105770wst:EmployeeStockPurchasePlanEsppMember2024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2024-01-012024-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2023-01-012023-12-310000105770srt:DirectorMemberus-gaap:DeferredCompensationShareBasedPaymentsMember2022-01-012022-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2024-12-310000105770us-gaap:DeferredCompensationShareBasedPaymentsMember2023-12-310000105770us-gaap:RestrictedStockMember2024-01-012024-12-310000105770us-gaap:RestrictedStockMember2023-01-012023-12-310000105770us-gaap:RestrictedStockMember2022-01-012022-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000105770country:US2022-01-012022-12-310000105770country:US2023-01-012023-12-310000105770country:US2024-01-012024-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2023-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2022-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000105770us-gaap:PensionPlansDefinedBenefitMember2024-12-310000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000105770us-gaap:ForeignPlanMember2024-12-310000105770us-gaap:ForeignPlanMember2023-12-310000105770country:US2024-12-310000105770country:US2023-12-310000105770srt:ScenarioForecastMember2031-01-012031-12-310000105770us-gaap:ForeignPlanMember2024-01-012024-12-310000105770us-gaap:ForeignPlanMember2023-01-012023-12-310000105770us-gaap:ForeignPlanMember2022-01-012022-12-310000105770srt:WeightedAverageMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:WeightedAverageMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770us-gaap:DefinedBenefitPlanDebtSecurityMember2023-12-310000105770us-gaap:OtherInvestmentsMember2024-12-310000105770us-gaap:OtherInvestmentsMember2023-12-310000105770us-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770srt:MinimumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770srt:MaximumMemberus-gaap:DefinedBenefitPlanDebtSecurityMember2024-12-310000105770srt:MinimumMemberus-gaap:OtherInvestmentsMember2024-12-310000105770srt:MaximumMemberus-gaap:OtherInvestmentsMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel2Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel3Memberwst:OtherMutualFundsMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Member2024-12-310000105770us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel1Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel2Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel3Memberwst:OtherMutualFundsMember2023-12-310000105770us-gaap:FairValueInputsLevel12And3Member2023-12-310000105770us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-3100001057702022-12-012022-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2023-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2023-12-310000105770wst:The2022RestructuringPlanMember2023-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2024-01-012024-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2024-01-012024-12-310000105770wst:The2022RestructuringPlanMember2024-01-012024-12-310000105770us-gaap:EmployeeSeveranceMemberwst:The2022RestructuringPlanMember2024-12-310000105770us-gaap:OtherRestructuringMemberwst:The2022RestructuringPlanMember2024-12-310000105770wst:The2022RestructuringPlanMember2024-12-3100001057702023-04-012023-06-300000105770us-gaap:StateAndLocalJurisdictionMember2024-12-310000105770us-gaap:ForeignCountryMember2024-12-310000105770wst:Year2025Memberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770wst:ThereafterMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2019-12-3100001057702019-12-310000105770us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310000105770country:DE2024-12-310000105770us-gaap:InsuranceClaimsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2022-01-012022-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2022-01-012022-12-310000105770us-gaap:IntersegmentEliminationMember2024-01-012024-12-310000105770us-gaap:IntersegmentEliminationMember2023-01-012023-12-310000105770us-gaap:IntersegmentEliminationMember2022-01-012022-12-310000105770wst:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310000105770wst:OneCustomerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310000105770country:US2024-01-012024-12-310000105770country:US2023-01-012023-12-310000105770country:US2022-01-012022-12-310000105770country:US2024-12-310000105770country:US2023-12-310000105770country:DE2024-01-012024-12-310000105770country:DE2023-01-012023-12-310000105770country:DE2022-01-012022-12-310000105770country:DE2023-12-310000105770country:IE2024-01-012024-12-310000105770country:IE2023-01-012023-12-310000105770country:IE2022-01-012022-12-310000105770country:IE2024-12-310000105770country:IE2023-12-310000105770country:FR2024-01-012024-12-310000105770country:FR2023-01-012023-12-310000105770country:FR2022-01-012022-12-310000105770country:FR2024-12-310000105770country:FR2023-12-310000105770wst:OtherEuropeCountriesMember2024-01-012024-12-310000105770wst:OtherEuropeCountriesMember2023-01-012023-12-310000105770wst:OtherEuropeCountriesMember2022-01-012022-12-310000105770wst:OtherEuropeCountriesMember2024-12-310000105770wst:OtherEuropeCountriesMember2023-12-310000105770wst:OtherCountriesMember2024-01-012024-12-310000105770wst:OtherCountriesMember2023-01-012023-12-310000105770wst:OtherCountriesMember2022-01-012022-12-310000105770wst:OtherCountriesMember2024-12-310000105770wst:OtherCountriesMember2023-12-310000105770us-gaap:OperatingSegmentsMember2024-01-012024-12-310000105770us-gaap:OperatingSegmentsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMember2022-01-012022-12-310000105770wst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770wst:CorporateAndReconcilingItemsMember2022-01-012022-12-310000105770us-gaap:SellingGeneralAndAdministrativeExpensesMemberwst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMemberwst:CorporateAndReconcilingItemsMember2024-01-012024-12-310000105770wst:OtherExpenseIncomeMemberwst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770us-gaap:CostOfSalesMemberwst:CorporateAndReconcilingItemsMember2023-01-012023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ProprietaryProductsMember2023-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2024-12-310000105770us-gaap:OperatingSegmentsMemberwst:ContractManufacturedProductsMember2023-12-310000105770wst:CorporateAndReconcilingItemsMember2024-12-310000105770wst:CorporateAndReconcilingItemsMember2023-12-3100001057702024-10-012024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-01-012024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-12-310000105770us-gaap:AllowanceForCreditLossMember2023-12-310000105770us-gaap:AllowanceForCreditLossMember2024-01-012024-12-310000105770us-gaap:AllowanceForCreditLossMember2024-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310000105770us-gaap:AllowanceForCreditLossMember2022-12-310000105770us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310000105770us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310000105770us-gaap:AllowanceForCreditLossMember2021-12-310000105770us-gaap:AllowanceForCreditLossMember2022-01-012022-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K

(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania23-1210010
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
  
530 Herman O. West Drive, Exton, PA
19341-1147
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: 610-594-2900

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $.25 per shareWSTNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☑ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                Yes þ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                                            Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☑ Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                    ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.                            ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes ☐    No ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.     ☐

Indicate by check mark whether any such corrections are restatements that triggered a compensation recovery analysis during the fiscal year.    ☐

The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2024 was approximately $23.9 billion based on the closing price as reported on the New York Stock Exchange.

As of February 6, 2025, there were 72,303,766 shares of the registrant’s common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
DocumentParts Into Which Incorporated
Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.Part III



TABLE OF CONTENTS
Page
ITEM 1C.

ITEM 9C.



PART I

Unless otherwise indicated, or the context otherwise requires, references in this report to “the Company,” “we,” “us,” “our” and “West” refer to West Pharmaceutical Services, Inc. and its majority-owned subsidiaries.

All trademarks and registered trademarks used in this report are our property, either directly or indirectly through our subsidiaries, unless noted otherwise. Daikyo Crystal Zenith® (“Crystal Zenith”) is a registered trademark of Daikyo Seiko, Ltd. (“Daikyo”).

Throughout this report, references to “Notes” refer to the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K (“Form 10-K”), unless otherwise indicated.

Information in this Form 10-K is current as of February 18, 2025, unless otherwise specified.

3

ITEM 1. BUSINESS

General

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Business Segments

Our business operations are organized into two global business segments, Proprietary Products and Contract-Manufactured Products.

Proprietary Products Segment

Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. Our packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability with active drug products, while also supporting operational efficiency for customers. These packaging products also include syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications, as well as administration systems that can enhance the safe delivery of drugs through advanced reconstitution, mixing and transfer technologies. We also provide films, coatings, washing, vision inspection and sterilization processes and services to enhance the quality of our packaging products and mitigate the risk of contamination and compatibility issues.

This segment’s product portfolio also includes drug containment solutions, including Crystal Zenith, a cyclic olefin polymer, in the form of vials, syringes and cartridges. These products can provide a high-quality solution to glass incompatibility issues and can stand up to cold storage environments, while reducing the risk of breakage that exists with glass. In addition, we offer a variety of self-injection devices, designed to address the need to provide at-home delivery of injectable therapies. These devices are patient-centric technologies that are easy-to-use and can be combined with connected health technologies that have the potential to increase adherence.

In addition to our Proprietary Products product portfolio, we provide our customers with a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. Offering the combination of primary proprietary packaging components, containment solutions, and drug delivery devices, as well as a broad range of integrated services, helps to position us as a leader in the integrated containment and delivery of injectable medicines.

This reportable segment has manufacturing facilities in North and South America, Europe, and Asia, with affiliated companies in Mexico and Japan. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

4

Contract-Manufactured Products Segment

Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. These products include a variety of custom contract-manufacturing and assembly solutions, which use technologies such as multi-component molding, in-mold labeling, ultrasonic welding, clean room molding, device assembly, and drug handling capabilities. We manufacture customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

We have vast expertise in product design and development, including in-house mold design, process design and validation and high-speed automated assemblies.

This reportable segment has manufacturing facilities in North America and Europe. Please refer to Item 2, Properties, for additional information on our manufacturing and other sites.

International

We have significant operations outside of the United States (“U.S.”), which are managed through the same business segments as our U.S. operations – Proprietary Products and Contract-Manufactured Products. Sales outside of the U.S. accounted for 57.5% of our net sales in 2024.

Although the general business processes are similar to the domestic business, international operations are exposed to additional risks. These risks include currency fluctuations relative to the U.S. Dollar (“USD”) and multiple tax jurisdictions.

See further discussion of our international operations, the risks associated with our international operations, and our attempt to minimize some of these risks in Part I, Item 1A, Risk Factors; Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations under the caption Financial Condition, Liquidity and Capital Resources; Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk; Note 1, Basis of Presentation and Summary of Significant Accounting Policies under the captions Financial Instruments and Foreign Currency Translation; and Note 11, Derivative Financial Instruments.

Raw Materials

We use three basic raw materials in the manufacture of our products: elastomers, aluminum and plastic. Elastomers include both synthetic and natural materials. We currently have access to adequate supplies of these raw materials to meet our production needs through agreements with suppliers. We are required to carry significant amounts of inventory to meet customer requirements. In addition, some of our supply agreements require us to purchase inventory in bulk orders, which increases inventory levels but decreases the risk of supply interruption.

We employ a supply chain management strategy in our business segments, which involves purchasing from integrated suppliers that control their own sources of supply. Due to regulatory control over our production processes, sole source availability, and the cost and time involved in qualifying suppliers, we rely on single-source suppliers for many critical raw materials. We generally purchase certain raw materials in the open market and therefore the results of our operations may be affected by price fluctuations. This strategy increases the risk that our supply chain may be interrupted in the event of a supplier production or distribution problem. These risks are managed, when and where possible, by selecting suppliers with multiple manufacturing sites, rigorous quality control systems, surplus inventory levels and other methods of maintaining supply in case of an interruption in production or distribution. Heightened inflation may result in unfavorable conditions, inclusive of an increase in raw material cost. To date, we have been able to manage these conditions without significant disruption to our business.

While we work closely with our suppliers, no assurance can be given that these efforts will be successful, and there may be events that cause supply interruption, reduction or termination that adversely impact our ability to manufacture and sell certain products. See further discussion of the risks related to the supply chain and raw materials in Item 1A. Risk Factors.
5


Intellectual Property

Our intellectual property, including patents, patent applications, trademarks, copyrights, know-how and trade secrets, is important to our business. We own or license intellectual property rights, including know-how and issued patents and pending patent applications in the U.S. and in other countries, which relate to various aspects of our business. In 2024, more than 170 utility and design patents were issued to West across the globe. Certain key value-added and proprietary products and processes are exclusively licensed from Daikyo. We believe, however, that neither our business nor any business segment is wholly dependent on a single intellectual property asset, license, or technology, by itself.

Government Regulation

Our business activities are global and are subject to various federal, state, local, and foreign laws, rules, and regulations to healthcare, environmental protection, occupational health and safety, anti-corruption, export control, product safety and efficacy, employment, privacy and other areas. The design, development, manufacturing, marketing and labeling of certain of our products and our customers’ products that incorporate our products are subject to regulation by governmental authorities in the U.S., Europe and other countries, including the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency and the National Medical Products Administration (China). Regulatory authorities, including regulatory review and oversight, can impact the time and cost associated with the development and continued availability of our products, and they have the authority to take various administrative and legal actions against West. Compliance with existing and forthcoming laws and regulations can be costly and time consuming, and may require changes to our information technologies, systems and practices.

Changes in tax policy or trade regulations, or the imposition of new tariffs on imported products, could have an adverse effect on our business and results of operations. Compliance with these laws, rules and regulations did not require material capital expenditures in 2024 and is not expected to have a material effect on our capital expenditures, results of operations and competitive position in 2025 as compared to prior periods. For more information on the potential impacts of government regulations affecting our business, see "Item 1A. Risk Factors." There were no required material capital expenditures for adherence to our government-led regulatory standards in our facilities in 2024 outside the normal course of business, and there are currently no needed or planned material expenditures for 2025.

West is also subject to various federal and state laws, and laws outside the United States, concerning fraud and abuse, global anti-corruption, and export control. Many of the agencies enforcing these laws have increased their enforcement actions with respect to healthcare manufacturers in recent years. We remain committed as a company to comply with all laws and regulations applicable to our business.

Environmental Regulations

We are subject to various national, state and local provisions regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. Our compliance with these laws and regulations has not had a material impact on our financial position, results of operations or cash flows. There were no required material capital expenditures for environmental controls in our facilities in 2024 and there are currently no needed or planned material expenditures for 2025.

6

Marketing

Our Proprietary Products customers primarily include many of the major biologic, generic, and pharmaceutical drug companies in the world, which incorporate our components and other offerings into their injectable products for distribution to the point of care and ultimate end-user, the patient. Our Contract-Manufactured Products customers include many of the world’s largest pharmaceutical, diagnostic, and medical device companies. Contract-Manufactured Products components generally are incorporated into our customers’ manufacturing lines for further processing or assembly. Our products and services are sold and distributed primarily through our own sales force and distribution network, with limited use of contract sales agents and regional distributors.

Our ten largest customers accounted for 43.4% of our consolidated net sales in 2024, and one of these customers, individually accounted for more than 10% of consolidated net sales, at 12.3% or $356.4 million, contributing to net sales in both the Proprietary and Contract Manufacturing reporting segments. Please refer to Note 3, Revenue, and Note 19, Segment Information, for additional information on our consolidated net sales.

Competition

With our range of proprietary technologies, we compete with several companies across our Proprietary Products product lines. Competition for these components is based primarily on product design and performance, quality, regulatory compliance, and scientific expertise, along with total cost.

In addition, there are a number of competitors supplying medical devices and medical device components, including a number of pharmaceutical manufacturers who are also potential customers of our medical devices and components. We compete in this market on the basis of our reputation for quality and reliability in engineering and project management, as well as our knowledge of, and experience in, compliance with regulatory requirements.

We have specialized knowledge of container closure components, which is integral to developing delivery systems. With our range of proprietary technologies, we compete with new and established companies in the area of drug delivery devices, including suppliers of prefillable syringes, auto-injectors, safety needles, and other proprietary systems.

We seek to differentiate ourselves from our competition by serving as a global supplier of integrated drug containment and delivery systems that can provide pre-approval primary packaging support and engineering development, analytical lab services and integrated solutions, regulatory expertise, and after-sale technical support. Customers also appreciate the global scope of our manufacturing capability and our ability to produce many products at multiple sites.

Our Contract-Manufactured Products business operates in very competitive markets for its products. The competition varies from smaller regional companies to large global assembly manufacturers. Given the cost pressures they face, many of our customers look to reduce costs by sourcing from low-cost locations. We seek to differentiate ourselves by leveraging our global capabilities and reputation and by employing new technologies such as high-speed automated assembly, insert-molding, multi-shot precision molding, and expertise with multiple-piece closure systems.

Research and Development Activities

We maintain our own research-scale production facilities and laboratories for developing new products and offer contract engineering design and development services to assist customers with new product development. Our quality control, regulatory and laboratory testing capabilities are used to ensure compliance with applicable manufacturing and regulatory standards for primary and secondary pharmaceutical packaging components and drug delivery systems. Technological advances and scientific discoveries have accelerated the pace of change in primary packaging, drug delivery and administration technologies.

7

Commercial development of our new products and services for medical and pharmaceutical applications commonly requires several years. New products that we develop may require separate approval as medical devices, and products that are intended to be used in the packaging and delivery of pharmaceutical products are subject to both customer acceptance of our products and regulatory approval of the customer’s products following our development period.

We continue to pursue strategic initiatives in drug containment components, integrated drug containment systems, novel drug delivery devices, novel therapeutic experiences and administration systems.

We also continue to seek new innovative opportunities for acquisition, licensing, partnering or development of products, services and technologies.

Human Capital Management

Our People

As of December 31, 2024, we employed approximately 10,600 people, excluding contractors and temporary workers, in our operations throughout the world. During 2024, West hired approximately 1,800 new team members and experienced an attrition rate of approximately 17%. The following table presents the approximate percentage of our employees by region:
North America44%
Europe41%
Asia Pacific12%
South America3%
Total 100%

As of December 31, 2024, the following table presents the approximate percentage of our employees by business unit:
Global Operations84%
Corporate6%
Sales and Marketing4%
Digital & Technology (D&T)4%
Research & Development2%
Total100%

As of December 31, 2024, we had the following global gender demographics:
MenWomen
West Global Employees63%37%
8

Training, Compliance and Talent Development

We strongly encourage our team members to engage in continuous learning and provide development opportunities to strengthen individual skills and gain new experiences with the goal to build talent from within. We offer resources such as our tuition reimbursement program and our online learning catalog, with more than 46,000 courses available. We centrally manage and organize on-the-job training, instructor-led trainings and online trainings in many different languages and topics through our global Learning Management System.

Our team members live our values (Passion for Customer, Leadership in Quality and One West Team) as they work together to support our mission to improve patients' lives. West’s Code of Conduct, available in multiple languages on westpharma.com, provides guidance to our team members on appropriate and ethical conduct. Every team member is required to undergo Code of Conduct and mutual respect in the workplace training annually.

Our focus on talent acquisition, performance management, resource planning and leadership assessment are strongly aligned with our inclusion, collaboration, and innovation strategies, all of which lead to more opportunities, better access to talent and stronger business performance.

Compensation and Benefits

West is committed to providing fair and competitive compensation and benefits programs to attract, retain and reward high-performing team members at all levels. We offer a comprehensive total rewards program to support the health, financial and home-life needs of our team members. Total Rewards at West are defined as the value of the Compensation and Benefits programs offered to employees, which aim to reflect the value of the job and the contribution of the individual, while linking employees’ performance to business and personal results. Based on country of employment, West may provide health care and retirement savings programs as well as paid time off, flexible work schedules, a Global Employee Assistance Program and an Employee Stock Purchase Program.

Health, Safety and Wellness

The health and safety of our team members has always been both a top priority and a cultural value. West's commitment to the safety of our teams starts at the top and is driven throughout our business by every level of management and by every team member across the globe. West has a Health, Safety, and Environment ("HSE") Governance Council consisting of West Leadership Team members and executive operations leaders to monitor and support our HSE process. West’s global HSE team is also a critical component in leading the safety efforts at our sites. Each manufacturing location has dedicated and trained HSE professionals, responsible for general safety oversight and regulatory compliance at the site. Through our SEE-DO-SAY program, we train, empower, and expect our team members to proactively identify and mitigate risk before an incident occurs. Our HSE and employee well-being can also be seen in our focus on quality implementation of proactive Leading Indicator programs and metrics, and team-member-led Hazard Identification programs that help to drive improved Lagging Indicator performance.

9

Environmental, Social and Governance (“ESG”) Commitment

West has been committed to ESG topics for many years. During 2024, we continued to increase internal and external awareness of our ESG commitment by expanding our education and communication regarding our ESG program and initiatives and more closely integrating ESG considerations into our business processes. Our ESG program includes a senior-level cross-functional ESG team which has been working with executive leadership, our board and other stakeholders to enhance our ESG framework and ensure alignment with our corporate mission, vision and values. Going forward, the ESG program will have an increased focus on compliance, given the increased regulatory requirements, as well as advancing our long-term strategic priorities. Our long-term strategic priorities include focus on talent attraction, retention and engagement; a climate and greenhouse gas ("GHG") reduction strategy that incorporates renewable energy and reduced absolute and intensity emissions; developing a more sustainable and responsible supply chain; research and development that focuses on issues of sustainability including secondary packaging, beneficial reuse and recyclability; and, reduction of waste and water in our operational processes. These areas of focus are in addition to our commitments to safety, quality, business continuity, as well as business compliance and integrity. Additionally, our philanthropic programs are an essential element of our corporate citizenship especially as we focus on the areas of children’s health; access to healthcare; and science, technology, engineering and math education. We are also expanding our philanthropic scope to include more sustainability related initiatives. We solicit input from a variety of stakeholders including employees, customers, and suppliers on ways to improve in these and other ESG areas and see continued progress in these areas as critical to maintaining an engaged and responsible workforce.

Available Information

We maintain a website at www.westpharma.com. Our Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) are available on our website under the Investors - Financial caption as soon as reasonably practical after we electronically file the material with, or furnish it to, the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public over the Internet at the SEC’s website, www.sec.gov.

In Part III of this Form 10-K, we incorporate by reference certain information from parts of other documents filed with the SEC and from our Proxy Statement for the 2025 Annual Meeting of Shareholders (“2025 Proxy Statement”), which will be filed with the SEC within 120 days following the end of our 2024 fiscal year. Our 2025 Proxy Statement will be available on our website under the caption Investors - Financial - Annual Reports & Proxy when complete.

Information about our corporate governance, including our Corporate Governance Principles and Code of Conduct, as well as information about our Directors, Board Committees, Committee Charters, and instructions on how to contact the Board, is available on our website under the Investors - Corporate Governance heading. We intend to make any required disclosures regarding any amendments of our Code of Conduct under the caption Investors - Corporate Governance on our website. Information relating to the West Pharmaceutical Services Dividend Reinvestment Plan is also available on our website under the Investors - Transfer Agent caption.

Information on our website does not constitute part of this document.

We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, West Pharmaceutical Services, Inc., 530 Herman O. West Drive, Exton, PA 19341.

10

ITEM 1A. RISK FACTORS

Investing in our common stock involves a high degree of risk. You should consider and carefully read all of the risks and uncertainties described below, as well as other information included in this Annual Report and in our other public filings. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your original investment. This Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.

Our disclosure and analysis in this Form 10-K contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public as well as oral forward-looking statements. Such statements give our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and phrases of similar meaning. In particular, these include statements relating to future actions, business plans and prospects, new products, future performance or results of current or anticipated products, sales efforts, expenses, interest rates, foreign-exchange rates, economic effects, the outcome of contingencies, such as legal proceedings, and financial results.

Many of the factors that will determine our future results are beyond our ability to control or predict. Achievement of future results is subject to known or unknown risks or uncertainties, including, without limitation, the risks set forth below. Therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you consider forward-looking statements.

Unless required by applicable securities law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. We also refer you to further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to the SEC.

Global and Economic Risks

Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations.

General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, may result in unfavorable conditions. Those conditions could negatively affect demand for our products due to customers decreasing their inventories in the near-term or long-term, reduction in sales due to raw material shortages, reduction in research and development efforts, our inability to sufficiently hedge our currency and raw material costs, insolvency of suppliers or customers, and exacerbate some of the other risks that affect our business, financial condition and results of operations.

11

Unauthorized access to our or our customers’ information and systems could negatively impact our business.

Our systems and networks, as well as those of our customers, suppliers, service providers, and banks, have and may in the future become the target of cyberattacks or information security breaches which, in turn, could result in the unauthorized release and misuse of confidential or proprietary information about our company, our employees or our customers, as well as disrupt our operations or damage our facilities or those of third parties. Additionally, our systems are subject to regulation to preserve the privacy of certain data held on those systems. We maintain an extensive network of technical security controls, policy enforcement mechanisms and monitoring systems, in order to address these threats. While these measures are designed to prevent, detect and respond to unauthorized activity in our systems, certain types of attacks could result in financial or information losses and/or reputational harm. If we cannot comply with regulations or prevent the unauthorized access, release and/or corruption of our or our customers’ confidential, classified or personally identifiable information, our reputation could be damaged, and/or we could face financial losses.

We may also be required to incur additional costs to modify or enhance our systems, or to try to prevent or remediate any such attacks. Modifying or enhancing our systems may result in unanticipated or prolonged disruption events, which could have a material adverse effect on our business and/or results of operations.

We are a global company with significant revenues and earnings generated internationally, which exposes us to the impact of foreign currency fluctuations, as well as political and economic risks.

A significant portion of our net sales and earnings are generated internationally. Sales outside of the U.S. accounted for 57.5% of our consolidated net sales in 2024 and we anticipate that sales from international operations will continue to represent a significant portion of our net sales in the future. In addition, many of our manufacturing facilities and suppliers are located outside of the U.S. and we intend to continue our expansion into emerging and/or faster-growing international markets. Our foreign operations subject us to certain commercial, political and financial risks. Our business in these foreign markets is subject to general political conditions, including any political instability (such as those resulting from war, terrorism and insurrections) and general economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability. Additionally, a number of factors, including U.S. relations with the governments of the foreign countries in which we operate, changes to international trade agreements and treaties, increases in trade protectionism, or the weakening or loss of certain intellectual property protection rights in some countries, may affect our business, financial condition and results of operations. Foreign regulatory requirements, including those related to the testing, authorization, and labeling of products and import or export licensing requirements, could affect the availability of our products in these markets.

In addition to risks associated with general political conditions, our international operations are subject to fluctuations in foreign currency exchange rates. The functional currency for most of our foreign operations is the applicable local currency. As a result, fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities, which in turn may adversely affect results of operations and cash flows and the comparability of period-to-period results of operations. Foreign governmental policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Given the unpredictability and volatility of foreign currency exchange rates, ongoing or unusual volatility may adversely impact our business and financial conditions.

In order to reduce our exposure to fluctuations in foreign currency exchange rates, we have entered, and expect to continue to enter, into hedging arrangements, including the use of financial derivatives. There can be no certainty that we will be able to enter into or maintain hedges of these currency risks, or that our hedges will be effective, which could have a significant effect on our financial condition and operating results.

12

In addition, our international operations are governed by the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption laws. Global enforcement of anti-corruption laws has increased substantially in recent years, with more enforcement proceedings by U.S. and foreign governmental agencies and the imposition of significant fines and penalties. While we have implemented policies and procedures relating to compliance with these laws, our international operations create the risk that there may be unauthorized payments or offers of payments made by employees, consultants, sales agents or distributors. Any alleged or actual violations of these laws may subject us to government investigations and significant criminal or civil sanctions and other liabilities, and negatively affect our reputation.

We are exposed to credit risk on accounts receivable and certain prepayments made in the normal course of business. This risk is heightened during periods when economic conditions worsen.

A substantial majority of our outstanding trade receivables are not covered by collateral or credit insurance. In addition, we have made prepayments and other advances in the normal course of business. While we have procedures to monitor and limit exposure to credit risk on trade receivables and other current assets, there can be no assurance such procedures will effectively limit our credit risk and avoid losses, which could have a material adverse effect on our financial condition and operating results.

Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business and financial condition.

Potential future disruptions in access to bank deposits or lending commitments due to bank failure could materially and adversely affect our liquidity, our business and financial condition. Even with our continued effort to mitigate counterparty risk by working with highly liquid, well capitalized counterparties, the failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.

Industry Risks

Our sales and profitability are largely dependent on the sale of drug products delivered by injection and the packaging of drug products. If the drug products developed by our customers in the future use another delivery system or are reconfigured to require less frequent dosing, our sales and profitability could suffer.

Our business depends to a substantial extent on customers’ continued sales and development of products that are delivered by injection. If (i) our customers fail to continue to sell, develop and deploy injectable products; (ii) our customers reconfigure their drug product or develop new drug products requiring less frequent dosing; or (iii) we are unable to develop new products that assist in the delivery of drugs by alternative methods, our sales and profitability may suffer.

If we are unable to provide comparative value advantages, timely fulfill customer orders, or resist pricing pressure, we will have to reduce our prices, which may reduce our profit margins.

We compete with several companies across our major product lines. Because of the special nature of these products, competition is based primarily on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost-control programs across their operations.



13

Companies often compete on the basis of price. We aim to differentiate ourselves from our competition by being a “full-service, value-added” global supplier that is able to provide pre-sale compatibility studies, engineering support, and other services and sophisticated post-sale technical support on a global basis. However, we face continued pricing pressure from our customers and competitors. If we are unable to resist or offset the effects of continued pricing pressure through our value-added services, improved operating efficiencies and reduced expenditures, or if we have to reduce our prices, our sales and profitability may suffer.

Consolidation in the pharmaceutical and healthcare industries could adversely affect our future revenues and operating income.

The pharmaceutical and healthcare industries continue to experience a significant amount of consolidation. As a result of this consolidation, competition to provide goods and services to customers has increased. In addition, group purchasing organizations and integrated health delivery networks have served to concentrate purchasing decisions for some customers, which has placed pricing pressure on suppliers. Further consolidation within the industries we serve could exert additional pressure on the prices of our products.

The medical technology industry is very competitive and customer demands and/or new products in the marketplace could cause a reduction in demand.

The medical technology industry is subject to rapid technological changes, and we face significant competition across our product lines and in each market in which our products are sold. We face this competition from a wide range of companies, including large medical device companies, some of which have greater financial and marketing resources than we do. We also face competition from firms that are more specialized than we are with respect to particular markets. In some instances, competitors, including pharmaceutical companies, also offer, or are attempting to develop, alternative therapies for diseases that may be delivered via their own, or without, a medical device. The development of new or improved products, processes or technologies by other companies (such as needle-free injection technology) may reduce customer demand for our products or render some of our products or proposed products obsolete or less competitive. In addition, any failure or inability to meet increased customer quality expectations could cause a reduction in demand.

Business and Operational Risks

Disruption in our manufacturing facilities could have a material adverse effect on our ability to make and sell products and have a negative impact on our reputation, performance or financial condition.

We have manufacturing sites throughout the world. In some instances, however, the manufacturing of certain product lines is concentrated in one or only a few of our plants. The functioning of our manufacturing and distribution assets and systems could be disrupted for reasons either within or beyond our control, including, without limitation: extreme weather, water scarcity and other longer-term climatic changes; natural or man-made disasters; pandemic; war; accidental damage; disruption to the supply of material or services; product quality and safety issues; power outages; systems failure; workforce actions; or environmental matters. There is a risk that incident management systems in place may prove inadequate and that any disruption may materially adversely affect our ability to make and sell products and therefore, materially adversely affect our reputation, performance or financial condition.

14

Our international sales and operations are subject to risks and uncertainties that vary by country and which could have a material adverse effect on our business and/or results of operations.

We conduct business in most of the major pharmaceutical markets in the world. Our international operations and our ability to implement our overall business strategy (including our plan to continue expanding into emerging and/or faster-growing markets outside of the U.S.) are subject to risks and uncertainties that can vary by country, and include: transportation delays and interruptions; political and economic instability and disruptions; imposition of duties and tariffs; import and export controls; the risks of divergent business expectations or cultural incompatibility inherent in establishing and maintaining operations in foreign countries; difficulties in staffing and managing multi-national operations; labor strikes and/or disputes; and potentially adverse tax consequences. Limitations on our ability to enforce legal rights and remedies with third parties or our joint venture partners outside of the U.S. could also create exposure. In addition, we may not be able to operate in compliance with foreign laws and regulations, or comply with applicable customs, currency exchange control regulations, transfer pricing regulations or any other laws or regulations to which we may be subject, in the event that these laws or regulations change. Any of these events could have an adverse effect on our international operations in the future by reducing the demand for our products or decreasing the prices at which we can sell our products, or otherwise have an adverse effect on our financial condition, results of operations and cash flows.

Disruptions in the supply of key raw materials could adversely impact our operations.

We generally purchase our raw materials and supplies required for the production of our products in the open market. For reasons of quality assurance, sole source availability or cost effectiveness, many components and raw materials are available and/or purchased only from a single supplier. Due to the stringent regulations and requirements of the FDA and other regulatory authorities regarding the manufacture of our products and the availability of such raw materials, we may not be able to quickly establish additional or replacement sources for these components or raw materials or do so without excessive cost. As a result, a reduction or interruption in supply, or an inability to secure alternative sources of raw materials or components, could have a material adverse effect on our business and/or results of operations.

Raw material and energy prices have a significant impact on our profitability. If raw material and/or energy prices increase, and we cannot pass those price increases on to our customers, our profitability and financial condition may suffer.

We use three basic raw materials in the manufacture of our products: elastomers (which include synthetic and natural material), aluminum and plastic. In addition, our manufacturing facilities consume a wide variety of energy products to fuel, heat and cool our operations. The price and supply of these materials and energy sources are cyclical and volatile and may be impacted or disrupted for reasons beyond our control, including supplier shutdowns, supplier capacity constraints, transportation delays, inflationary pricing pressures, work stoppages, labor shortages, geopolitical developments and governmental regulatory actions.

For example, the prices of certain commodities, particularly petroleum-based raw materials, have in the recent past exhibited rapid changes, affecting the cost of synthetic elastomers and plastic. While we generally attempt to pass along increased costs to our customers in the form of sales price increases, historically there has been a time delay between raw material and/or energy price increases and our ability to increase the prices of our products. In some circumstances, we may not be able to increase the prices of our products due to competitive pressure and other factors. If we are unable to pass along increased raw material prices and energy costs to our customers, our profitability, and thus our financial condition, may be adversely affected.

15

If we are not timely or successful in new-product innovation or the development and commercialization of proprietary multi-component systems, our future revenues and operating income could be adversely affected.

Our growth partly depends on new-product innovation and the development and commercialization of proprietary multi-component systems for injectable drug administration and other healthcare applications. Product development and commercialization is inherently uncertain and is subject to a number of factors outside of our control, including any necessary regulatory approvals and commercial acceptance for the products. The ultimate timing and successful commercialization of new products and systems requires substantial evaluations of the functional, operational, clinical, and economic viability of our products. In addition, the timely and adequate availability of filling capacity is essential to both conducting definitive stability trials and the timing of commercialization of customers’ products in Crystal Zenith vials, syringes and cartridges. Delays, interruptions or failures in developing and commercializing new-product innovations or proprietary multi-component systems could adversely affect future revenues and operating income. In addition, adverse conditions may also result in future charges to recognize impairment in the carrying value of our goodwill and other intangible assets, which could have a material adverse effect on our financial results.

We may not succeed in finding and completing acquisitions or other strategic transactions, which could have an adverse effect on our business and results of operations.

We expect to continue to seek acquisition opportunities that compliment and expand our existing operations. However, we may be unable to identify suitable targets, opportunistic or otherwise, for acquisitions or other strategic transactions in the future. If we identify a suitable candidate, our ability to successfully implement the strategic transaction would depend on a variety of factors, including our ability to obtain financing on acceptable terms and to comply with the restrictions contained in our debt agreements. Strategic transactions involve risks, including those associated with integrating the operations or maintaining the operations as separate (as applicable), financial reporting, disparate technologies, and personnel of acquired companies, joint ventures or related companies; managing geographically dispersed operations or other strategic investments; the diversion of management’s attention from other business concerns; the inherent risks in entering markets or lines of business in which we have either limited or no direct experience; the potential loss of key employees, customers and strategic partners of acquired companies, joint ventures or companies in which we may make strategic investments; and potentially other unknown risks. We may not successfully integrate any businesses or technologies we may acquire or strategically develop in the future and may not achieve anticipated revenue and cost benefits relating to any such strategic transactions. Strategic transactions may be expensive, time consuming and may strain our resources. Strategic transactions may not be accretive to our earnings and may negatively impact our results of operations as a result of, among other things, the incurrence of debt, one-time write-offs of goodwill, additional carrying costs of patent or trademark portfolios, and amortization expenses of other intangible assets. In addition, strategic transactions that we may pursue could result in dilutive issuances of equity securities.

Product defects could adversely affect the results of our operations.

The design, manufacturing and marketing of pharmaceutical packaging and medical devices involve certain inherent risks. Manufacturing or design defects, unanticipated use of our products, or inadequate disclosure of risks relating to the use of our products can lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to our products (either voluntary or required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market.

A recall could result in significant costs, as well as negative publicity and damage to our reputation that could reduce demand for our products. Personal injuries relating to the use of our products can also result in product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in new product approvals.

16

A loss of or inability to attract key personnel or highly skilled employees could disrupt our operations.

Our future success depends, in large part, on our ability to attract and retain key employees, including our executive officers and individuals in technical, marketing, sales, and research positions. Competition for experienced employees, particularly for persons with specialized skills, can be intense. Our ability to recruit such talent will depend on a number of factors, including compensation and benefits, work location and work environment. If we cannot effectively recruit and retain qualified executives and employees, our business could be adversely affected. Although we believe that we will be able to attract and retain talented personnel and replace key personnel should the need arise, our inability to do so on a timely basis could disrupt the operations of the unit affected or our overall operations. In addition, because of the complex nature of many of our products and programs, we are generally dependent on an educated and highly skilled engineering staff and workforce. Our operations could be disrupted by a shortage of available skilled employees.

We may be unable to increase capacity or efficiency at our own manufacturing facilities, which could adversely affect our business, financial condition, and results of operations.

We must adjust our production capacity in accordance with customer demand changes and remain focused on increasing capacity at various facilities through our capital strategy. If we are unable to increase capacity levels at the rate we expect, or if unforeseen costs or other challenges associated with increasing that capacity arise, we may not be able to achieve our financial targets.

Additionally, we are committed to supporting a full portfolio of our products for our customers. That commitment, along with shifts of product mix and complexity, may result in more frequent equipment change-overs and potentially increased costs because of the high fixed cost nature of our business, causing lower gross margins due to under-absorption of those fixed costs.

Our results of operations and earnings may not meet guidance or expectations.

We provide public guidance on our expected results of operations for future periods. This guidance is comprised of forward-looking statements subject to risks and uncertainties, including the risks and uncertainties described in this Form 10-K and in our other public filings and public statements, and is based on assumptions we make at the time we provide such guidance. Our guidance may not always be accurate. If, in the future, our results of operations for a particular period do not meet our guidance or the expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our common stock could decline significantly.

No assurance can be given that we will continue to pay or declare dividends.

We have historically paid dividends. However, there can be no assurance that we will pay or declare dividends in the future. The actual declaration and payment of future dividends, the amount of any such dividends, and the establishment of record and payment dates, if any, are subject to determination by our Board of Directors each quarter after its review of our then-current strategy, applicable debt covenants and financial performance and position, among other things. Our declaration and payment of future dividends is subject to risks and uncertainties, including deterioration of our financial condition or position; inability to declare a dividend in compliance with applicable laws or debt covenants; an increase in our cash needs or decrease in available cash; and the business judgment of the Board of Directors that a declaration of a dividend is not in our best interest.

If we fail to comply with our obligations under our distributorship or license agreements with Daikyo or the agreements are terminated early or not renewed, we could lose license rights and access to certain product and technology that are important to our business.

Key value-added and proprietary products and processes are licensed from our affiliate, Daikyo, including but not limited to, Crystal Zenith, FluroTec® and B2-coating technologies. Our rights to these products and processes are licensed pursuant to agreements that expire in 2027. However, if the agreements are terminated early or not renewed, our business could be adversely impacted.
17

Legal and Regulatory Risks

We are subject to regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.

As a multinational corporation with operations and distribution channels throughout the world, we are subject to and must comply with extensive laws and regulations in the United States and other jurisdictions in which we have operations and distribution channels. For example, the design, development, manufacturing, marketing and labeling of certain of our products and our customers’ products that incorporate our products are subject to regulation by governmental authorities in the U.S., Europe and other countries, including the FDA, the European Medicines Agency and the National Medical Products Administration (China). Complying with governmental regulation can be costly and can result in required modification or withdrawal of existing products and a substantial delay in the introduction of new products. Failure to comply with applicable regulatory requirements or failure to obtain regulatory approval for a new product could subject us to fines, sanctions or other penalties that could negatively affect our reputation, business, financial condition, and results of operations.

The global nature of our business also means legal and compliance risks, such as anti-bribery, anti-corruption, fraud, trade, environmental, competition, privacy, and other regulatory matters, will continue to exist and additional legal proceedings and other contingencies will arise from time to time, which could adversely affect us. In addition, the adoption of new laws or regulations, or changes in the interpretation of existing laws or regulations, may result in significant unanticipated legal and reputational risks. Any current or future legal or regulatory proceedings could divert management's attention from our operations and result in substantial legal fees.

Products that incorporate our technologies and medical devices that we produce are subject to regulations and extensive approval or clearance processes, which make the timing and success of new-product commercialization difficult to predict.

The process of obtaining and maintaining FDA and other required regulatory approvals is expensive and time-consuming. Historically, most medical devices that incorporate our technologies and medical devices that we produce have been subject to the FDA’s 510(k) marketing approval process, which typically lasts from six to nine months. Supplemental or full pre-market approval reviews require a significantly longer period, delaying commercialization. Changes in regulation on a global scale must be monitored and actions taken to ensure ongoing compliance. Pharmaceutical products that incorporate our technologies and medical devices that we produce are subject to the FDA’s New Drug Application process, which typically takes a number of years to complete. Additionally, biotechnology products that incorporate our technologies and medical devices that we produce are subject to the FDA’s Biologics License Application process, which also typically takes a number of years to complete. Outside of the U.S., sales of medical devices and pharmaceutical or biotechnology products are subject to international regulatory requirements that vary from country to country. The time required to obtain approval for sale internationally may be longer or shorter than that required for FDA approval. There is no certainty that any regulatory approval may be obtained or maintained indefinitely, and our ability to launch products to the market and maintain market presence is not guaranteed.

Changes in the regulation of drug products and devices may increase competitive pressure and adversely affect our business.

An effect of the governmental regulation of our medical devices and our customers’ drug products, devices, and manufacturing processes is that compliance with regulations makes it difficult to change components and devices produced by one supplier with those from another supplier, due to the large amount of data and information that customers must generate to demonstrate that the components and devices are equivalent and pose no additional risk to the patient. The regulation of our medical devices and our customers’ products that incorporate our components and devices has increased over time. If the applicable regulations were to be modified in a way that reduced the level of data and information needed to prove equivalency for a change from one supplier’s components or devices to those made by another, it is likely that the competitive pressure would increase and adversely affect our sales and profitability.
18


If we are not successful in protecting our intellectual property rights, our ability to compete may be affected.

Our patents, trademarks and other intellectual property are important to our business. We rely on patent, trademark, copyright, trade secret, and other intellectual property laws, as well as nondisclosure and confidentiality agreements and other methods, to protect our proprietary products, information, technologies and processes. We also have obligations with respect to the non-use and non-disclosure of third-party intellectual property. We may need to engage in litigation or similar activities to enforce our intellectual property rights, to protect our trade secrets or to determine the validity and scope of proprietary rights of others. Any such litigation could require us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. There can be no assurance that the steps we will take to prevent misappropriation, infringement or other violation of our intellectual property or the intellectual property of others will be successful. In addition, effective patent, trademark, copyright, and trade secret protection may be unavailable or limited for some of our proprietary products in some countries. Failure to protect our intellectual property or successfully invalidate or defend against intellectual property protections of third parties could harm our business and results of operations. In addition, if relevant and effective patent protection is not available or has expired, we may not be able to prevent competitors from independently developing products and services similar or duplicative to ours.

Significant developments in U.S. tax policies could have a material adverse effect on our business and/or results of operations.

We earn a substantial portion of our income in foreign countries and, as such, we are subject to the tax laws in the United States and numerous foreign jurisdictions. Current economic and political conditions make tax laws and regulations, or their interpretation and application, in any jurisdiction subject to significant change.

Proposals to reform U.S. and foreign tax laws could significantly impact how U.S. multinational corporations are taxed on foreign earnings and could increase the U.S. corporate tax rate. Although we cannot predict whether or in what form these proposals may pass, several of the proposals considered, if enacted into law, could have an adverse impact on our effective tax rate, income tax expense and cash flows.

We utilize tax rulings and other agreements to obtain certainty in treatment of certain tax matters. These rulings and agreements expire from time to time and may be extended when certain conditions are met or terminated if certain conditions are not met. The impact of any changes in conditions would be the loss of certainty in treatment thus potentially impacting our effective income tax rate.

We are also subject to the examination of our tax returns by the United States Internal Revenue Service (“IRS”) and other tax authorities. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of its provision for income taxes. Although we believe our tax provisions are adequate, the final determination of tax audits and any related disputes rapidly change and could be materially different from our historical income tax provisions and accruals. The results of audits or related disputes could have an adverse effect on our financial statements for the period or periods for which the applicable final determinations are made. For example, we and our subsidiaries are also engaged in a number of intercompany transactions across multiple tax jurisdictions. Although we believe we have clearly reflected the economics of these transactions and the proper local transfer pricing documentation is in place, tax authorities may propose and sustain adjustments that could result in changes that may impact our mix of earnings in countries with differing statutory tax rates.

19

We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm and other adverse business consequences.

In addition to our own sensitive and proprietary business information, we handle transactional and personal information worldwide. As a result, we must comply with increasingly complex and rigorous, and sometimes conflicting laws, regulatory standards, industry standards, external and internal privacy and security policies, contracts and other obligations that govern the processing of business and personal data by us and on our behalf. For example and not limited to, the European Union’s General Data Protection Regulation (the “EU GDPR”), the United Kingdom’s GDPR (the “UK GDPR”) and California’s Consumer Privacy Act of 2018 (the "CCPA"), as expanded by the California Privacy Rights Act of 2020 (“CPRA”), impose obligations on companies regarding the handling of personal data and provide certain individual privacy rights to persons whose data is stored. Furthermore, multiple states in the United States have enacted data privacy laws. Additionally, laws in certain jurisdictions require data localization and impose restrictions on the transfer of personal information across border. For example, the EU GDPR generally restricts the transfer of personal information to countries outside of the European Economic Area without appropriate safeguards or other measures. If we cannot implement a valid compliance mechanism for cross-border privacy and security transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal information from Europe or elsewhere.

Compliance with existing and forthcoming laws and regulations can be costly and time consuming, and may require changes to our information technologies, systems and practices and to those of any third parties that process personal information on our behalf. If we fail, or are perceived to have failed, to address or comply with obligations related to data privacy and security, we could face significant consequences, including, but not limited to, proceedings against the Company by governmental entities (e.g. investigations, fines, penalties, audits, inspections) or other entities or individuals, additional reporting requirements and/or governmental agency oversight, damage to our reputation and credibility, or inability to process data or operate in certain jurisdictions, any of which could have a negative impact on revenues and profits.

Changing climate, global climate change regulations and greenhouse gas effects may adversely affect our operations and financial performance.

There is continuing concern from members of the scientific community and the general public that emissions of GHG and other activities have or will cause significant changes in weather patterns and increase the frequency or severity of extreme weather events, including droughts, hurricanes, wildfires and flooding. These types of extreme weather events have and may continue to adversely impact us, raw material availability, our suppliers, our customers and their ability to purchase our products and our ability to timely manufacture and transport our products.

We believe it is likely that the scientific and political attention to issues concerning the extent and causes of climate change will continue, with new and more restrictive legislation or regulations and focus on ESG initiatives that could affect our financial condition, results of operations and cash flows. Foreign, federal, state and local regulatory and legislative bodies, such as the SEC, have proposed various legislative and regulatory measures relating to increased transparency and standardization of reporting related to factors that may include climate change, regulating GHG emissions, energy policies, recycling of plastic materials, waste taxes, and other governmental charges and mandates. If additional legislation or regulations were enacted, we could incur increased energy, environmental, administrative and other costs and capital expenditures to comply with the limitations.

Failure to comply with these regulations could result in fines and could affect our business, financial condition, results of operations and cash flows. We could also face increased costs related to defending and resolving legal claims and other litigation related to climate change and any alleged impact of our operations on climate change.

20

We, along with other companies in many business sectors have been implementing and expanding ESG and sustainability strategies, specifically ways to track and reduce GHG emissions. As a result, our customers may request that changes be made to our products, procedures or facilities, as well as other aspects of our business, that increase costs and may require the investment of capital or reduction in profit margins if not offset by price increases, customer investment or other cost savings. Failure to provide climate-friendly products or demonstrate GHG reductions could potentially result in loss of market share. Additionally, the costs of procuring energy, including renewable energy, or offsetting GHG emissions to meet our goals, satisfy government regulations or meet the requests of our customers may increase.

Failure to comply with anti-bribery, anti-corruption and anti-money laundering laws could subject us to penalties and other adverse consequences.

We are subject to the Foreign Corrupt Practices Act (the "FCPA"), the U.K. Bribery Act and other anti-bribery, anti-corruption, and anti-money laundering laws in various jurisdictions around the world. The FCPA, the U.K. Bribery Act and similar applicable laws generally prohibit companies, as well as their officers, directors, employees and third-party intermediaries, business partners and agents, from making improper payments or providing other improper things of value to government officials or other persons. We and our third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state owned or affiliated entities and other third parties where we may be held liable for corrupt or other illegal activities, even if we do not explicitly authorize them. While we have policies and procedures and internal controls to address compliance with such laws, we cannot provide assurance that all of our employees and third-party intermediaries, business partners and agents will not take actions in violation of such policies and laws, for which we may be ultimately held responsible. To the extent that we learn that any of our employees or third-party intermediaries, business partners or agents do not adhere to our policies, procedures, or internal controls, we are committed to taking appropriate remedial action. In the event that we believe or have reason to believe that our directors, officers, employees or third-party intermediaries, agents or business partners have or may have violated such laws, we may be required to investigate or to have outside counsel investigate the relevant facts and circumstances. Detecting, investigating and resolving actual or alleged violations can be extensive and require a significant diversion of time, resources, and attention from senior management. Any violation of the FCPA, the U.K. Bribery Act or other applicable anti-bribery, anti-corruption and anti-money laundering laws could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, and criminal or civil sanctions, penalties, and fines, any of which may adversely affect our business and financial condition.

Our operations must comply with environmental statutes and regulations, and any failure to comply could result in extensive costs which would harm our business.

The manufacturing of some of our products has involved, and may continue to involve, the use, transportation, storage, and disposal of hazardous or toxic materials and is subject to various environmental protection and occupational health and safety laws and regulations in the countries in which we operate. This has exposed us in the past, and could expose us in the future, to risks of accidental contamination and events of non-compliance with environmental laws. Any such occurrences could result in regulatory enforcement or personal injury and property damage claims or could lead to a shutdown of some of our operations, which could have an adverse effect on our business and results of operations. We currently incur costs to comply with environmental laws and regulations and these costs may become more significant, especially as the laws become more stringent and our use of materials changes.

21

Changes in reimbursement practices of third-party payers or other cost containment measures, including changes to applicable laws and regulations, could affect the demand for our products and the prices at which they are sold.

Our sales depend, in part, on the extent to which healthcare providers and facilities are reimbursed by government authorities (including Medicare, Medicaid and comparable foreign programs) and private insurers for the costs of our products. The coverage policies and reimbursement levels of third-party payers, which can vary among public and private sources and by country, may affect which products customers purchase and the prices they are willing to pay for those products in a particular jurisdiction. Reimbursement rates can also affect the market acceptance rate of new technologies and products. Reforms to reimbursement systems in the U.S. or abroad, changes in coverage by private payers, or adverse decisions by payers could significantly reduce reimbursement for procedures using our products, which could adversely affect customer demand or the price customers are willing to pay for such products.

Initiatives to limit the growth of healthcare costs in the U.S. and other countries where we do business may also put industry-wide pressure on medical device or clinical diagnostic pricing. In the U.S., these include, among others, value-based purchasing and managed care arrangements. Governments in other countries are also using various mechanisms to control healthcare expenditures, including increased use of competitive bidding and tenders as well as price regulation.

General Risk Factor

Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.

Stock markets in general and our common stock in particular have experienced significant price and trading volume volatility over recent years. The market price and trading volume of our common stock may continue to be subject to significant fluctuations due to factors described under this Item 1A. Risk Factors, as well as economic and geopolitical conditions in general and to variability in the prevailing sentiment regarding our operations or business prospects, as well as, among other things, changing investment priorities of our shareholders.

ITEM IB. UNRESOLVED STAFF COMMENTS

As of the filing of this Form 10-K, there were no unresolved comments from the Staff of the SEC.

22

ITEM 1C. CYBERSECURITY

Risk Management and Strategy

The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks. To safeguard our information assets, we have put various procedures and technologies in place. For example, our Cybersecurity Incident Response Plan clearly defines roles and responsibilities for the investigation of and response to information security incidents to minimize disruption of critical computing services and operations and prevent the loss or theft of sensitive or mission-critical information. Our plan covers various cyber incidents like ransomware attacks, cyber-intrusions, data loss, denial of service, insider threats, malware attacks, and others. In a material cybersecurity incident, our D&T team, inclusive of our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, address the threat via established escalation procedures, roles, responsibilities, and communication. Any cybersecurity incident that is declared as a crisis would follow our global Incident and Crisis Response and Management Procedure, which includes escalation to the West Leadership Team and Board of Directors, as deemed necessary pending the materiality of the incident. We have not encountered cybersecurity challenges that have materially impacted our operations or financial condition. In addition, we retain an external cybersecurity consultancy company to assist when a cybersecurity event arises, as needed and, in addition we maintain appropriate cybersecurity liability insurance.

The Company also educates and shares best practices globally with its employees to raise awareness of cybersecurity threats. As part of our onboarding process, we train all new employees on cybersecurity and conduct an annual retraining of all employees on cybersecurity standards. Training also includes how to recognize, report and properly respond to phishing and social engineering schemes. Multiple phishing simulation exercises are conducted throughout the year to increase cybersecurity awareness. Our cybersecurity defenses also utilize technologies such as next generation firewalls, Zero Trust architecture, intrusion detection and prevention measures, anti-malware software, advance threat protection, multifactor authentication, network segmentation and encryption to ensure the security of West intellectual properties, customer and vendor data. In addition, we have a dedicated 24-by-7 Security Operations Center to facilitate the monitoring of the Company's cybersecurity landscape and associated applications.

Governance

Our approach to cybersecurity begins with our responsibility for strong governance and controls. Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity.
23

ITEM 2. PROPERTIES

Our corporate headquarters are located at 530 Herman O. West Drive, Exton, Pennsylvania 19341.

The following table summarizes our facilities by segment and geographic region. All facilities shown are owned except where otherwise noted.
Type of Facility/ CountryLocationSegment
Manufacturing:
North America
United States of AmericaScottsdale, AZ (1) (2)Proprietary Products
Tempe, AZ (2)Contract Manufactured Products and Proprietary Products
St. Petersburg, FL (1)Proprietary Products
Grand Rapids, MI Contract Manufactured Products
Kinston, NCProprietary Products
Kearney, NEProprietary Products
Jersey Shore, PAProprietary Products
Williamsport, PAContract Manufactured Products
Cayey, Puerto RicoProprietary Products and Contract Manufactured Products
South America
BrazilSao PauloProprietary Products
Europe
DenmarkHorsensProprietary Products
EnglandSt. AustellProprietary Products
FranceLe NouvionProprietary Products
GermanyEschweiler (1) (2)Proprietary Products
StolbergProprietary Products
IrelandWaterfordProprietary Products
Dublin (2)Contract Manufactured Products
SerbiaKovinProprietary Products
Asia Pacific
ChinaQingpuProprietary Products
IndiaSri CityProprietary Products
SingaporeJurong (2)Proprietary Products
Mold-and-Die Tool Shop:
North America
United States of AmericaUpper Darby, PAProprietary Products
24

Type of Facility/ CountryLocationSegment
Europe
EnglandBodminProprietary Products
GermanyStolbergProprietary Products
Contract Analytical Laboratory:
North America
United States of AmericaExton, PAProprietary Products
Technology Center:
Asia Pacific
IndiaBangalore (2)Proprietary Products, Contract Manufactured Products

(1)This manufacturing facility is also used for research and development activities.
(2)This facility is leased in whole or in part.

Our Proprietary Products reportable segment leases facilities located in Scottsdale, AZ, Radnor, PA, Germany, and Israel for research and development, as well as other activities. Sales offices in various locations are leased under contractual arrangements.

ITEM 3. LEGAL PROCEEDINGS

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

The executive officers of the Company are set forth in this table. Generally, executive officers are elected by the Board of Directors annually at the regular meeting of the Board of Directors following the Annual Meeting of Shareholders. Additionally, executive officers may be elected upon hire or due to a promotion.
NameAgePosition
Bernard J. Birkett56Senior Vice President and Chief Financial Officer since April 2024. Senior Vice President and Chief Financial and Operations Officer from July 2022 to April 2024. Senior Vice President and Chief Financial Officer from June 2018 to July 2022. In addition, Treasurer from June 2018 to December 2019 and Principal Accounting Officer from October 2019 to April 2020. Prior to joining West, he spent more than 20 years at Merit Medical Systems, Inc., a leading manufacturer of disposable medical devices, where he served in a number of senior global leadership roles, including Chief Financial Officer and Treasurer, Controller for Europe, Middle East and Africa (EMEA) and Vice President of International Finance.
Annette F. Favorite60Senior Vice President and Chief Human Resources Officer since October 2015. Prior to joining West, she spent more than 25 years at IBM Corporation, an information technology services company, in a number of strategic and global human resources roles, including Vice President, Global Talent Management, Vice President of Human Resources for Worldwide Software Sales, and Human Resources Leader for the company’s Southwest European Region, based out of Spain.
25

Eric M. Green

55Chair of the Board since May 2022. Chief Executive Officer since April 2015 and President since December 2015. Prior to joining West, he was Executive Vice President and President of the Research Markets business unit at Sigma-Aldrich Corporation from 2013 to 2015. From 2009 to 2013, he served as Vice President and Managing Director, International, where he was responsible for Asia Pacific and Latin America, and prior thereto, held various commercial and operational roles.
Kimberly Banks MacKay59
Senior Vice President, General Counsel and Corporate Secretary since December 2020. Prior to joining West, from April 2019 to November 2020, she served as Senior Vice President, General Counsel and Corporate Secretary at the Segal Group in New York, a privately held firm specializing in employee benefits and investment consulting. Prior to Segal, she served for over 15 years in a variety of Legal leadership roles for Novartis, a global healthcare company, including Head of U.S. Legal for Novartis Business Service.
Cindy Reiss-Clark 51Chief Commercial Officer since May 2022. Senior Vice President, Global Markets and Commercial Solutions since November 2019. Vice President and General Manger Biologics Market Unit from September 2018 to November 2019. Prior to joining West, she served as Senior Vice President of Global Marketing at Lonza Pharma and Biotech, a leading Contract Development and Manufacturing Business from October 2017 to July 2018. From January 2016 to September 2017, served as Lonza Pharma and Biotech, Senior Vice President of Global Sales. Prior to Lonza, she served for over 15 years in a variety of Commercial leadership roles at SAFC, a division of Sigma-Aldrich Company.
Chad R. Winters46Vice President, Finance & Chief Accounting Officer since February 2024. Vice President, Chief Accounting Officer and Corporate Controller from May 2020 to February 2024. Vice President and Corporate Controller from October 2019 to May 2020. Prior to joining West, he served as Senior Vice President of Finance & Accounting and Controller of Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to Amneal, he held roles of increasing responsibility at the Chemours Company, UGI Corporation, and PricewaterhouseCoopers LLP.

26

PART II

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is listed on the New York Stock Exchange (“NYSE”) under the symbol “WST.” As of February 6, 2025, we had 523 shareholders of record, which excludes beneficial owners whose shares were held by brokerage firms, depositaries and other institutional firms in “street names” for their customers.

Dividends

We paid a quarterly dividend of $0.19 per share on our common stock in each of the first three quarters of 2023; $0.20 per share in the fourth quarter of 2023 and each of the first three quarters of 2024; and $0.21 per share in the fourth quarter of 2024. We will continue to review our ability to pay cash dividends on an ongoing basis and dividends may be declared at the discretion of our Board of Directors. When considering whether to declare a dividend, our Board of Directors will take into account:

•general economic and business conditions;
•our financial condition and operating results;
•our available cash and current and anticipated cash needs;
•our capital requirements;
•contractual, legal, tax and regulatory restrictions on the payment of dividends by us; and
•such other factors as our Board of Directors may deem relevant.

Issuer Purchases of Equity Securities

The following table shows information with respect to purchases of our common stock made during the three months ended December 31, 2024 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:
PeriodTotal number of shares purchased (1)Average price paid per share (1)Total number of shares purchased as part of publicly announced plans or programs (1)Approximate dollar value of shares that may yet be purchased under the plans or programs (1)
October 1 - 31, 202465,531 $297.81 65,531 $35,700,000 
November 1 - 30, 202452,917 321.15 52,917 18,700,000 
December 1 - 31, 202454,798 326.64 54,798 800,000 
Total173,246 $314.06 173,246 $800,000 

(1) In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program does not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. During the three months ended December 31, 2024, we purchased 173,246 shares of our common stock under the program at a cost of $54.4 million, or an average price of $314.06 per share. During the year ended December 31, 2024, we purchased 1,583,032 shares of our common stock under the program at a cost of $560.9 million, or an average price of $354.30 per share.
27

Performance Graph

The following performance graph compares the cumulative total return to holders of our common stock with the cumulative total return of the Standard & Poor’s 500 Index (“S&P 500”) and the Standard & Poor's 500 Health Care Index, for the five years ended December 31, 2024. The performance graph is based on historical data and is not indicative of, or intended to forecast, future performance of our common stock.

Cumulative total return to shareholders is measured by dividing total dividends (assuming dividend reinvestment) plus the per-share price change for the period by the share price at the beginning of the period. The cumulative shareholder return on our common stock is based on an investment of $100 on December 31, 2019 and is compared to the cumulative total return of the S&P indices mentioned above over the period with a like amount invested.
3857
*Five year total return data obtained from NASDAQ IR Insight



ITEM 6. RESERVED

28

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of the Company. It should be read in conjunction with our consolidated financial statements and the accompanying footnotes included in Part II, Item 8 of this Form 10-K. These historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of this Form 10-K.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to adjusted consolidated operating profit and adjusted consolidated operating profit margin, which exclude the effects of unallocated items. The unallocated items are not representative of ongoing operations, and generally include restructuring and related charges, certain asset impairments, and other specifically-identified income or expense items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and excluding the effects of unallocated items are not in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated in our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users with a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies around the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.

Our business operations are organized into two global segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain collaborations to share technologies and market products with affiliates in Japan and Mexico.

Macroeconomic Factors

We have operations based in Israel that conduct research and development activities and manufacture certain components for our devices. Our Israel-based facilities continue to substantially operate as they had prior to the conflict in Israel and surrounding area. We continue to monitor the impact of the conflict in Israel and surrounding areas on our operations and those of our suppliers, the possible expansion of such conflict and potential geopolitical consequences, if any, on our business and operations.

29

Components of and Key Factors Influencing Our Results of Operations

In assessing the performance of our business, we consider a variety of performance and financial measures. We believe the items discussed below provide insight into the factors that affect these key measures.

Net Sales

Our net sales result from the sale of goods or services and reflect the net consideration which we expect to receive in exchange for those goods or services.

Several factors affect our reported net sales in any period, including product, payer and geographic sales mix, operational effectiveness, pricing realization, timing of orders and shipments, regulatory actions, competition, and business acquisitions that involve our customers or competitors.

Cost of goods and services sold and gross profit

Cost of goods and services sold includes personnel costs, manufacturing costs, raw materials and product costs, freight costs, depreciation, and facility costs associated with our manufacturing and warehouse facilities. Fluctuations in our cost of goods sold correspond with the fluctuations in sales units as well as inflationary and other market factors that influence our cost base.

Gross profit is calculated as net sales less cost of goods and services sold. Our gross profit is affected by product and geographic sales mix, realized pricing of our products, the efficiency of our manufacturing operations and the costs of materials used to make our products.

Research and development expenses

Research and development expenses relate to our investments in improvements to our manufacturing processes, product enhancements, and additional investments in our elastomeric packaging components, formulation development, integrated drug containment systems, self-injection systems and drug administration consumables.

We expense research and development costs as incurred. Our research and development expenses fluctuate from period to period primarily based on the ongoing improvements to our manufacturing processes and product enhancements.

Selling, general and administrative expenses

Selling, general and administrative expenses primarily include personnel costs, incentive compensation, insurance, professional fees, and depreciation.

30

Financial Performance Summary

The following tables present a reconciliation from U.S. GAAP to non-U.S. GAAP financial measures:
($ in millions)
Operating profitIncome tax expenseNet incomeDiluted EPS
Year ended December 31, 2024 GAAP$569.9 $107.5 $492.7 $6.69 
Unallocated items:
Restructuring and other charges (1)
2.1 0.4 1.7 0.02 
Amortization of acquisition-related intangible assets (2)
0.8 0.1 2.8 0.04 
Year ended December 31, 2024 adjusted amounts (non-U.S. GAAP)$572.8 $108.0 $497.2 $6.75 
During 2024, we recorded a tax benefit of $19.5 million associated with stock-based compensation.

($ in millions)
Operating profitIncome tax expenseNet incomeDiluted EPS
Year ended December 31, 2023 GAAP$676.0 $122.3 $593.4 $7.88 
Unallocated items:
Restructuring and other charges (1)
(2.0)(0.9)(1.1)(0.02)
Amortization of acquisition-related intangible assets (2)
0.7 0.1 2.8 0.04 
Loss on disposal of plant (3)
11.6 (0.7)12.3 0.16 
Cost investment activity (4)
4.3 — 4.3 0.06 
Legal settlement (5)
— (0.9)(2.9)(0.04)
Year ended December 31, 2023 adjusted amounts (non-U.S. GAAP)$690.6 $119.9 $608.8 $8.08 

During 2023, we recorded a tax benefit of $32.0 million associated with stock-based compensation.

($ in millions)
Operating profitIncome tax expenseNet incomeDiluted EPS
Year ended December 31, 2022 GAAP$734.0 $114.7 $585.9 $7.73 
Unallocated items:
Restructuring and other charges (1)
23.8 2.0 21.8 0.29 
Amortization of acquisition-related intangible assets (2)
0.7 0.1 2.8 0.04 
Cost investment activity (4)
3.5 — 3.5 0.05 
Pension settlement (6)
— 20.6 31.6 0.42 
Royalty acceleration (7)
— 1.3 (1.3)(0.02)
Tax law changes (8)
— (5.7)5.7 0.07 
Year ended December 31, 2022 adjusted amounts (non-U.S. GAAP)$762.0 $133.0 $650.0 $8.58 

During 2022, we recorded a tax benefit of $16.5 million associated with stock-based compensation.


31

(1)During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.

(2)During 2024, 2023 and 2022, the Company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020. Additionally, during 2024, 2023 and 2022, the company recorded $2.1 million of amortization expense in association with an acquisition of increased ownership interest in Daikyo.

(3)During 2023, the Company recorded expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(4)During 2023 and 2022, the Company recorded cost investment impairment charges of $4.3 million and $3.5 million, respectively.

(5)During 2023, the Company recorded a benefit of $3.8 million within other nonoperating expense (income) as a result of a favorable legal settlement related to a matter not included in our normal operations.

(6)During 2022, we recorded a gross pension settlement charge of $52.2 million within other nonoperating expense (income), which primarily relates to the full settlement of the U.S. qualified defined benefit plan (the "U.S. pension plan"). Please refer to Note 15, Benefit Plans, for further discussion of these items.

(7)During 2022, the Company increased its expected tax benefit related to the prepayment of future royalties from one of its subsidiaries by $1.3 million.

(8)During 2022, the Company incurred additional tax expense of $5.7 million due to the impact of a tax law change in the state of Pennsylvania enacted during the period.


32

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items for which further information can be found above in the reconciliation from U.S. GAAP to non-U.S. GAAP financial measures. Discussion of the year-over-year changes for the fiscal year ended December 31, 2023 compared to the fiscal year ended December 31, 2022 and the results of operations and cash flows for the fiscal year ended December 31, 2022 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Result of Operations of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 20, 2024, and is incorporated herein by reference.

Percentages in the following tables and throughout this Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment:
Year Ended December 31,% Change
($ in millions)
2024
2023
2022
2024/2023
2023/2022
Proprietary Products$2,334.5 $2,397.3 $2,406.8 (2.6 %)(0.4 %)
Contract-Manufactured Products558.7 552.5 480.4 1.1 %15.0 %
Intersegment sales elimination— — (0.3)— %(100.0 %)
Consolidated net sales$2,893.2 $2,949.8 $2,886.9 (1.9 %)2.2 %

Consolidated net sales decreased by $56.6 million, or 1.9%, in 2024, including an unfavorable foreign currency translation impact of $7.0 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $4.3 million, consolidated net sales decreased by $45.3 million, or 1.5%.

Proprietary Products – Proprietary Products net sales decreased by $62.8 million, or 2.6%, in 2024, including an unfavorable foreign currency translation impact of $6.9 million. Excluding foreign currency translation effects and the impact related to the disposal of one of our plants of $4.3 million, net sales decreased by $51.6 million, or 2.2%, due to a decline in sales of certain High-Value Product ("HVP") offerings due to customer inventory management, primarily FluroTec® products, Westar® components and Daikyo® components. These reductions were partially offset by an increase in sales of self-injection device platforms and increased sales prices, which includes approximately $47 million in customer incentives earned in connection with volumes achieved during 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $6.2 million, or 1.1%, in 2024, including an unfavorable foreign currency translation impact of $0.1 million. Excluding foreign currency translation effects, net sales increased by $6.3 million, or 1.1%, primarily due to an increase in sales of self-injection devices for obesity and diabetes and sales price increases, offset by a decrease in sales of healthcare diagnostic devices.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

33

Gross Profit

The following table presents gross profit and related gross margins, consolidated and by reportable segment and by unallocated:
Year Ended December 31,% Change
($ in millions)2024202320222024/20232023/2022
Proprietary Products:     
Gross profit$900.5 $1,034.0 $1,053.3 (12.9 %)(1.8 %)
Gross profit margin38.6 %43.1 %43.8 %
Contract-Manufactured Products:  
Gross profit$98.0 $96.0 $82.9 2.1 %15.8 %
Gross profit margin17.5 %17.4 %17.3 %
Unallocated items$— $(0.8)$— 
Consolidated gross profit$998.5 $1,129.2 $1,136.2 (11.6 %)(0.6 %)
Consolidated gross profit margin34.5 %38.3 %39.4 %

Consolidated gross profit decreased by $130.7 million, or 11.6%, in 2024, including an unfavorable foreign currency translation impact of $2.1 million. Consolidated gross profit margin decreased by 3.8 margin points in 2024.

Proprietary Products – Proprietary Products gross profit decreased by $133.5 million, or 12.9%, in 2024, including an unfavorable foreign currency translation impact of $2.1 million. Proprietary Products gross profit margin decreased by 4.5 margin points in 2024. The decrease is driven by lower plant absorption from reduced customer demand and an unfavorable shift in mix of products sold from HVP Components to HVP Delivery Devices. These headwinds were partially offset by increased sales prices and approximately $47 million in customer incentives earned in connection with volumes achieved during 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products gross profit increased by $2.0 million, or 2.1%, in 2024. Contract-Manufactured Products gross profit margin increased by 0.1 margin points in 2024, primarily due to increased sales prices.

Research and Development (“R&D”) Costs

The following table presents consolidated R&D costs:
Year Ended December 31,% Change
($ in millions)
2024
2023
2022
2024/20232023/2022
Consolidated R&D costs$69.1 $68.4 $58.5 1.0 %16.9 %

Consolidated R&D costs increased by $0.7 million, or 1.0%, in 2024, as compared to 2023, due to increased depreciation as a result of recent investments and increased salary and wages, offset by lower annual incentive compensation. Efforts remain focused on the continued investment in elastomeric packaging components, formulation development, drug containment systems, self-injection systems and drug administration consumable.

All of the R&D costs incurred during 2024, 2023 and 2022 related to Proprietary Products.

34

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate and unallocated items:
Year Ended December 31, % Change
($ in millions)
2024
2023
2022
2024/20232023/2022
Proprietary Products$231.5 $240.6 $212.6 (3.8 %)13.2 %
Contract-Manufactured Products26.2 24.4 20.9 7.4 %16.7 %
Corporate and unallocated items80.8 88.4 83.4 (8.6 %)6.0 %
Consolidated SG&A costs$338.5 $353.4 $316.9 (4.2 %)11.5 %
SG&A as a % of net sales11.7 %12.0 %11.0 %

Consolidated SG&A costs decreased by $14.9 million, or 4.2%, in 2024, including a favorable foreign currency translation impact of $0.5 million, primarily due to lower annual incentive compensation and a decrease in expense related to stock-based compensation, partially offset by increased salary and wages.

Proprietary Products – Proprietary Products SG&A costs decreased by $9.1 million, or 3.8%, in 2024, including a favorable foreign currency translation impact of $0.5 million. Proprietary Products SG&A costs decreased primarily due to lower annual incentive compensation, partially offset by increased salary and wages.

Contract-Manufactured Products – Contract-Manufactured Products SG&A costs increased by $1.8 million, or 7.4%, in 2024, primarily due to increased salary and wages.

Corporate and unallocated items – Corporate SG&A costs decreased by $7.6 million, or 8.6%, in 2024, due primarily to a decrease in expense related to stock-based compensation, lower annual incentive compensation and decreased fees related to professional services, partially offset by increased salary and wages.

Other Expense (Income)

The following table presents other expense and income items, consolidated and by reportable segment and corporate and unallocated items:
Year Ended December 31,
($ in millions)
2024
2023
2022
Proprietary Products$22.1 $14.9 $(2.2)
Contract-Manufactured Products(0.5)(0.5)1.6 
Corporate and unallocated items(0.6)17.0 27.4 
Consolidated other expense (income)$21.0 $31.4 $26.8 

Other expense and income items consist of a loss on disposal of plant, asset impairments, foreign exchange transaction gains and losses, contingent consideration and miscellaneous income and charges.

Consolidated other expense (income) changed by $10.4 million in 2024 as compared to 2023, due to the factors described below.

Proprietary Products – Proprietary Products other expense (income) changed by $7.2 million in 2024 as compared to 2023, primarily due to increased losses on foreign exchange transactions and increased expense related to contingent consideration being recorded in 2024, as compared to 2023.

Contract-Manufactured Products – Contract-Manufactured Products other expense (income) remained consistent in 2024 as compared to 2023.
35


Corporate and unallocated items – Corporate and unallocated items changed by $17.6 million in 2024 as compared to 2023. This is primarily due to the Company recording expense of $11.6 million as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment during 2023, which was not repeated in 2024. Additionally, the Company recorded additional asset impairments related to our cost method investments in 2023, as compared to 2024.

Operating Profit

The following table presents operating profit and adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:
Year Ended December 31,% Change
($ in millions)
2024
2023
2022
2024/20232023/2022
Proprietary Products$577.8 $710.1 $784.4 (18.6 %)(9.5 %)
Contract-Manufactured Products72.3 72.1 60.4 0.3 %19.4 %
Corporate and unallocated(80.2)(106.2)(110.8)(24.5 %)(4.2 %)
Consolidated operating profit$569.9 $676.0 $734.0 (15.7 %)(7.9 %)
Consolidated operating profit margin19.7 %22.9 %25.4 %
Unallocated items2.9 14.6 28.0 
Adjusted consolidated operating profit$572.8 $690.6 $762.0 (17.1 %)(9.4 %)
Adjusted consolidated operating profit margin19.8 %23.4 %26.4 %

Consolidated operating profit decreased by $106.1 million, or 15.7%, in 2024, including an unfavorable foreign currency translation impact of $1.6 million, due to the factors described above.

Proprietary Products – Proprietary Products operating profit decreased by $132.3 million, or 18.6%, in 2024, including an unfavorable foreign currency translation impact of $1.6 million, due to the factors described above, most notably lower gross profit driven by lower sales volume and an unfavorable mix of products sold.

Contract-Manufactured Products – Contract-Manufactured Products operating profit increased by $0.2 million, or 0.3%, in 2024, due to the factors described above, most notably the increased sales prices.

Corporate and unallocated – Excluding the unallocated items, Corporate costs decreased by $14.3 million, or 15.6%, in 2024, due to the factors described above, most notably the decrease in expense related to stock-based compensation and lower annual incentive compensation.

For unallocated items, please refer to the Financial Performance Summary section above for details.

Interest Expense, Net and Interest Income

The following table presents interest expense, net, by significant component:
Year Ended December 31,% Change
($ in millions)
2024
2023
2022
2024/20232023/2022
Interest expense$16.2 $14.8 $11.6 9.5 %27.6 %
Capitalized interest(13.2)(5.8)(3.7)127.6 %56.8 %
Interest expense, net$3.0 $9.0 $7.9 (66.7)%13.9 %
Interest income$(19.6)$(28.0)$(5.1)(30.0)%449.0 %

36

Interest expense, net, decreased by $6.0 million, or 66.7%, in 2024, primarily due to an increase in capitalized interest.

Interest income decreased by $8.4 million in 2024, due primarily to the Company having a lower average cash balance during 2024, as compared to the same periods in 2023.

Other Nonoperating Expense (Income)

Other nonoperating expense (income) was $1.0 million, $(3.0) million and $51.3 million for the years 2024, 2023, and 2022, respectively. Other nonoperating expense (income) changed by $4.0 million in 2024, primarily due to a benefit from a favorable legal settlement recorded in 2023 that was not repeated in 2024.

Income Taxes

The provision for income taxes was $107.5 million, $122.3 million, and $114.7 million for the years 2024, 2023, and 2022, respectively, and the effective tax rate was 18.4%, 17.5%, and 16.9%, respectively.

The increase in the effective tax rate in 2024 of 0.9% is primarily due to a decrease in the tax benefit related to stock-based compensation in 2024, as compared to 2023, partially offset by a decrease in our tax liability on unremitted earnings of our Germany subsidiaries due to a tax law change in 2024.

Please refer to Note 17, Income Taxes, for further discussion of our income taxes.

Equity in Net Income of Affiliated Companies

Equity in net income of affiliated companies was $14.7 million, $17.7 million, and $20.7 million for the years 2024, 2023, and 2022, respectively. Equity in net income of affiliated companies decreased by $3.0 million, or 16.9%, in 2024, primarily due to less favorable operating results at Daikyo.

37

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the years ended December 31:
($ in millions)202420232022
Net cash provided by operating activities$653.4 $776.5 $724.0 
Net cash used in investing activities$(378.7)$(368.7)$(288.2)
Net cash used in financing activities$(622.6)$(459.6)$(293.6)

Net Cash Provided by Operating Activities

Net cash provided by operating activities decreased by $123.1 million in 2024, primarily due to a decline in operating results.

Net Cash Used in Investing Activities

Net cash used in investing activities increased by $10.0 million in 2024, due to an increase in capital expenditures for additional manufacturing capacity to meet future customer demand.

Net Cash Used in Financing Activities

Net cash used in financing activities increased by $163.0 million in 2024, primarily due to increases in purchases under our share repurchase program, increased principal repayments on finance leases and decreased proceeds from stock-based compensation awards in 2024, as compared to 2023.

Liquidity and Capital Resources

The table below presents selected liquidity and capital measures as of:
($ in millions)December 31, 2024December 31, 2023
Cash and cash equivalents$484.6 $853.9 
Accounts receivable, net$552.5 $512.0 
Inventories$377.0 $434.7 
Accounts payable$239.3 $242.4 
Debt$202.6 $206.8 
Equity$2,682.3 $2,881.0 
Working capital$987.7 $1,264.6 

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at December 31, 2024 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at December 31, 2024 included $94.4 million of cash held by subsidiaries within the U.S. and $390.2 million of cash held by subsidiaries outside of the U.S. For further information on our position regarding permanent reinvestment of foreign subsidiary earnings and profits refer to Note 17, Income Taxes.

38

Working capital - Working capital at December 31, 2024 decreased by $276.9 million, or 21.9%, as compared to December 31, 2023, which includes an unfavorable foreign currency translation impact of $41.8 million. Excluding the impact of currency exchange rates, cash and cash equivalents, total current liabilities and inventories decreased by $349.0 million, $103.3 million and $42.0 million, respectively, while accounts receivable increased by $58.8 million. The decrease in cash and cash equivalents was due to capital expenditures and share repurchases in 2024, offset by cash collections driven by positive operating results during the period. The decrease in total current liabilities was primarily due to the Company amending its Credit Facility Agreement during 2024. As part of this amendment, all current notes payable and other current debt amounts were repaid. The decrease in inventories and the increase in accounts receivable were both due to increased net sales leading up to the December 31, 2024 balance sheet date as compared to the December 31, 2023 balance sheet date.

Debt and credit facilities - The $4.2 million decrease in total debt at December 31, 2024, as compared to December 31, 2023, is due to the net activity of debt repayments and borrowings as mentioned in Note 10, Debt.

Our sources of liquidity include our multi-currency revolving credit facility. At December 31, 2024, we had no outstanding borrowings under the multi-currency revolving credit facility. At December 31, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. We do not expect any significant limitations on our ability to access this source of funds. Please refer to Note 10, Debt, for further discussion of our multi-currency revolving credit facility.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2024, we were in compliance with all of our debt covenants, and we expect to continue to be in compliance with the terms of these agreements throughout 2025.

We believe that cash on hand and cash generated from operations, together with availability under our multi-currency revolving credit facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

Commitments and Contractual Obligations

Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods, and include the following material items:

•Our business creates a need to enter into various commitments with suppliers, including for the purchase of raw materials and finished goods. In accordance with U.S. GAAP, these purchase obligations are not reflected in the accompanying consolidated balance sheets. At December 31, 2024, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $200.7 million, of which $46.7 million is due to be paid in 2025. These purchase commitments are in the normal course of business. The Company previously entered into a material supply agreement for butyl polymers used as a principal raw material in a broad range of the Company’s polymer-based pharmaceutical packaging products.

•Our long-term debt obligations, net of unamortized debt issuance costs including fixed and variable-rate debt, is further discussed in Note 10, Debt.

•Our lease obligations primarily related to land, buildings, and machinery and equipment, with lease terms through 2269 further discussed in Note 6, Leases.

•Our various tax-qualified and non-qualified defined benefit pension plan obligations in the U.S. and other countries that cover employees and former employees who meet eligibility requirements is further discussed in Note 15, Benefit Plans.

39

CRITICAL ACCOUNTING ESTIMATES

Management’s discussion and analysis addresses consolidated financial statements that are prepared in accordance with U.S. GAAP. The application of these principles requires management to make estimates and assumptions, some of which are subjective and complex, that affect the amounts reported in the consolidated financial statements. We believe the following accounting policies and estimates are critical to understanding and evaluating our results of operations and financial position:

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances, such as a deterioration in general macroeconomic conditions or a change in company strategy, increased competition, declining product demand, plans to dispose of an asset or asset group, or recent financial or legal factors that could impact the expected cash flows, indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with its business plans and a market participant view of the assets being evaluated. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Considerable management judgment is necessary to estimate fair value. Amounts and assumptions used in our goodwill impairment test, such as future sales, future cash flows and long-term growth rates, are consistent with internal projections and operating plans. Amounts and assumptions used in our goodwill impairment test are also largely dependent on the continued sale of drug products delivered by injection and the packaging of drug products, as well as our timeliness and success in new-product innovation or the development and commercialization of proprietary multi-component systems. Changes in the estimate of fair value, including the estimate of future cash flows, could have a material impact on our future results of operations and financial position. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our qualitative assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year.

Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates.

40

Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.

Income Taxes: We estimate income taxes payable based upon current domestic and international tax legislation. In addition, deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and country level. Changes in tax legislation, business plans and other factors may affect the ultimate recoverability of tax assets or final tax payments, which could result in adjustments to tax expense in the period such change is determined.

When accounting for uncertainty in income taxes recognized in our financial statements, we apply a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.

Please refer to Note 1, Basis of Presentation and Summary of Significant Accounting Policies to our consolidated financial statements for additional information on our significant accounting policies.

41

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK     

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. These risk factors can impact our results of operations, cash flows and financial position. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

Foreign Currency Exchange Risk

Sales outside of the U.S. accounted for 57.5% of our consolidated net sales in 2024. Virtually all of these sales and related operating costs are denominated in the currency of the local country and translated into USD for consolidated reporting purposes. Although the majority of the assets and liabilities of these subsidiaries are denominated in the functional currency of the subsidiary, they may also hold assets or liabilities denominated in other currencies. These items may give rise to foreign currency transaction gains and losses. As a result, our results of operations and financial position are exposed to changing currency exchange rates. We periodically use forward exchange contracts to hedge certain transactions or to manage month-end balance sheet exposures on cross-currency intercompany balances.

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2024 the total amount of these forward exchange contracts was Singapore Dollar ("SGD") 421.9 million and $13.4 million. As of December 31, 2023 the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of December 31, 2024, the total amount of these forward exchange contracts was Euro ("EUR") 145.3 million and $47.1 million. As of December 31, 2023, the total amount of these forward exchange contracts was EUR 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEURSGD
EUR20.8 22.9 — — 
JPY6,683.7 28.4 14.8 1.8 
SGD39.8 16.9 12.2 — 

In December 2019, we entered into a five-year floating-to-floating forward-starting cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. This cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of December 31, 2024, the notional amount of the cross-currency swap is Japanese Yen ("JPY") 17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the current cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.

42

A sensitivity analysis of changes in fair value of these contracts outstanding as of December 31, 2024, while not predictive in nature, indicated that a 10% decrease or increase in the foreign currency exchange rates from their level would increase or decrease the fair value of these contracts by $7.0 million or $5.8 million, respectively, the majority of which relates to our hedges of the movement between the Euro and United States Dollar contracts.

Interest Rate Risk

As a result of our normal borrowing activities, we have long-term debt with both fixed and variable interest rates. Long-term debt consists of our Term Loan and Series C notes.

The following table summarizes our interest rate risk-sensitive instruments:
($ in millions)20252026202720282029ThereafterCarrying ValueFair Value
Long-Term Debt:
U.S. dollar denominated$130.0$130.0$130.0
Average interest rate - variable5.68%
U.S. dollar denominated$73.0$73.0$70.9
Average interest rate - fixed4.02%

A change of 1.0% in variable interest rates would decrease or increase annual interest expense by $1.3 million based on our outstanding debt as of December 31, 2024.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. In recent years, raw material costs have fluctuated due to crude oil price fluctuations. We expect this volatility to continue and will continue to pursue pricing and hedging strategies, and ongoing cost control initiatives, to offset the effects on gross profit.

We regularly purchase call options on crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of December 31, 2024, we had outstanding contracts to purchase 190,773 barrels of crude oil from December 2024 to June 2026, at a weighted-average strike price of $84.70 per barrel.

During 2024, the loss recorded in other expense (income) related to these options was $0.7 million. During 2023, the loss recorded in other expense (income) related to these options was $1.3 million.

A sensitivity analysis of changes in brent crude oil prices indicated that a 10% decrease or increase in pricing would decrease or increase the fair value of our commodity call options by $0.2 million or $0.4 million, respectively, as of December 31, 2024.
43

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

CONSOLIDATED STATEMENTS OF INCOME
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2024, 2023 and 2022
(in millions, except per share data)

 202420232022
Net sales$2,893.2 $2,949.8 $2,886.9 
Cost of goods and services sold1,894.7 1,820.6 1,750.7 
Gross profit998.5 1,129.2 1,136.2 
Research and development69.1 68.4 58.5 
Selling, general and administrative expenses338.5 353.4 316.9 
Other expense (income) (Note 16)21.0 31.4 26.8 
Operating profit569.9 676.0 734.0 
Interest expense3.0 9.0 7.9 
Interest income(19.6)(28.0)(5.1)
Other nonoperating expense (income)1.0 (3.0)51.3 
Income before income taxes and equity in net income of affiliated companies585.5 698.0 679.9 
Income tax expense107.5 122.3 114.7 
Equity in net income of affiliated companies(14.7)(17.7)(20.7)
Net income$492.7 $593.4 $585.9 
Net income per share:  
Basic$6.75 $7.98 $7.87 
Diluted$6.69 $7.88 $7.73 
Weighted average shares outstanding:  
Basic73.0 74.3 74.4 
Diluted73.7 75.3 75.8 

The accompanying notes are an integral part of the consolidated financial statements.
44

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2024, 2023 and 2022
(in millions)
 202420232022
Net income$492.7 $593.4 $585.9 
Other comprehensive (loss) income, net of tax:  
Foreign currency translation adjustments, net of tax of $3.6, $1.0, and $2.2
(112.3)39.4 (47.3)
Defined benefit pension and other postretirement plans:
Net actuarial gain (loss) arising during period, net of tax of $0.3, $0.4, and $(2.4)
1.1 0.8 (9.3)
Settlement effects arising during period, net of tax of $0.0, $0.0, and $20.3
— 0.1 31.9 
Less: amortization of actuarial (gain) loss, net of tax of $(0.2), $(0.4), and $(0.1)
(0.8)(1.3)(0.5)
Less: amortization of other, net of tax of $0.0, $(0.1), and $0.1
— (0.3)0.3 
Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, and $0.0
0.2 0.7 0.1 
Net (loss) gain on derivatives, net of tax of $(0.9), $0.0, and $0.2
(2.5)(0.2)1.4 
Other comprehensive (loss) income, net of tax(114.3)39.2 (23.4)
Comprehensive income$378.4 $632.6 $562.5 


The accompanying notes are an integral part of the consolidated financial statements.
45

CONSOLIDATED BALANCE SHEETS
West Pharmaceutical Services, Inc. and Subsidiaries at December 31, 2024 and 2023
 (in millions, except per share data)20242023
ASSETS  
Current assets:  
Cash and cash equivalents$484.6 $853.9 
Accounts receivable, net552.5 512.0 
Inventories377.0 434.7 
Other current assets124.0 135.8 
Total current assets1,538.1 1,936.4 
Property, plant and equipment2,985.8 2,738.0 
Less: accumulated depreciation and amortization1,404.2 1,324.7 
Property, plant and equipment, net1,581.6 1,413.3 
Operating lease right-of-use assets104.5 99.2 
Investments in affiliated companies202.1 210.0 
Goodwill106.0 108.5 
Intangible assets, net10.8 15.1 
Deferred income taxes26.0 25.7 
Other noncurrent assets74.3 21.3 
Total Assets$3,643.4 $3,829.5 
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$— $134.0 
Accounts payable239.3 242.4 
Accrued salaries, wages and benefits73.5 105.9 
Income taxes payable31.5 16.6 
Operating lease liabilities17.9 17.7 
Other current liabilities188.2 155.2 
Total current liabilities550.4 671.8 
Long-term debt202.6 72.8 
Deferred income taxes20.5 12.7 
Pension and other postretirement benefits28.2 29.6 
Operating lease liabilities81.8 84.5 
Deferred compensation benefits15.4 18.6 
Other long-term liabilities62.2 58.5 
Total Liabilities961.1 948.5 
Commitments and contingencies (Note 18)
Equity:
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2024 and 2023
— — 
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2024 and 2023; shares outstanding: 72.3 million and 73.5 million in 2024 and 2023
18.8 18.8 
Capital in excess of par value22.1 120.2 
Retained earnings3,956.6 3,523.4 
Accumulated other comprehensive loss(258.1)(143.8)
Treasury stock, at cost (3.0 million and 1.8 million shares in 2024 and 2023)
(1,057.1)(637.6)
Total Equity2,682.3 2,881.0 
Total Liabilities and Equity$3,643.4 $3,829.5 

The accompanying notes are an integral part of the consolidated financial statements.
46

CONSOLIDATED STATEMENTS OF EQUITY
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2024, 2023 and 2022
(in millions)
 Common shares issuedCommon stockCapital in excess of par valueNumber of treasury sharesTreasury stockRetained earningsAccumulated other comprehensive lossTotal
Balance, December 31, 202175.3 $18.8 $249.0 1.1 $(229.5)$2,456.7 $(159.6)$2,335.4 
Net Income— — — — — 585.9 — 585.9 
Activity related to stock-based compensation— — (16.8)(0.5)61.4 — — 44.6 
Shares purchased under share repurchase program— — — 0.6 (202.8)— — (202.8)
Dividends declared ($0.74 per share)
— — — — — (54.8)— (54.8)
Other comprehensive loss, net of tax— — — — — — (23.4)(23.4)
Balance, December 31, 202275.3 18.8 232.2 1.2 (370.9)2,987.8 (183.0)2,684.9 
Net income— — — — — 593.4 — 593.4 
Activity related to stock-based compensation— — (112.0)(0.7)171.6 — — 59.6 
Shares purchased under share repurchase program— — — 1.3 (438.3)— — (438.3)
Dividends declared ($0.78 per share)
— — — — — (57.8)— (57.8)
Other comprehensive income, net of tax— — — — — — 39.2 39.2 
Balance, December 31, 202375.3 18.8 120.2 1.8 (637.6)3,523.4 (143.8)2,881.0 
Net income— — — — — 492.7 — 492.7 
Activity related to stock-based compensation— — (98.1)(0.4)141.4 — — 43.3 
Shares purchased under share repurchase program— — — 1.6 (560.9)— — (560.9)
Dividends declared ($0.82 per share)
— — — — — (59.5)— (59.5)
Other comprehensive loss, net of tax— — — — — — (114.3)(114.3)
Balance, December 31, 202475.3 $18.8 $22.1 3.0 $(1,057.1)$3,956.6 $(258.1)$2,682.3 

The accompanying notes are an integral part of the consolidated financial statements.
47

CONSOLIDATED STATEMENTS OF CASH FLOWS
West Pharmaceutical Services, Inc. and Subsidiaries for the years ended December 31, 2024, 2023 and 2022
(in millions)
 202420232022
Cash flows from operating activities:  
Net income$492.7 $593.4 $585.9 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation151.8 133.7 116.9 
Amortization3.6 3.6 3.7 
Stock-based compensation18.7 23.3 23.7 
Non-cash restructuring charges— — 15.3 
Pension settlement charges— 0.1 52.2 
Loss on disposal of plant— 11.6 — 
Asset impairments7.3 9.6 6.2 
Deferred income taxes(3.5)37.5 (30.8)
Pension and other retirement plans, net(2.0)(2.6)(14.0)
Equity in undistributed earnings of affiliates, net of dividends(13.4)(14.3)(18.1)
Other, net(4.7)1.0 (2.0)
Changes in assets and liabilities:
(Increase) decrease in accounts receivable(58.8)4.0 (35.6)
Decrease (increase) in inventories42.0 (13.5)(49.8)
(Increase) decrease in other current assets(5.8)(21.3)18.5 
Increase (decrease) in accounts payable2.9 4.4 (2.8)
Changes in other assets and liabilities22.6 6.0 54.7 
Net cash provided by operating activities653.4 776.5 724.0 
Cash flows from investing activities:  
Capital expenditures(377.0)(362.0)(284.6)
Other, net(1.7)(6.7)(3.6)
Net cash used in investing activities(378.7)(368.7)(288.2)
Cash flows from financing activities:  
Borrowings of long-term debt164.7 — — 
Repayments of long-term debt(169.0)(2.3)(44.3)
Debt issuance cost— — (1.2)
Principal repayments on finance leases(23.3)(0.1)— 
Dividend payments(59.1)(57.0)(54.1)
Excise tax payments(2.0)— — 
Proceeds from stock-based compensation awards25.5 43.9 20.9 
Employee stock purchase plan contributions7.2 7.1 7.3 
Shares purchased under share repurchase programs(560.9)(438.3)(202.8)
Shares repurchased for employee tax withholdings(5.7)(12.9)(19.4)
Net cash used in financing activities(622.6)(459.6)(293.6)
Effect of exchange rates on cash(21.4)11.4 (10.5)
Net (decrease) increase in cash and cash equivalents(369.3)(40.4)131.7 
Cash, including cash equivalents at beginning of period853.9 894.3 762.6 
Cash, including cash equivalents at end of period$484.6 $853.9 $894.3 
Supplemental cash flow information:
Interest paid, net of amounts capitalized$0.5 $6.0 $6.6 
Income taxes paid, net$71.4 $90.8 $109.7 
Accrued capital expenditures$53.0 $53.3 $33.2 
Dividends declared, not paid$15.2 $14.8 $14.1 

The accompanying notes are an integral part of the consolidated financial statements.
48

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Note 1:  Basis of Presentation and Summary of Significant Accounting Policies

Principles of Consolidation: The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. ("West") after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents: Cash equivalents include money market funds, time deposits and all highly liquid short-term instruments with maturities of three months or less at the time of purchase.

Accounts Receivable: Our accounts receivable balance was net of an allowance for credit losses of $0.8 million at both December 31, 2024 and 2023. Under the current expected credit loss model, we utilize a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions.

Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. The Company provides for cost adjustments for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. The following is a summary of inventories at December 31:
($ in millions)20242023
Raw materials$166.9 $172.3 
Work in process65.2 87.3 
Finished goods144.9 175.1 
$377.0 $434.7 

Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other expense (income). Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

Leases: Lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for operating leases is recognized on a straight-line basis over the lease term. Conversely, lease expense for finance leases is a front loaded expense recognition pattern over the lease term. Lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. Please refer to Note 6, Leases, for additional information.

49

Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year.

Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates. Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 3 to 25 years and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.

Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.

50

Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as a hedge of the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as a hedge of the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as a hedge of the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.

Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.

Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less. In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less. Please refer to Note 3, Revenue, for additional information.

Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include salaries and outside services for those directly involved in research and development activities and are primarily expensed as incurred.

Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.

51

Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other expense (income). The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, Stock-Based Compensation, for a more detailed discussion of our stock-based compensation plans.

Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.

Note 2:  New Accounting Standards

Recently Adopted Standards

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU") No. 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company has adopted and implemented the applicable disclosure requirements within this annual report.

Standards Issued Not Yet Adopted

In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.

In November 2024, the FASB issued guidance that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.

Note 3:  Revenue

Revenue Recognition

We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of December 31, 2024.

Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.

Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience and specific identification of customer claims.

52

The following table presents the approximate percentage of our net sales by market group:
202420232022
Biologics39 %37 %41 %
Generics17 %20 %18 %
Pharma25 %24 %24 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

The following table presents the approximate percentage of our net sales by product category:
202420232022
High-Value Product Components45 %50 %55 %
High-Value Product Delivery Devices14 %10 %5 %
Standard Packaging 22 %21 %23 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
202420232022
Americas45 %45 %48 %
Europe, Middle East, Africa46 %46 %43 %
Asia Pacific9 %9 %9 %
100 %100 %100 %

Contract Assets and Liabilities

Contract assets and liabilities result from transactions with revenue primarily recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet within other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.

53

The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2023
$21.5 
Contract assets, December 31, 2024
23.3 
Change in contract assets - increase (decrease)$1.8 
Deferred income, December 31, 2023
$(53.9)
Deferred income, December 31, 2024
(53.2)
Change in deferred income - decrease (increase)$0.7 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. The decrease in deferred income during 2024 was primarily due to the recognition of current year revenue of $94.8 million and the recognition of $37.7 million of revenue that was included in deferred income at the beginning of the year, offset by additional cash payments of $132.8 million received in advance of satisfying future performance obligations.

Note 4:  Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
(in millions)202420232022
Net income$492.7 $593.4 $585.9 
Weighted average common shares outstanding73.0 74.3 74.4 
Dilutive effect of equity awards, based on the treasury stock method
0.7 1.0 1.4 
Weighted average shares assuming dilution73.7 75.3 75.8 

During 2024, 2023 and 2022, there were 0.3 million, 0.2 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive.

In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program did not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions depended on a variety of factors, including market conditions. The below table summarizes share repurchases under this program during the years ended December 31:
20242023
Shares repurchased1,583,032 1,265,661 
Total cost of repurchases ($ in millions)$560.9 $438.3 
Average price per repurchased share$354.30 $346.34 

In December 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2025.

54

Note 5: Property, Plant and Equipment

A summary of gross property, plant and equipment at December 31 is presented in the following table:
($ in millions)Expected useful lives (years)20242023
Land$27.9 $33.7 
Buildings and improvements
15-35
916.1 771.5 
Machinery and equipment
5-12
1,229.0 1,136.5 
Molds and dies
4-7
169.5 164.5 
Computer hardware and software
3-10
232.5 216.6 
Construction in progress410.8 415.2 
$2,985.8 $2,738.0 

Depreciation expense for the years ended December 31, 2024, 2023 and 2022 was $151.8 million, $133.7 million and $116.9 million, respectively.

We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2024, 2023 and 2022 was $13.2 million, $5.8 million and $3.7 million, respectively.

Note 6: Leases

As of December 31, 2024, we had leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2269. Certain of our leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one year or more. At this time, the Company is not able to assert whether any of these options will be exercised.

Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

55

The components of lease expense were as follows:
($ in millions)202420232022
Operating lease cost$24.2 $20.3 $15.5 
Finance lease - amortization of right-of-use (ROU) assets0.9 — — 
Finance lease - interest on lease liabilities0.1 — — 
Short-term lease cost2.5 6.1 1.3 
Variable lease cost9.0 5.5 6.8 
Total lease cost$36.7 $31.9 $23.6 

As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:
December 31,
($ in millions)Balance Sheet Classification2024
ROU assets, netOther noncurrent assets$29.7 
Lease liabilities (current)Other current liabilities$0.9 
Lease liabilities (noncurrent)Other long-term liabilities$2.1 

Supplemental information related to leases was as follows:
($ in millions)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$32.5 $19.1 $13.3 
Operating cash flows from finance leases$0.1 $— $— 
Financing cash flows from finance leases$23.3 $0.1 $— 
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases$41.2 $10.7 $47.6 
Finance leases$24.6 $— $— 

As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.3 years and 9.8 years. As of December 31, 2024, the weighted average remaining lease term for finance leases was 6.3 years. As of December 31, 2023, finance leases were not material.

As of December 31, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.99% and 3.55%, respectively. As of December 31, 2024, the weighted average discount rate for finance leases was 4.80%. As of December 31, 2023, finance leases were not material.

56

Maturities of lease liabilities as of December 31, 2024 were as follows:
($ in millions)OperatingFinance
YearLeasesLeases
2025$23.4 $0.9 
202620.7 0.9 
202716.3 0.9 
202814.9 0.5 
202911.5 0.1 
Thereafter26.3 — 
113.1 3.3 
Less: imputed lease interest(13.4)(0.3)
Total lease liabilities$99.7 $3.0 

Practical Expedients and Exemptions

We have elected to adopt practical expedients around the combination of lease and non-lease components and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases.

We have elected not to recognize lease right-of-use assets and lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.

Note 7: Affiliated Companies

At December 31, 2024, the following affiliated companies were accounted for under the equity method:
LocationOwnership interest
The West Company Mexico, S.A. de C.V.Mexico49%
Aluplast S.A. de C.V.Mexico49%
Pharma Tap S.A. de C.V.Mexico49%
Pharma Rubber S.A. de C.V.Mexico49%
Daikyo Seiko, Ltd. ("Daikyo")
Japan49%

The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:
December 31,December 31
($ in millions)20242023
Aggregate carrying value of investments in affiliated companies:
   Equity method affiliates$194.9 $203.2 
   Non-equity method affiliates7.2 6.8 
Total investments in affiliated companies$202.1 $210.0 

We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.
57


The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:
December 31,December 31
($ in millions)20242023
Payables due to affiliates$18.7 $25.9 
Receivables due from affiliates$2.5 $1.6 

The following table summarizes the Company's affiliate transactions:

(in millions)202420232022
Purchases from (and payments to) affiliates$110.0 $142.5 $167.6 
Sales to affiliates$15.3 $11.2 $14.2 
Unremitted income of affiliates$161.4 $148.0 $133.6 
Dividends received from affiliates$1.3 $3.4 $2.6 
Equity in unrealized (gains) losses of Daikyo's investments & derivatives$2.4 $2.2 $1.6 

The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.

Note 8: Goodwill and Intangible Assets

The changes in the carrying amount of goodwill by reportable segment were as follows:
($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
Balance, December 31, 2022$77.9 $29.4 $107.3 
Foreign currency translation1.0 0.2 1.2 
Balance, December 31, 202378.9 29.6 108.5 
Foreign currency translation(2.1)(0.4)(2.5)
Balance, December 31, 2024$76.8 $29.2 $106.0 

As of December 31, 2024, we had $0.1 million of accumulated goodwill impairment losses.

Intangible assets and accumulated amortization as of December 31 were as follows:
20242023
($ in millions)CostAccumulated amortizationNetCostAccumulated amortizationNet
Patents and licensing$24.7 $(23.0)$1.7 $24.8 $(21.8)$3.0 
Technology3.3 (2.7)0.6 3.3 (2.5)0.8 
Trademarks1.2 (1.2)— 1.2 (1.2)— 
Customer relationships38.9 (30.8)8.1 39.5 (29.0)10.5 
Customer contracts8.0 (7.6)0.4 8.0 (7.2)0.8 
$76.1 $(65.3)$10.8 $76.8 $(61.7)$15.1 

58

The cost basis of intangible assets includes a foreign currency translation loss of $0.7 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. Amortization expense for the years ended December 31, 2024, 2023 and 2022 was $3.6 million, $3.6 million and $3.7 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2025 - $2.8 million, 2026 - $2.5 million, 2027 - $2.3 million, 2028 - $1.7 million and 2029 - $0.9 million.

Note 9: Other Current Liabilities

Other current liabilities as of December 31 included the following:
($ in millions)20242023
Deferred income$49.6 $41.7 
Accrued commissions, rebates & royalties24.6 22.4 
Short term derivative instruments17.4 2.1 
Dividends payable15.2 14.8 
Accrued taxes other than income12.9 9.2 
Accrued retirement plans (excl. pension)12.6 10.9 
Accrued professional services6.8 5.1 
International value added tax payable6.0 5.2 
Restructuring and severance related charges1.6 3.8 
Accrued interest1.6 2.6 
Other39.9 37.4 
Total other current liabilities$188.2 $155.2 

Note 10:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.
($ in millions)20242023
Term Loan, due July 2, 2027 (5.68%)
$130.0 $— 
Term Loan, due December 31, 2024 (6.32%)
— 81.0 
Series B notes, due July 5, 2024 (3.82%)
— 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
203.0 207.0 
Less: unamortized debt issuance costs for Term Loan and Series notes0.4 0.2 
Total debt202.6 206.8 
Less: current portion of long-term debt— 134.0 
Long-term debt, net$202.6 $72.8 

59

Multi-Currency Revolving Credit Facility

In March 2022, we amended and extended the existing multi-currency revolving credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The multi-currency revolving credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve-month period in the aggregate through an increase in the multi-currency revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2024 and 2023, total unamortized debt issuance costs of $1.0 million and $1.0 million, respectively, were recorded in other current assets and other noncurrent assets and are being amortized as additional interest expense over the term of the multi-currency revolving credit facility.

At December 31, 2024, we had no outstanding borrowings under the multi-currency revolving credit facility. At December 31, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.

Term Loan

On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement (entered into in December 2019). Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0 million (the “New Term Loan”), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9 million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0 million of the Company’s 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012. Interest accrues on the New Term Loan based on a term secured overnight financing rate (“SOFR”) or a base rate, at the Company’s option, plus a margin ranging from 1.250% to 1.625% for SOFR interest rates and 0.250% to 0.625% for base rates according to the Company’s net leverage ratio as defined in the Amended Credit Agreement. Interest rates based on a term SOFR rate is also subject to a credit spread adjustment of 10 basis points. At closing, the Company elected for the New Term Loan to accrue interest at a 3-month term SOFR rate plus a margin of 1.250%. As of December 31, 2024, there were unamortized debt issuance costs remaining of $0.3 million which are being amortized as additional interest expense over the term of the New Term Loan. As of December 31, 2023, there were unamortized debt issuance costs remaining of $0.1 million, which were amortized as additional interest expense over the term of the Term Loan (entered into in December 2019).

60

At December 31, 2024, we had $130.0 million in borrowings under the New Term Loan which were classified as long-term. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Private Placement

In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes outstanding as of December 31, 2024 is 3.94%. As of December 31, 2024 and 2023, there were unamortized debt issuance costs remaining of $0.1 million and $0.1 million, respectively, which are being amortized as additional interest expense over the term of the Notes.

Covenants

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2024, we were in compliance with all of our debt covenants.

Interest costs incurred during 2024, 2023 and 2022 were $16.2 million, $14.8 million and $11.6 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, are as follows: $0.0 million in 2025 and 2026, $203.0 million in 2027 and $0.0 million in 2028 and thereafter.

Note 11:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

Foreign Currency Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2024 the total amount of these forward exchange contracts was Singapore Dollar ("SGD") 421.9 million and $13.4 million. As of December 31, 2023 the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of December 31, 2024, the total amount of these forward exchange contracts was Euro ("EUR") 145.3 million and $47.1 million. As of December 31, 2023, the total amount of these forward exchange contracts was EUR 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies.

61

As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEURSGD
EUR20.8 22.9 — — 
JPY6,683.7 28.4 14.8 1.8 
SGD39.8 16.9 12.2 — 

In December 2019, we entered into a five-year floating-to-floating forward-starting cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. This cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of December 31, 2024, the notional amount of the cross-currency swap is Japanese Yen ("JPY") 17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the current cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.

Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

We regularly purchase call options on crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of December 31, 2024, we had outstanding contracts to purchase 190,773 barrels of crude oil from December 2024 to June 2026, at a weighted-average strike price of $84.70 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 12, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of December 31, 2024 and 2023.

62

The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Fair Value Hedges:
Hedged item (intercompany loan)$1.6 $(0.3)$(28.3)Other expense (income)
Derivative designated as hedging instrument(1.6)0.3 28.3 Other expense (income)
Amount excluded from effectiveness testing(5.9)(1.4)5.2 Other expense (income)
Total$(5.9)$(1.4)$5.2 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The expense recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2024 and 2023 was $5.9 million and $0.2 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the year ended December 31, 2022 was $4.0 million. We expect to recognize an expense of $0.3 million in earnings, pre-tax, for forward point components in 2025.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:
 Amount of Gain (Loss) Recognized in OCI
($ in millions)202420232022
Fair Value Hedges:
Foreign currency hedge contracts$0.2 $(2.0)$1.3 
Total$0.2 $(2.0)$1.3 
Cash Flow Hedges:  
Foreign currency hedge contracts (hedges of net sales)$1.1 $(0.8)$0.3 
Foreign currency hedge contracts (hedges of cost of goods and services sold)(6.9)(4.0)(1.1)
Forward treasury locks— — — 
Total$(5.8)$(4.8)$(0.8)
Net Investment Hedges:  
Cross-currency swap$6.8 $8.6 $9.1 
Total$6.8 $8.6 $9.1 

63

 Amount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
($ in millions)202420232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.7)$2.9 $(1.6)Other expense (income)
Total$(0.7)$2.9 $(1.6)
Cash Flow Hedges:   
Foreign currency hedge contracts$(0.5)$1.3 $(1.2)Net sales
Foreign currency hedge contracts4.2 2.2 3.5 Cost of goods and services sold
Forward treasury locks0.1 0.2 0.2 Interest expense
Total$3.8 $3.7 $2.5  
Net Investment Hedges:   
Cross-currency swap— — — Other expense (income)
Total$— $— $—  

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our consolidated statements of income for the years ended December 31. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our consolidated statements of income for the years ended December 31:

($ in millions)202420232022
Net sales$(0.5)$1.3 $(1.2)
Cost of goods and services sold$4.2 $2.2 $3.5 
Interest expense$0.1 $0.2 $0.2 

The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Commodity call options$(0.7)$(1.3)$1.5 Other expense (income)
Currency forwards(2.5)0.1— Other expense (income)
Total$(3.2)$(1.2)$1.5 

During 2024, 2023 and 2022 there was no material ineffectiveness related to our hedges.

64

Note 12:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2024		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.1 $11.1 $— $— 
Money market funds117.6 117.6 — — 
Time deposits71.3 — 71.3 — 
Foreign currency contracts17.3 — 17.3 — 
Cross-currency swap23.6 — 23.6 — 
Commodity call options0.3 — 0.3 — 
 $241.2 $128.7 $112.5 $— 
Liabilities:    
Contingent consideration$3.0 $— $— $3.0 
Deferred compensation liabilities11.2 11.2 — — 
Foreign currency contracts18.3 — 18.3 — 
 $32.5 $11.2 $18.3 $3.0 

65

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$10.2 $10.2 $— $— 
Money market funds404.4 404.4 — — 
Time deposits47.9 — 47.9 — 
Foreign currency contracts5.0 — 5.0 — 
Cross-currency swap18.4 — 18.4 — 
Commodity call options0.6 — 0.6 — 
 $496.7 $424.8 $71.9 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities10.4 10.4 — — 
Foreign currency contracts2.2 — 2.2 — 
 $16.2 $10.4 $2.2 $3.6 

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets as of December 31, 2024 and other current assets as of December 31, 2023, is valued using a market approach. Please refer to Note 11, Derivative Financial Instruments, for further discussion of our derivatives.

Other Financial Instruments

We believe that the carrying amounts of our cash and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2024, the estimated fair value of long-term debt was $200.5 million compared to a carrying amount of $202.6 million. At December 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of December 31, 2024, all debt is long-term.

66

Note 13: Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
($ in millions)DerivativesEquity affiliate investment AOCIDefined benefit pension and other postretirement plansForeign currency translationTotal
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications0.5 0.1 (9.3)(47.3)(56.0)
Amounts reclassified out0.9 — 31.7 — 32.6 
Other comprehensive (loss) income, net of tax1.4 0.1 22.4 (47.3)(23.4)
Balance, December 31, 20220.2 1.6 (9.4)(175.4)(183.0)
Other comprehensive income (loss) before reclassifications(6.8)0.7 0.8 39.4 34.1 
Amounts reclassified out6.6 — (1.5)— 5.1 
Other comprehensive income (loss), net of tax(0.2)0.7 (0.7)39.4 39.2 
Balance, December 31, 2023— 2.3 (10.1)(136.0)(143.8)
Other comprehensive (loss) income before reclassifications(5.6)0.2 1.1 (112.3)(116.6)
Amounts reclassified out3.1 — (0.8)— 2.3 
Other comprehensive (loss) income, net of tax(2.5)0.2 0.3 (112.3)(114.3)
Balance, December 31, 2024$(2.5)$2.5 $(9.8)$(248.3)$(258.1)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
Detail of components202420232022Location on Statement of Income
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(1.5)$1.4 Net sales
Foreign currency contracts(5.5)(3.1)(4.1)Cost of goods and services sold
Foreign currency contracts1.0 (4.2)2.4 Other expense (income)
Forward treasury locks(0.1)(0.3)(0.3)Interest expense
Total before tax(4.1)(9.1)(0.6)
Tax benefit (expense)1.0 2.5 (0.3)
Net of tax$(3.1)$(6.6)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$1.0 $1.7 $0.6 (a)
Settlements— (0.1)(52.2)(a)
Other— 0.4 (0.4)(a)
Total before tax1.0 2.0 (52.0)
Tax (expense) benefit (0.2)(0.5)20.3 
Net of tax$0.8 $1.5 $(31.7)
Total reclassifications for the period, net of tax$(2.3)$(5.1)$(32.6)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
67

Note 14:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2024, there were 1.3 million shares remaining in the 2016 Plan for future grants.

Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.

The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:
($ in millions)202420232022
Stock option and appreciation rights$11.0 $11.3 $5.6 
Performance share units2.2 5.9 15.6 
Employee stock purchase plan1.3 1.3 1.3 
Deferred compensation plans and restricted share awards4.2 4.8 1.2 
Total stock-based compensation expense$18.7 $23.3 $23.7 

The Company estimates expected forfeitures. The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2024 was $25.8 million, which is expected to be recognized over a weighted average period of 1.6 years.

Stock Options

Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.

The following table summarizes changes in outstanding options:
(in millions, except per share data)Stock OptionsWeighted Average Exercise Price
Options outstanding, January 1, 2024
1.4 $145.40 
Granted0.1 348.25 
Exercised(0.3)77.88 
Forfeited0.0 331.97 
Options outstanding, December 31, 2024
1.2 $176.37 
Options vested and expected to vest, December 31, 2024
1.1 $172.07 
Options vested and exercisable, December 31, 2024
0.9 $137.48 

As of December 31, 2024, the weighted average remaining contractual life of options outstanding and of options exercisable was 4.6 years and 3.7 years, respectively. As of December 31, 2024, the aggregate intrinsic value of total options outstanding was $182.0 million, of which $178.7 million represented vested options.

68

The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2024, 2023 and 2022: a risk-free interest rate of 4.3%, 4.1%, and 1.8%, respectively; stock volatility of 32.0%, 29.8%, and 25.1%, respectively; and dividend yields of 0.3%, 0.3%, and 0.2%, respectively. Stock volatility is estimated based on historical data and the impact from expected future trends. Expected lives, which are based on prior experience, averaged 6.0 years for 2024, 5.7 years for 2023 and 5.6 years for 2022. The weighted average grant date fair value of options granted in 2024, 2023 and 2022 was $134.25, $108.95 and $96.43, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.

For the years ended December 31, 2024, 2023 and 2022, the intrinsic value of options exercised was $90.5 million, $151.0 million and $60.1 million, respectively. The grant date fair value of options vested during those same periods was $10.8 million, $8.6 million and $8.8 million, respectively.

Performance Awards

In addition to stock options, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.

The following table summarizes changes in our outstanding stock-settled PSU awards:
UnitsWeighted Average Fair Value
Non-vested stock-settled PSU awards, January 1, 2024
98,441 $334.03 
Granted at target level34,484 348.20 
Adjustments above/(below) target2,523 339.07 
Vested and converted(35,388)350.18 
Forfeited(6,686)331.62 
Non-vested stock-settled PSU awards, December 31, 2024
93,374 $326.56 

Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2024, 2023 and 2022 was $348.20, $306.97 and $362.40, respectively. Including forfeiture and target achievement expectations, we expect that the stock-settled PSU awards, for which the performance period has completed, will convert to 7,946 shares to be issued during 2025.

As described above, certain eligible employees are entitled to cash-settled PSU awards. The fair value of these cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities. The amount of cash-settled PSU awards granted during the years 2024, 2023 and 2022 were immaterial.

69

Employee Stock Purchase Plan

We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 25,237 shares, 23,955 shares and 27,894 shares for the years 2024, 2023 and 2022, respectively. At December 31, 2024, there were 3.7 million shares available for issuance under the ESPP.

Deferred Compensation Plans and Restricted Share Awards

Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash or stock retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, annual stock awards are granted on the date of our annual meeting and are distributed in shares of common stock at the next annual meeting, unless deferred. In 2024, 2023 and 2022, we granted 6,064, 6,160 and 4,827 deferred stock awards with weighted average grant-date fair values of $386.03, $357.00 and $300.78, respectively.

As of December 31, 2024, the two deferred compensation plans held a total of 332,897 deferred stock units, including 8,851 units to be paid in cash. As of December 31, 2023, the two deferred compensation plans held a total of 352,541 deferred stock units, including 8,931 units to be paid in cash.

During 2024, 2023 and 2022, we granted 9,660, 8,343 and 9,648 stock-settled restricted share unit (“RSU”) awards, respectively, at weighted grant-date fair values of $339.32, $314.06 and $310.52 per share, respectively, to employees under the 2016 Plan. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Note 15:  Benefit Plans

Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $23.2 million for 2024, $22.7 million for 2023 and $22.8 million for 2022.

70

Pension and Other Retirement Benefits

The components of net periodic benefit cost and other amounts recognized in OCI were as follows:
Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
Net periodic benefit cost:
Service cost$1.2 $1.1 $1.5 $— $— $— 
Interest cost2.1 2.4 4.2 0.2 0.2 0.2 
Expected return on plan assets(1.3)(1.2)(6.1)— — — 
Amortization of actuarial loss (gain)0.6 0.6 1.3 (1.6)(2.0)(1.9)
Settlement loss— 0.1 52.2 — — — 
Other1.0 0.3 1.0 — 0.4 0.4 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
Net (gain) loss arising during period$(0.7)$(1.4)$16.0 $(0.5)$(0.5)$(2.0)
Amortization of actuarial (loss) gain(0.6)(0.3)(1.3)1.6 2.0 1.9 
Settlement loss— (0.1)(52.2)— — — 
Foreign currency translation(0.2)0.7 (2.3)— — — 
Other— 0.4 — — — (0.4)
Total recognized in OCI$(1.5)$(0.7)$(39.8)$1.1 $1.5 $(0.5)
Total recognized in net periodic benefit cost and OCI$2.1 $2.6 $14.3 $(0.3)$0.1 $(1.8)

Net periodic benefit cost by geographic location is as follows:
 Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
U.S. plans$1.1 $0.8 $51.7 $(1.4)$(1.4)$(1.3)
International plans2.5 2.5 2.4 — — — 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)

The service cost component included within net periodic benefit cost is considered employee compensation and is therefore presented within the selling, general, and administrative and costs of goods and services sold financial statement line items of our consolidated statements of income. The remaining components of net periodic benefit cost are reported separately and are therefore presented within the other nonoperating expense (income) financial statement line item of our consolidated statements of income.

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). During 2021, a Notice of Intent to Terminate was sent to all interested parties and in 2022 a favorable determination letter was received from the Internal Revenue Service. During 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $7.1 million was made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations, as well as to cover any ancillary benefits and expenses remaining. During 2022, we recorded a $52.2 million pension settlement charge within other nonoperating expense (income), which primarily related to the full settlement and relief of the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan.

71

During 2024 and 2023, we did not contribute to our U.S. pension plan due to the termination of the plan in 2022. During 2022, we contributed $7.1 million to our U.S. pension plan.

The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Change in benefit obligation:
Benefit obligation, January 1$(57.5)$(55.5)$(3.7)$(3.9)
Service cost(1.2)(1.1)— — 
Interest cost(2.1)(2.4)(0.2)(0.2)
Participants’ contributions(0.1)(0.2)(0.2)(0.4)
Actuarial gain2.2 0.7 0.6 0.5 
Benefits paid3.4 2.5 0.3 0.3 
Settlement loss— 0.5 — — 
Foreign currency translation2.1 (2.0)— — 
Benefit obligation, December 31$(53.2)$(57.5)$(3.2)$(3.7)
Change in plan assets:
Fair value of assets, January 1$32.3 $29.4 $— $— 
Actual return on plan assets(0.6)2.4 — — 
Employer contribution0.7 1.1 0.1 (0.1)
Participants’ contributions0.1 0.2 0.2 0.4 
Benefits paid(2.5)(1.8)(0.3)(0.3)
Settlement loss— (0.5)— — 
Foreign currency translation(0.8)1.5 — — 
Fair value of assets, December 31$29.2 $32.3 $— $— 
Funded status at end of year$(24.0)$(25.2)$(3.2)$(3.7)

International pension plan assets, at fair value, included in the preceding table were $29.2 million and $32.3 million at December 31, 2024 and 2023, respectively.

Amounts recognized in the balance sheet were as follows:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Noncurrent assets$2.9 $2.7 $— $— 
Current liabilities(1.4)(1.4)(0.5)(0.6)
Noncurrent liabilities(25.5)(26.5)(2.7)(3.1)
$(24.0)$(25.2)$(3.2)$(3.7)

72

The amounts in accumulated other comprehensive loss, pre-tax, consisted of:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Net actuarial loss (gain)$14.4 $15.8 $(2.6)$(3.6)
Prior service credit(1.2)(1.1)— — 
Total$13.2 $14.7 $(2.6)$(3.6)

The accumulated benefit obligation for all defined benefit pension plans was $49.5 million and $53.7 million at December 31, 2024 and 2023, respectively, including $44.0 million and $47.7 million, respectively, for international pension plans.

As of December 31, 2024 and December 31, 2023, our United Kingdom qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2024 and December 31, 2023, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets.

Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows. The expected benefit payments listed correspond to regular ongoing benefit payments expected to be made by the plans during future years.
 ($ in millions)Domestic International Total
2025$1.3 $2.5 $3.8 
20261.1 3.1 4.2 
20271.0 3.6 4.6 
20281.0 3.2 4.2 
20290.9 4.0 4.9 
2030 to 20343.6 17.2 20.8 
$8.9 $33.6 $42.5 

In 2025, we expect to contribute $0.6 million to pension plans, all of which is in the U.S. In addition, we expect to contribute $0.5 million for other retirement benefits in 2025. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.

Weighted average assumptions used to determine net periodic benefit cost were as follows:
Pension benefitsOther retirement benefits
202420232022202420232022
Discount rate3.95 %4.35 %2.48 %5.20 %5.55 %2.75 %
Rate of compensation increase3.08 %3.09 %2.79 %— — — 
Expected long-term rate of return on assets4.01 %4.22 %4.14 %— — — 

Weighted average assumptions used to determine the benefit obligations were as follows:
Pension benefitsOther retirement benefits
2024202320242023
Discount rate4.38 %3.95 %5.60 %5.20 %
Rate of compensation increase3.07 %3.08 %— — 

73

The discount rate used to determine the benefit obligations for U.S. pension plans was 5.60% and 5.20% as of December 31, 2024 and 2023, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 4.24% and 3.80% as of December 31, 2024 and 2023, respectively. The weighted average rate of compensation increase for all international plans was 3.07% for 2024 and 3.08% for 2023, while there was no rate increase for the U.S. plans since they are frozen. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans was not applicable for 2024 and 2023, and 3.70% for 2022.

The assumed healthcare cost trend rate used to determine benefit obligations was 6.50% for all participants in 2024, decreasing to 5.00% by 2031. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.75% for all participants in 2024, decreasing to 5.00% by 2031.

The defined benefit pension plan benefit obligation decreased for the year ended December 31, 2024, due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation. The net actuarial losses will be impacted in future periods by actual asset returns, discount rate changes, currency exchange rate fluctuations, actual demographic experience, and certain other factors. The other retirement plan benefit obligation decreased due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation.

The Company has cash balance plans and other plans with promised interest crediting rates. For these plans, the interest crediting rates are set in line with plan rules or country legislation and do not change with market conditions.

The weighted average interest crediting rating used to determine net periodic benefit cost by geographic location for our pension plans, at December 31, were as follows:
202420232022
U.S. plans4.00 %4.00 %3.31 %
International plans1.13 %1.13 %1.75 %

The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:
20242023
Equity securities21 %16 %
Debt securities75 %80 %
Other4 %4 %
100 %100 %

Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.

The following are the target asset allocations and acceptable allocation ranges across:
Target allocationAllocation range
Equity securities
19%
15% - 20%
Debt securities
79%
75% - 85%
Other
2%
2% - 5%

74

The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2024Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds6.2 — 6.2 — 
Fixed income securities:
International mutual funds21.8 — 21.8 — 
Other mutual funds0.6 — 0.6 — 
Pension plan assets in the fair value hierarchy$29.2 $0.6 $28.6 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$29.2 
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2023Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds5.3 — 5.3 — 
Fixed income securities:
International mutual funds25.9 — 25.9 — 
Other mutual funds0.5 — 0.5 — 
Pension plan assets in the fair value hierarchy$32.3 $0.6 $31.7 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$32.3 

Note 16:  Other Expense (Income)

Other expense (income) consisted of:
($ in millions)202420232022
Restructuring and related charges:
Severance and benefits$(2.5)$(2.8)$8.7 
Asset-related charges— — 15.3 
Other charges— — (0.2)
Total restructuring and related charges$(2.5)$(2.8)$23.8 
Asset impairments7.3 9.6 6.2 
Foreign exchange transaction losses (gains)10.2 9.4 (4.1)
Contingent consideration5.1 2.3 3.0 
Loss on disposal of plant— 11.6 — 
Other items0.9 1.3 (2.1)
Total other expense (income) $21.0 $31.4 $26.8 

75

Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of the approval. The plan provided annualized savings of approximately $17 million. As of December 31, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:
($ in millions)Severance and benefitsOther chargesTotal
Balance, December 31, 2023$3.0 $— $3.0 
(Credits) charges(2.5)— (2.5)
Cash payments(0.5)— (0.5)
Balance, December 31, 2024$— $— $— 

Asset Impairments

The Company's asset impairment expense includes impairment charges to its cost method investments and expense related to fixed assets impaired or taken out of service. During the periods ended December 31, asset impairments consisted of:

($ in millions)202420232022
Cost method investment impairment charges$0.3 $4.3 $3.5 
Fixed asset impairment expense7.0 5.3 2.7 
Total asset impairments$7.3 $9.6 $6.2 

Foreign Exchange Transaction Losses (Gains)

During 2024 and 2023, the Company recorded a loss on foreign exchange transactions of $10.2 million and $9.4 million, respectively. During 2024, the increase in losses on foreign exchange transactions was the result of increased expense related to exchange rate activity in Europe, partially offset by a decrease in losses related to Argentina's high inflationary environment year over year. During 2023, the loss on foreign exchange transactions was primarily driven by a highly inflationary environment in Argentina. During 2022, the Company recorded a gain on foreign exchange transactions of $4.1 million.

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 12, Fair Value Measurements, for additional details.

Loss on Disposal of Plant

During 2023, the Company recorded expense of $11.6 million, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.

76

Note 17:  Income Taxes

As a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. As of December 31, 2024, the statute of limitations for the U.S. federal tax years 2018 through 2024 remain open to examination. For U.S. state and local jurisdictions, tax years 2020 through 2024 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2017 through 2024.

A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:
($ in millions)202420232022
Balance at January 1$38.8 $36.5 $24.9 
Increase due to current year position5.3 6.4 11.4 
Increase (decrease) due to prior year position0.7 (1.0)0.6 
Reduction for expiration of statute of limitations/audits(1.2)(3.1)(0.4)
Balance at December 31$43.6 $38.8 $36.5 

In addition, we had balances in accrued liabilities for interest and penalties of $6.6 million and $3.8 million at December 31, 2024 and 2023, respectively. As of December 31, 2024, we had $43.6 million of total gross unrecognized tax benefits, which, if recognized, $43.6 million would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $3.3 million during the next twelve months, which would favorably impact our effective tax rate.

The components of income before income taxes and equity in net income of affiliated companies are:
($ in millions)202420232022
U.S. operations$243.4 $369.4 $394.4 
International operations342.1 328.6 285.5 
Total income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 
The related provision for income taxes consists of:
($ in millions)202420232022
Current:
Federal$29.8 $30.2 $75.7 
State2.1 (4.2)8.4 
International79.1 58.8 61.4 
Current income tax provision111.0 84.8 145.5 
Deferred:
Federal and state(18.3)(11.6)(20.3)
International14.8 49.1 (10.5)
Deferred income tax provision(3.5)37.5 (30.8)
Income tax expense$107.5 $122.3 $114.7 

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.

77

The significant components of our deferred tax assets and liabilities at December 31 are:
($ in millions)20242023
Deferred tax assets:
Net operating loss carryforwards$6.1 $10.0 
Tax credit carryforwards2.1 1.1 
Pension and deferred compensation28.9 22.7 
Royalty acceleration— 15.0 
Other17.9 22.4 
Capitalized R&D expenses30.1 23.9 
Leases21.5 18.6 
Valuation allowance(12.8)(15.5)
Total deferred tax assets93.8 98.2 
Deferred tax liabilities:
Property, plant, and equipment60.9 61.7 
Tax on undistributed earnings of subsidiaries0.4 3.8 
Leases22.0 18.1 
Other5.0 1.6 
Total deferred tax liabilities88.3 85.2 
Net deferred tax asset$5.5 $13.0 

A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes and equity in net income of affiliated companies is as follows:
202420232022
U.S. federal corporate tax rate21.0 %21.0 %21.0 %
Tax on international operations other than U.S. tax rate1.5 1.2 (1.5)
Adjustments to reserves for unrecognized tax benefits0.8 0.3 2.9 
U.S. tax on international earnings, net of foreign tax credits0.1 0.5 (0.3)
Foreign-Derived Intangible Income Deductions (FDII)(1.2)(1.6)(2.1)
State income taxes, net of federal tax effect0.3 0.1 1.0 
U.S. research and development credits(0.6)(0.7)(0.6)
Excess tax benefits on share-based payments(3.3)(4.6)(2.4)
Royalty acceleration— 0.5 — 
Pension settlement— — (1.2)
Tax on undistributed earnings of subsidiaries(0.5)0.3 — 
Other0.3 0.5 0.1 
Effective tax rate18.4 %17.5 %16.9 %

During 2024, we recorded a tax benefit of $19.5 million associated with stock-based compensation. The Company recognized a $2.3 million tax benefit related to a reduction in the tax liability on the unremitted earnings of its Germany subsidiaries due to a law change in 2024.

During 2023, we recorded a tax benefit of $32.0 million associated with stock-based compensation. The Company recognized a $3.0 million state tax benefit based on the outcome of a recent court case. In addition, the Company recorded $2.8 million of tax expense due to a change in the permanent reinvestment assertion of its German subsidiaries.

78

During 2022, we recorded tax expense of $5.7 million due to the impact of tax law changes enacted during the year, $19.8 million of tax expense due to the Company's recognition of reserves for unrecognized tax benefits, and a tax benefit of $16.5 million associated with stock-based compensation. A tax benefit of $20.6 million was recognized for the 2022 termination of our U.S. pension plan. The Company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.6 million pension termination benefit is a deferred tax benefit of $8.0 million.

State operating loss carryforwards of $98.8 million created a deferred tax asset of $5.4 million, while foreign operating loss carryforwards of $2.3 million created a deferred tax asset of $0.7 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been appropriately reserved. State loss carryforwards expire as follows: $35.7 million in 2025 and $63.1 million thereafter. Foreign loss carryforwards will begin to expire in 2028, while $0.2 million of the total $2.3 million will not expire.

During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. State research and development credit carryforwards of $2.7 million created a deferred tax asset of $2.1 million. As of December 31, 2024, $0.4 million of state research and development credits expire in 2025.

Since 2018, West has reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Beginning in 2023 and consistent with the approved plan mentioned in Note 4, Net Income Per Share, the Company began repurchasing common stock on the open market. To support the funding for this program, West may continue to repatriate earnings from its German affiliates in the future and has recorded a tax liability of $0.3 million. Accordingly, West will continue to not assert permanent reinvestment related to all of the earnings of its wholly owned German affiliates through 2024. West will continue to assert permanent reinvestment of earnings for all other foreign jurisdictions and intends to only repatriate earnings when the tax impact is de minimis.

Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $651 million of undistributed earnings from foreign subsidiaries (except our German affiliates) to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.

Note 18:  Commitments and Contingencies

At December 31, 2024, we were obligated under various operating lease agreements. Please refer to Note 6, Leases, for additional details.

At December 31, 2024, we were obligated under debt agreements, net of unamortized debt issuance costs including fixed and variable-rate debt. Please refer to Note 10, Debt, for additional details.

At December 31, 2024, we were obligated under various tax-qualified and non-qualified defined benefit pension plans in the U.S. and other countries that cover employees and former employees who meet eligibility requirements. Please refer to Note 15, Benefit Plans, for additional details.

At December 31, 2024, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $200.7 million, the majority of which is to be paid over the next four years, with $46.7 million due to be paid in 2025.

79

We have letters of credit totaling $2.4 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $1.6 million at December 31, 2024, of which $0.4 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.

Note 19:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customer.

The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM evaluates the performance of our segments based upon, among other things, segment net sales and segment operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The CODM considers budget-to-actual variances and variances against prior years within segment operating profit when making decisions about allocating resources to the segments.

The following table presents net sales information about our reportable segments, reconciled to consolidated totals:
($ in millions)202420232022
Net sales:
Proprietary Products$2,334.5 $2,397.3 $2,406.8 
Contract-Manufactured Products558.7 552.5 480.4 
Intersegment sales elimination— — (0.3)
Consolidated net sales$2,893.2 $2,949.8 $2,886.9 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

In 2024, one of our customers individually accounted for more than 10% of consolidated net sales, at 12.3% or $356.4 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. In 2023, one of our customers individually accounted for more than 10% of consolidated net sales, at 10.9% or $322.1 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. We did not have any customers accounting for greater than 10% of consolidated net sales in 2022.

80

The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:
Net SalesLong-Lived Assets
($ in millions)20242023202220242023
United States$1,230.8 $1,238.5 $1,286.5 $832.0 $757.1 
Germany372.5 406.1 398.7 191.1 176.0 
Ireland323.2 285.7 240.3 299.6 207.0 
France242.2 282.9 237.9 84.7 78.5 
Other European countries385.5 388.1 359.2 98.1 99.2 
Other339.0 348.5 364.3 210.3 194.7 
$2,893.2 $2,949.8 $2,886.9 $1,715.8 $1,512.5 

81

202420232022
($ in millions)Proprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotal
Net sales$2,334.5 $558.7 $2,893.2 $2,397.3 $552.5 $2,949.8 $2,406.8 $480.4 $2,887.2 
Cost of goods and services sold1,434.0 460.7 1,363.3 456.5 1,353.5 397.5 
Research and development69.1 — 68.4 — 58.5 — 
Selling, general and administrative expenses231.5 26.2 240.6 24.4 212.6 20.9 
Other segment expense (income)(6)
22.1 (0.5)14.9 (0.5)(2.2)1.6 
Segment operating profit$577.8 $72.3 $650.1 $710.1 $72.1 $782.2 $784.4 $60.4 $844.8 
Reconciliation of profit or loss:
Stock Based Compensation(18.7)(23.3)(23.7)
Corporate general costs(1)
(58.6)(68.3)(59.1)
Unallocated items:
Restructuring and related charges(2)
(2.1)2.0 (23.8)
Amortization of acquisition-related intangible assets(3)
(0.8)(0.7)(0.7)
Cost investment activity(4)
— (4.3)(3.5)
Loss on disposal of plant(5)
— (11.6)— 
Total consolidated operating profit569.9 676.0 734.0 
Interest (income) expense and other nonoperating expense (income), net(15.6)(22.0)54.1 
Income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 

(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
82

(2) During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.

(3) During 2024, 2023 and 2022, the company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020.

(4) During 2023, the Company recorded a cost investment impairment charge of $4.3 million. During 2022, the net cost investment activity was equal to $3.5 million.

(5) During 2023, the Company recorded expense of $11.6 million, as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(6) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2024, 2023 and 2022.

Please refer to Note 16, Other Expense (Income), for further discussion of unallocated items.

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:
($ in millions)
Assets20242023
Proprietary Products$2,621.1 $2,629.1 
Contract-Manufactured Products612.2 527.5 
Corporate and Unallocated(1)
410.1 672.9 
Total consolidated$3,643.4 $3,829.5 

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.

($ in millions)
Depreciation and Amortization202420232022
Proprietary Products$130.3 $112.9 $96.9 
Contract-Manufactured Products21.3 20.4 19.0 
Corporate and Unallocated3.8 4.0 4.7 
Total consolidated$155.4 $137.3 $120.6 

83

($ in millions)
Capital Expenditures202420232022
Proprietary Products$246.5 $259.1 $237.3 
Contract-Manufactured Products121.0 90.2 34.0 
Corporate and Unallocated9.5 12.7 13.3 
Total consolidated$377.0 $362.0 $284.6 
84

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of West Pharmaceutical Services, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of West Pharmaceutical Services, Inc. and its subsidiaries (the "Company") as of December 31, 2024 and 2023, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2024 appearing under Item 15(a)(2) (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

85

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Provision for Income Taxes

As described in Notes 1 and 17 to the consolidated financial statements, the Company’s consolidated deferred tax assets were $93.8 million, net of a valuation allowance of $12.8 million, as of December 31, 2024, and income tax expense was $107.5 million for the year ended December 31, 2024. As a global organization, the Company files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. As disclosed by management, management estimates income taxes payable based upon current domestic and international tax legislation. Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to estimates of future taxable income, generally at the respective subsidiary company and the country level.

The principal considerations for our determination that performing procedures relating to the provision for income taxes is a critical audit matter are the significant judgment by management in determining the income tax provision due to the Company’s global footprint and complexity in the various tax laws applicable in determining the Company’s effective tax rate. This in turn led to a high degree of auditor judgment, effort, and subjectivity in performing procedures and in evaluating audit evidence related to the income tax provision. Also, the audit effort involved the use of professionals with specialized skill and knowledge.

86

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to income taxes, including controls over the determination of the income tax provision. These procedures also included, among others, (i) testing the income tax provision, including testing the Company’s rate reconciliation, return to provision adjustments, permanent and temporary differences, and financial data used in the income tax provision calculation, and (ii) testing the accuracy of the income tax rates utilized in the provision. Professionals with specialized skill and knowledge were used to assist in evaluating the appropriateness of management’s application of relevant income tax law in certain jurisdictions.

/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 18, 2025

We have served as the Company’s auditor since 1963.
87


ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this annual report, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our CEO and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls include some, but not all, components of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Form 10-K. Based on this evaluation, our CEO and CFO have concluded that, as of December 31, 2024, our disclosure controls and procedures are effective.

Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our CEO and CFO to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024 based on the framework established in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has determined that our internal control over financial reporting was effective as of December 31, 2024.

Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included herein.

Changes in Internal Controls
During the fourth quarter ended December 31, 2024, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

88

ITEM 9B. OTHER INFORMATION

Rule 10b5-1 Trading Plans
During the three months ended December 31, 2024, no director or officer (as defined in Rule 16a-1(f) promulgated under the Exchange Act) of the Company adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the period covered by this Report.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information is incorporated by reference from the discussion under the heading Proposal 1 - Election of Directors; Corporate Governance Documents and Policies - West's Code of Conduct; Voting and Other Information - Shareholder Proposals or Nominations; and Board and Director Information and Policies - Committees - Audit Committee in our 2025 Proxy Statement. The balance of the information required by this item is contained in the discussion entitled Information About Our Executive Officers in Part I of this Form 10-K. A copy of the Company's Insider Trading Policy is filed as Exhibit 19 to this Form 10-K.

ITEM 11. EXECUTIVE COMPENSATION

Information about director and executive compensation is incorporated by reference from the discussion under the headings Director Compensation, Compensation Committee Report, Compensation Discussion and Analysis, and Compensation Tables in our 2025 Proxy Statement.

89

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Information required by this Item is incorporated by reference from the discussion under the heading Stock Ownership in our 2025 Proxy Statement.

Equity Compensation Plan Information Table

The following table sets forth information about the grants of stock options, all share units and other rights under all of the Company’s equity compensation plans as of the close of business on December 31, 2024. The table does not include information about tax-qualified plans such as the West 401(k) Plan or the West Contract Manufacturing Savings and Retirement Plan.
Plan Category
Number of Securities
to be Issued Upon
Exercise of
Outstanding Options,
Warrants and Rights (a)
Weighted-Average
Exercise Price of
Outstanding Options,
Warrants and Rights (b)
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans (Excluding Securities
Reflected in Columns (a)) (c)
Equity compensation plans approved by security holders1,493,423 
(1)
$176.37 
(2)
5,023,907 
(3)
Equity compensation plans not approved by security holders— — — 
Total1,493,423 $176.37 5,023,907 

(1)    Includes 1,047,352 outstanding stock options, 93,373 restricted performance share units, 18,468 restricted retention share units, and 110,960 deferred stock-equivalents units under the 2016 Plan. Includes 116,941 outstanding stock options and 89,201 deferred stock-equivalents units under the 2011 Omnibus Incentive Compensation Plan (which was terminated in 2016). Includes 17,128 deferred stock-equivalents under the 2007 Omnibus Incentive Compensation Plan (which was terminated in 2011). Excludes cash-settled performance share units, cash-settled restricted retention share units, cash-settled deferred stock-equivalents units and cash-settled stock appreciation rights. The average term of remaining options is 4.6 years. No future grants or awards may be made under the terminated plans. The total includes restricted performance share units at 100% of grant. The restricted performance share unit payouts were at 107.64%, 200.00%, and 189.25% in 2024, 2023 and 2022, respectively.

(2)    All restricted performance share units, restricted retention share units, deferred stock-equivalent units and stock appreciation rights are excluded when determining the weighted-average exercise price of outstanding options.

(3)    Represents 3,689,116 shares reserved under the Company’s Employee Stock Purchase Plan and 1,334,791 shares remaining available for issuance under the 2016 Plan. The estimated number of shares that could be issued for 2024 from the Employee Stock Purchase Plan is 150,738. This number of shares is calculated by multiplying the 74 shares per offering period per participant limit by 2,037, the number of current participants in the plan.
90

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information called for by this Item is incorporated by reference from the discussion under the heading Corporate Governance Documents and Policies - Related Person Transactions and Procedures in our 2025 Proxy Statement. Information about director independence is incorporated by reference from the discussion under the heading Corporate Governance Documents and Policies - Director Independence in our 2025 Proxy Statement.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information is incorporated by reference from the discussion under the heading Independent Auditors and Fees - Fees Paid to PricewaterhouseCoopers LLP and Independent Auditors and Fees - Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services in our 2025 Proxy Statement.

PART IV

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) 1. Financial Statements

The following documents are included in Part II, Item 8:

Consolidated Statements of Income for the years ended December 31, 2024, 2023 and 2022
Consolidated Statements of Comprehensive Income for the years ended December 31, 2024, 2023 and 2022
Consolidated Balance Sheets at December 31, 2024 and 2023
Consolidated Statements of Equity for the years ended December 31, 2024, 2023 and 2022
Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022
Notes to Consolidated Financial Statements
Report of Independent Registered Public Accounting Firm (PCAOB ID 238)

91

(a) 2. Financial Statement Schedules

Schedule II - Valuation and Qualifying Accounts
($ in millions)
Balance at
beginning of
period
Charged to costs and expenses
Deductions (1)
Balance at
end of
period
For the year ended December 31, 2024
Allowances deducted from assets:
Deferred tax asset valuation allowance$15.5 $— $(2.7)$12.8 
Allowance for credit losses0.8 0.1 (0.1)0.8 
Total allowances deducted from assets$16.3 $0.1 $(2.8)$13.6 
For the year ended December 31, 2023
Allowances deducted from assets:
Deferred tax asset valuation allowance$13.3 $2.2 $— $15.5 
Allowance for credit losses0.2 2.3 (1.7)0.8 
Total allowances deducted from assets$13.5 $4.5 $(1.7)$16.3 
For the year ended December 31, 2022
Allowances deducted from assets:
Deferred tax asset valuation allowance$12.2 $1.1 $— $13.3 
Allowance for credit losses0.4 0.3 (0.5)0.2 
Total allowances deducted from assets$12.6 $1.4 $(0.5)$13.5 
(1)Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments.

All other schedules are omitted because they are either not applicable, not required or because the information required is contained in the consolidated financial statements or notes thereto.

(a) 3. Exhibits - An index of the exhibits is included in this Form 10-K beginning on page 93.
(b)    See subsection (a) 3. above.
(c)    Financial Statements of affiliates are omitted because they do not meet the tests of a significant subsidiary at the 20% level.












92

EXHIBIT INDEX
Exhibit NumberDescription
3.1
3.2
4.1
4.2
4.3
4.4
4.5 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries constituting less than 10% of West's total assets have been omitted.
10.1
10.2
10.3
10.4
10.5
10.6 (2)
10.7 (2)
10.8 (2)
10.9 (2)
93

10.10(2)
10.11 (2)
10.12 (2)
10.13 (2)
10.14 (2)
10.15 (2)
10.16 (2)
10.17 (2)
10.18 (2)
10.19 (2)
10.20 (2)
10.21 (2)
10.22 (2)
10.23 (2)
10.24 (2)
10.25 (2)
10.26 (2)
10.27 (2)
10.28
10.29 (2)
94

10.30 (3)
10.31 (3)
10.32 (3)
10.33 (3)
10.34 (3)
10.35 (3)
10.36 (4)
10.37 (4)
10.38 (4)
10.39
19
21
23
31.1
31.2
32.1*
32.2*
97
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
95

101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
104*Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.

(1)    We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

(2)    Management compensatory plan.

(3)    Certain portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment order of the SEC.

(4)    Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment.

*    Furnished, not filed.





ITEM 16. FORM 10-K SUMMARY

None.

96


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial Officer



February 18, 2025
97

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. and in the capacities and on the dates indicated.
SignatureTitleDate
/s/ Eric M. GreenPresident, Chief Executive Officer and Chair of the BoardFebruary 18, 2025
Eric M. Green(Principal Executive Officer)
/s/ Bernard J. BirkettSenior Vice President, Chief Financial OfficerFebruary 18, 2025
Bernard J. Birkett(Principal Financial Officer)
/s/ Chad R. WintersVice President, Finance & Chief Accounting OfficerFebruary 18, 2025
Chad R. Winters(Principal Accounting Officer)
/s/ Mark A. ButhmanDirectorFebruary 18, 2025
Mark A. Buthman
/s/ William F. Feehery, Ph.D.DirectorFebruary 18, 2025
William F. Feehery, Ph.D.
/s/ Robert F. FrielDirectorFebruary 18, 2025
Robert F. Friel
/s/ Janet HaugenDirectorFebruary 18, 2025
Janet Haugen
/s/ Thomas W. HofmannDirectorFebruary 18, 2025
Thomas W. Hofmann
/s/ Molly E. JosephDirectorFebruary 18, 2025
Molly E. Joseph
/s/ Deborah L.V. KellerDirectorFebruary 18, 2025
Deborah L.V. Keller
/s/ Myla P. Lai-Goldman, M.D.DirectorFebruary 18, 2025
Myla P. Lai-Goldman, M.D.
/s/ Stephen Lockhart, Ph.D.DirectorFebruary 18, 2025
Stephen Lockhart, Ph.D.
/s/ Douglas A. MichelsDirectorFebruary 18, 2025
Douglas A. Michels
/s/ Paolo PucciDirectorFebruary 18, 2025
Paolo Pucci

98
 EX-19 2 ex19insidertradingpolicy.htm EX-19 Document

SECURITIES TRADING POLICY
Effective 4/15/2021



1.SCOPE OF THIS POLICY

This Policy applies to all officers and employees (“Employees”) of West Pharmaceutical Services, Inc. and its subsidiaries worldwide (the “Company” or “West”). This Policy also applies to members of the Board of Directors of the Company (“Directors”).

2.OVERVIEW

Trading in the securities of the Company and the companies with which we do business can create significant personal risk for Employees and Directors if such trades are deemed to have been completed in violation of U.S. securities laws. This Policy is intended to assist Employees and Directors in complying with relevant securities laws.

This Policy sets out:

•the basic obligations of Employees and Directors having knowledge of Material Non- Public Information (as defined below) concerning West or the companies with which West does business;

•additional obligations of: (i) Employees who are working on confidential projects or have regular access to Material Non-Public Information; and (ii) Directors and Section 16 Officers (as defined below) when trading West securities;

•rules relating to special transactions such as hedging, margin accounts and pledged securities; and

•rules relating to Trading Windows (as defined below) and Approved Trading Plans (see Section 7 below).

3.MATERIAL NON-PUBLIC INFORMATION

Material Non-Public Information is information that, if known by the public, could reasonably be expected to have an effect on the price of publicly-traded securities of West or the securities of companies with which West does business.

Examples of Material Non-Public Information include plans for mergers or significant acquisitions, pending public release of earnings and financial results and news of major changes in senior management or organizational structure. Material Non-Public Information is commonly referred to as ‘inside information.’ It is not always easy to discern that which is and is not Material Non-Public Information. Persons with questions or who seek clarification should
contact the General Counsel’s office.


4.TRADING RESTRICTIONS BASED ON POSSESSION OF MATERIAL NON-PUBLIC INFORMATION

Employees and Directors who are in possession of Material Non-Public Information must abide by the following rules:

A.Universal Rule Applicable to all Employees and Directors

Employees and Directors who are in possession of Material Non-Public Information cannot buy or sell the securities of the company to which the information pertains until such time as that information has been made public. Employees and Directors are also under a duty not to disclose Material Non-Public Information to: (i) anyone within the Company whose jobs do not require them to have such information; or (ii) to anyone outside the Company, including family and friends.

If an Employee or Director is in possession of Material Non-Public Information concerning West or a company with which West does business, that person may not buy or sell the securities of West or that company until such time as that information has been made public and only then after the passing of two (2) full trading days from the date such information has been made public. Questions as to when one can trade in the securities of the Company in compliance with this Policy should be directed to the
General Counsel’s office. See below for additional rules that apply to those Employees who have been designated Insiders (as defined below).

B.Rule for Directors and Section 16 Officers

Directors of the Company and Employees who are designated as executive officers under Section 16 of the Securities Exchange Act of 1934 (the “Exchange Act”) (such
Employees also are referred to as “Section 16 Officers”) must immediately report their trades in Company securities to the person designated by the General Counsel who then arranges for notifications required by law to be filed with the Securities and Exchange Commission. Because most notifications must be filed within two (2) business days of the trade, it is essential that all trades be reported on the day they are ordered.

C.Rules for Employees Who Have Been Designated as Insiders

An Employee may be deemed a “Temporary Insider” or a “Continuing Insider” depending on his/her role within the Company and his/her exposure to Material Non- Public Information.

An Employee who works on a confidential project may be exposed to Material Non- Public Information and shall be designated as a “Temporary Insider” for the project’s duration. An Employee who, on a regular basis, has access to Material Non-Public Information related to the Company shall be designated by the General Counsel’s office as a “Continuing Insider.” Temporary Insiders, together with Continuing Insiders, are collectively referred to as “Insiders.”

In the event that a Temporary Insider has been informed that he/she should not trade in the securities of West or another company, the Temporary Insider must refrain from such trading activity until he/she has been informed by the General Counsel’s office that trading may resume. Trading restrictions apply to Temporary Insiders only after
receiving written direction to that effect from the General Counsel’s office.




Continuing Insiders may only trade in West securities during certain periods (see Section 6 below) and only then after having obtained clearance from the General Counsel.

D. “Tipping”

Directors, officers and other Employees may be liable for communicating — or “tipping”
— Material Non-Public Information to any third party regarding the Company (or any vendor, supplier or customer of the Company) or to whom a Director, officer or other Employee has made recommendations or expressed an opinion on trading in the Company’s securities based on such information (“tippee”). Further, insider trading violations are not limited to trading or tipping by Insiders. Persons other than Insiders also can be liable for insider trading, including tippees who trade on Material Non-Public Information tipped to them and individuals who trade on Material Non-Public Information which has been misappropriated.

Tippees inherit an Insider’s duties and are liable for trading on Material Non-Public Information illegally tipped to them by an Insider. Similarly, just as Insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words, a tippee’s liability for insider trading is no different from that of an Insider. Tippees can obtain Material Non-Public Information by receiving overt tips from others or through, among other things, conversations at social, business or other gatherings.

5.SPECIAL TRANSACTIONS

A.Prohibition on Speculative Trading

Speculative trading in Company securities is prohibited. No Director or Employee shall engage in “short selling” of Company securities or in the trading of “puts,” “calls” or

other derivatives on Company securities. “Wash sales” also must be avoided. This type of speculative trading is further explained in the Frequently Asked Questions attached to this Policy as Appendix A.

B.Hedging Transactions

As a Director or Employee, you may not engage in hedging or monetization transactions, including the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds without gaining prior clearance to do so from the General Counsel. Any Employee or Director wishing to enter into such an arrangement must first submit the proposed transaction, and the reasons why the Employee/Director wishes to conduct the same, to the General Counsel at least two weeks prior to entering into the proposed transaction. Hedging transactions are further explained in the Frequently Asked Questions attached to this Policy as Appendix A.













C.Margin Accounts and Pledged Securities

Directors and Section 16 Officers may not hold Company securities in a margin account or pledge Company securities as collateral for a loan without gaining prior clearance to do so from the General Counsel. Any Director or Section 16 Officer wishing to hold Company securities in a margin account or otherwise pledge Company securities as collateral for a loan must first submit the proposed transaction, and the reasons why the Director/Section 16 Officer wishes to conduct the same, to the General Counsel at least two weeks prior to the proposed transaction. Margin accounts and pledging transactions are further explained in the Frequently Asked Questions attached to this Policy.

D.Short-Swing Trading

Any Director or Section 16 Officer who purchases Company securities in the open market may not sell any Company securities during the six-month period immediately following the purchase. Any Director or Section 16 Officer who sells Company securities in the open market may not purchase any Company securities during the six- month period immediately following the sale. This prohibition on short-swing trading is intended to limit exposure of Directors and Section 16 Officers to short-swing liability arising from these types of trades under applicable securities laws.

6.TRADING WINDOWS

Directors and those Employees who have been designated as Continuing Insiders may trade Company securities only during designated Trading Windows. All days falling outside a Trading Window are blackout periods during which Directors and Continuing Insiders may not trade the securities of the Company.

The General Counsel’s office will communicate Trading Windows to all Directors and Continuing Insiders at least quarterly. Trading Windows commence after the passing of two (2) full trading days from the date the Company’s financial results are publicly disclosed and generally end on the last business day on or before the 15th of month of the last month of the fiscal quarter for which such results are publicly disclosed. From time to time, the Company may reduce the number of days in a Trading Window when it is faced with a developing situation which, if made public, may be deemed to constitute Material Non-Public Information. All such changes will be communicated to Directors, Continuing Insiders and pertinent Employees by the General Counsel’s office. Any Director or Employee receiving such a communication may not trade in Company or designated third-party securities during such periods.

Continuing Insiders who wish to make a trade during a Trading Window must always request and obtain from the General Counsel clearance to trade before they actually undertake any trades in West securities. A trading clearance is valid for the period specified in the clearance communication. If a trade is not completed within that period and the person requesting clearance wishes to make a trade thereafter, that person must again request clearance from the General Counsel. Directors are encouraged to obtain clearance in a similar manner.











For the purpose of clarification, Temporary Insiders are not subject to the Trading Window restrictions described herein. Similarly, gifts of Company securities to be made by Directors and Continuing Insiders are not subject to the Trading Window requirements so long as the gift is cleared by the General Counsel in advance of the gift, timely communicated to the General Counsel’s office upon its occurrence, and the recipient of the gift agrees not to sell the gifted shares until at least sixty (60) days have passed from the date the gift was made.

There are two things all Directors and Employees must remember:

•The existence of an open Trading Window is not a safe harbor protecting Directors or Continuing Insiders from charges of unlawful trading if the Director or Continuing Insider possesses Material Non-Public Information at the time of the trade, even if made during a Trading Window. No one in possession of Material Non-Public Information should trade in the securities of the Company or any third party until the information has been made publicly available or is no longer material.

•Do not rely solely on a communication from the General Counsel’s office as to whether or not you can trade the securities of West or a company with which we do business. If a Director or Employee is aware of Material Non-Public Information, there is an absolute prohibition on trading, irrespective of whether or not the General Counsel’s office has informed the Employees not to trade.

Employees are encouraged to seek guidance from the General Counsel’s office if they have questions or are unsure of how this Policy applies to them.

7.APPROVED TRADING PLANS

Approved Trading Plans enable Directors and Continuing Insiders to trade West securities according to pre-determined parameters even if such trades are conducted outside of Trading Windows. Through the use of these plans, a Director or Continuing Insider may, in an orderly fashion, better diversify his/her investment portfolio or ensure access to cash that may be required at some future point during which trading restrictions could be in place. Approved Trading Plans are reviewed and cleared by the General Counsel’s office and must meet all of the criteria set forth below.

Approved Trading Plans must:

•be a pre-existing written plan, contract, instruction or arrangement;

•be reviewed and cleared by the General Counsel at least one (1) month in advance of the first trade made thereunder (or, if revised or amended, such revisions or amendments have been reviewed and approved by the General Counsel at least one (1) month in advance of the first subsequent trade);

•be entered into in good faith by the Director or Continuing Insider at a time when the Director or Continuing Insider was not in possession of Material Non-Public Information; and














•contain an agreement by the Director or Continuing Insider to relinquish all discretion over the trading activity. Discretion may be relinquished in either of the following ways:

othe plan explicitly specifies the security or securities to be purchased or sold, the number of shares, the prices and/or dates of transactions or other formula(s) describing such transactions, or

othe plan gives a third party the discretionary authority to execute purchases and sales outside the control of the Director or Continuing Insider so long as such third party does not possess any Material Non-Public Information.

More information on Approved Trading Plans can be obtained from the General Counsel’s office.

8.HOLDING COMPANY SECURITIES

All Company securities granted under Company equity plans should be held in the brokerage account established for each Employee participating in such equity plans.

9.VIOLATIONS OF THIS POLICY AND COMPLIANCE WITH LAW

A.Violations of this Policy

Violations or apparent violations of this Policy are to be reported consistent with
violations of the Company’s Code of Business Conduct. West will regard any violation of this Policy as a serious breach of an Employee’s obligations and will take disciplinary action up to and including termination of employment.

The various securities laws relating to ‘insider trading’ also provide for punishment of persons who violate those laws. Persons (including tippers and tippees) who trade on inside information are subject to significant civil penalties, criminal fines and imprisonment. Similarly, civil penalties, criminal fines and imprisonment may apply to Company personnel who fail to take appropriate steps to prevent illegal insider trading.

B.Compliance with Law

Compliance with applicable securities laws is the responsibility of each Employee and Director, and the Company makes no representation that compliance with this Policy will insulate anyone from charges of illegal trading.

10.INQUIRIES

Refer to the Frequently Asked Questions attached to this Policy as Appendix A for more information. Questions or concerns should be addressed to the General Counsel’s office.

APPENDIX A

Frequently Asked Questions Regarding West’s Securities Trading Policy (CP-046)
What is Insider Trading?

An Insider is a person who has ‘material information’ that is not known to the public regarding West or other companies. Trading is the buying and selling of securities of a company. Insider Trading is where the Insider decides to buy or sell securities of a company based on his/her knowledge of material information that is not publicly known.

What is a Security?

Securities are shares of stock, options, bonds/notes and other financial instruments with respect to West that are regularly bought and sold in public markets like the NASDAQ stock exchange or the New York Stock Exchange. In some cases the shares of certain mutual or index funds could also be securities covered by the Policy. Similar securities of other companies are also considered “securities” under the Policy if an Employee becomes aware of Material Non-Public Information about that company through his/her employment with West.

Securities include:

•Registered shares of stock of West;
•Registered bonds or notes of West;
•All derivatives of the foregoing, including options to purchase securities and any other types of securities that West or a counterparty may issue, such as bearer shares, preferred stock and convertible debentures, as well as exchange-traded options or other derivative securities;
•Securities of index funds that include securities described herein as a significant component thereof (more than 15%); and
•Similar securities of companies with respect to which an Employee becomes aware of Material Non-Public Information about that company through his/her employment with West.

What is Material Non-Public Information?

Material Non-Public Information is information that reasonably could be expected to have an effect on the price of the securities if made generally known.

If you are unsure whether information is material, consult the General Counsel’s office before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates.

When does non-publicly available information become Material Non-Public Information?

There are no precise definitions as to which non-publicly available information constitutes Material Non- Public Information, but some common types of such information include an important license project, the sale or purchase of companies or significant assets, a major litigation risk, critical decision points in the process of development of major products or the withdrawal of a major product from the market. Any significant information that is not widely known can qualify; the final determination as to whether or not something meets the materiality standard is made only after the fact and with the benefit of 20/20 hindsight.


APPENDIX A


What Speculative Trading is prohibited by this Policy?

The Policy prohibits all speculative trading in Company securities, including short selling Company securities, “puts,” “calls” and “wash sales.”

Short selling means borrowing a security from a broker and selling it with the understanding that it must be bought back later and returned to the broker.

Puts are an option giving the holder the right to sell a security at a specified price within a particular period of time.

Calls are options giving the holder the right to buy a security at a specified price within a particular period of time.

Wash sales are instances where a security is bought and sold almost simultaneously in order to give the impression that the security is being actively traded.

What are hedging transactions?

Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Hedging transactions enable a person to continue to own Company securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the person may no longer have the same objectives as the Company’s other shareholders.

Why are Directors and Section 16 Officers prohibited from pledging securities and holding securities in margin accounts?

Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer’s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. As a result, a margin sale or foreclosure sale may occur at a time when the pledgor is aware of Material Non- Public Information or otherwise is not permitted to trade in Company securities. Such a sale under those conditions could be deemed to be unlawful insider trading. In addition, securities laws require the Company to disclose any pledges of Company securities (including through the use of margin accounts) by its Directors and Section 16 Officers.

What is short-swing trading and why should I be concerned about it?

Short-swing trading consists of a purchase and sale, or a sale and purchase (or any number of these transactions), of Company securities that take place within any period of less than six months. Section 16(b) of the Exchange Act requires Directors and Section 16 Officers to pay to the Company any “short- swing” profit realized upon any short-swing trading.

Why should I be concerned about Insider Trading?

Insider trading is unethical and illegal in the U.S. and in many other countries around the world. These countries have decided that a person (i.e., an Insider) has an unfair advantage if he/she is allowed to buy


APPENDIX A


or sell securities based on information that is material but is not known to other investors. For these reasons, the Policy and the Company’s Code of Business Conduct prohibit Insider Trading by Employees.

Can I tell my friends and family about Material Non-Public Information?

No, you must always treat Material Non-Public Information confidentially and not tell persons outside of West, including your friends and family members. Even within the Company, you should not share this kind of information unless you are certain the Employee with whom you are speaking is also aware of the information. In many countries, the persons who receive Material Non-Public Information from you could be subject to criminal charges and those charges could apply to you as well.

If I have information about a company that does business with West, can I buy or sell securities in that company?

If the information is material to the company doing business with West and if it is not known generally to the public, you must not buy or sell the securities of that company.

If I have Material Non-Public Information, when can I buy and sell securities of West (or other companies)?

Once Material Non-Public Information is made public you can buy and sell securities of a company. Information is typically made public through a press release. The Policy states that you must wait two (2) full trading days after the press release has been issued before you can buy and sell Company securities. You cannot buy or sell securities until after that time has lapsed, even if the market price for the security is changing significantly. Please note that even after a press release has been issued, those persons designated as Insiders may only trade during a Trading Window after receiving prior clearance from the General Counsel.

Do I have any continuing restrictions after I leave the Company?

Yes. If you are aware of Material Non-Public Information when your service terminates, you may not trade in West securities until that information has become public or is no longer material.

Who are Continuing and Temporary Insiders?

A Continuing Insider is an Employee who regularly has, or is deemed to have, access to Material Non- Public Information. A Temporary Insider is an Employee who is in, or may come into, possession of Material Non-Public Information and has been designated as a Temporary Insider by the General Counsel’s office. Special rules apply for these Employees. Continuing and Temporary Insiders will be told in writing that they have Insider status. When trading restrictions are imposed, all Insiders will be so informed by the General Counsel’s office. If you have not been formally told that you are a Continuing or a Temporary Insider, then you do not have to follow the special trading rules; but, you must always follow the Policy and avoid trading Company securities when you have knowledge of Material Non- Public Information.

What is a Trading Window?

A Trading Window is a period of time when Continuing Insiders are generally permitted to trade in Company securities, subject to compliance with the Policy. There is a period of time, referred to as a “blackout period,” prior to the public release of Material Non-Public Information when trading of


APPENDIX A


securities is prohibited for Continuing Insiders. Trading Windows occur when no blackout period is in effect. Trading Windows generally will open at the close of business on the second trading day following the release of the Company’s quarterly financial results and close on the last business day on or before the 15th of the month of the last month of the fiscal quarter in which such financial results are released.
Trading Windows will be communicated by email to all Continuing Insiders.

What is an Approved Trading Plan?

An Approved Trading Plan enables Continuing Insiders to trade in West securities outside of Trading Windows according to pre-determined parameters and without violating insider trading laws. Such plans allow Continuing Insiders to diversify their investments or ensure access to cash that may be required at some future point during which trading restrictions could be in place. Approved Trading Plans have very specific requirements and must be cleared by the General Counsel during a Trading Window and only then if the Continuing Insider is not in possession of Material Non-Public Information.

What is Pre-clearance of Trades?

Best practice in avoiding inadvertent Insider Trading is to require that all Insiders get clearance from the General Counsel before making a planned trade in West securities. This restriction applies only to Insiders. If you have not been informed that you are an Insider, you do not need to obtain pre-clearance. Regardless of your status as an Insider, you must never trade Company securities if you hold Material Non-Public Information. If you have questions, contact the General Counsel’s office.

Please note that clearance does not insulate you from potential charges that your trade has been made unlawfully.

Are all trades subject to the Pre-clearance of Trades requirement?

No, only trades by Insiders involving the use of discretion are subject to the Pre-clearance of Trades requirement.

The following activities are not discretionary and no clearance is required:

•exercising options without selling any Company shares into the market (e.g., a net exercise, stock swap or cash exercise);
•acquiring Company shares in the 401(k) Plan, Nonqualified Deferred Compensation Plan or Employee Stock Purchase Plan on an automated basis through an allocation of contributed funds (e.g., payroll deduction). Please note that if you are an Insider, you must have sought and obtained clearance from the General Counsel’s office before making any changes to an automated acquisition in such an account;
•acquiring Company shares in a dividend re-investment program that was approved in the past (please note, however, that Directors and Section 16 Officers may not set up such a plan for Company shares); and
•acquiring or selling Company shares pursuant to an Approved Trading Plan.

Please note, however, that Directors and Section 16 Officers have public filing requirements that can be triggered by one or more of the foregoing activities and hence are obliged to inform the General Counsel’s office immediately upon commissioning the same.


APPENDIX A


Does the Policy apply to securities held in Employee Benefit Plans?

Yes. Where, such as in the U.S., Employees have the ability to acquire Company securities through the West 401(k) Retirement Savings Plan (the “401(k) Plan”), West’s Nonqualified Deferred Compensation Plan (the “Deferred Compensation Plan”) or West’s Employee Stock Purchase Plan (the “Employee Stock Purchase Plan”), employees must follow this Policy when making choices concerning investing in Company securities through such plan.

With regard to each of the 401(k) Plan, Nonqualified Deferred Compensation Plan and Employee Stock Purchase Plan, an Employee should not elect to participate in, or withdraw from, investments involving Company securities in such plan, or make any change in investment instructions with respect to investments involving Company securities within such plan, at a time when the Employee is in possession of Material Non-Public Information. Insiders may only elect to participate in, or withdraw from, investments involving Company securities in such plan, or make any change in investment instructions with respect to investments involving Company securities within such plan, during a Trading Window after receiving clearance from the General Counsel. Once an Employee has given investment instructions for any investment involving Company securities within such plan in compliance with this Policy, automatic purchases of Company securities through such plan for the Employee’s account can continue pursuant to those instructions even if the Employee later comes into possession of Material Non-Public Information. Investment instructions cannot be changed at a time when the Employee is in the possession of Material Non-Public Information or, for Insiders, during a blackout period.

With regard to West’s Dividend Reinvestment Plan (the “DRIP”), purchases of Company securities under the DRIP resulting from an Employee’s reinvestment of dividends paid on the Company’s securities would not require pre-clearance under this Policy; however, any of the following activities in connection with the DRIP would be subject to the Policy:

•voluntary purchases of Company securities resulting from additional contributions an employee chooses to make to the DRIP;
•an Employee’s election to participate in the DRIP or to increase his/her level of participation in the DRIP; and
•any sale of Company securities purchased under the DRIP.

Do I need pre-clearance for discretionary 401(k) and non-qualified plan transactions?

Yes. Prior to contacting Vanguard for discretionary plan transactions you will need pre-clearance.

When does the Policy apply to stock option exercises?

The trading restrictions required by the Policy apply to the acquisition of Company securities pursuant to the exercise of stock options through a cashless exercise or any other market sale for the purpose of generating the cash needed to pay the exercise price. A cashless exercise of stock options occurs when the holder of stock options borrows money from his/her broker to exercise the stock options and simultaneously sells enough shares of the underlying stock to pay the purchase price of the stock options, taxes and broker commissions. By contrast, the trading restrictions required by the Policy do not apply to the acquisition of Company securities pursuant to the exercise of stock options without selling any Company shares into the market (e.g., a net exercise, stock swap or cash exercise).


APPENDIX A


Clearance from the General Counsel is required prior to the exercise of stock options (other than an exercise of options without selling any Company shares into the market) for all Insiders and such exercise can only occur during a Trading Window.

How do I know whether I am a Section 16 Officer or a Continuing Insider?

The General Counsel’s office will inform Employees of their status as a Continuing Insider or Section 16 Officer. If you have not received such a notification, then you are not impacted by those portions of the Policy pertaining to Continuing Insiders or Section 16 Officers.



Section 10b5-1 Approved Trading Plan Guidelines

(Effective February 27. 2023)

Under SEC rules and our Securities Trading Policy (CP-046), an “insider” is (a) any officer who has been designated a Section 16 officer by the Company, (b) any director; and (c) individuals who have been designated Temporary Insiders or Continuing Insiders due to their role or access to material nonpublic information. Additionally, the Securities Trading Policy prohibits any employee who is in possession of material nonpublic information with respect to the Company or its securities from buying or selling securities or disclose that information to others at the Company unless necessary to do their job or to anyone outside the Company, including family and friends.
The SEC, pursuant to Rule 10b5-1, has established an affirmative defense for insiders who want to trade in Company stock. These are called “Approved Trading Plans” under our Policy. Approved Trading Plans enable directors and continuing insiders to trade in securities according to pre-determined parameters. Pursuant to Rule 10b5-1, these insiders may enter into a plan for the purchase or sale of company securities which provides a defense for the insider from allegations of insider trading, provided that, among other requirements, the insider acted in good faith and did not enter into such plan while aware of any material non-public information, and that the plan specifies the amount of securities to be purchased or sold (or a formula for calculating the number of securities to be purchased or sold), and the price and date on which the transaction is to occur.
The Company is required to report the adoption, modification or termination of any Rule 10b5-1 trading plan in accordance with applicable SEC rules.
In addition to complying with the foregoing principles and applicable rules, West insiders must also comply with our Securities Trading Policy and these Guidelines, including the following:
•The Plan must be a pre-existing, written plan, contract, instruction or arrangement;

•Fidelity is the exclusive broker for all 10b5-1 transactions – you may not use any other financial institution to put in place an Approved Trading Plan. If you hold shares outside of Fidelity, you must transfer them to your Fidelity account if you wish to trade such securities in an Approved Trading Plan;
•Plans may only be entered into during the Company’s open trading windows;

•Cooling Off Period (Time between adoption / modification & commencement of Plan) The first transaction following the establishment of a Plan may not occur until the later of (a) 90 days after adoption / modification or (b) 2 business days following filing of Form 10-Q / 10-K during which plan was adopted (120 days max) – this waiting period is a crucial aspect of plans that are deemed appropriate by the Company (See Explanatory Note 1 below for details);


•Even during an open trading window, an insider must certify and enter into a plan in good faith when he or she is not aware of any material non-public information with respect to the Company or its securities and is not otherwise subject to a blackout notice;
•Insiders may have only a single Approved Trading Plan in place at any given time. Multiple, overlapping plans are prohibited;
•The trading plan must either:
-Specify the number of shares of Company securities to be purchased or sold at specific dates and/or prices, or a formula for calculating the number of shares of Company securities to be purchased or sold at specific dates and/or prices; OR
-Give a third party exclusive discretionary authority to exercise purchase and sales outside the control of the director or continuing insider as long as the person exercising that authority does not have any material non-public information. (See Explanatory Note 2 for details);

•The Approved Trading Plan may include automatic suspension and termination features, which if acceptable to the Law Department, will not need further approval to be effective. (See Explanatory Note 3 for details).
•There are limits on the amount of shares that can be traded under an Approved Trading Plan. Please consult with the Law Department well in advance if you wish to trade more than 100,000 shares pursuant to a Plan.
•Any plans entered into by insiders must have a minimum duration of at least nine months;

•Single-trade plans are prohibited if you have adopted another single-trade plan within the prior twelve months;
•If through the transaction contemplated in an Approved Trading Plan the insider would fall below the Company’s stock ownership guidelines, the Plan will not be permitted;
•No Approved Trading Plan may violate the Company’s prohibition on insiders hedging, pledging or engaging in any derivatives trading with respect to Company Stock;
•Terminations of, modifications to or deviations from Approved Trading Plans are only permitted in exceptional circumstances and must comply with all applicable cooling off periods and requirements to transact when not in possession of material nonpublic information. If an unanticipated situation arises that may impose an undue hardship on an insider with an Approved Trading Plan, that insider must consult with the General Counsel who will consider modification or termination of a Plan in good faith. If a change is permitted, the General Counsel may determine in his or her sole discretion that it may only occur during open trading windows (and then only if the insider is not aware of any material non-public information and otherwise complies with all of the requirements applicable to the adoption of a new plan at the time of the modification), or that any modifications may only take effect at least 90 days following the date on which the modification is submitted;


•Once an Approved Trading Plan is established, insiders may not execute any trades of Company securities outside the plan until the termination of that plan without the approval of the General Counsel. This means that you cannot the exercise stock options on a cashless basis (e.g. selling underlying shares to pay the strike price of the options and withholding taxes) if you have an Approved Trading Plan in place – unless the plan itself contemplates such a sale. Consulting with advisors is important to plan properly;
•If a plan expires according to its terms, a new plan may be established immediately thereafter (but the waiting period to effect trades and other requirements applicable to new plans still apply);
•Once an Approved Trading Plan has become effective, the insider must avoid any communications with Fidelity regarding execution of trades under the Approved Trading Plan to avoid the perception of “subsequent influence.” If a communication to Fidelity is essential for the sake of clarification, you must first advise the Law Department;
•Depending on the facts and circumstances, the Company may, but is not required to, publicly disclose modifications, terminations or entrance into a 10b5-1 plan by any insider, and an insider must agree to permit Fidelity and the Law Department to communicate directly to obtain any necessary information concerning an Approved Trading Plan; and
•The Company encourages insiders to prepare simple plans, which allow for the calculation of shares and execution with little director, to reduce potential errors or confusion.

image_2.jpg


Process for Putting an Approved Plan in Place

Step 1 – If applicable, contact your financial/tax/legal advisers to ensure that you are planning properly. Fidelity Executive Services advisors are also available to assist with the set up of the plan.
Step 2 – Complete the pre-clearance trading form or email West Legal, indicating your intention to enter into a 10b5-1 plan. Provide details regarding awards / shares to be included in the plan.
Insiders must have plans pre-approved by the General Counsel, and to obtain approval an insider must certify to the General Counsel in writing
-That the proposed trading plan meets all of the requirements of SEC Rule 10b5-1 and does not violate the trading restrictions of Section 16 of the Exchange Act or Rule 144 promulgated under the Securities Act of 1933,
-Insider is not aware of material non-public information and is acting in good faith & not attempting to evade Rule 10b5-1


Step 3 – Upon confirmation of approval from Legal, West will inform Fidelity’s Executive Services of your approval and they will contact you to set up the plan..
Step 4 – Fidelity will set up the necessary plan documents and will obtain the Executive’s signature, who will provide information to HR, Executive Compensation and Associate General Counsel.
Explanatory Notes

1.If a trading window opens on February 21 and closes on March 15, and if you obtain approval of an Approved Trading Plan on February 21, the earliest date you could put the plan into effect is May 21 (90 days after approval of the plan).
2.So long as the transaction instructions you provide Fidelity are clear and unambiguous, you have wide discretion in instructing the form and nature of trades. Fidelity may impose certain limitations on instructions and you should consult with Fidelity before submitting a completed trading plan form for approval. For example, you may instruct Fidelity to: a) sell 100 shares on the first Monday of every month so long as the share price is above $XX with a total limit during the plan of XXX shares; b) exercise 1000 vested options on a cashless basis if the stock price hits $XX; or c) acquire 100 shares the first Monday of each month so long as the share price does not exceed $XX up to XXX shares. There a many permutations that are possible. Consult your financial advisors and Fidelity.
3.A number of events that are unanticipated now but which could have a tremendous impact on the economic outcomes to the insider should an Approved Trading Plan continue in the face of such an event can be written into the plan, subject to Fidelity’s internal guidelines. For example, Approved Trading Plans should be written to provide for automatic termination in the event a third party announces that it has reached an agreement, or has otherwise taken steps, to obtain control over the Company. Control in this case means either ownership of 50% of the outstanding shares of the Company or the ability to elect a majority of the Company’s Board of Directors.

 EX-21 3 ex21listofsubsidiaries_2024.htm EX-21 Document

Exhibit 21

SUBSIDIARIES OF THE COMPANY
State/ Country of Incorporation
Stock Ownership
West Pharmaceutical Services, Inc.PennsylvaniaParent Co.
Tech Group Europe LimitedIreland100.0 
Tech Group Grand Rapids, Inc.Delaware100.0 
TGPR Holdings LimitedIreland100.0 
West Services and Solutions, LLCDelaware100.0 
West Contract Manufacturing, LLCDelaware100.0 
West Pharma. Services IL, Ltd.Israel100.0 
West Pharmaceutical Packaging (China) Company Ltd.China100.0 
West Pharmaceutical Packaging India Private LimitedIndia100.0 
West Pharmaceutical Products Ireland, Ltd.Ireland100.0 
West Pharmaceutical Services Argentina S.A.Argentina100.0 
West Pharmaceutical Services Asia, Ltd.Taiwan100.0 
West Pharmaceutical Services Australia Pty. Ltd.Australia100.0 
West Pharmaceutical Services AZ, Inc.Arizona100.0 
West Pharmaceutical Services Beograd d.o.o.Serbia100.0 
West Pharmaceutical Services Brasil Ltda.Brazil100.0 
West Pharmaceutical Services Colombia S.A.S.Colombia100.0 
West Pharmaceutical Services Cornwall LimitedEngland100.0 
West Pharmaceutical Services Danmark ApSDenmark100.0 
West Pharmaceutical Services Delaware Acquisition, Inc.Delaware100.0 
West Pharmaceutical Services Deutschland GmbH & Co. KGGermany100.0 
West Pharmaceutical Services European Holdings ApSDenmark100.0 
West Pharmaceutical Services France S.A.France100.0 
West Pharmaceutical Services Group LimitedEngland100.0 
West Pharmaceutical Services Hispania S.A.Spain100.0 
West Pharmaceutical Services Holding II GmbHGermany100.0 
West Pharmaceutical Services Holding Danmark ApSDenmark100.0 
West Pharmaceutical Services Holding France SASFrance100.0 
West Pharmaceutical Services Holding GmbHGermany100.0 
West Pharmaceutical Services Holding Ireland North, Ltd.Ireland100.0 
West Pharmaceutical Services Holding Ireland South, Ltd.Ireland100.0 
West Pharmaceutical Services Holding Japan, GKJapan100.0 
West Pharmaceutical Services Holdings Ltd.Israel100.0 
West Pharmaceutical Services Italia S.r.L.Italy100.0 
West Pharmaceutical Services Korea, Ltd.South Korea100.0 
West Pharmaceutical Services Lakewood, Inc.Delaware100.0 
West Pharmaceutical Services of Delaware, Inc.Delaware100.0 
West Pharmaceutical Services of Florida, Inc.Florida100.0 
West Pharmaceutical Services Shanghai Medical Rubber Products Co., Ltd.China100.0 
West Pharmaceutical Services Singapore Pte. Ltd.Singapore100.0 
West Pharmaceutical Services Switzerland GmbH In LiquidationSwitzerland100.0 
West Pharmaceutical Services Venezuela C.A.Venezuela100.0 
West Pharmaceutical Services Verwaltungs GmbHGermany100.0 


 EX-23 4 ex23consent_2024.htm EX-23 Document

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-106977, 333-143129, 333-174153 and 333-211088) of West Pharmaceutical Services, Inc. of our report dated February 18, 2025 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 18, 2025



 EX-31.1 5 ex311ceo302certification_2.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this Annual Report on Form 10-K of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: February 18, 2025

EX-31.2 6 ex312cfo302certification_2.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this Annual Report on Form 10-K of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial Officer

Date: February 18, 2025

EX-32.1 7 ex321ceo906certification_2.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of West Pharmaceutical Services, Inc. (the “Company”) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer, Chair of the Board of Directors of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer, Chair of the Board of Directors

Date: February 18, 2025

 EX-32.2 8 ex322cfo906certification_2.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report on Form 10-K of West Pharmaceutical Services, Inc. (the “Company”) for the period ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial Officer

Date: February 18, 2025


 EX-97 9 ex97clawbackpolicy.htm EX-97 Document

WEST PHARMACEUTICAL SERVICES, INC.
EXECUTIVE OFFICER INCENTIVE-BASED COMPENSATION RECOVERY POLICY
(Effective October 2, 2023)

PURPOSE

The Board of Directors (the “Board”) of West Pharmaceutical Services, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to adopt this Clawback Policy (the “Policy”), which provides for the recovery of covered incentive compensation in the event of an “Accounting Restatement” (as defined below) and in other covered circumstances described below.

This Policy includes mandatory provisions that are designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D-1 promulgated under the Exchange Act (“Rule 10D- 1”) and Section 303A.14 of the New York Stock Exchange Listed Company Manual (the “Listing Standards”). This Policy also includes discretionary provisions, which shall be interpreted by the Board broadly but in a manner that does not override Rule 10D-1 or the Listing Standards.

POLICY

1. ADMINISTRATION

Except as specifically set forth herein, this Policy shall be administered by the Compensation Committee of the Board (the “Administrator”). The Administrator is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. Any determinations made by the Administrator shall be final and binding on all affected individuals and need not be uniform with respect to each individual covered by the Policy. In the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board, as may be necessary or appropriate as to matters within the scope of such other committees’ responsibility and authority.

Subject to any limitation at applicable law, the Administrator may authorize and empower any officer or employee of the Company (or its affiliates, if applicable) to take any and all actions necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).

2. DEFINITIONS

In addition to the terms defined above, as used in this Policy, the following definitions shall apply:

•“Accounting Restatement” means an accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

•“Applicable Period” means the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, as well as any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year). The “date on which the Company is required to prepare an Accounting Restatement” is the earlier to occur of (a) the


date the Audit Committee or authorized officer(s) of the Company concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement or (b) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement, in each case regardless of if or when the restated financial statements are filed.

•“Code” means the Internal Revenue Code of 1986, as amended, and regulations promulgated thereunder.

•“Covered Executives” means the Company’s current and former executive officers, as determined by the Administrator in accordance with the definition of executive officer set forth in Rule 10D-1 and the Listing Standards.

•“Financial Reporting Measure” is any measure that is determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measure. Financial Reporting Measures include but are not limited to the following (and any measures derived from the following): Company stock price; total shareholder return (“TSR”); revenues; net income; operating income; profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates); earnings before interest, taxes, depreciation and amortization (“EBITDA”); funds from operations and adjusted funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital, return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to an Accounting Restatement; revenue per user, or average revenue per user, where revenue is subject to an Accounting Restatement; cost per employee, where cost is subject to an Accounting Restatement; any of such financial reporting measures relative to a peer group, where the Company’s financial reporting measure is subject to an Accounting Restatement; and tax basis income. A Financial Reporting Measure need not be presented within the Company’s financial statements or included in a filing with the Securities Exchange Commission (“SEC”).

•“Incentive-Based Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation is received for purposes of this Policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive- Based Compensation award is attained, even if the payment or grant of such Incentive- Based Compensation occurs after the end of that period.



















3. MANDATORY COVERED EXECUTIVES AND COMPENSATION

The mandatory provisions this Policy applies to Incentive-Based Compensation received by a Covered Executive (a) after beginning services as a Covered Executive; (b) if that person served as a Covered Executive at any time during the performance period for such Incentive- Based Compensation; and (c) while the Company had a listed class of securities on a national securities exchange.

The mandatory provisions of this Policy does not apply with respect to (1) any compensation received while an individual was serving in a non-executive capacity prior to becoming a Covered Executive nor (2) any individual who is an executive officer on the date the Company is required to prepare an Accounting Restatement but was not an executive officer at any time during the performance period that ended during the Applicable Period. Compensation that is not covered by the mandatory provisions may be Discretionary Covered Compensation subject to the remaining provisions of this Policy as described below.

4. MANDATORY RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION IN THE EVENT OF AN ACCOUNTING RESTATEMENT

In the event the Company is required to prepare an Accounting Restatement, the Company shall promptly recover the amount of any Erroneously Awarded Compensation received by any Covered Executive, as calculated pursuant to Section 5 hereof, during the Applicable Period.

5. ERRONEOUSLY AWARDED COMPENSATION: AMOUNT SUBJECT TO RECOVERY

The amount of “Erroneously Awarded Compensation” subject to mandatory recovery under the Policy, as determined by the Administrator, is the amount of Incentive-Based Compensation received by the Covered Executive that exceeds the amount of Incentive-Based Compensation that would have been received by the Covered Executive had it been determined based on the restated amounts.

Erroneously Awarded Compensation shall be computed by the Administrator without regard to any taxes that may have been incurred, accrued, paid or should have been paid by the Covered Executive in respect of the Erroneously Awarded Compensation.

For Incentive-Based Compensation based on stock price or TSR: (a) the Administrator shall determine the amount of Erroneously Awarded Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive- Based Compensation was received; and (b) the Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the NYSE to the extent required by applicable law or rule.

6. RECOVERY METHOD

The Administrator shall determine, in its sole discretion to the extent permitted by applicable law or regulation, the timing and method for promptly recovering Erroneously Awarded Compensation hereunder, which may include without limitation (a) seeking reimbursement of all or part of any cash or equity-based award, (b) cancelling prior cash or equity-based awards, whether vested or unvested or paid or unpaid, (c) cancelling or offsetting against any planned future cash or equity-based awards, (d) forfeiture of deferred compensation, subject to compliance with Section 409A of the Code and (e) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may affect recovery under this Policy from any amount otherwise payable to the Covered Executive, including amounts payable to such individual under any otherwise applicable Company plan or program, including base salary, bonuses or commissions and compensation previously deferred by the Covered Executive.



The Company is authorized and directed pursuant to this Policy to recover Erroneously Awarded Compensation in compliance with this Policy unless the Administrator (or Compensation Committee if the Administrator is not the Compensation Committee) has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements:

(a)The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Administrator must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover and provide that documentation to the NYSE;

(b)Recovery would violate home country law of the issuer where that law was adopted prior to November 28, 2022. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law of the issuer, the Administrator must satisfy the applicable opinion and disclosure requirements of Rule 10D-1 and the Listing Standards; or

(c)Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Code.


7. RECOVERY OF DISCRETIONARY COVERED COMPENSATION

Notwithstanding anything else in this Policy to the contrary, with respect to Executive Officers, the Administrator also may, in its sole and absolute discretion exercised at any time, and subject to applicable law recover compensation paid to a Covered Executive that meets this Section 7.

(a)Discretionary Covered Compensation. For purposes of this Section 7, Discretionary Covered Compensation includes amount payable pursuant to any annual, quarterly or similar bonus plan, performance-vesting equity awards, and time-vesting equity awards (including stock options and restricted stock units).

(b) Calculation Errors. Even if no financial results are restated, if any Discretionary Covered Compensation is paid, earned or vested, should have been less than the amount calculated due to mathematical errors, fraud, misconduct or gross negligence, the Company may seek repayment of an award from any Covered Executive during the three-year period following the payment of the award.

(c) Detrimental Conduct. If a Covered Executive who has received Discretionary Covered Compensation directly or indirectly engages in conduct that competes with the Company, or any conduct that is materially inimical, contrary, harmful to, or not in the best interests of the Company or if such Covered Executive fails to comply with any of the material terms and conditions of a Discretionary Covered Compensation award (unless the failure is remedied within ten days after having been notified of such failure), then subject to the requirements of applicable law and any valid agreements to the contrary, the Company has the discretion to immediately cancel any and all such awards and require that the such Covered Executive repay all or any portion of such an award, including the gain realized on the exercise of a stock option, stock appreciation right or the disposition of any other equity-based award. To be subject to this Section 7, the detrimental conduct must have occurred while the Covered Executive was rendering service to the Company, or during the six-month period following the later of (1) the


date the Covered Executive ceases rendering service to the Company or, (2) the date the award is paid (or an option or stock appreciation right is exercised).

(d) Administrative Discretion. Unless the Board determines otherwise, the Administrator has the sole and absolute authority to determine whether to exercise its discretion to seek repayment or cancel any Discretionary Covered Compensation and what portion thereof should be recovered or canceled. The Administrator shall consider all relevant facts and circumstances in exercising their discretion. These facts and circumstances include: (1) the materiality of any changes to calculations or financial results, (2) the potential windfall received by the Covered Executive, (3) the culpability and involvement of the Covered Executive, (4) the controls in place to limit misconduct or incorrect reporting, (5) the period during which any misconduct occurred, (6) any other negative repercussions experienced by the Covered Executive, (7) the period that has elapsed since the date of any misconduct and (8) the feasibility and costs of recovering the Discretionary Covered Compensation.

8. NO INDEMNIFICATION OF COVERED EXECUTIVES

Notwithstanding the terms of any indemnification or insurance policy or any contractual arrangement with any Covered Executive that may be interpreted to the contrary, the Company shall not indemnify any Covered Executives against the loss of any Erroneously Awarded Compensation or Discretionary Covered Compensation, including any payment or reimbursement for the cost of third-party insurance purchased by any Covered Executives to fund potential clawback obligations under this Policy.

9. ADMINISTRATOR INDEMNIFICATION

Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.

10. ENFORCEMENT; APPLICABLE LAW; JURISDICTION; INJUNCTIVE RELIEF

(a)The Board intends that this Policy will be applied to the fullest extent permitted by applicable law. The Company has the authority to seek recovery through any available means including litigation or the filing of liens, if necessary. The Company also has the authority, to the extent permitted by law, to deduct the amount to be repaid from any amounts otherwise owed to the Covered Executive, including wages or other compensation, fringe benefits, or vacation paid. Whether or not the Company elects to make any deduction, if the Company does not recover the full amount that it has determined should be recovered, the Covered Executive must immediately repay the unpaid balance. To the maximum extent permitted by applicable law, by agreeing to accept an award or other incentive-based compensation, each Covered Executive consents to the Company’s right to make these deductions.

(b)This Policy shall be governed by the federal laws of the United States of America, and, as applicable, the Commonwealth of Pennsylvania.

(c) Any dispute which may arise between individuals covered by this Policy shall be adjudicated before a court located in Chester County, Pennsylvania and Covered Executives agree to submit to the exclusive jurisdiction of the federal and state courts of the Commonwealth of Pennsylvania located in Chester County, Pennsylvania or the Eastern District of Pennsylvania.




(d) If a court of competent jurisdiction holds that all or a portion of this Policy is unenforceable for any reason, by accepting Incentive-Based Compensation or Covered Discretionary Compensation from the Company, each Covered Executive and the Company agree to modify such provision, or allow a court of competent jurisdiction to have the power to modify such provision, to reduce the scope of such provision, or to add or delete specific words or phrases, and, in its modified form, the provision shall then be enforced.

(e) By accepting Incentive-Based Compensation or Covered Discretionary Compensation, a Covered Executive further agrees that a breach of this Policy will cause the Company and its Affiliates immediate and irreparable harm for which the Company’s remedies at law (such as money damages) will be inadequate. The Company shall have the right, in addition to any other rights it may have, to obtain an injunction to restrain any breach or threatened breach of the Policy.

(f) If the Company is successful in seeking repayment under this Policy and a Covered Executive does not immediately agree to repay applicable amounts under this Policy such that the Company must commence an enforcement action, the Covered Executive agrees to reimburse the Company for all reasonable costs and expenses, including any attorney’s fees, required to bring such enforcement action.

11. EFFECTIVE DATE AND RETROACTIVE APPLICATION

This Policy shall be effective as of October 2, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive-Based Compensation that is received by Covered Executives on or after the Effective Date, even if such Incentive-Based Compensation was approved, awarded, granted or paid to Covered Executives prior to the Effective Date. Without limiting the generality of the foregoing, and subject to applicable law, the Administrator may affect recovery under this Policy from any amount of compensation approved, awarded, granted, payable or paid to the Covered Executive prior to, on or after the Effective Date.

12. AMENDMENT; TERMINATION

The Board may amend, modify, supplement, rescind or replace all or any portion of this Policy at any time and from time to time in its discretion, and shall amend this Policy as it deems necessary to comply with applicable law or any rules or standards adopted by a national securities exchange on which the Company’s securities are listed.

13. OTHER RECOVERY RIGHTS AND CLAIMS

The Board intends that this Policy shall be applied to the fullest extent of the law. Any right of repayment under this Policy is in addition to, and not in lieu of, any other remedies or rights of repayment that may be available to the Company under applicable law or pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

Nothing contained in this Policy, and no recoupment or recovery as contemplated by this Policy, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Executive arising out of or resulting from any actions or omissions by the Covered Executive.







14. NO THIRD-PARTY BENEFICIARIES

Nothing expressed or implied in this Policy is intended, or shall be construed, to confer upon or give any person or entity other than the Covered Executives and the Company any rights or remedies under or by reason of this Policy.

15. SUCCESSORS

This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

 EX-101.SCH 10 wst-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Other Expense (Income) link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952177 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Affiliated Companies (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Other Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Revenue - Contracts Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Net Income Per Share - Schedule of Reconciliation of Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Net Income Per Share - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Property, Plant and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Leases - Assets And Liabilities, Lessee (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Affiliated Companies - Schedule of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Affiliated Companies-Schedule of Aggregate Carrying Amount (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Affiliated Companies - Schedule of Company's Affiliate Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Goodwill and Intangible Assets - Intangible Assets by Major Class (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Derivative Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Stock-Based Compensation - Nonvested Performance-based Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Benefit Plans - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - Benefit Plans - Amounts Recognized in Balance Sheet (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - Benefit Plans - Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - Benefit Plans - Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - Benefit Plans - Allocation of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - Other Expense (Income) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955582 - Disclosure - Income Taxes - Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - Income Taxes - Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955587 - Disclosure - Segment Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955588 - Disclosure - Segment Information - Sales by Product Group (Details) link:presentationLink link:calculationLink link:definitionLink 9955589 - Disclosure - Segment Information - Sales and Long-lived Assets by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 9955590 - Disclosure - Segment Information - Segment Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955591 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 wst-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 wst-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 wst-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Limitation on payroll deductions of employee's base salary (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Repayments of long-term debt Repayments of Long-Term Debt Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Excise tax payments Payments For Excise Tax Payments For Excise Tax Cover [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] International plans Foreign Plan [Member] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Hedged item (intercompany loan) Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Trading Symbol Trading Symbol Ownership interest Equity Method Investment, Ownership Percentage Fair Value Hedges: Fair Value Hedging [Member] Non-NEOs Non-NEOs [Member] Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Position [Axis] Position [Axis] 2028 and thereafter Long-Term Debt, Maturity, Year Four And After Year Four Long-Term Debt, Maturity, Year Four And After Year Four (Increase) decrease in accounts receivable Increase (Decrease) in Accounts Receivable Cross-currency swap Currency Swap [Member] Net Income Per Share Earnings Per Share, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Adjustments above/(below) target (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Land Land [Member] Award Timing Disclosures [Line Items] Net Investment Hedges: Net Investment Hedging [Member] Equity Method Investee, Name [Domain] Investment, Name [Domain] Award Types Other than Stock Options and Stock Appreciation Rights Award Types Other than Stock Options and Stock Appreciation Rights [Member] Award Types Other than Stock Options and Stock Appreciation Rights [Member] International value added tax payable Sales and Excise Tax Payable, Current Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Debt issuance costs Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment United States UNITED STATES Rate shares are reduced for each award granted Reduction In Number Of Shares Available For Grant For Each Award Granted Reduction In Number Of Shares Available For Grant For Each Award Granted Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Assumed healthcare cost trend rate used to determine benefit obligations Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Benefit Obligation Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Benefit Obligation Other noncurrent assets Other Assets, Noncurrent Leases [Abstract] Cost Finite-Lived Intangible Assets, Gross Operating Segments Operating Segments [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Operating loss carryforwards, state and local Deferred Tax Assets, Operating Loss Carryforwards, State and Local Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Line of credit facility, additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Line Of Credit Facility Additional Borrowing Capacity Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted average remaining lease term (years) Finance Lease, Weighted Average Remaining Lease Term Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Lease, operating lease, terminate term (in years) Lessee, Operating Lease, Option To Terminate, Term Lessee, Operating Lease, Option To Terminate, Term Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Molds and dies Tools, Dies and Molds [Member] Debt issuance cost Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expected long-term rate of return on assets (as a percent) Expected long-term rate of return on assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Tax benefit from stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Less: imputed lease interest Finance Lease, Liability, Undiscounted Excess Amount Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Credit Facility [Domain] Credit Facility [Domain] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Shares repurchased for employee tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Customer contracts Customer Contracts [Member] Asset-related charges Restructuring And Related Costs, Asset Impairment Charges Restructuring And Related Costs, Asset Impairment Charges Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Stock Option Share-Based Payment Arrangement, Option [Member] Foreign Exchange Forward Foreign Exchange Forward Foreign Exchange Forward [Member] Depreciation Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension benefits Pension Plan [Member] Income taxes payable Accrued Income Taxes, Current Weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 2025 Finance Lease, Liability, to be Paid, Year One Award Type [Axis] Award Type [Axis] Schedule of Sales and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Stock-settled PSU awards Stock-Settled PSU Awards [Member] Stock-Settled PSU Awards Work in process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total Liabilities Liabilities Long-Lived Assets Long-Lived Assets Amount available for issuance of letters of credit Credit Available For The Issuance Of Letters Of Credit Credit Available For The Issuance Of Letters Of Credit Options vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Litigation Legal Matters, Contingencies and Legal Costs [Policy Text Block] Legal Matters, Contingencies and Legal Costs [Policy Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Property, plant and equipment Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Settlement loss Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Participants’ contributions Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Debt Instrument [Line Items] Line of Credit Facility [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Impairment of Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Reduction for expiration of statute of limitations/audits Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total Equity Beginning balance Ending balance Equity, Attributable to Parent Insurance Claims Insurance Claims [Member] Borrowings of long-term debt Proceeds from Issuance of Debt Schedule of Goodwill Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Interest income Investment Income, Net Selling, general and administrative expenses Selling, general and administrative expenses Selling, General and Administrative Expense 401 (k) plan contributions Defined Contribution Plan, Cost Cost of goods and services sold Cost of Sales [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Schedule of Restructuring Obligations Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Estimated annual amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Amount reimbursable by the insurance company Loss Contingency, Receivable Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted average remaining contractual life of options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Derivative Contract Type [Domain] Derivative Contract [Domain] Actuarial gains Actuarial gain Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Number of deferred stock units payable in cash (in shares) Deferred Stock Units Payable In Cash Deferred Stock Units Payable In Cash Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Amortization of other, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, Tax Weighted average remaining contractual life of options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other comprehensive income (loss), derivative, excluded component, increase (decrease), adjustments, before tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Defined Benefit Plan [Table] Defined Benefit Plan [Table] Noncurrent assets Assets, Defined Benefit Plans, Noncurrent Amount of assets, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent Patents and licensing Patents and Licensing [Member] Patents and Licensing [Member] Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Net Finite-Lived Intangible Assets, Net Accounts payable Accounts Payable, Current Federal and state Deferred Federal, State and Local Income Tax Expense (Benefit) Deferred Federal, State and Local Income Tax Expense (Benefit) Total lease cost Lease, Cost Restructuring and related activities, period of implementation (up to) Restructuring And Related Activities, Period Of Implementation Restructuring And Related Activities, Period Of Implementation Statistical Measurement [Axis] Statistical Measurement [Axis] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes and equity in net income of affiliated companies Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Property, plant, and equipment Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost Title and Position [Axis] Title and Position [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] Dividend payments Payments of Ordinary Dividends, Common Stock Equity Method Investee, Name [Axis] Investment, Name [Axis] Customer relationships Customer Relationships [Member] Forecast Forecast [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Revenue Recognition Revenue from Contract with Customer [Policy Text Block] U.S. operations Income (Loss) from Continuing Operations before Income Taxes, Domestic State and Local Jurisdiction State and Local Jurisdiction [Member] Change in deferred income - decrease (increase) Increase (Decrease) in Contract with Customer, Liability Current income tax provision Current Income Tax Expense (Benefit) Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Settlement effects arising during period, tax Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Foreign exchange transaction losses (gains) Foreign exchange transaction (losses) gains Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Notes payable and other current debt Notes Payable and Other Debt, Current Notes Payable and Other Debt, Current Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other Deferred Tax Liabilities, Other Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax expense Tax (expense) benefit Income tax expense Income Tax Expense (Benefit) Interest cost Interest cost Defined Benefit Plan, Interest Cost Derivative, notional amount Derivative, Notional Amount Net periodic benefit cost: Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Commodity call options Derivative Asset Weighted average period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, and $0.0 OCI, Equity Method Investment, after Tax, Parent Net sales Net Sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other changes in plan assets and benefit obligations recognized in OCI, pre-tax: Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Debt, fair value Debt, Fair Value Debt, Fair Value Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Applicable margin ratio Debt Instrument, Applicable Margin Ratio Debt Instrument, Applicable Margin Ratio Capital in excess of par value Additional Paid in Capital Restructuring and related charges, net Restructuring Charges Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Scenario [Domain] Scenario [Domain] Cash Defined Benefit Plan, Cash [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Derivatives Gains (losses) on derivatives: Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] (Credits) charges Restructuring (Charges) Credits Restructuring (Charges) Credits Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule of Other Income and Expense, by Component [Table Text Block] Maximum number of shares per employee, per year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year Financial Instruments [Domain] Financial Instruments [Domain] Outstanding, beginning (in dollars per share) Outstanding, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Total liabilities Liability, Defined Benefit Plan Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Total restructuring and related charges Restructuring and Related Cost, Incurred Cost Schedule of Repurchase of Common Stock Schedule Of Common Stock Repurchases [Table Text Block] Schedule Of Common Stock Repurchases Restatement Determination Date Restatement Determination Date Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Charged to costs and expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Weighted-average interest crediting rating used to determine net periodic benefit cost Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Options outstanding, beginning (in dollars per share) Options outstanding, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Options outstanding, beginning (in shares) Options outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Currency [Axis] Currency [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Dividends declared, not paid Dividends payable Dividends Payable, Current Settlement loss Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement Gain (Loss), Before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement Gain (Loss), Before Tax Net Income Per Share Earnings Per Share [Text Block] Pension settlement charges Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment U.S. research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Granted at target level (in dollars per share) Granted at target level (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Segment [Domain] Segments [Domain] Finance Lease, Liability, to be Paid, Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Reconciliation of Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Term Loan, due December 31, 2024 (6.32%) Term Loan Due 2024 [Member] Term Loan Due 2024 Year 2025 Year 2025 [Member] Year 2025 PEO PEO [Member] Name Trading Arrangement, Individual Name Funded status at end of year Defined Benefit Plan, Funded (Unfunded) Status of Plan Pharma Rubber S.A. de C.V. Pharma Rubber S.A. de C.V. [Member] Pharma Rubber S.A. de C.V. [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Total Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax Entity Public Float Entity Public Float Excess tax benefits on share-based payments Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Treasury stock, at cost (3.0 million and 1.8 million shares in 2024 and 2023) Treasury Stock, Common, Value Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Balance Balance Defined Benefit Plan, Benefit Obligation Income before income taxes and equity in net income of affiliated companies Total before tax Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Total Gain (Loss) on Fair Value Hedges Recognized in Earnings Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Other comprehensive income (loss), cash flow hedge, reclassification for discontinuance, before tax Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Pharma Pharma Customers [Member] Pharma Customers [Member] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Deferred tax benefit Effective Income Tax Rate Reconciliation, Deferred Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Deferred Tax Benefit, Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Stock repurchase program, shares authorized (in shares) Share Repurchase Program, Authorized, Number of Shares Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Foreign Line of Credit Foreign Line of Credit [Member] Other charges Other Restructuring [Member] Deferred compensation liabilities Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent Equity Method Investment [Table] Equity Method Investment [Table] Americas Americas [Member] Corporate and Unallocated Corporate And Reconciling Items [Member] Corporate And Reconciling Items Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other European countries Other Europe Countries [Member] Other Europe Countries [Member] Foreign currency translation adjustments, tax Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Percentage of current market price for sales to eligible employees (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Number of shares to be issued upon conversion (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting Schedule of Intangible Assets by Major Class [Line Items] Schedule Of Intangible Assets By Major Class [Line Items] [Line Items] for Schedule of Intangible Assets by Major Class [Table] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Accrued interest Interest Payable, Current Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common stock Common Stock [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Unrecorded Unconditional Purchase Obligation, Term Unrecorded Unconditional Purchase Obligation, Term Effect on future earnings, amount Effect on Future Earnings, Amount Weighted average of the coupon interest rate (as a percent) Long-Term Debt, Weighted Average Interest Rate, at Point in Time Series A notes, due July 5, 2022 (3.67%) Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Domestic Line of Credit Domestic Line of Credit [Member] Deferred compensation benefits Deferred Compensation Liability, Classified, Noncurrent Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Other expense (income) Segment Reporting, Other Segment Item, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Net sales Net Sales [Member] Net sales member Accrued liabilities for interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Other charges Other Restructuring Costs Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount United States of America, Dollars United States of America, Dollars Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Less: current portion of long-term debt Long-Term Debt, Current Maturities Segment Information Segment Reporting Disclosure [Text Block] Pension plan assets in the fair value hierarchy Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Outstanding unconditional contractual commitments due to be paid in 2024 Unrecorded Unconditional Purchase Obligation, to be Paid, Year One New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Restricted Stock Restricted Stock [Member] Preceding period (in months) Debt Instrument, Increase In Facility, Preceding Period Debt Instrument, Increase In Facility, Preceding Period Title Trading Arrangement, Individual Title Deferred compensation plans and restricted share awards Deferred Compensation, Share-Based Payments [Member] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Amortization of actuarial (gain) loss, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax Schedule of Components of Income Before Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Balance at January 1 Balance at December 31 Total gross unrecognized tax benefits Unrecognized Tax Benefits Geographic Concentration Risk Geographic Concentration Risk [Member] Position [Domain] Position [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Auditor Location Auditor Location Contingent consideration Business Combination, Contingent Consideration, Liability Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Line of credit facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Shares purchased under share repurchase programs Payments for Repurchase of Common Stock Deferred tax asset valuation allowance SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Deferred compensation conversion unit (in shares) Deferred Compensation Arrangement With Individual, Conversion Unit Deferred Compensation Arrangement With Individual, Conversion Unit Employee Benefits Pension and Other Postretirement Plans, Policy [Policy Text Block] Tax on undistributed earnings of subsidiaries Deferred Tax Liabilities, Undistributed Foreign Earnings Long-term debt Long-term debt, net Long-Term Debt, Excluding Current Maturities SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Tax expense (benefit) from impact of tax law changes enacted Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Weighted Average Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity: Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained Earnings (Accumulated Deficit) Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Schedule of Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Purchase Long [Member] Schedule of Nonvested Performance-based Share Activity Schedule of Nonvested Share Activity [Table Text Block] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Decrease (increase) in inventories Increase (Decrease) in Inventories Tax on undistributed earnings of subsidiaries Effective Income Tax Rate Reconciliation, Undistributed Earnings Of Subsidiaries, Percentage Effective Income Tax Rate Reconciliation, Undistributed Earnings Of Subsidiaries, Percentage Corporate general costs General and Administrative Expense Schedule of Long-term Debt Obligations, Net of Current Maturities Schedule of Debt [Table Text Block] 2026 Long-Term Debt, Maturity, Year Two Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total lease liabilities Operating Lease, Liability Underlying Securities Award Underlying Securities Amount Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Performance share units Performance Shares [Member] Deferred income Deferred Revenue, Current Weighted average assumptions used in net periodic benefit cost: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] 2029 Finance Lease, Liability, to be Paid, Year Five Dividends declared Dividends, Common Stock, Cash Amendment Flag Amendment Flag Participants’ contributions Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Loss on disposal of plant Loss on disposal of plant Loss on disposal of plant Gain (Loss) on Disposition of Property Plant Equipment Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Assumed healthcare cost trend rate used to determine net periodic benefit cost Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Net Periodic Benefit Cost Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Net Periodic Benefit Cost Machinery and equipment Machinery and Equipment [Member] Debt securities Defined Benefit Plan, Debt Security [Member] Finance lease - amortization of right-of-use (ROU) assets Finance Lease, Right-of-Use Asset, Amortization Other Expense (Income) Other Income and Other Expense Disclosure [Text Block] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cost investment activity Cost Investment Impairment Cost Investment Impairment Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Technology Technology-Based Intangible Assets [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Schedule of Amounts Recognized in Balance Sheet Schedule of Amounts Recognized in Balance Sheet [Table Text Block] Other, net Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Auditor Name Auditor Name Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Line of credit, noncurrent Long-Term Line of Credit, Noncurrent Expected useful lives (years) Property, Plant and Equipment, Useful Life Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Increase (decrease) in accounts payable Increase (Decrease) in Accounts Payable Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Principal repayments on finance leases Financing cash flows from finance leases Finance Lease, Principal Payments Amortization Amortization Designated as Hedging Instrument Designated as Hedging Instrument [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Foreign currency translation Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total Assets Assets Assets Cost of goods and services sold Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Total recognized in net periodic benefit cost and OCI Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax Distributorship Agreement Distributorship Agreement [Member] Distributorship Agreement Capital expenditures Payments to Acquire Property, Plant, and Equipment Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 18) Commitments and Contingencies Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] 2025 Long-Term Debt, Maturity, Year One Other mutual funds Other Mutual Funds [Member] Other Mutual Funds Number of quarters following acquisition Debt Instrument, Number Of Fiscal Quarters Following Acquisition Debt Instrument, Number Of Fiscal Quarters Following Acquisition Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Debt Instrument [Axis] Debt Instrument [Axis] Other items Other Operating Income (Expense), Net Net income Net income Total reclassifications for the period, net of tax Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] 2030 to 2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Schedule of Assumptions Used Defined Benefit Plan, Assumptions [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Federal Current Federal Tax Expense (Benefit) Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Estimated increase (decrease) in the liability for unrecognized tax benefits Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Restructuring Plan [Domain] Restructuring Plan [Domain] Operating lease, term of contract (in months) Lessee, Operating Lease, Term of Contract Name Forgone Recovery, Individual Name Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Other, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Decrease due to prior year position Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Details of Impairment of Long-Lived Assets Held and Used by Asset Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block] Other Other Defined Benefit Plan, Other Cost (Credit) Adjustment to Compensation: Adjustment to Compensation [Axis] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Adjustments to reserves for unrecognized tax benefits Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Accrued professional services Accrued Professional Fees, Current Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forward treasury locks Treasury Lock [Member] Entity Filer Category Entity Filer Category One Customer One Customer [Member] One Customer Amount excluded from effectiveness testing Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Revenue recognized during the period Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance Loss Contingencies [Line Items] Loss Contingencies [Line Items] Fed Funds Effective Rate Overnight Index Swap Rate Fed Funds Effective Rate Overnight Index Swap Rate [Member] Limitation on payroll deductions of employee's base salary, amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount Statistical Measurement [Domain] Statistical Measurement [Domain] Capital Expenditures Segment, Expenditure, Addition to Long-Lived Assets Contract assets, December 31, 2023 Contract assets, December 31, 2024 Contract with Customer, Asset, after Allowance for Credit Loss, Current Schedule of Lease, Cost Lease, Cost [Table Text Block] Non-Employee Directors Director [Member] International mutual funds Mutual Fund [Member] Other current liabilities Payables due to affiliates Total other current liabilities Other Liabilities, Current Intercompany Demand Notes Intercompany Demand Notes [Member] Intercompany Demand Notes Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Tax credit carryforward Tax Credit Carryforward, Amount Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Income taxes paid, net Income Taxes Paid, Net JPY Japan, Yen Schedule of Allocation of Share-based Compensation Costs by Plan Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Equity method affiliates Equity Method Investments Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Actual payout range Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage Derivative [Table] Derivative [Table] Income Tax Contingency [Table] Income Tax Contingency [Table] Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Tax benefit from termination of pension plans Effective Income Tax Rate Reconciliation, Termination Of Pension Plan, Amount Effective Income Tax Rate Reconciliation, Termination Of Pension Plan, Amount Restructuring and Related Activities [Abstract] Changes in other assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Performance Measure, Amount Other Performance Measure, Amount Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Estimated annual amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Goodwill [Line Items] Goodwill [Line Items] Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease cost Operating Lease, Cost Tax expense from recognition of reserves for unrecognized tax benefits Effective Income Tax Rate Reconciliation, Recognition Of Reserves For Unrecognized Tax Benefits, Amount Effective Income Tax Rate Reconciliation, Recognition Of Reserves For Unrecognized Tax Benefits, Amount Shares available for issuance under the 2016 Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities Operating Lease, Liability, Noncurrent Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Finance lease - interest on lease liabilities Finance Lease, Interest Expense Thereafter Thereafter [Member] Thereafter Service cost Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Equity securities Defined Benefit Plan, Equity Securities [Member] Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Increase due to prior year position Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Shares purchased under share repurchase program (in shares) Shares repurchased (in shares) Treasury Stock, Shares, Acquired International Deferred Foreign Income Tax Expense (Benefit) Retirement Plan Type [Axis] Retirement Plan Type [Axis] Money market funds Money Market Funds [Member] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Rate of compensation increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Net actuarial gain (loss) arising during period, tax Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax Treasury stock Treasury Stock, Common [Member] Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Intersegment sales elimination Intersegment Eliminations [Member] Thereafter Finance Lease, Liability, to be Paid, after Year Five Equity Components [Axis] Equity Components [Axis] Finance lease, liability payment due Finance Lease, Liability, to be Paid Other current assets Receivables due from affiliates Other Assets, Current Net (loss) gain on derivatives, net of tax of $(0.9), $0.0, and $0.2 Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax (Loss) gain recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Research and Development Research and Development Expense, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Policy Text Block] Other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax Net actuarial loss (gain) Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax Aggregate intrinsic value of total options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Revolving Credit Facility, Due 2024 Revolving Credit Facility, Due 2024 [Member] Revolving Credit Facility, Due 2024 Geographical [Axis] Geographical [Axis] 2022 Restructuring Plan The 2022 Restructuring Plan [Member] The 2022 Restructuring Plan Net deferred tax asset Deferred Tax Assets, Net Derivative, nonmonetary notional amount outstanding Derivative, Nonmonetary Notional Amount 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Europe, Middle East, Africa EMEA [Member] Accrued commissions, rebates & royalties Accrued Sales Commission Schedule of Assets And Liabilities, Lessee Schedule Of Assets And Liabilities, Lessee [Table Text Block] Schedule Of Assets And Liabilities, Lessee Weighted Average Weighted Average [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Accrual for insurance obligations Loss Contingency Accrual Purchases of shares (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status Schedule Of Changes In Fair Value Of Plan Assets, Projected Benefit Obligations And Net Funded Status [Table Text Block] Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block] Generics Generics Customers [Member] Generics Customers [Member] Prior service credit Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax Cash payments Payments for Restructuring Shipping and Handling Costs Cost of Goods and Service [Policy Text Block] Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Less: amortization of actuarial (gain) loss, net of tax of $(0.2), $(0.4), and $(0.1) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax Unrecognized compensation expense for all nonvested awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount International Current Foreign Tax Expense (Benefit) Net (gain) loss arising during period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Current assets: Assets, Current [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Treasury stock, at cost (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Derivative designated as hedging instrument Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Short-term lease cost Short-Term Lease, Cost Allowance for credit losses SEC Schedule, 12-09, Allowance, Credit Loss [Member] Vested and converted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Basis spread on variable interest rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Related Party Transaction [Domain] Related Party Transaction [Domain] Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenue from Contract with Customer, Product and Service Benchmark Revenue from Contract with Customer, Product and Service Benchmark [Member] Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] State Current State and Local Tax Expense (Benefit) Applicable Margin Applicable Margin [Member] Applicable Margin Pharma Tap S.A. de C.V. Pharma Tap S.A de C.V. [Member] Pharma Tap S.A de C.V. [Member] Aluplast S.A. de C.V. Aluplast S.A. de C.V. [Member] Aluplast S.A. de C.V. [Member] Foreign currency contracts Foreign Currency Contracts, Liability, Fair Value Disclosure Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and Development Expense Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Schedule of Intangible Assets by Major Class [Table] Schedule Of Intangible Assets By Major Class [Table] Schedule of Intangible Assets by Major Class [Table] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Amortization of actuarial (loss) gain Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Percentage of net sales Concentration Risk, Percentage Less: amortization of other, net of tax of $0.0, $(0.1), and $0.1 Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, after Tax Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Commodity Call Options Options Held [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Ratio of debt to EBITDA Debt Instrument, Ratio Of Debt To EBITDA Debt Instrument, Ratio Of Debt To EBITDA Settlement loss Defined Benefit Plan, Plan Assets, Payment for Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Entity Voluntary Filers Entity Voluntary Filers Amortization of actuarial loss (gain) Defined Benefit Plan, Amortization of Gain (Loss) Hedging Designation [Domain] Hedging Designation [Domain] Interest expense Interest expense Interest Expense, Nonoperating Deferred income taxes Deferred income tax provision Deferred Income Tax Expense (Benefit) Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Discount rate (as a percent) Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Settlements Settlement loss Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Other comprehensive (loss) income, net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Maximum number of shares per employee (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Asset impairments Asset impairments Asset impairments Asset Impairment Charges Total debt Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets Balance Balance Defined Benefit Plan, Plan Assets, Amount Term Loan, due July 2, 2027 (5.68%) Term Loan, Due 2027 [Member] Term Loan, Due 2027 Computer hardware and software Computer Hardware and Software [Member] Computer Hardware and Software [Member] Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Leases Deferred Tax Assets, Leasing Arrangements Deferred Tax Assets, Leasing Arrangements Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Average price per repurchased share (in dollars per share) Shares Acquired, Average Cost Per Share Investments in affiliated companies Total investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Document Annual Report Document Annual Report Equity in unrealized (gains) losses of Daikyo's investments & derivatives Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect 2027 Finance Lease, Liability, to be Paid, Year Three Credit facility is available for swing-line loans Credit facility is available for swing-line loans This refers to credit facility is available for swing-line loans Vested and converted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred compensation assets Deferred Compensation Plan Assets Standard Packaging Standard Packaging [Member] Standard Packaging [Member] Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Amortization of intangible assets Amortization of Intangible Assets Deferred income, December 31, 2023 Deferred income, December 31, 2024 Contract with Customer, Liability SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Accounting Policies [Abstract] Accounting Policies [Abstract] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Balance at beginning of period Balance at end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Name PEO Name Award Type [Domain] Award Type [Domain] Activity related to stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Pension and other postretirement benefits Noncurrent liabilities Liability, Defined Benefit Plan, Noncurrent Deferred income taxes Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Estimated useful life of finite-lived intangible assets (in years) Finite-Lived Intangible Asset, Useful Life Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Capital in excess of par value Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Lease liabilities (noncurrent) Finance Lease, Liability, Noncurrent Change in contract assets - increase (decrease) Increase (Decrease) in Contract with Customer, Asset Benefit Plans Retirement Benefits [Text Block] Type of Deferred Compensation [Axis] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] SGD Singapore, Dollars Recently Adopted Standards and Standards Issued Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Title of Individual with Relationship to Entity [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2028 Finance Lease, Liability, to be Paid, Year Four Name Measure Name Number of loss on disposal manufacturing facility Number of Manufacturing Facilities Sold Number of Manufacturing Facilities Sold Contract-Manufactured Products Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Fixed asset impairment expense Tangible Asset Impairment Charges New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Foreign-Derived Intangible Income Deductions (FDII) Effective Income Tax Rate Reconciliation, FDII, Percent Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Severance and benefits Employee Severance [Member] Cash payments received in advance Contract With Customer, Liability, Increase (Decrease) Due To Additional Cash Payments Contract With Customer, Liability, Increase (Decrease) Due To Additional Cash Payments Type of Deferred Compensation, All Types [Domain] Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain] Other Other Comprehensive Income (Loss), Defined Benefit Plan, Other Costs, before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Other Costs, before Tax Stock-based compensation Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Pension plan assets measured at NAV Fair Value Measured at Net Asset Value Per Share [Member] Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans: Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt instrument, stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Capitalized R&D expenses Deferred Tax Asset, In-Process Research and Development Pension and other retirement plans, net Pension And Other Postretirement Benefit Expense, Net The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period); net of cash contributed during the reporting period by the entity to fund its benefit plans. Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Capitalized interest Interest Costs Capitalized Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule II - Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Auditor Firm ID Auditor Firm ID Effective tax rate Effective Income Tax Rate Reconciliation, Percent Operating profit Operating Income (Loss) Commodity call options Commodity [Member] Variable Rate [Domain] Variable Rate [Domain] Expiration Period [Axis] Expiration Period [Axis] Expiration Period [Axis] Number of reportable segments Number of Reportable Segments Total Liabilities and Equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating loss carryforwards, foreign Deferred Tax Assets, Operating Loss Carryforwards, Foreign Number of tranches Debt Instrument, Number Of Tranches Debt Instrument, Number Of Tranches Hedging Designation [Axis] Hedging Designation [Axis] Short term derivative instruments Derivative Liability, Current Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] 2026 Finance Lease, Liability, to be Paid, Year Two Foreign currency translation Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Individual: Individual [Axis] Buildings and improvements Building and Building Improvements [Member] Accumulated other comprehensive loss Total AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Total inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Net gain (loss) on equity affiliate accumulated other comprehensive income, tax OCI, Equity Method Investment, Tax, Parent Tax benefit from recent court case Effective Income Tax Rate Reconciliation, Litigation Settlement, State and Local, Amount Effective Income Tax Rate Reconciliation, Litigation Settlement, State and Local, Amount Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Derivative contract term Derivative, Term of Contract Financial Instruments Derivatives, Policy [Policy Text Block] Asia Pacific Asia Pacific [Member] Minimum Minimum [Member] Number of deferred compensation plans Deferred Compensation Arrangement With Individual, Number Of Plans Deferred Compensation Arrangement With Individual, Number Of Plans Less: unamortized debt issuance costs for Term Loan and Series notes Unamortized debt issuance costs remaining Unamortized Debt Issuance Expense U.S. tax on international earnings, net of foreign tax credits Effective Income Tax Rate Reconciliation, Repatriation Of Foreign Earnings, Net Of Foreign Tax Credits, Percent Effective Income Tax Rate Reconciliation, Repatriation Of Foreign Earnings, Net Of Foreign Tax Credits, Percent Adoption Date Trading Arrangement Adoption Date Business Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] U.S. federal corporate tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross Exercise Price Award Exercise Price Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] High-Value Product Components High-Value Product Components [Member] High-Value Components [Member] Arrangement Duration Trading Arrangement Duration Operating loss carryforwards Operating Loss Carryforwards Leases Lessee, Finance Leases [Text Block] Total recognized in OCI Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Settlement effects arising during period, net of tax of $0.0, $0.0, and $20.3 Other Comprehensive Loss, Defined Benefit Plans Settlement Effects, Net Of Tax The adjustment out of other comprehensive income for settlement effects recognized as a component of net periodic benefit cost during the period, net of tax. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Estimated annual amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Total lease liabilities Finance Lease, Liability All Individuals All Individuals [Member] France FRANCE Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance [Abstract] Foreign currency translation Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other nonoperating expense (income) Other Nonoperating Income (Expense) Other retirement benefits Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Fair value and net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Schedule of Amounts Recognized in Other Comprehensive Loss Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Non-cash restructuring charges Restructuring Reserve, Settled without Cash Undistributed earnings of foreign subsidiaries Undistributed Earnings of Foreign Subsidiaries Change in plan assets: Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Current liabilities Liability, Defined Benefit Plan, Current Daikyo Seiko, Ltd. ("Daikyo") Daikyo Seiko, Ltd. (Daikyo) [Member] Daikyo Seiko, Ltd. (Daikyo) [Member] Assets: Assets, Fair Value Disclosure [Abstract] Related and Nonrelated Parties [Domain] Related and Nonrelated Parties [Domain] Operating loss carryforwards, not subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Intercompany Loans Intercompany Loans [Member] Intercompany Loans Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Liability Class [Axis] Liability Class [Axis] Germany GERMANY Employee stock purchase plan Employee Stock Purchase Plan (ESPP) [Member] Employee Stock Purchase Plan (ESPP) [Member] Deferred income taxes Deferred Income Tax Liabilities, Net Royalty acceleration Deferred Tax Assets, Royalty Acceleration Deferred Tax Assets, Royalty Acceleration Stock volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Interest expense Interest Expense [Member] Tax on international operations other than U.S. tax rate Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Change in benefit obligation: Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Measure: Measure [Axis] Activity related to stock-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Increase due to current year position Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year One Entity Emerging Growth Company Entity Emerging Growth Company Other Other Sundry Liabilities, Current Total liabilities at fair value Liabilities, Fair Value Disclosure Commodity call options Commodity Option [Member] Other Other Investments [Member] Adjustments above/(below) target (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value Sell Short [Member] The West Company Mexico, S.A. de C.V. The West Company Mexico, S.A. de C.V. [Member] The West Company Mexico, S.A. de C.V. [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] ROU assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Equity Component [Domain] Equity Component [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Four SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Unremitted income of affiliates Retained Earnings, Undistributed Earnings from Equity Method Investees Schedule of Investments in and Advances to Affiliates Investments in and Advances to Affiliates [Table Text Block] Statement [Table] Statement [Table] Ireland IRELAND Interest expense Interest Expense, Debt Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Schedule of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Other Other Countries [Member] Other Non-European Countries [Member] Interest paid, net of amounts capitalized Interest Paid, Excluding Capitalized Interest, Operating Activities Restructuring and related cost Restructuring and Related Cost, Expected Cost Remaining Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Pension and deferred compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Right-of-use assets obtained in exchange for new lease liabilities: Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities [Abstract] Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities Accrued salaries, wages and benefits Accrued Salaries, Wages, and Benefits, Current Accrued Salaries, Wages, and Benefits, Current Options vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2027 Long-Term Debt, Maturity, Year Three Stock option and appreciation rights Stock Option and Appreciation Rights [Member] Stock Option and Appreciation Rights [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Employer contribution Defined Benefit Plan, Plan Assets, Contributions by Employer High-Value Product Delivery Devices High Value Product Delivery Devices [Member] High Value Product Delivery Devices Member Weighted average grant date fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-equity method affiliates Equity Securities without Readily Determinable Fair Value, Amount Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment Unrecorded Unconditional Purchase Obligation Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Time deposits Bank Time Deposits [Member] EUR Euro Member Countries, Euro Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Sales by Significant Product Group Revenue from External Customers by Products and Services [Table Text Block] Accrued taxes other than income Accrual for Taxes Other than Income Taxes, Current Domestic Plan Domestic Plan [Member] Expiration Period [Domain] Expiration Period [Domain] [Domain] for Expiration Period [Axis] Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Other expense (income) (Note 16) Other expense (income) Total other expense (income) Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Credit Facility [Axis] Credit Facility [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Long-term debt, fair value Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and Amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Foreign currency translation adjustments, net of tax of $3.6, $1.0, and $2.2 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Tax benefit related to a reduction in the liability on the unremitted earnings Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Customer Concentration Risk Customer Concentration Risk [Member] Affiliated Entity Affiliated Entity [Member] Pension settlement Effective Income Tax Rate Reconciliation, Pension Settlement, Percent Effective Income Tax Rate Reconciliation, Pension Settlement, Percent Level 2 Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Royalty acceleration Effective Income Tax Rate Reconciliation, Royalty Acceleration, Percent Effective Income Tax Rate Reconciliation, Royalty Acceleration, Percent Restructuring Cost [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2024 and 2023; shares outstanding: 72.3 million and 73.5 million in 2024 and 2023 Common Stock, Value, Issued Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Expected contribution to the plan Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Number of deferred stock units (in shares) Deferred Compensation Arrangement With Individual, Share Equivalents Balance Deferred Compensation Arrangement With Individual, Share Equivalents Balance State income taxes, net of federal tax effect Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Net (loss) gain on derivatives, tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax Aggregate intrinsic value of total options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Other Deferred Tax Assets, Other Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] All Currencies [Domain] All Currencies [Domain] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2024 and 2023 Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Currency forwards Forward Contracts [Member] Aggregate annual maturities of long-term debt [Abstract] Long-Term Debt, Fiscal Year Maturity [Abstract] Total deferred tax liabilities Deferred Tax Liabilities, Gross Basic (in dollars per share) Earnings Per Share, Basic Operating cash flows from operating leases Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Awards, expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Audit Information [Abstract] Audit Information [Abstract] Accrued retirement plans (excl. pension) Liability, Other Retirement Benefits Trademarks Trademarks [Member] Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Allocation range Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage Goodwill [Table] Goodwill [Table] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Total current liabilities Liabilities, Current Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Other Current Liabilities Other Liabilities Disclosure [Text Block] Dividends received from affiliates Proceeds from Equity Method Investment, Distribution Estimated annual amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Letters of credit supporting the reimbursement of workers' compensation and other claims Long-Term Line of Credit Granted at target level (in shares) Granted at target level (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Net actuarial gain (loss) arising during period, net of tax of $0.3, $0.4, and $(2.4) Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Leases Lessee, Leases [Policy Text Block] Proprietary Products Proprietary Products [Member] Proprietary Products [Member] Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock compensation expense Share-Based Payment Arrangement, Expense Segment Reporting, Revenue Reconciling Items [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted average assumptions used in benefit obligations: Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign Tax Jurisdiction Foreign Tax Jurisdiction [Member] Leases Deferred Tax Liabilities, Leasing Arrangements Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Finance Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Revenue Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Employer contribution Defined Benefit Plan, Plan Assets, Contributions By Employer, Net Of Premiums Defined Benefit Plan, Plan Assets, Contributions By Employer, Net Of Premiums Product Concentration Risk Product Concentration Risk [Member] Shares purchased under share repurchase program Total cost of repurchases ($ in millions) Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Severance and benefits Severance related costs Severance Costs Total assets at fair value Assets, Fair Value Disclosure International operations Income (Loss) from Continuing Operations before Income Taxes, Foreign Total benefit payments expected Defined Benefit Plan, Expected Future Benefit Payments Defined Benefit Plan, Expected Future Benefit Payments Estimated annual amortization expense, 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Interest (income) expense and other nonoperating expense (income), net Interest Income (Expense) And Other Nonoperating (Expense) Income, Net Interest Income (Expense) And Other Nonoperating (Expense) Income, Net Lease liabilities (current) Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Cost method investment impairment charges Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Base Rate Base Rate [Member] Operating lease liability payments due Lessee, Operating Lease, Liability, to be Paid Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of instances ratio of debt to EBITDA not to exceed threshold Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded Equity in undistributed earnings of affiliates, net of dividends Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Insider Trading Arrangements [Line Items] Other Current Liabilities [Abstract] Other Current Liabilities [Abstract] Other Current Liabilities [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] (Increase) decrease in other current assets Increase (Decrease) in Other Current Assets 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Purchases from (and payments to) affiliates Related Party Transaction, Purchases from Related Party Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Schedule of Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Retained earnings Retained Earnings [Member] Biologics Biologics Customers [Member] Biologics Customers [Member] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Other expense (income) Other Expense (Income) [Member] Other Expense (Income) Increase (Decrease) in Stockholders' Equity [Roll Forward] Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Ratio of debt to EBITDA after acquisition Debt Instrument, Ratio Of Debt To EBITDA After Acquisition Debt Instrument, Ratio Of Debt To EBITDA After Acquisition Schedule of Components of Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Foreign currency translation losses Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Repayments of other long-term debt Repayments of Other Long-Term Debt Amounts reclassified out Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Restructuring and severance related charges Balance, December 31, 2023 Balance, December 31, 2024 Restructuring Reserve Grant date fair value of options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Letter of Credit Letter of Credit [Member] Company Selected Measure Name Company Selected Measure Name Equity affiliate investment AOCI AOCI, Equity Method Investment, Parent [Member] EX-101.PRE 14 wst-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 image_2.jpg GRAPHIC begin 644 image_2.jpg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wst-20241231_g1.jpg GRAPHIC begin 644 wst-20241231_g1.jpg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§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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2024
Feb. 06, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-8036    
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.    
Entity Incorporation, State or Country Code PA    
Entity Tax Identification Number 23-1210010    
Entity Address, Address Line One 530 Herman O. West Drive    
Entity Address, City or Town Exton    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19341-1147    
City Area Code 610    
Local Phone Number 594-2900    
Title of 12(b) Security Common Stock, par value $.25 per share    
Trading Symbol WST    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Document Financial Statement Error Correction false    
Entity Public Float     $ 23.9
Entity Common Stock, Shares Outstanding   72,303,766  
Documents Incorporated by Reference
DocumentParts Into Which Incorporated
Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.Part III
    
Entity Central Index Key 0000105770    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Philadelphia, Pennsylvania
Auditor Firm ID 238
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Cost of goods and services sold 1,894.7 1,820.6 1,750.7
Gross profit 998.5 1,129.2 1,136.2
Research and development 69.1 68.4 58.5
Selling, general and administrative expenses 338.5 353.4 316.9
Other expense (income) (Note 16) 21.0 31.4 26.8
Operating profit 569.9 676.0 734.0
Interest expense 3.0 9.0 7.9
Interest income (19.6) (28.0) (5.1)
Other nonoperating expense (income) 1.0 (3.0) 51.3
Income before income taxes and equity in net income of affiliated companies 585.5 698.0 679.9
Income tax expense 107.5 122.3 114.7
Equity in net income of affiliated companies (14.7) (17.7) (20.7)
Net income $ 492.7 $ 593.4 $ 585.9
Net income per share:      
Basic (in dollars per share) $ 6.75 $ 7.98 $ 7.87
Diluted (in dollars per share) $ 6.69 $ 7.88 $ 7.73
Weighted average shares outstanding:      
Basic (in shares) 73.0 74.3 74.4
Diluted (in shares) 73.7 75.3 75.8
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Net income $ 492.7 $ 593.4 $ 585.9
Other comprehensive (loss) income, net of tax:      
Foreign currency translation adjustments, net of tax of $3.6, $1.0, and $2.2 (112.3) 39.4 (47.3)
Net actuarial gain (loss) arising during period, net of tax of $0.3, $0.4, and $(2.4) 1.1 0.8 (9.3)
Settlement effects arising during period, net of tax of $0.0, $0.0, and $20.3 0.0 0.1 31.9
Less: amortization of actuarial (gain) loss, net of tax of $(0.2), $(0.4), and $(0.1) (0.8) (1.3) (0.5)
Less: amortization of other, net of tax of $0.0, $(0.1), and $0.1 0.0 (0.3) 0.3
Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, and $0.0 0.2 0.7 0.1
Net (loss) gain on derivatives, net of tax of $(0.9), $0.0, and $0.2 (2.5) (0.2) 1.4
Other comprehensive (loss) income, net of tax (114.3) 39.2 (23.4)
Comprehensive income $ 378.4 $ 632.6 $ 562.5
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Foreign currency translation adjustments, tax $ 3.6 $ 1.0 $ 2.2
Net actuarial gain (loss) arising during period, tax 0.3 0.4 (2.4)
Settlement effects arising during period, tax 0.0 0.0 20.3
Amortization of actuarial (gain) loss, tax (0.2) (0.4) (0.1)
Amortization of other, tax 0.0 (0.1) 0.1
Net gain (loss) on equity affiliate accumulated other comprehensive income, tax 0.0 0.0 0.0
Net (loss) gain on derivatives, tax $ (0.9) $ 0.0 $ 0.2
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 484.6 $ 853.9
Accounts receivable, net 552.5 512.0
Inventories 377.0 434.7
Other current assets 124.0 135.8
Total current assets 1,538.1 1,936.4
Property, plant and equipment 2,985.8 2,738.0
Less: accumulated depreciation and amortization 1,404.2 1,324.7
Property, plant and equipment, net 1,581.6 1,413.3
Operating lease right-of-use assets 104.5 99.2
Investments in affiliated companies 202.1 210.0
Goodwill 106.0 108.5
Intangible assets, net 10.8 15.1
Deferred income taxes 26.0 25.7
Other noncurrent assets 74.3 21.3
Total Assets 3,643.4 3,829.5
Current liabilities:    
Notes payable and other current debt 0.0 134.0
Accounts payable 239.3 242.4
Accrued salaries, wages and benefits 73.5 105.9
Income taxes payable 31.5 16.6
Operating lease liabilities 17.9 17.7
Other current liabilities 188.2 155.2
Total current liabilities 550.4 671.8
Long-term debt 202.6 72.8
Deferred income taxes 20.5 12.7
Pension and other postretirement benefits 28.2 29.6
Operating lease liabilities 81.8 84.5
Deferred compensation benefits 15.4 18.6
Other long-term liabilities 62.2 58.5
Total Liabilities 961.1 948.5
Commitments and contingencies (Note 18)
Equity:    
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2024 and 2023 0.0 0.0
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2024 and 2023; shares outstanding: 72.3 million and 73.5 million in 2024 and 2023 18.8 18.8
Capital in excess of par value 22.1 120.2
Retained earnings 3,956.6 3,523.4
Accumulated other comprehensive loss (258.1) (143.8)
Treasury stock, at cost (3.0 million and 1.8 million shares in 2024 and 2023) (1,057.1) (637.6)
Total Equity 2,682.3 2,881.0
Total Liabilities and Equity $ 3,643.4 $ 3,829.5
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
shares in Millions
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 3.0 3.0
Preferred stock, shares issued (in shares) 0.0 0.0
Preferred stock, shares outstanding (in shares) 0.0 0.0
Common stock, par value (in dollars per share) $ 0.25 $ 0.25
Common stock, shares authorized (in shares) 200.0 200.0
Common stock, shares issued (in shares) 75.3 75.3
Common stock, shares outstanding (in shares) 72.3 73.5
Treasury stock, at cost (in shares) 3.0 1.8
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Millions
Total
Common stock
Capital in excess of par value
Treasury stock
Retained earnings
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2021   75,300,000        
Beginning balance at Dec. 31, 2021 $ 2,335.4 $ 18.8 $ 249.0 $ (229.5) $ 2,456.7 $ (159.6)
Beginning balance (in shares) at Dec. 31, 2021       1,100,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 585.9       585.9  
Activity related to stock-based compensation 44.6   (16.8) $ 61.4    
Activity related to stock-based compensation (in shares)       (500,000)    
Shares purchased under share repurchase program (in shares)       600,000    
Shares purchased under share repurchase program (202.8)     $ (202.8)    
Dividends declared (54.8)       (54.8)  
Other comprehensive income (loss), net of tax (23.4)         (23.4)
Ending balance (in shares) at Dec. 31, 2022   75,300,000        
Ending balance at Dec. 31, 2022 2,684.9 $ 18.8 232.2 $ (370.9) 2,987.8 (183.0)
Ending balance (in shares) at Dec. 31, 2022       1,200,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 593.4       593.4  
Activity related to stock-based compensation $ 59.6   (112.0) $ 171.6    
Activity related to stock-based compensation (in shares)       (700,000)    
Shares purchased under share repurchase program (in shares) 1,265,661     1,300,000    
Shares purchased under share repurchase program $ (438.3)     $ (438.3)    
Dividends declared (57.8)       (57.8)  
Other comprehensive income (loss), net of tax $ 39.2         39.2
Ending balance (in shares) at Dec. 31, 2023 75,300,000 75,300,000        
Ending balance at Dec. 31, 2023 $ 2,881.0 $ 18.8 120.2 $ (637.6) 3,523.4 (143.8)
Ending balance (in shares) at Dec. 31, 2023 1,800,000     1,800,000    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income $ 492.7       492.7  
Activity related to stock-based compensation $ 43.3   (98.1) $ 141.4    
Activity related to stock-based compensation (in shares)       (400,000)    
Shares purchased under share repurchase program (in shares) 1,583,032     1,600,000    
Shares purchased under share repurchase program $ (560.9)     $ (560.9)    
Dividends declared (59.5)       (59.5)  
Other comprehensive income (loss), net of tax $ (114.3)         (114.3)
Ending balance (in shares) at Dec. 31, 2024 75,300,000 75,300,000        
Ending balance at Dec. 31, 2024 $ 2,682.3 $ 18.8 $ 22.1 $ (1,057.1) $ 3,956.6 $ (258.1)
Ending balance (in shares) at Dec. 31, 2024 3,000,000.0     3,000,000.0    
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]      
Dividends declared per share (in dollars per share) $ 0.82 $ 0.78 $ 0.74
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net income $ 492.7 $ 593.4 $ 585.9
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation 151.8 133.7 116.9
Amortization 3.6 3.6 3.7
Stock-based compensation 18.7 23.3 23.7
Non-cash restructuring charges 0.0 0.0 15.3
Pension settlement charges 0.0 0.1 52.2
Loss on disposal of plant 0.0 11.6 0.0
Asset impairments 7.3 9.6 6.2
Deferred income taxes (3.5) 37.5 (30.8)
Pension and other retirement plans, net (2.0) (2.6) (14.0)
Equity in undistributed earnings of affiliates, net of dividends (13.4) (14.3) (18.1)
Other, net (4.7) 1.0 (2.0)
Changes in assets and liabilities:      
(Increase) decrease in accounts receivable (58.8) 4.0 (35.6)
Decrease (increase) in inventories 42.0 (13.5) (49.8)
(Increase) decrease in other current assets (5.8) (21.3) 18.5
Increase (decrease) in accounts payable 2.9 4.4 (2.8)
Changes in other assets and liabilities 22.6 6.0 54.7
Net cash provided by operating activities 653.4 776.5 724.0
Cash flows from investing activities:      
Capital expenditures (377.0) (362.0) (284.6)
Other, net (1.7) (6.7) (3.6)
Net cash used in investing activities (378.7) (368.7) (288.2)
Cash flows from financing activities:      
Borrowings of long-term debt 164.7 0.0 0.0
Repayments of long-term debt (169.0) (2.3) (44.3)
Debt issuance cost 0.0 0.0 (1.2)
Principal repayments on finance leases (23.3) (0.1) 0.0
Dividend payments (59.1) (57.0) (54.1)
Excise tax payments (2.0) 0.0 0.0
Proceeds from stock-based compensation awards 25.5 43.9 20.9
Employee stock purchase plan contributions 7.2 7.1 7.3
Shares purchased under share repurchase programs (560.9) (438.3) (202.8)
Shares repurchased for employee tax withholdings (5.7) (12.9) (19.4)
Net cash used in financing activities (622.6) (459.6) (293.6)
Effect of exchange rates on cash (21.4) 11.4 (10.5)
Net (decrease) increase in cash and cash equivalents (369.3) (40.4) 131.7
Cash, including cash equivalents at beginning of period 853.9 894.3 762.6
Cash, including cash equivalents at end of period 484.6 853.9 894.3
Supplemental cash flow information:      
Interest paid, net of amounts capitalized 0.5 6.0 6.6
Income taxes paid, net 71.4 90.8 109.7
Accrued capital expenditures 53.0 53.3 33.2
Dividends declared, not paid $ 15.2 $ 14.8 $ 14.1
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Principles of Consolidation: The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. ("West") after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.

Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents: Cash equivalents include money market funds, time deposits and all highly liquid short-term instruments with maturities of three months or less at the time of purchase.

Accounts Receivable: Our accounts receivable balance was net of an allowance for credit losses of $0.8 million at both December 31, 2024 and 2023. Under the current expected credit loss model, we utilize a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions.

Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. The Company provides for cost adjustments for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. The following is a summary of inventories at December 31:
($ in millions)20242023
Raw materials$166.9 $172.3 
Work in process65.2 87.3 
Finished goods144.9 175.1 
$377.0 $434.7 

Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other expense (income). Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.

Leases: Lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for operating leases is recognized on a straight-line basis over the lease term. Conversely, lease expense for finance leases is a front loaded expense recognition pattern over the lease term. Lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. Please refer to Note 6, Leases, for additional information.
Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.

Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year.

Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates. Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 3 to 25 years and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.

Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.
Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as a hedge of the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as a hedge of the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as a hedge of the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.

Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.

Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less. In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less. Please refer to Note 3, Revenue, for additional information.

Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.

Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include salaries and outside services for those directly involved in research and development activities and are primarily expensed as incurred.

Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.
Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other expense (income). The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.

Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, Stock-Based Compensation, for a more detailed discussion of our stock-based compensation plans.

Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
New Accounting Standards
 12 Months Ended
Dec. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU") No. 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company has adopted and implemented the applicable disclosure requirements within this annual report.

Standards Issued Not Yet Adopted

In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.

In November 2024, the FASB issued guidance that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
Revenue Recognition

We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of December 31, 2024.

Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.

Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience and specific identification of customer claims.
The following table presents the approximate percentage of our net sales by market group:
202420232022
Biologics39 %37 %41 %
Generics17 %20 %18 %
Pharma25 %24 %24 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

The following table presents the approximate percentage of our net sales by product category:
202420232022
High-Value Product Components45 %50 %55 %
High-Value Product Delivery Devices14 %10 %5 %
Standard Packaging 22 %21 %23 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
202420232022
Americas45 %45 %48 %
Europe, Middle East, Africa46 %46 %43 %
Asia Pacific9 %9 %9 %
100 %100 %100 %

Contract Assets and Liabilities

Contract assets and liabilities result from transactions with revenue primarily recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet within other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.
The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2023
$21.5 
Contract assets, December 31, 2024
23.3 
Change in contract assets - increase (decrease)$1.8 
Deferred income, December 31, 2023
$(53.9)
Deferred income, December 31, 2024
(53.2)
Change in deferred income - decrease (increase)$0.7 

Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. The decrease in deferred income during 2024 was primarily due to the recognition of current year revenue of $94.8 million and the recognition of $37.7 million of revenue that was included in deferred income at the beginning of the year, offset by additional cash payments of $132.8 million received in advance of satisfying future performance obligations.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Income Per Share
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
(in millions)202420232022
Net income$492.7 $593.4 $585.9 
Weighted average common shares outstanding73.0 74.3 74.4 
Dilutive effect of equity awards, based on the treasury stock method
0.7 1.0 1.4 
Weighted average shares assuming dilution73.7 75.3 75.8 

During 2024, 2023 and 2022, there were 0.3 million, 0.2 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive.

In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program did not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions depended on a variety of factors, including market conditions. The below table summarizes share repurchases under this program during the years ended December 31:
20242023
Shares repurchased1,583,032 1,265,661 
Total cost of repurchases ($ in millions)$560.9 $438.3 
Average price per repurchased share$354.30 $346.34 

In December 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2025.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment Property, Plant and Equipment
A summary of gross property, plant and equipment at December 31 is presented in the following table:
($ in millions)Expected useful lives (years)20242023
Land$27.9 $33.7 
Buildings and improvements
15-35
916.1 771.5 
Machinery and equipment
5-12
1,229.0 1,136.5 
Molds and dies
4-7
169.5 164.5 
Computer hardware and software
3-10
232.5 216.6 
Construction in progress410.8 415.2 
$2,985.8 $2,738.0 

Depreciation expense for the years ended December 31, 2024, 2023 and 2022 was $151.8 million, $133.7 million and $116.9 million, respectively.

We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2024, 2023 and 2022 was $13.2 million, $5.8 million and $3.7 million, respectively.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Leases Leases
As of December 31, 2024, we had leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2269. Certain of our leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one year or more. At this time, the Company is not able to assert whether any of these options will be exercised.

Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
The components of lease expense were as follows:
($ in millions)202420232022
Operating lease cost$24.2 $20.3 $15.5 
Finance lease - amortization of right-of-use (ROU) assets0.9 — — 
Finance lease - interest on lease liabilities0.1 — — 
Short-term lease cost2.5 6.1 1.3 
Variable lease cost9.0 5.5 6.8 
Total lease cost$36.7 $31.9 $23.6 

As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:
December 31,
($ in millions)Balance Sheet Classification2024
ROU assets, netOther noncurrent assets$29.7 
Lease liabilities (current)Other current liabilities$0.9 
Lease liabilities (noncurrent)Other long-term liabilities$2.1 

Supplemental information related to leases was as follows:
($ in millions)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$32.5 $19.1 $13.3 
Operating cash flows from finance leases$0.1 $— $— 
Financing cash flows from finance leases$23.3 $0.1 $— 
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases$41.2 $10.7 $47.6 
Finance leases$24.6 $— $— 

As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.3 years and 9.8 years. As of December 31, 2024, the weighted average remaining lease term for finance leases was 6.3 years. As of December 31, 2023, finance leases were not material.

As of December 31, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.99% and 3.55%, respectively. As of December 31, 2024, the weighted average discount rate for finance leases was 4.80%. As of December 31, 2023, finance leases were not material.
Maturities of lease liabilities as of December 31, 2024 were as follows:
($ in millions)OperatingFinance
YearLeasesLeases
2025$23.4 $0.9 
202620.7 0.9 
202716.3 0.9 
202814.9 0.5 
202911.5 0.1 
Thereafter26.3 — 
113.1 3.3 
Less: imputed lease interest(13.4)(0.3)
Total lease liabilities$99.7 $3.0 

Practical Expedients and Exemptions

We have elected to adopt practical expedients around the combination of lease and non-lease components and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases.

We have elected not to recognize lease right-of-use assets and lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.
Leases Leases
As of December 31, 2024, we had leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2269. Certain of our leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one year or more. At this time, the Company is not able to assert whether any of these options will be exercised.

Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.
The components of lease expense were as follows:
($ in millions)202420232022
Operating lease cost$24.2 $20.3 $15.5 
Finance lease - amortization of right-of-use (ROU) assets0.9 — — 
Finance lease - interest on lease liabilities0.1 — — 
Short-term lease cost2.5 6.1 1.3 
Variable lease cost9.0 5.5 6.8 
Total lease cost$36.7 $31.9 $23.6 

As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:
December 31,
($ in millions)Balance Sheet Classification2024
ROU assets, netOther noncurrent assets$29.7 
Lease liabilities (current)Other current liabilities$0.9 
Lease liabilities (noncurrent)Other long-term liabilities$2.1 

Supplemental information related to leases was as follows:
($ in millions)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$32.5 $19.1 $13.3 
Operating cash flows from finance leases$0.1 $— $— 
Financing cash flows from finance leases$23.3 $0.1 $— 
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases$41.2 $10.7 $47.6 
Finance leases$24.6 $— $— 

As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.3 years and 9.8 years. As of December 31, 2024, the weighted average remaining lease term for finance leases was 6.3 years. As of December 31, 2023, finance leases were not material.

As of December 31, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.99% and 3.55%, respectively. As of December 31, 2024, the weighted average discount rate for finance leases was 4.80%. As of December 31, 2023, finance leases were not material.
Maturities of lease liabilities as of December 31, 2024 were as follows:
($ in millions)OperatingFinance
YearLeasesLeases
2025$23.4 $0.9 
202620.7 0.9 
202716.3 0.9 
202814.9 0.5 
202911.5 0.1 
Thereafter26.3 — 
113.1 3.3 
Less: imputed lease interest(13.4)(0.3)
Total lease liabilities$99.7 $3.0 

Practical Expedients and Exemptions

We have elected to adopt practical expedients around the combination of lease and non-lease components and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases.

We have elected not to recognize lease right-of-use assets and lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Affiliated Companies Affiliated Companies
At December 31, 2024, the following affiliated companies were accounted for under the equity method:
LocationOwnership interest
The West Company Mexico, S.A. de C.V.Mexico49%
Aluplast S.A. de C.V.Mexico49%
Pharma Tap S.A. de C.V.Mexico49%
Pharma Rubber S.A. de C.V.Mexico49%
Daikyo Seiko, Ltd. ("Daikyo")
Japan49%

The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:
December 31,December 31
($ in millions)20242023
Aggregate carrying value of investments in affiliated companies:
   Equity method affiliates$194.9 $203.2 
   Non-equity method affiliates7.2 6.8 
Total investments in affiliated companies$202.1 $210.0 

We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.
The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:
December 31,December 31
($ in millions)20242023
Payables due to affiliates$18.7 $25.9 
Receivables due from affiliates$2.5 $1.6 

The following table summarizes the Company's affiliate transactions:

(in millions)202420232022
Purchases from (and payments to) affiliates$110.0 $142.5 $167.6 
Sales to affiliates$15.3 $11.2 $14.2 
Unremitted income of affiliates$161.4 $148.0 $133.6 
Dividends received from affiliates$1.3 $3.4 $2.6 
Equity in unrealized (gains) losses of Daikyo's investments & derivatives$2.4 $2.2 $1.6 
The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
The changes in the carrying amount of goodwill by reportable segment were as follows:
($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
Balance, December 31, 2022$77.9 $29.4 $107.3 
Foreign currency translation1.0 0.2 1.2 
Balance, December 31, 202378.9 29.6 108.5 
Foreign currency translation(2.1)(0.4)(2.5)
Balance, December 31, 2024$76.8 $29.2 $106.0 

As of December 31, 2024, we had $0.1 million of accumulated goodwill impairment losses.

Intangible assets and accumulated amortization as of December 31 were as follows:
20242023
($ in millions)CostAccumulated amortizationNetCostAccumulated amortizationNet
Patents and licensing$24.7 $(23.0)$1.7 $24.8 $(21.8)$3.0 
Technology3.3 (2.7)0.6 3.3 (2.5)0.8 
Trademarks1.2 (1.2)— 1.2 (1.2)— 
Customer relationships38.9 (30.8)8.1 39.5 (29.0)10.5 
Customer contracts8.0 (7.6)0.4 8.0 (7.2)0.8 
$76.1 $(65.3)$10.8 $76.8 $(61.7)$15.1 
The cost basis of intangible assets includes a foreign currency translation loss of $0.7 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. Amortization expense for the years ended December 31, 2024, 2023 and 2022 was $3.6 million, $3.6 million and $3.7 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2025 - $2.8 million, 2026 - $2.5 million, 2027 - $2.3 million, 2028 - $1.7 million and 2029 - $0.9 million.
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Current Liabilities
 12 Months Ended
Dec. 31, 2024
Other Current Liabilities [Abstract]  
Other Current Liabilities Other Current Liabilities
Other current liabilities as of December 31 included the following:
($ in millions)20242023
Deferred income$49.6 $41.7 
Accrued commissions, rebates & royalties24.6 22.4 
Short term derivative instruments17.4 2.1 
Dividends payable15.2 14.8 
Accrued taxes other than income12.9 9.2 
Accrued retirement plans (excl. pension)12.6 10.9 
Accrued professional services6.8 5.1 
International value added tax payable6.0 5.2 
Restructuring and severance related charges1.6 3.8 
Accrued interest1.6 2.6 
Other39.9 37.4 
Total other current liabilities$188.2 $155.2 
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.
($ in millions)20242023
Term Loan, due July 2, 2027 (5.68%)
$130.0 $— 
Term Loan, due December 31, 2024 (6.32%)
— 81.0 
Series B notes, due July 5, 2024 (3.82%)
— 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
203.0 207.0 
Less: unamortized debt issuance costs for Term Loan and Series notes0.4 0.2 
Total debt202.6 206.8 
Less: current portion of long-term debt— 134.0 
Long-term debt, net$202.6 $72.8 
Multi-Currency Revolving Credit Facility

In March 2022, we amended and extended the existing multi-currency revolving credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The multi-currency revolving credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve-month period in the aggregate through an increase in the multi-currency revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2024 and 2023, total unamortized debt issuance costs of $1.0 million and $1.0 million, respectively, were recorded in other current assets and other noncurrent assets and are being amortized as additional interest expense over the term of the multi-currency revolving credit facility.

At December 31, 2024, we had no outstanding borrowings under the multi-currency revolving credit facility. At December 31, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million.

Term Loan

On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement (entered into in December 2019). Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0 million (the “New Term Loan”), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9 million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0 million of the Company’s 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012. Interest accrues on the New Term Loan based on a term secured overnight financing rate (“SOFR”) or a base rate, at the Company’s option, plus a margin ranging from 1.250% to 1.625% for SOFR interest rates and 0.250% to 0.625% for base rates according to the Company’s net leverage ratio as defined in the Amended Credit Agreement. Interest rates based on a term SOFR rate is also subject to a credit spread adjustment of 10 basis points. At closing, the Company elected for the New Term Loan to accrue interest at a 3-month term SOFR rate plus a margin of 1.250%. As of December 31, 2024, there were unamortized debt issuance costs remaining of $0.3 million which are being amortized as additional interest expense over the term of the New Term Loan. As of December 31, 2023, there were unamortized debt issuance costs remaining of $0.1 million, which were amortized as additional interest expense over the term of the Term Loan (entered into in December 2019).
At December 31, 2024, we had $130.0 million in borrowings under the New Term Loan which were classified as long-term. Please refer to Note 11, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Private Placement

In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes outstanding as of December 31, 2024 is 3.94%. As of December 31, 2024 and 2023, there were unamortized debt issuance costs remaining of $0.1 million and $0.1 million, respectively, which are being amortized as additional interest expense over the term of the Notes.

Covenants

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2024, we were in compliance with all of our debt covenants.

Interest costs incurred during 2024, 2023 and 2022 were $16.2 million, $14.8 million and $11.6 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, are as follows: $0.0 million in 2025 and 2026, $203.0 million in 2027 and $0.0 million in 2028 and thereafter.
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.

Foreign Currency Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2024 the total amount of these forward exchange contracts was Singapore Dollar ("SGD") 421.9 million and $13.4 million. As of December 31, 2023 the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of December 31, 2024, the total amount of these forward exchange contracts was Euro ("EUR") 145.3 million and $47.1 million. As of December 31, 2023, the total amount of these forward exchange contracts was EUR 278.6 million and SGD 94.0 million.

In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies.
As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEURSGD
EUR20.8 22.9 — — 
JPY6,683.7 28.4 14.8 1.8 
SGD39.8 16.9 12.2 — 

In December 2019, we entered into a five-year floating-to-floating forward-starting cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. This cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of December 31, 2024, the notional amount of the cross-currency swap is Japanese Yen ("JPY") 17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the current cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.

Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

We regularly purchase call options on crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of December 31, 2024, we had outstanding contracts to purchase 190,773 barrels of crude oil from December 2024 to June 2026, at a weighted-average strike price of $84.70 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 12, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of December 31, 2024 and 2023.
The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Fair Value Hedges:
Hedged item (intercompany loan)$1.6 $(0.3)$(28.3)Other expense (income)
Derivative designated as hedging instrument(1.6)0.3 28.3 Other expense (income)
Amount excluded from effectiveness testing(5.9)(1.4)5.2 Other expense (income)
Total$(5.9)$(1.4)$5.2 

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The expense recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2024 and 2023 was $5.9 million and $0.2 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the year ended December 31, 2022 was $4.0 million. We expect to recognize an expense of $0.3 million in earnings, pre-tax, for forward point components in 2025.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:
 Amount of Gain (Loss) Recognized in OCI
($ in millions)202420232022
Fair Value Hedges:
Foreign currency hedge contracts$0.2 $(2.0)$1.3 
Total$0.2 $(2.0)$1.3 
Cash Flow Hedges:  
Foreign currency hedge contracts (hedges of net sales)$1.1 $(0.8)$0.3 
Foreign currency hedge contracts (hedges of cost of goods and services sold)(6.9)(4.0)(1.1)
Forward treasury locks— — — 
Total$(5.8)$(4.8)$(0.8)
Net Investment Hedges:  
Cross-currency swap$6.8 $8.6 $9.1 
Total$6.8 $8.6 $9.1 
 Amount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
($ in millions)202420232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.7)$2.9 $(1.6)Other expense (income)
Total$(0.7)$2.9 $(1.6)
Cash Flow Hedges:   
Foreign currency hedge contracts$(0.5)$1.3 $(1.2)Net sales
Foreign currency hedge contracts4.2 2.2 3.5 Cost of goods and services sold
Forward treasury locks0.1 0.2 0.2 Interest expense
Total$3.8 $3.7 $2.5  
Net Investment Hedges:   
Cross-currency swap— — — Other expense (income)
Total$— $— $—  

Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our consolidated statements of income for the years ended December 31. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our consolidated statements of income for the years ended December 31:

($ in millions)202420232022
Net sales$(0.5)$1.3 $(1.2)
Cost of goods and services sold$4.2 $2.2 $3.5 
Interest expense$0.1 $0.2 $0.2 

The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Commodity call options$(0.7)$(1.3)$1.5 Other expense (income)
Currency forwards(2.5)0.1— Other expense (income)
Total$(3.2)$(1.2)$1.5 

During 2024, 2023 and 2022 there was no material ineffectiveness related to our hedges.
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2024		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.1 $11.1 $— $— 
Money market funds117.6 117.6 — — 
Time deposits71.3 — 71.3 — 
Foreign currency contracts17.3 — 17.3 — 
Cross-currency swap23.6 — 23.6 — 
Commodity call options0.3 — 0.3 — 
 $241.2 $128.7 $112.5 $— 
Liabilities:    
Contingent consideration$3.0 $— $— $3.0 
Deferred compensation liabilities11.2 11.2 — — 
Foreign currency contracts18.3 — 18.3 — 
 $32.5 $11.2 $18.3 $3.0 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$10.2 $10.2 $— $— 
Money market funds404.4 404.4 — — 
Time deposits47.9 — 47.9 — 
Foreign currency contracts5.0 — 5.0 — 
Cross-currency swap18.4 — 18.4 — 
Commodity call options0.6 — 0.6 — 
 $496.7 $424.8 $71.9 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities10.4 10.4 — — 
Foreign currency contracts2.2 — 2.2 — 
 $16.2 $10.4 $2.2 $3.6 

Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets as of December 31, 2024 and other current assets as of December 31, 2023, is valued using a market approach. Please refer to Note 11, Derivative Financial Instruments, for further discussion of our derivatives.

Other Financial Instruments

We believe that the carrying amounts of our cash and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2024, the estimated fair value of long-term debt was $200.5 million compared to a carrying amount of $202.6 million. At December 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of December 31, 2024, all debt is long-term.
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
($ in millions)DerivativesEquity affiliate investment AOCIDefined benefit pension and other postretirement plansForeign currency translationTotal
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications0.5 0.1 (9.3)(47.3)(56.0)
Amounts reclassified out0.9 — 31.7 — 32.6 
Other comprehensive (loss) income, net of tax1.4 0.1 22.4 (47.3)(23.4)
Balance, December 31, 20220.2 1.6 (9.4)(175.4)(183.0)
Other comprehensive income (loss) before reclassifications(6.8)0.7 0.8 39.4 34.1 
Amounts reclassified out6.6 — (1.5)— 5.1 
Other comprehensive income (loss), net of tax(0.2)0.7 (0.7)39.4 39.2 
Balance, December 31, 2023— 2.3 (10.1)(136.0)(143.8)
Other comprehensive (loss) income before reclassifications(5.6)0.2 1.1 (112.3)(116.6)
Amounts reclassified out3.1 — (0.8)— 2.3 
Other comprehensive (loss) income, net of tax(2.5)0.2 0.3 (112.3)(114.3)
Balance, December 31, 2024$(2.5)$2.5 $(9.8)$(248.3)$(258.1)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
Detail of components202420232022Location on Statement of Income
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(1.5)$1.4 Net sales
Foreign currency contracts(5.5)(3.1)(4.1)Cost of goods and services sold
Foreign currency contracts1.0 (4.2)2.4 Other expense (income)
Forward treasury locks(0.1)(0.3)(0.3)Interest expense
Total before tax(4.1)(9.1)(0.6)
Tax benefit (expense)1.0 2.5 (0.3)
Net of tax$(3.1)$(6.6)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$1.0 $1.7 $0.6 (a)
Settlements— (0.1)(52.2)(a)
Other— 0.4 (0.4)(a)
Total before tax1.0 2.0 (52.0)
Tax (expense) benefit (0.2)(0.5)20.3 
Net of tax$0.8 $1.5 $(31.7)
Total reclassifications for the period, net of tax$(2.3)$(5.1)$(32.6)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2024, there were 1.3 million shares remaining in the 2016 Plan for future grants.

Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.
The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:
($ in millions)202420232022
Stock option and appreciation rights$11.0 $11.3 $5.6 
Performance share units2.2 5.9 15.6 
Employee stock purchase plan1.3 1.3 1.3 
Deferred compensation plans and restricted share awards4.2 4.8 1.2 
Total stock-based compensation expense$18.7 $23.3 $23.7 
The Company estimates expected forfeitures. The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2024 was $25.8 million, which is expected to be recognized over a weighted average period of 1.6 years.
Stock Options

Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.

The following table summarizes changes in outstanding options:
(in millions, except per share data)Stock OptionsWeighted Average Exercise Price
Options outstanding, January 1, 2024
1.4 $145.40 
Granted0.1 348.25 
Exercised(0.3)77.88 
Forfeited0.0 331.97 
Options outstanding, December 31, 2024
1.2 $176.37 
Options vested and expected to vest, December 31, 2024
1.1 $172.07 
Options vested and exercisable, December 31, 2024
0.9 $137.48 

As of December 31, 2024, the weighted average remaining contractual life of options outstanding and of options exercisable was 4.6 years and 3.7 years, respectively. As of December 31, 2024, the aggregate intrinsic value of total options outstanding was $182.0 million, of which $178.7 million represented vested options.
The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2024, 2023 and 2022: a risk-free interest rate of 4.3%, 4.1%, and 1.8%, respectively; stock volatility of 32.0%, 29.8%, and 25.1%, respectively; and dividend yields of 0.3%, 0.3%, and 0.2%, respectively. Stock volatility is estimated based on historical data and the impact from expected future trends. Expected lives, which are based on prior experience, averaged 6.0 years for 2024, 5.7 years for 2023 and 5.6 years for 2022. The weighted average grant date fair value of options granted in 2024, 2023 and 2022 was $134.25, $108.95 and $96.43, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.

For the years ended December 31, 2024, 2023 and 2022, the intrinsic value of options exercised was $90.5 million, $151.0 million and $60.1 million, respectively. The grant date fair value of options vested during those same periods was $10.8 million, $8.6 million and $8.8 million, respectively.
Performance Awards

In addition to stock options, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.

The following table summarizes changes in our outstanding stock-settled PSU awards:
UnitsWeighted Average Fair Value
Non-vested stock-settled PSU awards, January 1, 2024
98,441 $334.03 
Granted at target level34,484 348.20 
Adjustments above/(below) target2,523 339.07 
Vested and converted(35,388)350.18 
Forfeited(6,686)331.62 
Non-vested stock-settled PSU awards, December 31, 2024
93,374 $326.56 

Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2024, 2023 and 2022 was $348.20, $306.97 and $362.40, respectively. Including forfeiture and target achievement expectations, we expect that the stock-settled PSU awards, for which the performance period has completed, will convert to 7,946 shares to be issued during 2025.

As described above, certain eligible employees are entitled to cash-settled PSU awards. The fair value of these cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities. The amount of cash-settled PSU awards granted during the years 2024, 2023 and 2022 were immaterial.
Employee Stock Purchase Plan

We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 25,237 shares, 23,955 shares and 27,894 shares for the years 2024, 2023 and 2022, respectively. At December 31, 2024, there were 3.7 million shares available for issuance under the ESPP.

Deferred Compensation Plans and Restricted Share Awards

Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash or stock retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, annual stock awards are granted on the date of our annual meeting and are distributed in shares of common stock at the next annual meeting, unless deferred. In 2024, 2023 and 2022, we granted 6,064, 6,160 and 4,827 deferred stock awards with weighted average grant-date fair values of $386.03, $357.00 and $300.78, respectively.

As of December 31, 2024, the two deferred compensation plans held a total of 332,897 deferred stock units, including 8,851 units to be paid in cash. As of December 31, 2023, the two deferred compensation plans held a total of 352,541 deferred stock units, including 8,931 units to be paid in cash.

During 2024, 2023 and 2022, we granted 9,660, 8,343 and 9,648 stock-settled restricted share unit (“RSU”) awards, respectively, at weighted grant-date fair values of $339.32, $314.06 and $310.52 per share, respectively, to employees under the 2016 Plan. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Benefit Plans Benefit Plans
Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $23.2 million for 2024, $22.7 million for 2023 and $22.8 million for 2022.
Pension and Other Retirement Benefits

The components of net periodic benefit cost and other amounts recognized in OCI were as follows:
Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
Net periodic benefit cost:
Service cost$1.2 $1.1 $1.5 $— $— $— 
Interest cost2.1 2.4 4.2 0.2 0.2 0.2 
Expected return on plan assets(1.3)(1.2)(6.1)— — — 
Amortization of actuarial loss (gain)0.6 0.6 1.3 (1.6)(2.0)(1.9)
Settlement loss— 0.1 52.2 — — — 
Other1.0 0.3 1.0 — 0.4 0.4 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
Net (gain) loss arising during period$(0.7)$(1.4)$16.0 $(0.5)$(0.5)$(2.0)
Amortization of actuarial (loss) gain(0.6)(0.3)(1.3)1.6 2.0 1.9 
Settlement loss— (0.1)(52.2)— — — 
Foreign currency translation(0.2)0.7 (2.3)— — — 
Other— 0.4 — — — (0.4)
Total recognized in OCI$(1.5)$(0.7)$(39.8)$1.1 $1.5 $(0.5)
Total recognized in net periodic benefit cost and OCI$2.1 $2.6 $14.3 $(0.3)$0.1 $(1.8)

Net periodic benefit cost by geographic location is as follows:
 Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
U.S. plans$1.1 $0.8 $51.7 $(1.4)$(1.4)$(1.3)
International plans2.5 2.5 2.4 — — — 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)

The service cost component included within net periodic benefit cost is considered employee compensation and is therefore presented within the selling, general, and administrative and costs of goods and services sold financial statement line items of our consolidated statements of income. The remaining components of net periodic benefit cost are reported separately and are therefore presented within the other nonoperating expense (income) financial statement line item of our consolidated statements of income.

During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). During 2021, a Notice of Intent to Terminate was sent to all interested parties and in 2022 a favorable determination letter was received from the Internal Revenue Service. During 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $7.1 million was made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations, as well as to cover any ancillary benefits and expenses remaining. During 2022, we recorded a $52.2 million pension settlement charge within other nonoperating expense (income), which primarily related to the full settlement and relief of the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan.
During 2024 and 2023, we did not contribute to our U.S. pension plan due to the termination of the plan in 2022. During 2022, we contributed $7.1 million to our U.S. pension plan.

The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Change in benefit obligation:
Benefit obligation, January 1$(57.5)$(55.5)$(3.7)$(3.9)
Service cost(1.2)(1.1)— — 
Interest cost(2.1)(2.4)(0.2)(0.2)
Participants’ contributions(0.1)(0.2)(0.2)(0.4)
Actuarial gain2.2 0.7 0.6 0.5 
Benefits paid3.4 2.5 0.3 0.3 
Settlement loss— 0.5 — — 
Foreign currency translation2.1 (2.0)— — 
Benefit obligation, December 31$(53.2)$(57.5)$(3.2)$(3.7)
Change in plan assets:
Fair value of assets, January 1$32.3 $29.4 $— $— 
Actual return on plan assets(0.6)2.4 — — 
Employer contribution0.7 1.1 0.1 (0.1)
Participants’ contributions0.1 0.2 0.2 0.4 
Benefits paid(2.5)(1.8)(0.3)(0.3)
Settlement loss— (0.5)— — 
Foreign currency translation(0.8)1.5 — — 
Fair value of assets, December 31$29.2 $32.3 $— $— 
Funded status at end of year$(24.0)$(25.2)$(3.2)$(3.7)

International pension plan assets, at fair value, included in the preceding table were $29.2 million and $32.3 million at December 31, 2024 and 2023, respectively.

Amounts recognized in the balance sheet were as follows:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Noncurrent assets$2.9 $2.7 $— $— 
Current liabilities(1.4)(1.4)(0.5)(0.6)
Noncurrent liabilities(25.5)(26.5)(2.7)(3.1)
$(24.0)$(25.2)$(3.2)$(3.7)
The amounts in accumulated other comprehensive loss, pre-tax, consisted of:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Net actuarial loss (gain)$14.4 $15.8 $(2.6)$(3.6)
Prior service credit(1.2)(1.1)— — 
Total$13.2 $14.7 $(2.6)$(3.6)

The accumulated benefit obligation for all defined benefit pension plans was $49.5 million and $53.7 million at December 31, 2024 and 2023, respectively, including $44.0 million and $47.7 million, respectively, for international pension plans.

As of December 31, 2024 and December 31, 2023, our United Kingdom qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2024 and December 31, 2023, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets.

Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows. The expected benefit payments listed correspond to regular ongoing benefit payments expected to be made by the plans during future years.
 ($ in millions)Domestic International Total
2025$1.3 $2.5 $3.8 
20261.1 3.1 4.2 
20271.0 3.6 4.6 
20281.0 3.2 4.2 
20290.9 4.0 4.9 
2030 to 20343.6 17.2 20.8 
$8.9 $33.6 $42.5 

In 2025, we expect to contribute $0.6 million to pension plans, all of which is in the U.S. In addition, we expect to contribute $0.5 million for other retirement benefits in 2025. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors.

Weighted average assumptions used to determine net periodic benefit cost were as follows:
Pension benefitsOther retirement benefits
202420232022202420232022
Discount rate3.95 %4.35 %2.48 %5.20 %5.55 %2.75 %
Rate of compensation increase3.08 %3.09 %2.79 %— — — 
Expected long-term rate of return on assets4.01 %4.22 %4.14 %— — — 

Weighted average assumptions used to determine the benefit obligations were as follows:
Pension benefitsOther retirement benefits
2024202320242023
Discount rate4.38 %3.95 %5.60 %5.20 %
Rate of compensation increase3.07 %3.08 %— — 
The discount rate used to determine the benefit obligations for U.S. pension plans was 5.60% and 5.20% as of December 31, 2024 and 2023, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 4.24% and 3.80% as of December 31, 2024 and 2023, respectively. The weighted average rate of compensation increase for all international plans was 3.07% for 2024 and 3.08% for 2023, while there was no rate increase for the U.S. plans since they are frozen. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans was not applicable for 2024 and 2023, and 3.70% for 2022.

The assumed healthcare cost trend rate used to determine benefit obligations was 6.50% for all participants in 2024, decreasing to 5.00% by 2031. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.75% for all participants in 2024, decreasing to 5.00% by 2031.

The defined benefit pension plan benefit obligation decreased for the year ended December 31, 2024, due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation. The net actuarial losses will be impacted in future periods by actual asset returns, discount rate changes, currency exchange rate fluctuations, actual demographic experience, and certain other factors. The other retirement plan benefit obligation decreased due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation.

The Company has cash balance plans and other plans with promised interest crediting rates. For these plans, the interest crediting rates are set in line with plan rules or country legislation and do not change with market conditions.

The weighted average interest crediting rating used to determine net periodic benefit cost by geographic location for our pension plans, at December 31, were as follows:
202420232022
U.S. plans4.00 %4.00 %3.31 %
International plans1.13 %1.13 %1.75 %

The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:
20242023
Equity securities21 %16 %
Debt securities75 %80 %
Other4 %4 %
100 %100 %

Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.

The following are the target asset allocations and acceptable allocation ranges across:
Target allocationAllocation range
Equity securities
19%
15% - 20%
Debt securities
79%
75% - 85%
Other
2%
2% - 5%
The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2024Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds6.2 — 6.2 — 
Fixed income securities:
International mutual funds21.8 — 21.8 — 
Other mutual funds0.6 — 0.6 — 
Pension plan assets in the fair value hierarchy$29.2 $0.6 $28.6 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$29.2 
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2023Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds5.3 — 5.3 — 
Fixed income securities:
International mutual funds25.9 — 25.9 — 
Other mutual funds0.5 — 0.5 — 
Pension plan assets in the fair value hierarchy$32.3 $0.6 $31.7 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$32.3 
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income)
 12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consisted of:
($ in millions)202420232022
Restructuring and related charges:
Severance and benefits$(2.5)$(2.8)$8.7 
Asset-related charges— — 15.3 
Other charges— — (0.2)
Total restructuring and related charges$(2.5)$(2.8)$23.8 
Asset impairments7.3 9.6 6.2 
Foreign exchange transaction losses (gains)10.2 9.4 (4.1)
Contingent consideration5.1 2.3 3.0 
Loss on disposal of plant— 11.6 — 
Other items0.9 1.3 (2.1)
Total other expense (income) $21.0 $31.4 $26.8 
Restructuring and Related Charges

In December 2022, the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of the approval. The plan provided annualized savings of approximately $17 million. As of December 31, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:
($ in millions)Severance and benefitsOther chargesTotal
Balance, December 31, 2023$3.0 $— $3.0 
(Credits) charges(2.5)— (2.5)
Cash payments(0.5)— (0.5)
Balance, December 31, 2024$— $— $— 
Asset Impairments

The Company's asset impairment expense includes impairment charges to its cost method investments and expense related to fixed assets impaired or taken out of service. During the periods ended December 31, asset impairments consisted of:

($ in millions)202420232022
Cost method investment impairment charges$0.3 $4.3 $3.5 
Fixed asset impairment expense7.0 5.3 2.7 
Total asset impairments$7.3 $9.6 $6.2 

Foreign Exchange Transaction Losses (Gains)

During 2024 and 2023, the Company recorded a loss on foreign exchange transactions of $10.2 million and $9.4 million, respectively. During 2024, the increase in losses on foreign exchange transactions was the result of increased expense related to exchange rate activity in Europe, partially offset by a decrease in losses related to Argentina's high inflationary environment year over year. During 2023, the loss on foreign exchange transactions was primarily driven by a highly inflationary environment in Argentina. During 2022, the Company recorded a gain on foreign exchange transactions of $4.1 million.

Contingent Consideration

Contingent consideration represents changes in the fair value of the SmartDose® contingent consideration. Please refer to Note 12, Fair Value Measurements, for additional details.

Loss on Disposal of Plant

During 2023, the Company recorded expense of $11.6 million, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
As a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. As of December 31, 2024, the statute of limitations for the U.S. federal tax years 2018 through 2024 remain open to examination. For U.S. state and local jurisdictions, tax years 2020 through 2024 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2017 through 2024.

A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:
($ in millions)202420232022
Balance at January 1$38.8 $36.5 $24.9 
Increase due to current year position5.3 6.4 11.4 
Increase (decrease) due to prior year position0.7 (1.0)0.6 
Reduction for expiration of statute of limitations/audits(1.2)(3.1)(0.4)
Balance at December 31$43.6 $38.8 $36.5 

In addition, we had balances in accrued liabilities for interest and penalties of $6.6 million and $3.8 million at December 31, 2024 and 2023, respectively. As of December 31, 2024, we had $43.6 million of total gross unrecognized tax benefits, which, if recognized, $43.6 million would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $3.3 million during the next twelve months, which would favorably impact our effective tax rate.

The components of income before income taxes and equity in net income of affiliated companies are:
($ in millions)202420232022
U.S. operations$243.4 $369.4 $394.4 
International operations342.1 328.6 285.5 
Total income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 
The related provision for income taxes consists of:
($ in millions)202420232022
Current:
Federal$29.8 $30.2 $75.7 
State2.1 (4.2)8.4 
International79.1 58.8 61.4 
Current income tax provision111.0 84.8 145.5 
Deferred:
Federal and state(18.3)(11.6)(20.3)
International14.8 49.1 (10.5)
Deferred income tax provision(3.5)37.5 (30.8)
Income tax expense$107.5 $122.3 $114.7 

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.
The significant components of our deferred tax assets and liabilities at December 31 are:
($ in millions)20242023
Deferred tax assets:
Net operating loss carryforwards$6.1 $10.0 
Tax credit carryforwards2.1 1.1 
Pension and deferred compensation28.9 22.7 
Royalty acceleration— 15.0 
Other17.9 22.4 
Capitalized R&D expenses30.1 23.9 
Leases21.5 18.6 
Valuation allowance(12.8)(15.5)
Total deferred tax assets93.8 98.2 
Deferred tax liabilities:
Property, plant, and equipment60.9 61.7 
Tax on undistributed earnings of subsidiaries0.4 3.8 
Leases22.0 18.1 
Other5.0 1.6 
Total deferred tax liabilities88.3 85.2 
Net deferred tax asset$5.5 $13.0 

A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes and equity in net income of affiliated companies is as follows:
202420232022
U.S. federal corporate tax rate21.0 %21.0 %21.0 %
Tax on international operations other than U.S. tax rate1.5 1.2 (1.5)
Adjustments to reserves for unrecognized tax benefits0.8 0.3 2.9 
U.S. tax on international earnings, net of foreign tax credits0.1 0.5 (0.3)
Foreign-Derived Intangible Income Deductions (FDII)(1.2)(1.6)(2.1)
State income taxes, net of federal tax effect0.3 0.1 1.0 
U.S. research and development credits(0.6)(0.7)(0.6)
Excess tax benefits on share-based payments(3.3)(4.6)(2.4)
Royalty acceleration— 0.5 — 
Pension settlement— — (1.2)
Tax on undistributed earnings of subsidiaries(0.5)0.3 — 
Other0.3 0.5 0.1 
Effective tax rate18.4 %17.5 %16.9 %

During 2024, we recorded a tax benefit of $19.5 million associated with stock-based compensation. The Company recognized a $2.3 million tax benefit related to a reduction in the tax liability on the unremitted earnings of its Germany subsidiaries due to a law change in 2024.

During 2023, we recorded a tax benefit of $32.0 million associated with stock-based compensation. The Company recognized a $3.0 million state tax benefit based on the outcome of a recent court case. In addition, the Company recorded $2.8 million of tax expense due to a change in the permanent reinvestment assertion of its German subsidiaries.
During 2022, we recorded tax expense of $5.7 million due to the impact of tax law changes enacted during the year, $19.8 million of tax expense due to the Company's recognition of reserves for unrecognized tax benefits, and a tax benefit of $16.5 million associated with stock-based compensation. A tax benefit of $20.6 million was recognized for the 2022 termination of our U.S. pension plan. The Company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.6 million pension termination benefit is a deferred tax benefit of $8.0 million.

State operating loss carryforwards of $98.8 million created a deferred tax asset of $5.4 million, while foreign operating loss carryforwards of $2.3 million created a deferred tax asset of $0.7 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been appropriately reserved. State loss carryforwards expire as follows: $35.7 million in 2025 and $63.1 million thereafter. Foreign loss carryforwards will begin to expire in 2028, while $0.2 million of the total $2.3 million will not expire.

During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. State research and development credit carryforwards of $2.7 million created a deferred tax asset of $2.1 million. As of December 31, 2024, $0.4 million of state research and development credits expire in 2025.

Since 2018, West has reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Beginning in 2023 and consistent with the approved plan mentioned in Note 4, Net Income Per Share, the Company began repurchasing common stock on the open market. To support the funding for this program, West may continue to repatriate earnings from its German affiliates in the future and has recorded a tax liability of $0.3 million. Accordingly, West will continue to not assert permanent reinvestment related to all of the earnings of its wholly owned German affiliates through 2024. West will continue to assert permanent reinvestment of earnings for all other foreign jurisdictions and intends to only repatriate earnings when the tax impact is de minimis.

Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $651 million of undistributed earnings from foreign subsidiaries (except our German affiliates) to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
At December 31, 2024, we were obligated under various operating lease agreements. Please refer to Note 6, Leases, for additional details.

At December 31, 2024, we were obligated under debt agreements, net of unamortized debt issuance costs including fixed and variable-rate debt. Please refer to Note 10, Debt, for additional details.

At December 31, 2024, we were obligated under various tax-qualified and non-qualified defined benefit pension plans in the U.S. and other countries that cover employees and former employees who meet eligibility requirements. Please refer to Note 15, Benefit Plans, for additional details.

At December 31, 2024, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $200.7 million, the majority of which is to be paid over the next four years, with $46.7 million due to be paid in 2025.
We have letters of credit totaling $2.4 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $1.6 million at December 31, 2024, of which $0.4 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customer.

The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM evaluates the performance of our segments based upon, among other things, segment net sales and segment operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The CODM considers budget-to-actual variances and variances against prior years within segment operating profit when making decisions about allocating resources to the segments.

The following table presents net sales information about our reportable segments, reconciled to consolidated totals:
($ in millions)202420232022
Net sales:
Proprietary Products$2,334.5 $2,397.3 $2,406.8 
Contract-Manufactured Products558.7 552.5 480.4 
Intersegment sales elimination— — (0.3)
Consolidated net sales$2,893.2 $2,949.8 $2,886.9 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

In 2024, one of our customers individually accounted for more than 10% of consolidated net sales, at 12.3% or $356.4 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. In 2023, one of our customers individually accounted for more than 10% of consolidated net sales, at 10.9% or $322.1 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. We did not have any customers accounting for greater than 10% of consolidated net sales in 2022.
The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:
Net SalesLong-Lived Assets
($ in millions)20242023202220242023
United States$1,230.8 $1,238.5 $1,286.5 $832.0 $757.1 
Germany372.5 406.1 398.7 191.1 176.0 
Ireland323.2 285.7 240.3 299.6 207.0 
France242.2 282.9 237.9 84.7 78.5 
Other European countries385.5 388.1 359.2 98.1 99.2 
Other339.0 348.5 364.3 210.3 194.7 
$2,893.2 $2,949.8 $2,886.9 $1,715.8 $1,512.5 
202420232022
($ in millions)Proprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotal
Net sales$2,334.5 $558.7 $2,893.2 $2,397.3 $552.5 $2,949.8 $2,406.8 $480.4 $2,887.2 
Cost of goods and services sold1,434.0 460.7 1,363.3 456.5 1,353.5 397.5 
Research and development69.1 — 68.4 — 58.5 — 
Selling, general and administrative expenses231.5 26.2 240.6 24.4 212.6 20.9 
Other segment expense (income)(6)
22.1 (0.5)14.9 (0.5)(2.2)1.6 
Segment operating profit$577.8 $72.3 $650.1 $710.1 $72.1 $782.2 $784.4 $60.4 $844.8 
Reconciliation of profit or loss:
Stock Based Compensation(18.7)(23.3)(23.7)
Corporate general costs(1)
(58.6)(68.3)(59.1)
Unallocated items:
Restructuring and related charges(2)
(2.1)2.0 (23.8)
Amortization of acquisition-related intangible assets(3)
(0.8)(0.7)(0.7)
Cost investment activity(4)
— (4.3)(3.5)
Loss on disposal of plant(5)
— (11.6)— 
Total consolidated operating profit569.9 676.0 734.0 
Interest (income) expense and other nonoperating expense (income), net(15.6)(22.0)54.1 
Income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 

(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
(2) During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.

(3) During 2024, 2023 and 2022, the company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020.

(4) During 2023, the Company recorded a cost investment impairment charge of $4.3 million. During 2022, the net cost investment activity was equal to $3.5 million.

(5) During 2023, the Company recorded expense of $11.6 million, as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(6) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2024, 2023 and 2022.

Please refer to Note 16, Other Expense (Income), for further discussion of unallocated items.

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:
($ in millions)
Assets20242023
Proprietary Products$2,621.1 $2,629.1 
Contract-Manufactured Products612.2 527.5 
Corporate and Unallocated(1)
410.1 672.9 
Total consolidated$3,643.4 $3,829.5 

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.

($ in millions)
Depreciation and Amortization202420232022
Proprietary Products$130.3 $112.9 $96.9 
Contract-Manufactured Products21.3 20.4 19.0 
Corporate and Unallocated3.8 4.0 4.7 
Total consolidated$155.4 $137.3 $120.6 
($ in millions)
Capital Expenditures202420232022
Proprietary Products$246.5 $259.1 $237.3 
Contract-Manufactured Products121.0 90.2 34.0 
Corporate and Unallocated9.5 12.7 13.3 
Total consolidated$377.0 $362.0 $284.6 
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Schedule II - Valuation and Qualifying Accounts
 12 Months Ended
Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
Schedule II - Valuation and Qualifying Accounts
($ in millions)
Balance at
beginning of
period
Charged to costs and expenses
Deductions (1)
Balance at
end of
period
For the year ended December 31, 2024
Allowances deducted from assets:
Deferred tax asset valuation allowance$15.5 $— $(2.7)$12.8 
Allowance for credit losses0.8 0.1 (0.1)0.8 
Total allowances deducted from assets$16.3 $0.1 $(2.8)$13.6 
For the year ended December 31, 2023
Allowances deducted from assets:
Deferred tax asset valuation allowance$13.3 $2.2 $— $15.5 
Allowance for credit losses0.2 2.3 (1.7)0.8 
Total allowances deducted from assets$13.5 $4.5 $(1.7)$16.3 
For the year ended December 31, 2022
Allowances deducted from assets:
Deferred tax asset valuation allowance$12.2 $1.1 $— $13.3 
Allowance for credit losses0.4 0.3 (0.5)0.2 
Total allowances deducted from assets$12.6 $1.4 $(0.5)$13.5 
(1)Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments.
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net income $ 492.7 $ 593.4 $ 585.9
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks. To safeguard our information assets, we have put various procedures and technologies in place. For example, our Cybersecurity Incident Response Plan clearly defines roles and responsibilities for the investigation of and response to information security incidents to minimize disruption of critical computing services and operations and prevent the loss or theft of sensitive or mission-critical information. Our plan covers various cyber incidents like ransomware attacks, cyber-intrusions, data loss, denial of service, insider threats, malware attacks, and others. In a material cybersecurity incident, our D&T team, inclusive of our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, address the threat via established escalation procedures, roles, responsibilities, and communication. Any cybersecurity incident that is declared as a crisis would follow our global Incident and Crisis Response and Management Procedure, which includes escalation to the West Leadership Team and Board of Directors, as deemed necessary pending the materiality of the incident. We have not encountered cybersecurity challenges that have materially impacted our operations or financial condition. In addition, we retain an external cybersecurity consultancy company to assist when a cybersecurity event arises, as needed and, in addition we maintain appropriate cybersecurity liability insurance.

The Company also educates and shares best practices globally with its employees to raise awareness of cybersecurity threats. As part of our onboarding process, we train all new employees on cybersecurity and conduct an annual retraining of all employees on cybersecurity standards. Training also includes how to recognize, report and properly respond to phishing and social engineering schemes. Multiple phishing simulation exercises are conducted throughout the year to increase cybersecurity awareness. Our cybersecurity defenses also utilize technologies such as next generation firewalls, Zero Trust architecture, intrusion detection and prevention measures, anti-malware software, advance threat protection, multifactor authentication, network segmentation and encryption to ensure the security of West intellectual properties, customer and vendor data. In addition, we have a dedicated 24-by-7 Security Operations Center to facilitate the monitoring of the Company's cybersecurity landscape and associated applications.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] Our approach to cybersecurity begins with our responsibility for strong governance and controls. Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Audit Committee
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness.
Cybersecurity Risk Role of Management [Text Block] Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support,
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation: The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. ("West") after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.
Use of Estimates
Use of Estimates: The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents: Cash equivalents include money market funds, time deposits and all highly liquid short-term instruments with maturities of three months or less at the time of purchase.
Accounts Receivable Accounts Receivable: Our accounts receivable balance was net of an allowance for credit losses of $0.8 million at both December 31, 2024 and 2023. Under the current expected credit loss model, we utilize a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions.
Inventories Inventories: Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value.
Property, Plant and Equipment
Property, Plant and Equipment: Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other expense (income). Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.
Leases Leases: Lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for operating leases is recognized on a straight-line basis over the lease term. Conversely, lease expense for finance leases is a front loaded expense recognition pattern over the lease term. Lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets: Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.
Impairment of Goodwill and Other Intangible Assets
Impairment of Goodwill and Other Intangible Assets: Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year.

Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates. Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 3 to 25 years and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.
Employee Benefits Employee Benefits: The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, Benefit Plans, for a more detailed discussion of our pension and other retirement plans.
Financial Instruments
Financial Instruments: All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as a hedge of the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as a hedge of the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as a hedge of the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.
Foreign Currency Translation
Foreign Currency Translation: Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.
Revenue Recognition Revenue Recognition: Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less. In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less.
We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.

We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.

For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.

Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.
Shipping and Handling Costs
Shipping and Handling Costs: Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.
Research and Development Research and Development: Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include salaries and outside services for those directly involved in research and development activities and are primarily expensed as incurred.
Litigation
Litigation: From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.
Income Taxes
Income Taxes: Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. Please refer to Note 17, Income Taxes, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other expense (income). The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.
Stock-Based Compensation Stock-Based Compensation: Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model.
Net Income Per Share
Net Income Per Share: Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.
Recently Adopted Standards and Standards Issued Not Yet Adopted
Recently Adopted Standards

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU") No. 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company has adopted and implemented the applicable disclosure requirements within this annual report.

Standards Issued Not Yet Adopted

In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.

In November 2024, the FASB issued guidance that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.
Fair Value Measurement Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Inventories The following is a summary of inventories at December 31:
($ in millions)20242023
Raw materials$166.9 $172.3 
Work in process65.2 87.3 
Finished goods144.9 175.1 
$377.0 $434.7 
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents the approximate percentage of our net sales by market group:
202420232022
Biologics39 %37 %41 %
Generics17 %20 %18 %
Pharma25 %24 %24 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

The following table presents the approximate percentage of our net sales by product category:
202420232022
High-Value Product Components45 %50 %55 %
High-Value Product Delivery Devices14 %10 %5 %
Standard Packaging 22 %21 %23 %
Contract-Manufactured Products19 %19 %17 %
100 %100 %100 %

Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023.

The following table presents the approximate percentage of our net sales by geographic location:
202420232022
Americas45 %45 %48 %
Europe, Middle East, Africa46 %46 %43 %
Asia Pacific9 %9 %9 %
100 %100 %100 %
Schedule of Change in Contract with Customer, Asset and Liability
The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2023
$21.5 
Contract assets, December 31, 2024
23.3 
Change in contract assets - increase (decrease)$1.8 
Deferred income, December 31, 2023
$(53.9)
Deferred income, December 31, 2024
(53.2)
Change in deferred income - decrease (increase)$0.7 
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Income Per Share (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic to Diluted Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
(in millions)202420232022
Net income$492.7 $593.4 $585.9 
Weighted average common shares outstanding73.0 74.3 74.4 
Dilutive effect of equity awards, based on the treasury stock method
0.7 1.0 1.4 
Weighted average shares assuming dilution73.7 75.3 75.8 
Schedule of Repurchase of Common Stock The below table summarizes share repurchases under this program during the years ended December 31:
20242023
Shares repurchased1,583,032 1,265,661 
Total cost of repurchases ($ in millions)$560.9 $438.3 
Average price per repurchased share$354.30 $346.34 
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
A summary of gross property, plant and equipment at December 31 is presented in the following table:
($ in millions)Expected useful lives (years)20242023
Land$27.9 $33.7 
Buildings and improvements
15-35
916.1 771.5 
Machinery and equipment
5-12
1,229.0 1,136.5 
Molds and dies
4-7
169.5 164.5 
Computer hardware and software
3-10
232.5 216.6 
Construction in progress410.8 415.2 
$2,985.8 $2,738.0 
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Schedule of Lease, Cost
The components of lease expense were as follows:
($ in millions)202420232022
Operating lease cost$24.2 $20.3 $15.5 
Finance lease - amortization of right-of-use (ROU) assets0.9 — — 
Finance lease - interest on lease liabilities0.1 — — 
Short-term lease cost2.5 6.1 1.3 
Variable lease cost9.0 5.5 6.8 
Total lease cost$36.7 $31.9 $23.6 
Supplemental information related to leases was as follows:
($ in millions)202420232022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$32.5 $19.1 $13.3 
Operating cash flows from finance leases$0.1 $— $— 
Financing cash flows from finance leases$23.3 $0.1 $— 
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases$41.2 $10.7 $47.6 
Finance leases$24.6 $— $— 
Schedule of Assets And Liabilities, Lessee The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:
December 31,
($ in millions)Balance Sheet Classification2024
ROU assets, netOther noncurrent assets$29.7 
Lease liabilities (current)Other current liabilities$0.9 
Lease liabilities (noncurrent)Other long-term liabilities$2.1 
Schedule of Lessee, Operating Lease, Liability, Maturity
Maturities of lease liabilities as of December 31, 2024 were as follows:
($ in millions)OperatingFinance
YearLeasesLeases
2025$23.4 $0.9 
202620.7 0.9 
202716.3 0.9 
202814.9 0.5 
202911.5 0.1 
Thereafter26.3 — 
113.1 3.3 
Less: imputed lease interest(13.4)(0.3)
Total lease liabilities$99.7 $3.0 
Finance Lease, Liability, to be Paid, Maturity
Maturities of lease liabilities as of December 31, 2024 were as follows:
($ in millions)OperatingFinance
YearLeasesLeases
2025$23.4 $0.9 
202620.7 0.9 
202716.3 0.9 
202814.9 0.5 
202911.5 0.1 
Thereafter26.3 — 
113.1 3.3 
Less: imputed lease interest(13.4)(0.3)
Total lease liabilities$99.7 $3.0 
XML 58 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies (Tables)
 12 Months Ended
Dec. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Equity Method Investments
At December 31, 2024, the following affiliated companies were accounted for under the equity method:
LocationOwnership interest
The West Company Mexico, S.A. de C.V.Mexico49%
Aluplast S.A. de C.V.Mexico49%
Pharma Tap S.A. de C.V.Mexico49%
Pharma Rubber S.A. de C.V.Mexico49%
Daikyo Seiko, Ltd. ("Daikyo")
Japan49%
Schedule of Investments in and Advances to Affiliates
The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:
December 31,December 31
($ in millions)20242023
Aggregate carrying value of investments in affiliated companies:
   Equity method affiliates$194.9 $203.2 
   Non-equity method affiliates7.2 6.8 
Total investments in affiliated companies$202.1 $210.0 
The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:
December 31,December 31
($ in millions)20242023
Payables due to affiliates$18.7 $25.9 
Receivables due from affiliates$2.5 $1.6 

The following table summarizes the Company's affiliate transactions:

(in millions)202420232022
Purchases from (and payments to) affiliates$110.0 $142.5 $167.6 
Sales to affiliates$15.3 $11.2 $14.2 
Unremitted income of affiliates$161.4 $148.0 $133.6 
Dividends received from affiliates$1.3 $3.4 $2.6 
Equity in unrealized (gains) losses of Daikyo's investments & derivatives$2.4 $2.2 $1.6 
XML 59 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The changes in the carrying amount of goodwill by reportable segment were as follows:
($ in millions)Proprietary ProductsContract-Manufactured ProductsTotal
Balance, December 31, 2022$77.9 $29.4 $107.3 
Foreign currency translation1.0 0.2 1.2 
Balance, December 31, 202378.9 29.6 108.5 
Foreign currency translation(2.1)(0.4)(2.5)
Balance, December 31, 2024$76.8 $29.2 $106.0 
Schedule of Finite-Lived Intangible Assets
Intangible assets and accumulated amortization as of December 31 were as follows:
20242023
($ in millions)CostAccumulated amortizationNetCostAccumulated amortizationNet
Patents and licensing$24.7 $(23.0)$1.7 $24.8 $(21.8)$3.0 
Technology3.3 (2.7)0.6 3.3 (2.5)0.8 
Trademarks1.2 (1.2)— 1.2 (1.2)— 
Customer relationships38.9 (30.8)8.1 39.5 (29.0)10.5 
Customer contracts8.0 (7.6)0.4 8.0 (7.2)0.8 
$76.1 $(65.3)$10.8 $76.8 $(61.7)$15.1 
XML 60 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2024
Other Current Liabilities [Abstract]  
Schedule of Other Current Liabilities
Other current liabilities as of December 31 included the following:
($ in millions)20242023
Deferred income$49.6 $41.7 
Accrued commissions, rebates & royalties24.6 22.4 
Short term derivative instruments17.4 2.1 
Dividends payable15.2 14.8 
Accrued taxes other than income12.9 9.2 
Accrued retirement plans (excl. pension)12.6 10.9 
Accrued professional services6.8 5.1 
International value added tax payable6.0 5.2 
Restructuring and severance related charges1.6 3.8 
Accrued interest1.6 2.6 
Other39.9 37.4 
Total other current liabilities$188.2 $155.2 
XML 61 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Obligations, Net of Current Maturities
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.
($ in millions)20242023
Term Loan, due July 2, 2027 (5.68%)
$130.0 $— 
Term Loan, due December 31, 2024 (6.32%)
— 81.0 
Series B notes, due July 5, 2024 (3.82%)
— 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
203.0 207.0 
Less: unamortized debt issuance costs for Term Loan and Series notes0.4 0.2 
Total debt202.6 206.8 
Less: current portion of long-term debt— 134.0 
Long-term debt, net$202.6 $72.8 
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments (Tables)
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Contracts
As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEURSGD
EUR20.8 22.9 — — 
JPY6,683.7 28.4 14.8 1.8 
SGD39.8 16.9 12.2 — 
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings
The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Fair Value Hedges:
Hedged item (intercompany loan)$1.6 $(0.3)$(28.3)Other expense (income)
Derivative designated as hedging instrument(1.6)0.3 28.3 Other expense (income)
Amount excluded from effectiveness testing(5.9)(1.4)5.2 Other expense (income)
Total$(5.9)$(1.4)$5.2 
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:
 Amount of Gain (Loss) Recognized in OCI
($ in millions)202420232022
Fair Value Hedges:
Foreign currency hedge contracts$0.2 $(2.0)$1.3 
Total$0.2 $(2.0)$1.3 
Cash Flow Hedges:  
Foreign currency hedge contracts (hedges of net sales)$1.1 $(0.8)$0.3 
Foreign currency hedge contracts (hedges of cost of goods and services sold)(6.9)(4.0)(1.1)
Forward treasury locks— — — 
Total$(5.8)$(4.8)$(0.8)
Net Investment Hedges:  
Cross-currency swap$6.8 $8.6 $9.1 
Total$6.8 $8.6 $9.1 
 Amount of (Gain) Loss Reclassified from Accumulated OCI into IncomeLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
($ in millions)202420232022 
Fair Value Hedges:
Foreign currency hedge contracts$(0.7)$2.9 $(1.6)Other expense (income)
Total$(0.7)$2.9 $(1.6)
Cash Flow Hedges:   
Foreign currency hedge contracts$(0.5)$1.3 $(1.2)Net sales
Foreign currency hedge contracts4.2 2.2 3.5 Cost of goods and services sold
Forward treasury locks0.1 0.2 0.2 Interest expense
Total$3.8 $3.7 $2.5  
Net Investment Hedges:   
Cross-currency swap— — — Other expense (income)
Total$— $— $—  
The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our consolidated statements of income for the years ended December 31:
($ in millions)202420232022
Net sales$(0.5)$1.3 $(1.2)
Cost of goods and services sold$4.2 $2.2 $3.5 
Interest expense$0.1 $0.2 $0.2 
Schedule of Derivatives Not Designated as Hedging Instruments
The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:
Amount of Gain (Loss) Recognized in IncomeLocation on Statement of Income
($ in millions)202420232022
Commodity call options$(0.7)$(1.3)$1.5 Other expense (income)
Currency forwards(2.5)0.1— Other expense (income)
Total$(3.2)$(1.2)$1.5 
XML 63 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2024		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.1 $11.1 $— $— 
Money market funds117.6 117.6 — — 
Time deposits71.3 — 71.3 — 
Foreign currency contracts17.3 — 17.3 — 
Cross-currency swap23.6 — 23.6 — 
Commodity call options0.3 — 0.3 — 
 $241.2 $128.7 $112.5 $— 
Liabilities:    
Contingent consideration$3.0 $— $— $3.0 
Deferred compensation liabilities11.2 11.2 — — 
Foreign currency contracts18.3 — 18.3 — 
 $32.5 $11.2 $18.3 $3.0 
 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2023		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$10.2 $10.2 $— $— 
Money market funds404.4 404.4 — — 
Time deposits47.9 — 47.9 — 
Foreign currency contracts5.0 — 5.0 — 
Cross-currency swap18.4 — 18.4 — 
Commodity call options0.6 — 0.6 — 
 $496.7 $424.8 $71.9 $— 
Liabilities:    
Contingent consideration$3.6 $— $— $3.6 
Deferred compensation liabilities10.4 10.4 — — 
Foreign currency contracts2.2 — 2.2 — 
 $16.2 $10.4 $2.2 $3.6 
XML 64 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:
($ in millions)DerivativesEquity affiliate investment AOCIDefined benefit pension and other postretirement plansForeign currency translationTotal
Balance, December 31, 2021$(1.2)$1.5 $(31.8)$(128.1)$(159.6)
Other comprehensive (loss) income before reclassifications0.5 0.1 (9.3)(47.3)(56.0)
Amounts reclassified out0.9 — 31.7 — 32.6 
Other comprehensive (loss) income, net of tax1.4 0.1 22.4 (47.3)(23.4)
Balance, December 31, 20220.2 1.6 (9.4)(175.4)(183.0)
Other comprehensive income (loss) before reclassifications(6.8)0.7 0.8 39.4 34.1 
Amounts reclassified out6.6 — (1.5)— 5.1 
Other comprehensive income (loss), net of tax(0.2)0.7 (0.7)39.4 39.2 
Balance, December 31, 2023— 2.3 (10.1)(136.0)(143.8)
Other comprehensive (loss) income before reclassifications(5.6)0.2 1.1 (112.3)(116.6)
Amounts reclassified out3.1 — (0.8)— 2.3 
Other comprehensive (loss) income, net of tax(2.5)0.2 0.3 (112.3)(114.3)
Balance, December 31, 2024$(2.5)$2.5 $(9.8)$(248.3)$(258.1)
Schedule of Reclassification out of Accumulated Other Comprehensive Loss
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
Detail of components202420232022Location on Statement of Income
Gains (losses) on derivatives:
Foreign currency contracts$0.5 $(1.5)$1.4 Net sales
Foreign currency contracts(5.5)(3.1)(4.1)Cost of goods and services sold
Foreign currency contracts1.0 (4.2)2.4 Other expense (income)
Forward treasury locks(0.1)(0.3)(0.3)Interest expense
Total before tax(4.1)(9.1)(0.6)
Tax benefit (expense)1.0 2.5 (0.3)
Net of tax$(3.1)$(6.6)$(0.9)
Amortization of defined benefit pension and other postretirement plans:
Actuarial gains$1.0 $1.7 $0.6 (a)
Settlements— (0.1)(52.2)(a)
Other— 0.4 (0.4)(a)
Total before tax1.0 2.0 (52.0)
Tax (expense) benefit (0.2)(0.5)20.3 
Net of tax$0.8 $1.5 $(31.7)
Total reclassifications for the period, net of tax$(2.3)$(5.1)$(32.6)

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, Benefit Plans, for additional details.
XML 65 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation of Share-based Compensation Costs by Plan
The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:
($ in millions)202420232022
Stock option and appreciation rights$11.0 $11.3 $5.6 
Performance share units2.2 5.9 15.6 
Employee stock purchase plan1.3 1.3 1.3 
Deferred compensation plans and restricted share awards4.2 4.8 1.2 
Total stock-based compensation expense$18.7 $23.3 $23.7 
Schedule of Stock Options Activity
The following table summarizes changes in outstanding options:
(in millions, except per share data)Stock OptionsWeighted Average Exercise Price
Options outstanding, January 1, 2024
1.4 $145.40 
Granted0.1 348.25 
Exercised(0.3)77.88 
Forfeited0.0 331.97 
Options outstanding, December 31, 2024
1.2 $176.37 
Options vested and expected to vest, December 31, 2024
1.1 $172.07 
Options vested and exercisable, December 31, 2024
0.9 $137.48 
Schedule of Nonvested Performance-based Share Activity
The following table summarizes changes in our outstanding stock-settled PSU awards:
UnitsWeighted Average Fair Value
Non-vested stock-settled PSU awards, January 1, 2024
98,441 $334.03 
Granted at target level34,484 348.20 
Adjustments above/(below) target2,523 339.07 
Vested and converted(35,388)350.18 
Forfeited(6,686)331.62 
Non-vested stock-settled PSU awards, December 31, 2024
93,374 $326.56 
XML 66 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans (Tables)
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The components of net periodic benefit cost and other amounts recognized in OCI were as follows:
Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
Net periodic benefit cost:
Service cost$1.2 $1.1 $1.5 $— $— $— 
Interest cost2.1 2.4 4.2 0.2 0.2 0.2 
Expected return on plan assets(1.3)(1.2)(6.1)— — — 
Amortization of actuarial loss (gain)0.6 0.6 1.3 (1.6)(2.0)(1.9)
Settlement loss— 0.1 52.2 — — — 
Other1.0 0.3 1.0 — 0.4 0.4 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:
Net (gain) loss arising during period$(0.7)$(1.4)$16.0 $(0.5)$(0.5)$(2.0)
Amortization of actuarial (loss) gain(0.6)(0.3)(1.3)1.6 2.0 1.9 
Settlement loss— (0.1)(52.2)— — — 
Foreign currency translation(0.2)0.7 (2.3)— — — 
Other— 0.4 — — — (0.4)
Total recognized in OCI$(1.5)$(0.7)$(39.8)$1.1 $1.5 $(0.5)
Total recognized in net periodic benefit cost and OCI$2.1 $2.6 $14.3 $(0.3)$0.1 $(1.8)

Net periodic benefit cost by geographic location is as follows:
 Pension benefitsOther retirement benefits
($ in millions)202420232022202420232022
U.S. plans$1.1 $0.8 $51.7 $(1.4)$(1.4)$(1.3)
International plans2.5 2.5 2.4 — — — 
Net periodic benefit cost$3.6 $3.3 $54.1 $(1.4)$(1.4)$(1.3)
Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status
The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Change in benefit obligation:
Benefit obligation, January 1$(57.5)$(55.5)$(3.7)$(3.9)
Service cost(1.2)(1.1)— — 
Interest cost(2.1)(2.4)(0.2)(0.2)
Participants’ contributions(0.1)(0.2)(0.2)(0.4)
Actuarial gain2.2 0.7 0.6 0.5 
Benefits paid3.4 2.5 0.3 0.3 
Settlement loss— 0.5 — — 
Foreign currency translation2.1 (2.0)— — 
Benefit obligation, December 31$(53.2)$(57.5)$(3.2)$(3.7)
Change in plan assets:
Fair value of assets, January 1$32.3 $29.4 $— $— 
Actual return on plan assets(0.6)2.4 — — 
Employer contribution0.7 1.1 0.1 (0.1)
Participants’ contributions0.1 0.2 0.2 0.4 
Benefits paid(2.5)(1.8)(0.3)(0.3)
Settlement loss— (0.5)— — 
Foreign currency translation(0.8)1.5 — — 
Fair value of assets, December 31$29.2 $32.3 $— $— 
Funded status at end of year$(24.0)$(25.2)$(3.2)$(3.7)
Schedule of Amounts Recognized in Balance Sheet
Amounts recognized in the balance sheet were as follows:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Noncurrent assets$2.9 $2.7 $— $— 
Current liabilities(1.4)(1.4)(0.5)(0.6)
Noncurrent liabilities(25.5)(26.5)(2.7)(3.1)
$(24.0)$(25.2)$(3.2)$(3.7)
Schedule of Amounts Recognized in Other Comprehensive Loss
The amounts in accumulated other comprehensive loss, pre-tax, consisted of:
Pension benefitsOther retirement benefits
($ in millions)2024202320242023
Net actuarial loss (gain)$14.4 $15.8 $(2.6)$(3.6)
Prior service credit(1.2)(1.1)— — 
Total$13.2 $14.7 $(2.6)$(3.6)
Schedule of Expected Benefit Payments
Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows. The expected benefit payments listed correspond to regular ongoing benefit payments expected to be made by the plans during future years.
 ($ in millions)Domestic International Total
2025$1.3 $2.5 $3.8 
20261.1 3.1 4.2 
20271.0 3.6 4.6 
20281.0 3.2 4.2 
20290.9 4.0 4.9 
2030 to 20343.6 17.2 20.8 
$8.9 $33.6 $42.5 
Schedule of Assumptions Used
Weighted average assumptions used to determine net periodic benefit cost were as follows:
Pension benefitsOther retirement benefits
202420232022202420232022
Discount rate3.95 %4.35 %2.48 %5.20 %5.55 %2.75 %
Rate of compensation increase3.08 %3.09 %2.79 %— — — 
Expected long-term rate of return on assets4.01 %4.22 %4.14 %— — — 

Weighted average assumptions used to determine the benefit obligations were as follows:
Pension benefitsOther retirement benefits
2024202320242023
Discount rate4.38 %3.95 %5.60 %5.20 %
Rate of compensation increase3.07 %3.08 %— — 
The weighted average interest crediting rating used to determine net periodic benefit cost by geographic location for our pension plans, at December 31, were as follows:
202420232022
U.S. plans4.00 %4.00 %3.31 %
International plans1.13 %1.13 %1.75 %
Schedule of Allocation of Plan Assets
The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:
20242023
Equity securities21 %16 %
Debt securities75 %80 %
Other4 %4 %
100 %100 %
The following are the target asset allocations and acceptable allocation ranges across:
Target allocationAllocation range
Equity securities
19%
15% - 20%
Debt securities
79%
75% - 85%
Other
2%
2% - 5%
The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, Fair Value Measurements. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2024Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds6.2 — 6.2 — 
Fixed income securities:
International mutual funds21.8 — 21.8 — 
Other mutual funds0.6 — 0.6 — 
Pension plan assets in the fair value hierarchy$29.2 $0.6 $28.6 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$29.2 
Balance at
December 31,Basis of Fair Value Measurements
($ in millions)2023Level 1Level 2Level 3
Cash$0.6 $0.6 $— $— 
Equity securities:
International mutual funds5.3 — 5.3 — 
Fixed income securities:
International mutual funds25.9 — 25.9 — 
Other mutual funds0.5 — 0.5 — 
Pension plan assets in the fair value hierarchy$32.3 $0.6 $31.7 $— 
Pension plan assets measured at NAV— 
Pension plan assets at fair value$32.3 
XML 67 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income) (Tables)
 12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Schedule of Other Expense (Income)
Other expense (income) consisted of:
($ in millions)202420232022
Restructuring and related charges:
Severance and benefits$(2.5)$(2.8)$8.7 
Asset-related charges— — 15.3 
Other charges— — (0.2)
Total restructuring and related charges$(2.5)$(2.8)$23.8 
Asset impairments7.3 9.6 6.2 
Foreign exchange transaction losses (gains)10.2 9.4 (4.1)
Contingent consideration5.1 2.3 3.0 
Loss on disposal of plant— 11.6 — 
Other items0.9 1.3 (2.1)
Total other expense (income) $21.0 $31.4 $26.8 
Schedule of Restructuring Obligations The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:
($ in millions)Severance and benefitsOther chargesTotal
Balance, December 31, 2023$3.0 $— $3.0 
(Credits) charges(2.5)— (2.5)
Cash payments(0.5)— (0.5)
Balance, December 31, 2024$— $— $— 
Details of Impairment of Long-Lived Assets Held and Used by Asset During the periods ended December 31, asset impairments consisted of:
($ in millions)202420232022
Cost method investment impairment charges$0.3 $4.3 $3.5 
Fixed asset impairment expense7.0 5.3 2.7 
Total asset impairments$7.3 $9.6 $6.2 
XML 68 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:
($ in millions)202420232022
Balance at January 1$38.8 $36.5 $24.9 
Increase due to current year position5.3 6.4 11.4 
Increase (decrease) due to prior year position0.7 (1.0)0.6 
Reduction for expiration of statute of limitations/audits(1.2)(3.1)(0.4)
Balance at December 31$43.6 $38.8 $36.5 
Schedule of Components of Income Before Income Taxes
The components of income before income taxes and equity in net income of affiliated companies are:
($ in millions)202420232022
U.S. operations$243.4 $369.4 $394.4 
International operations342.1 328.6 285.5 
Total income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 
Schedule of Components of Income Tax Expense
The related provision for income taxes consists of:
($ in millions)202420232022
Current:
Federal$29.8 $30.2 $75.7 
State2.1 (4.2)8.4 
International79.1 58.8 61.4 
Current income tax provision111.0 84.8 145.5 
Deferred:
Federal and state(18.3)(11.6)(20.3)
International14.8 49.1 (10.5)
Deferred income tax provision(3.5)37.5 (30.8)
Income tax expense$107.5 $122.3 $114.7 
Schedule of Deferred Tax Assets and Liabilities
The significant components of our deferred tax assets and liabilities at December 31 are:
($ in millions)20242023
Deferred tax assets:
Net operating loss carryforwards$6.1 $10.0 
Tax credit carryforwards2.1 1.1 
Pension and deferred compensation28.9 22.7 
Royalty acceleration— 15.0 
Other17.9 22.4 
Capitalized R&D expenses30.1 23.9 
Leases21.5 18.6 
Valuation allowance(12.8)(15.5)
Total deferred tax assets93.8 98.2 
Deferred tax liabilities:
Property, plant, and equipment60.9 61.7 
Tax on undistributed earnings of subsidiaries0.4 3.8 
Leases22.0 18.1 
Other5.0 1.6 
Total deferred tax liabilities88.3 85.2 
Net deferred tax asset$5.5 $13.0 
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes and equity in net income of affiliated companies is as follows:
202420232022
U.S. federal corporate tax rate21.0 %21.0 %21.0 %
Tax on international operations other than U.S. tax rate1.5 1.2 (1.5)
Adjustments to reserves for unrecognized tax benefits0.8 0.3 2.9 
U.S. tax on international earnings, net of foreign tax credits0.1 0.5 (0.3)
Foreign-Derived Intangible Income Deductions (FDII)(1.2)(1.6)(2.1)
State income taxes, net of federal tax effect0.3 0.1 1.0 
U.S. research and development credits(0.6)(0.7)(0.6)
Excess tax benefits on share-based payments(3.3)(4.6)(2.4)
Royalty acceleration— 0.5 — 
Pension settlement— — (1.2)
Tax on undistributed earnings of subsidiaries(0.5)0.3 — 
Other0.3 0.5 0.1 
Effective tax rate18.4 %17.5 %16.9 %
XML 69 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Sales by Significant Product Group
The following table presents net sales information about our reportable segments, reconciled to consolidated totals:
($ in millions)202420232022
Net sales:
Proprietary Products$2,334.5 $2,397.3 $2,406.8 
Contract-Manufactured Products558.7 552.5 480.4 
Intersegment sales elimination— — (0.3)
Consolidated net sales$2,893.2 $2,949.8 $2,886.9 
Schedule of Sales and Long-Lived Assets, by Geographical Areas
The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:
Net SalesLong-Lived Assets
($ in millions)20242023202220242023
United States$1,230.8 $1,238.5 $1,286.5 $832.0 $757.1 
Germany372.5 406.1 398.7 191.1 176.0 
Ireland323.2 285.7 240.3 299.6 207.0 
France242.2 282.9 237.9 84.7 78.5 
Other European countries385.5 388.1 359.2 98.1 99.2 
Other339.0 348.5 364.3 210.3 194.7 
$2,893.2 $2,949.8 $2,886.9 $1,715.8 $1,512.5 
Schedule of Segment Reporting Information, by Segment
202420232022
($ in millions)Proprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotalProprietary ProductsContract ManufacturingTotal
Net sales$2,334.5 $558.7 $2,893.2 $2,397.3 $552.5 $2,949.8 $2,406.8 $480.4 $2,887.2 
Cost of goods and services sold1,434.0 460.7 1,363.3 456.5 1,353.5 397.5 
Research and development69.1 — 68.4 — 58.5 — 
Selling, general and administrative expenses231.5 26.2 240.6 24.4 212.6 20.9 
Other segment expense (income)(6)
22.1 (0.5)14.9 (0.5)(2.2)1.6 
Segment operating profit$577.8 $72.3 $650.1 $710.1 $72.1 $782.2 $784.4 $60.4 $844.8 
Reconciliation of profit or loss:
Stock Based Compensation(18.7)(23.3)(23.7)
Corporate general costs(1)
(58.6)(68.3)(59.1)
Unallocated items:
Restructuring and related charges(2)
(2.1)2.0 (23.8)
Amortization of acquisition-related intangible assets(3)
(0.8)(0.7)(0.7)
Cost investment activity(4)
— (4.3)(3.5)
Loss on disposal of plant(5)
— (11.6)— 
Total consolidated operating profit569.9 676.0 734.0 
Interest (income) expense and other nonoperating expense (income), net(15.6)(22.0)54.1 
Income before income taxes and equity in net income of affiliated companies$585.5 $698.0 $679.9 

(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.
(2) During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.

(3) During 2024, 2023 and 2022, the company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020.

(4) During 2023, the Company recorded a cost investment impairment charge of $4.3 million. During 2022, the net cost investment activity was equal to $3.5 million.

(5) During 2023, the Company recorded expense of $11.6 million, as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

(6) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2024, 2023 and 2022.
The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:
($ in millions)
Assets20242023
Proprietary Products$2,621.1 $2,629.1 
Contract-Manufactured Products612.2 527.5 
Corporate and Unallocated(1)
410.1 672.9 
Total consolidated$3,643.4 $3,829.5 

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.

($ in millions)
Depreciation and Amortization202420232022
Proprietary Products$130.3 $112.9 $96.9 
Contract-Manufactured Products21.3 20.4 19.0 
Corporate and Unallocated3.8 4.0 4.7 
Total consolidated$155.4 $137.3 $120.6 
($ in millions)
Capital Expenditures202420232022
Proprietary Products$246.5 $259.1 $237.3 
Contract-Manufactured Products121.0 90.2 34.0 
Corporate and Unallocated9.5 12.7 13.3 
Total consolidated$377.0 $362.0 $284.6 
XML 70 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Allowance for doubtful accounts $ 0.8 $ 0.8
Minimum    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life of finite-lived intangible assets (in years) 3 years  
Maximum    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful life of finite-lived intangible assets (in years) 25 years  
XML 71 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Raw materials $ 166.9 $ 172.3
Work in process 65.2 87.3
Finished goods 144.9 175.1
Total inventories $ 377.0 $ 434.7
XML 72 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Revenue Recognition (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 100.00% 100.00% 100.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Biologics      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 39.00% 37.00% 41.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Generics      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 17.00% 20.00% 18.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Pharma      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 25.00% 24.00% 24.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Contract-Manufactured Products      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 19.00% 19.00% 17.00%
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 100.00% 100.00% 100.00%
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Americas      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 45.00% 45.00% 48.00%
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Europe, Middle East, Africa      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 46.00% 46.00% 43.00%
Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Asia Pacific      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 9.00% 9.00% 9.00%
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 100.00% 100.00% 100.00%
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | High-Value Product Components      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 45.00% 50.00% 55.00%
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | High-Value Product Delivery Devices      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 14.00% 10.00% 5.00%
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Standard Packaging      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 22.00% 21.00% 23.00%
Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Contract-Manufactured Products      
Disaggregation of Revenue [Line Items]      
Percentage of net sales 19.00% 19.00% 17.00%
XML 73 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Contracts Assets and Liabilities (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Contract With Customer, Asset [Roll Forward]  
Contract assets, December 31, 2023 $ 21.5
Contract assets, December 31, 2024 23.3
Change in contract assets - increase (decrease) 1.8
Contract With Customer, Liability [Roll Forward]  
Deferred income, December 31, 2023 (53.9)
Deferred income, December 31, 2024 (53.2)
Change in deferred income - decrease (increase) $ 0.7
XML 74 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Revenue from Contract with Customer [Abstract]  
Revenue recognized during the period $ 94.8
Revenue recognized that was included in the deferred income balance 37.7
Cash payments received in advance $ 132.8
XML 75 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Income Per Share - Schedule of Reconciliation of Shares (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Net income $ 492.7 $ 593.4 $ 585.9
Weighted average common shares outstanding (in shares) 73.0 74.3 74.4
Dilutive effect of equity awards, based on the treasury stock method (in shares) 0.7 1.0 1.4
Weighted average shares assuming dilution (in shares) 73.7 75.3 75.8
XML 76 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Income Per Share - Narratives (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Feb. 28, 2023
Earnings Per Share [Abstract]        
Antidilutive options excluded from computation of diluted net income per share (in shares) 300,000 200,000 200,000  
Stock repurchase program, shares authorized (in shares) 550,000     1,000,000,000
XML 77 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Income Per Share - Schedule of Repurchase of Common Stock (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Shares repurchased (in shares) 1,583,032 1,265,661  
Total cost of repurchases ($ in millions) $ 560.9 $ 438.3 $ 202.8
Average price per repurchased share (in dollars per share) $ 354.30 $ 346.34  
XML 78 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 2,985.8 $ 2,738.0
Land    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment 27.9 33.7
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 916.1 771.5
Buildings and improvements | Minimum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 15 years  
Buildings and improvements | Maximum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 35 years  
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 1,229.0 1,136.5
Machinery and equipment | Minimum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 5 years  
Machinery and equipment | Maximum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 12 years  
Molds and dies    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 169.5 164.5
Molds and dies | Minimum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 4 years  
Molds and dies | Maximum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 7 years  
Computer hardware and software    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 232.5 216.6
Computer hardware and software | Minimum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 3 years  
Computer hardware and software | Maximum    
Property, Plant and Equipment [Line Items]    
Expected useful lives (years) 10 years  
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment $ 410.8 $ 415.2
XML 79 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Property, Plant and Equipment - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]      
Depreciation $ 151.8 $ 133.7 $ 116.9
Capitalized interest $ 13.2 $ 5.8 $ 3.7
XML 80 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Narrative (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Lease, operating lease, terminate term (in years) 1 year  
Weighted average remaining lease term (in years) 8 years 3 months 18 days 9 years 9 months 18 days
Weighted average remaining lease term (years) 6 years 3 months 18 days  
Weighted average discount rate (as a percent) 3.99% 3.55%
Weighted average discount rate 4.80%  
Maximum    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Operating lease, term of contract (in months) 12 months  
XML 81 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Lease Cost (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]      
Operating lease cost $ 24.2 $ 20.3 $ 15.5
Finance lease - amortization of right-of-use (ROU) assets 0.9 0.0 0.0
Finance lease - interest on lease liabilities 0.1 0.0 0.0
Short-term lease cost 2.5 6.1 1.3
Variable lease cost 9.0 5.5 6.8
Total lease cost $ 36.7 $ 31.9 $ 23.6
XML 82 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Assets And Liabilities, Lessee (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Leases [Abstract]  
ROU assets, net $ 29.7
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other noncurrent assets
Lease liabilities (current) $ 0.9
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other current liabilities
Lease liabilities (noncurrent) $ 2.1
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other long-term liabilities
XML 83 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows from operating leases $ 32.5 $ 19.1 $ 13.3
Operating cash flows from finance leases 0.1 0.0 0.0
Financing cash flows from finance leases 23.3 0.1 0.0
Right-of-use assets obtained in exchange for new lease liabilities:      
Operating leases 41.2 10.7 47.6
Finance leases $ 24.6 $ 0.0 $ 0.0
XML 84 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Leases - Maturities of Operating Lease Liabilities (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Operating Leases  
2025 $ 23.4
2026 20.7
2027 16.3
2028 14.9
2029 11.5
Thereafter 26.3
Operating lease liability payments due 113.1
Less: imputed lease interest (13.4)
Total lease liabilities 99.7
Finance Leases  
2025 0.9
2026 0.9
2027 0.9
2028 0.5
2029 0.1
Thereafter 0.0
Finance lease, liability payment due 3.3
Less: imputed lease interest (0.3)
Total lease liabilities $ 3.0
XML 85 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies - Schedule of Investments (Details)
Dec. 31, 2024
The West Company Mexico, S.A. de C.V.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest 49.00%
Aluplast S.A. de C.V.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest 49.00%
Pharma Tap S.A. de C.V.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest 49.00%
Pharma Rubber S.A. de C.V.  
Schedule of Equity Method Investments [Line Items]  
Ownership interest 49.00%
Daikyo Seiko, Ltd. ("Daikyo")  
Schedule of Equity Method Investments [Line Items]  
Ownership interest 49.00%
XML 86 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies-Schedule of Aggregate Carrying Amount (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Equity Method Investments and Joint Ventures [Abstract]    
Equity method affiliates $ 194.9 $ 203.2
Non-equity method affiliates 7.2 6.8
Total investments in affiliated companies $ 202.1 $ 210.0
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]    
Payables due to affiliates $ 188.2 $ 155.2
Receivables due from affiliates 124.0 135.8
Affiliated Entity    
Schedule of Equity Method Investments [Line Items]    
Payables due to affiliates 18.7 25.9
Receivables due from affiliates $ 2.5 $ 1.6
XML 88 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1
Affiliated Companies - Schedule of Company's Affiliate Transactions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]      
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Unremitted income of affiliates 161.4 148.0 133.6
Dividends received from affiliates 1.3 3.4 2.6
Distributorship Agreement      
Schedule of Equity Method Investments [Line Items]      
Purchases from (and payments to) affiliates 110.0 142.5 167.6
Daikyo Seiko, Ltd. ("Daikyo")      
Schedule of Equity Method Investments [Line Items]      
Equity in unrealized (gains) losses of Daikyo's investments & derivatives 2.4 2.2 1.6
Affiliated Entity      
Schedule of Equity Method Investments [Line Items]      
Net sales $ 15.3 $ 11.2 $ 14.2
XML 89 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets - Goodwill (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 108.5 $ 107.3
Foreign currency translation (2.5) 1.2
Goodwill, ending balance 106.0 108.5
Proprietary Products    
Goodwill [Roll Forward]    
Goodwill, beginning balance 78.9 77.9
Foreign currency translation (2.1) 1.0
Goodwill, ending balance 76.8 78.9
Contract-Manufactured Products    
Goodwill [Roll Forward]    
Goodwill, beginning balance 29.6 29.4
Foreign currency translation (0.4) 0.2
Goodwill, ending balance $ 29.2 $ 29.6
XML 90 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]      
Accumulated goodwill impairment losses $ 0.1    
Foreign currency translation losses (0.7) $ (0.1)  
Amortization of intangible assets 3.6 $ 3.6 $ 3.7
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
Estimated annual amortization expense, 2025 2.8    
Estimated annual amortization expense, 2026 2.5    
Estimated annual amortization expense, 2027 2.3    
Estimated annual amortization expense, 2028 1.7    
Estimated annual amortization expense, 2029 $ 0.9    
XML 91 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets - Intangible Assets by Major Class (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Schedule of Intangible Assets by Major Class [Line Items]    
Cost $ 76.1 $ 76.8
Accumulated amortization (65.3) (61.7)
Net 10.8 15.1
Patents and licensing    
Schedule of Intangible Assets by Major Class [Line Items]    
Cost 24.7 24.8
Accumulated amortization (23.0) (21.8)
Net 1.7 3.0
Technology    
Schedule of Intangible Assets by Major Class [Line Items]    
Cost 3.3 3.3
Accumulated amortization (2.7) (2.5)
Net 0.6 0.8
Trademarks    
Schedule of Intangible Assets by Major Class [Line Items]    
Cost 1.2 1.2
Accumulated amortization (1.2) (1.2)
Net 0.0 0.0
Customer relationships    
Schedule of Intangible Assets by Major Class [Line Items]    
Cost 38.9 39.5
Accumulated amortization (30.8) (29.0)
Net 8.1 10.5
Customer contracts    
Schedule of Intangible Assets by Major Class [Line Items]    
Cost 8.0 8.0
Accumulated amortization (7.6) (7.2)
Net $ 0.4 $ 0.8
XML 92 R75.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Current Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Current Liabilities [Abstract]      
Deferred income $ 49.6 $ 41.7  
Accrued commissions, rebates & royalties 24.6 22.4  
Short term derivative instruments 17.4 2.1  
Dividends payable 15.2 14.8 $ 14.1
Accrued taxes other than income 12.9 9.2  
Accrued retirement plans (excl. pension) 12.6 10.9  
Accrued professional services 6.8 5.1  
International value added tax payable 6.0 5.2  
Restructuring and severance related charges 1.6 3.8  
Accrued interest 1.6 2.6  
Other 39.9 37.4  
Total other current liabilities $ 188.2 $ 155.2  
XML 93 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt - Schedule of Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Jul. 05, 2012
Debt Instrument [Line Items]      
Long-term debt, gross $ 203.0 $ 207.0  
Less: unamortized debt issuance costs for Term Loan and Series notes 0.4 0.2  
Total debt 202.6 206.8  
Less: current portion of long-term debt 0.0 134.0  
Long-term debt, net $ 202.6 72.8  
Term Loan, due July 2, 2027 (5.68%)      
Debt Instrument [Line Items]      
Debt instrument, stated interest rate (as a percent) 5.68%    
Long-term debt, gross $ 130.0 0.0  
Term Loan, due December 31, 2024 (6.32%)      
Debt Instrument [Line Items]      
Debt instrument, stated interest rate (as a percent) 6.32%    
Long-term debt, gross $ 0.0 81.0  
Series B notes, due July 5, 2024 (3.82%)      
Debt Instrument [Line Items]      
Debt instrument, stated interest rate (as a percent) 3.82%   3.82%
Long-term debt, gross $ 0.0 53.0  
Series C notes, due July 5, 2027 (4.02%)      
Debt Instrument [Line Items]      
Debt instrument, stated interest rate (as a percent) 4.02%    
Long-term debt, gross $ 73.0 $ 73.0  
XML 94 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Debt - Narrative (Details)
 1 Months Ended 12 Months Ended
Jul. 02, 2024
USD ($)
Mar. 31, 2022
USD ($)
fiscal_quarter
instance
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Feb. 28, 2022
USD ($)
Dec. 31, 2012
USD ($)
tranche
Jul. 05, 2012
Line of Credit Facility [Line Items]                
Long-term debt, gross     $ 203,000,000.0 $ 207,000,000.0        
Number of tranches | tranche             3  
Unamortized debt issuance costs remaining     400,000 200,000        
Interest expense     16,200,000 14,800,000 $ 11,600,000      
Aggregate annual maturities of long-term debt [Abstract]                
2025     0.0          
2026     0.0          
2027     203,000,000.0          
2028 and thereafter     0.0          
Secured Overnight Financing Rate (SOFR)                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent) 1.25%              
Secured Overnight Financing Rate (SOFR) | Minimum                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent) 1.25%              
Secured Overnight Financing Rate (SOFR) | Maximum                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent) 1.625%              
Base Rate | Minimum                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent) 0.25%              
Base Rate | Maximum                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent) 0.625%              
Revolving Credit Facility, Due 2024                
Line of Credit Facility [Line Items]                
Line of credit facility, current borrowing capacity   $ 500,000,000       $ 300,000,000    
Amount available for issuance of letters of credit   50,000,000            
Line of credit facility, additional borrowing capacity   $ 929,000,000            
Preceding period (in months)   12 months            
Ratio of debt to EBITDA   3.5            
Number of instances ratio of debt to EBITDA not to exceed threshold | instance   3            
Number of quarters following acquisition | fiscal_quarter   4            
Ratio of debt to EBITDA after acquisition   4.0            
Debt issuance costs     1,000,000 1,000,000        
Line of credit, noncurrent     0          
Line of credit facility, unused commitment level     497,600,000          
Revolving Credit Facility, Due 2024 | Applicable Margin                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent)   0.10%            
Revolving Credit Facility, Due 2024 | Fed Funds Effective Rate Overnight Index Swap Rate                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent)   0.50%            
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR)                
Line of Credit Facility [Line Items]                
Basis spread on variable interest rate (as a percent)   1.00%            
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR) | Minimum                
Line of Credit Facility [Line Items]                
Applicable margin ratio   0.00875            
Revolving Credit Facility, Due 2024 | Secured Overnight Financing Rate (SOFR) | Maximum                
Line of Credit Facility [Line Items]                
Applicable margin ratio   0.01375            
Revolving Credit Facility, Due 2024 | Base Rate | Minimum                
Line of Credit Facility [Line Items]                
Applicable margin ratio   0            
Revolving Credit Facility, Due 2024 | Base Rate | Maximum                
Line of Credit Facility [Line Items]                
Applicable margin ratio   0.00375            
Revolving Credit Facility, Due 2024 | Domestic Line of Credit                
Line of Credit Facility [Line Items]                
Credit facility is available for swing-line loans   $ 50,000,000            
Revolving Credit Facility, Due 2024 | Foreign Line of Credit                
Line of Credit Facility [Line Items]                
Credit facility is available for swing-line loans   $ 40,000,000            
Revolving Credit Facility, Due 2024 | Letter of Credit                
Line of Credit Facility [Line Items]                
Letters of credit supporting the reimbursement of workers' compensation and other claims     $ 2,400,000          
Term Loan, due July 2, 2027 (5.68%)                
Line of Credit Facility [Line Items]                
Debt instrument, face amount $ 130,000,000.0              
Debt instrument, stated interest rate (as a percent)     5.68%          
Long-term debt, gross     $ 130,000,000.0 0        
Term Loan, due December 31, 2024 (6.32%)                
Line of Credit Facility [Line Items]                
Debt issuance costs     $ 300,000 100,000        
Repayments of other long-term debt 79,900,000              
Debt instrument, stated interest rate (as a percent)     6.32%          
Long-term debt, gross     $ 0 81,000,000.0        
Series B notes, due July 5, 2024 (3.82%)                
Line of Credit Facility [Line Items]                
Repayments of other long-term debt $ 53,000,000.0              
Debt instrument, stated interest rate (as a percent)     3.82%         3.82%
Long-term debt, gross     $ 0 53,000,000.0        
Senior Notes                
Line of Credit Facility [Line Items]                
Debt instrument, face amount             $ 168,000,000.0  
Weighted average of the coupon interest rate (as a percent)     3.94%          
Unamortized debt issuance costs remaining     $ 100,000 $ 100,000        
Senior Notes | Series A notes, due July 5, 2022 (3.67%)                
Line of Credit Facility [Line Items]                
Debt instrument, face amount             $ 42,000,000.0  
Debt instrument, stated interest rate (as a percent)             3.67%  
Senior Notes | Series B notes, due July 5, 2024 (3.82%)                
Line of Credit Facility [Line Items]                
Debt instrument, face amount             $ 53,000,000.0  
Debt instrument, stated interest rate (as a percent)             3.82%  
Senior Notes | Series C notes, due July 5, 2027 (4.02%)                
Line of Credit Facility [Line Items]                
Debt instrument, face amount             $ 73,000,000.0  
Debt instrument, stated interest rate (as a percent)             4.02%  
XML 95 R78.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments - Narrative (Details)
€ in Millions, $ in Millions, $ in Millions, ¥ in Billions
 1 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
SGD ($)
bbl
$ / bbl
Dec. 31, 2024
USD ($)
bbl
$ / bbl
Dec. 31, 2024
EUR (€)
bbl
$ / bbl
Dec. 31, 2024
JPY (¥)
bbl
$ / bbl
Jul. 31, 2024
USD ($)
Dec. 31, 2023
SGD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Fair Value Hedges:                          
Derivative [Line Items]                          
(Loss) gain recognized in earnings     $ (5.9) $ (0.2) $ 4.0                
Fair Value Hedges: | Forecast                          
Derivative [Line Items]                          
(Loss) gain recognized in earnings   $ (0.3)                      
Currency forwards | SGD | Intercompany Loans                          
Derivative [Line Items]                          
Derivative, notional amount           $ 421.9         $ 601.5    
Currency forwards | SGD | Intercompany Demand Notes                          
Derivative [Line Items]                          
Derivative, notional amount                     $ 94.0    
Currency forwards | United States of America, Dollars | Intercompany Loans                          
Derivative [Line Items]                          
Derivative, notional amount             $ 13.4         $ 13.4  
Currency forwards | United States of America, Dollars | Intercompany Demand Notes                          
Derivative [Line Items]                          
Derivative, notional amount             47.1            
Currency forwards | EUR | Intercompany Demand Notes                          
Derivative [Line Items]                          
Derivative, notional amount | €               € 145.3         € 278.6
Foreign Exchange Forward                          
Derivative [Line Items]                          
Derivative contract term     18 months                    
Cross Currency Interest Rate Contract | United States of America, Dollars | Net Investment Hedges:                          
Derivative [Line Items]                          
Derivative, notional amount $ 90.0           $ 130.0   ¥ 17.0 $ 130.0      
Derivative contract term 5 years                        
Commodity Call Options                          
Derivative [Line Items]                          
Derivative, nonmonetary notional amount outstanding | bbl           190,773 190,773 190,773 190,773        
Derivative, average price risk option strike price | $ / bbl           84.70 84.70 84.70 84.70        
XML 96 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) - Dec. 31, 2024 - Foreign Exchange Forward - Designated as Hedging Instrument
€ in Millions, ¥ in Millions, $ in Millions, $ in Millions
SGD ($)
USD ($)
EUR (€)
JPY (¥)
EUR | Purchase        
Derivative [Line Items]        
Derivative, notional amount | €     € 20.8  
EUR | Sell        
Derivative [Line Items]        
Derivative, notional amount $ 0.0 $ 22.9 0.0  
JPY | Purchase        
Derivative [Line Items]        
Derivative, notional amount | ¥       ¥ 6,683.7
JPY | Sell        
Derivative [Line Items]        
Derivative, notional amount 1.8 28.4 14.8  
SGD | Purchase        
Derivative [Line Items]        
Derivative, notional amount | $ 39.8      
SGD | Sell        
Derivative [Line Items]        
Derivative, notional amount $ 0.0 $ 16.9 € 12.2  
XML 97 R80.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments - Effects of Derivative Instruments (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]      
Total $ (5.9) $ (1.4) $ 5.2
Other expense (income)      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged item (intercompany loan) 1.6 (0.3) (28.3)
Derivative designated as hedging instrument (1.6) 0.3 28.3
Amount excluded from effectiveness testing $ (5.9) $ (1.4) $ 5.2
XML 98 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedges, amount of gain (loss) recognized in OCI $ (5.8) $ (4.8) $ (0.8)
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 6.8 8.6 9.1
Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax 3.8 3.7 2.5
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0
Net sales      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) on derivative instruments, net, pretax (0.5) 1.3 (1.2)
Cost of goods and services sold      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) on derivative instruments, net, pretax 4.2 2.2 3.5
Interest expense      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) on derivative instruments, net, pretax 0.1 0.2 0.2
Fair Value Hedges:      
Derivative Instruments, Gain (Loss) [Line Items]      
Other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax 0.2 (2.0) 1.3
Other comprehensive income (loss), derivative, excluded component, increase (decrease), adjustments, before tax (0.7) 2.9 (1.6)
Foreign currency hedge contracts | Net sales      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedges, amount of gain (loss) recognized in OCI 1.1 (0.8) 0.3
Other comprehensive income (loss), cash flow hedge, reclassification for discontinuance, before tax (0.5) 1.3 (1.2)
Foreign currency hedge contracts | Cost of goods and services sold      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedges, amount of gain (loss) recognized in OCI (6.9) (4.0) (1.1)
Other comprehensive income (loss), cash flow hedge, reclassification for discontinuance, before tax 4.2 2.2 3.5
Foreign currency hedge contracts | Fair Value Hedges:      
Derivative Instruments, Gain (Loss) [Line Items]      
Other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax 0.2 (2.0) 1.3
Other comprehensive income (loss), derivative, excluded component, increase (decrease), adjustments, before tax (0.7) 2.9 (1.6)
Forward treasury locks      
Derivative Instruments, Gain (Loss) [Line Items]      
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.0 0.0
Other comprehensive income (loss), cash flow hedge, reclassification for discontinuance, before tax 0.1 0.2 0.2
Cross-currency swap      
Derivative Instruments, Gain (Loss) [Line Items]      
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 6.8 8.6 9.1
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income $ 0.0 $ 0.0 $ 0.0
XML 99 R82.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) - Not Designated as Hedging Instrument - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative instruments not designated as hedging instruments, gain (loss), net $ (3.2) $ (1.2) $ 1.5
Commodity call options      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative instruments not designated as hedging instruments, gain (loss), net (0.7) (1.3) 1.5
Currency forwards      
Derivative Instruments, Gain (Loss) [Line Items]      
Derivative instruments not designated as hedging instruments, gain (loss), net $ (2.5) $ 0.1 $ 0.0
XML 100 R83.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Assets:    
Deferred compensation assets $ 11.1 $ 10.2
Foreign currency contracts 17.3 5.0
Total assets at fair value 241.2 496.7
Liabilities:    
Contingent consideration 3.0 3.6
Deferred compensation liabilities 11.2 10.4
Total liabilities at fair value 32.5 16.2
Cross-currency swap    
Assets:    
Commodity call options 23.6 18.4
Commodity call options    
Assets:    
Commodity call options 0.3 0.6
Foreign currency hedge contracts    
Liabilities:    
Foreign currency contracts 18.3 2.2
Money market funds    
Assets:    
Money market funds 117.6 404.4
Time deposits    
Assets:    
Money market funds 71.3 47.9
Level 1    
Assets:    
Deferred compensation assets 11.1 10.2
Foreign currency contracts 0.0 0.0
Total assets at fair value 128.7 424.8
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 11.2 10.4
Total liabilities at fair value 11.2 10.4
Level 1 | Cross-currency swap    
Assets:    
Commodity call options 0.0 0.0
Level 1 | Commodity call options    
Assets:    
Commodity call options 0.0 0.0
Level 1 | Foreign currency hedge contracts    
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 1 | Money market funds    
Assets:    
Money market funds 117.6 404.4
Level 1 | Time deposits    
Assets:    
Money market funds 0.0 0.0
Level 2    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts 17.3 5.0
Total assets at fair value 112.5 71.9
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 18.3 2.2
Level 2 | Cross-currency swap    
Assets:    
Commodity call options 23.6 18.4
Level 2 | Commodity call options    
Assets:    
Commodity call options 0.3 0.6
Level 2 | Foreign currency hedge contracts    
Liabilities:    
Foreign currency contracts 18.3 2.2
Level 2 | Money market funds    
Assets:    
Money market funds 0.0 0.0
Level 2 | Time deposits    
Assets:    
Money market funds 71.3 47.9
Level 3    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts 0.0 0.0
Total assets at fair value 0.0 0.0
Liabilities:    
Contingent consideration 3.0 3.6
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 3.0 3.6
Level 3 | Cross-currency swap    
Assets:    
Commodity call options 0.0 0.0
Level 3 | Commodity call options    
Assets:    
Commodity call options 0.0 0.0
Level 3 | Foreign currency hedge contracts    
Liabilities:    
Foreign currency contracts 0.0 0.0
Level 3 | Money market funds    
Assets:    
Money market funds 0.0 0.0
Level 3 | Time deposits    
Assets:    
Money market funds $ 0.0 $ 0.0
XML 101 R84.htm IDEA: XBRL DOCUMENT v3.25.0.1
Fair Value Measurements - Other Financial Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Fair Value Disclosures [Abstract]    
Long-term debt, fair value $ 200.5  
Long-term debt 202.6 $ 72.8
Debt, fair value   204.4
Long-term debt $ 202.6 $ 206.8
XML 102 R85.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance $ 2,881.0 $ 2,684.9 $ 2,335.4
Other comprehensive (loss) income before reclassifications (116.6) 34.1 (56.0)
Amounts reclassified out 2.3 5.1 32.6
Other comprehensive (loss) income, net of tax (114.3) 39.2 (23.4)
Ending balance 2,682.3 2,881.0 2,684.9
Derivatives      
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance 0.0 0.2 (1.2)
Other comprehensive (loss) income before reclassifications (5.6) (6.8) 0.5
Amounts reclassified out 3.1 6.6 0.9
Other comprehensive (loss) income, net of tax (2.5) (0.2) 1.4
Ending balance (2.5) 0.0 0.2
Equity affiliate investment AOCI      
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance 2.3 1.6 1.5
Other comprehensive (loss) income before reclassifications 0.2 0.7 0.1
Amounts reclassified out 0.0 0.0 0.0
Other comprehensive (loss) income, net of tax 0.2 0.7 0.1
Ending balance 2.5 2.3 1.6
Defined benefit pension and other postretirement plans      
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance (10.1) (9.4) (31.8)
Other comprehensive (loss) income before reclassifications 1.1 0.8 (9.3)
Amounts reclassified out (0.8) (1.5) 31.7
Other comprehensive (loss) income, net of tax 0.3 (0.7) 22.4
Ending balance (9.8) (10.1) (9.4)
Foreign currency translation      
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance (136.0) (175.4) (128.1)
Other comprehensive (loss) income before reclassifications (112.3) 39.4 (47.3)
Amounts reclassified out 0.0 0.0 0.0
Other comprehensive (loss) income, net of tax (112.3) 39.4 (47.3)
Ending balance (248.3) (136.0) (175.4)
Total      
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]      
Beginning balance (143.8) (183.0) (159.6)
Other comprehensive (loss) income, net of tax (114.3) 39.2 (23.4)
Ending balance $ (258.1) $ (143.8) $ (183.0)
XML 103 R86.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Cost of goods and services sold (1,894.7) (1,820.6) (1,750.7)
Other expense (income) (21.0) (31.4) (26.8)
Interest expense (3.0) (9.0) (7.9)
Total before tax 585.5 698.0 679.9
Tax (expense) benefit (107.5) (122.3) (114.7)
Total reclassifications for the period, net of tax 492.7 593.4 585.9
Reclassification out of Accumulated Other Comprehensive Loss      
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Total reclassifications for the period, net of tax (2.3) (5.1) (32.6)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives:      
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Total before tax (4.1) (9.1) (0.6)
Tax (expense) benefit 1.0 2.5 (0.3)
Total reclassifications for the period, net of tax (3.1) (6.6) (0.9)
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Foreign currency contracts      
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Net sales 0.5 (1.5) 1.4
Cost of goods and services sold (5.5) (3.1) (4.1)
Other expense (income) 1.0 (4.2) 2.4
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives: | Forward treasury locks      
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Interest expense (0.1) (0.3) (0.3)
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans:      
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]      
Actuarial gains 1.0 1.7 0.6
Settlements 0.0 (0.1) (52.2)
Other 0.0 0.4 (0.4)
Total before tax 1.0 2.0 (52.0)
Tax (expense) benefit (0.2) (0.5) 20.3
Total reclassifications for the period, net of tax $ 0.8 $ 1.5 $ (31.7)
XML 104 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
plan
$ / shares
shares
Dec. 31, 2023
USD ($)
plan
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Shares available for issuance under the 2016 Plan (in shares) 1,300,000    
Unrecognized compensation expense for all nonvested awards | $ $ 25,800    
Weighted average period for recognition (in years) 1 year 7 months 6 days    
Weighted average remaining contractual life of options outstanding (in years) 4 years 7 months 6 days    
Weighted average remaining contractual life of options exercisable (in years) 3 years 8 months 12 days    
Aggregate intrinsic value of total options outstanding | $ $ 182,000    
Aggregate intrinsic value of total options vested | $ $ 178,700    
Weighted average grant date fair value of options granted (in dollars per share) | $ / shares $ 134.25 $ 108.95 $ 96.43
Intrinsic value of options exercised | $ $ 90,500 $ 151,000 $ 60,100
Grant date fair value of options vested | $ $ 10,800 $ 8,600 $ 8,800
Deferred compensation plans and restricted share awards      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Deferred compensation conversion unit (in shares) 1    
Number of deferred compensation plans | plan 2 2  
Number of deferred stock units (in shares) 332,897 352,541  
Number of deferred stock units payable in cash (in shares) 8,851 8,931  
Deferred compensation plans and restricted share awards | Non-Employee Directors      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted at target level (in dollars per share) | $ / shares $ 386.03 $ 357.00 $ 300.78
Granted at target level (in shares) 6,064 6,160 4,827
Stock Option      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Rate shares are reduced for each award granted 1    
Awards, expiration period (in years) 10 years    
Risk-free interest rate (as a percent) 4.30% 4.10% 1.80%
Stock volatility (as a percent) 32.00% 29.80% 25.10%
Dividend yield (as a percent) 0.30% 0.30% 0.20%
Expected life (in years) 6 years 5 years 8 months 12 days 5 years 7 months 6 days
Award Types Other than Stock Options and Stock Appreciation Rights      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Rate shares are reduced for each award granted 2.5    
Stock-settled PSU awards      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted at target level (in dollars per share) | $ / shares $ 348.20 $ 306.97 $ 362.40
Number of shares to be issued upon conversion (in shares) 7,946    
Granted at target level (in shares) 34,484    
Stock-settled PSU awards | Minimum      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Actual payout range 0.00%    
Stock-settled PSU awards | Maximum      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Actual payout range 200.00%    
Employee stock purchase plan      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Shares available for issuance under the 2016 Plan (in shares) 3,700,000    
Percentage of current market price for sales to eligible employees (as a percent) 85.00%    
Limitation on payroll deductions of employee's base salary (as a percent) 25.00%    
Limitation on payroll deductions of employee's base salary, amount | $ $ 25    
Maximum number of shares per employee (in shares) 2,000    
Maximum number of shares per employee, per year (in shares) 8,000    
Purchases of shares (in shares) 25,237 23,955 27,894
Restricted Stock      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Granted at target level (in dollars per share) | $ / shares $ 339.32 $ 314.06 $ 310.52
Granted at target level (in shares) 9,660 8,343 9,648
XML 105 R88.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Stock compensation expense $ 18.7 $ 23.3 $ 23.7
Stock option and appreciation rights      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Stock compensation expense 11.0 11.3 5.6
Performance share units      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Stock compensation expense 2.2 5.9 15.6
Employee stock purchase plan      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Stock compensation expense 1.3 1.3 1.3
Deferred compensation plans and restricted share awards      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Stock compensation expense $ 4.2 $ 4.8 $ 1.2
XML 106 R89.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation - Stock Options Activity (Details)
shares in Millions
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Stock Options  
Options outstanding, beginning (in shares) | shares 1.4
Granted (in shares) | shares 0.1
Exercised (in shares) | shares (0.3)
Forfeited (in shares) | shares (0.0)
Options outstanding, ending (in shares) | shares 1.2
Options vested and expected to vest (in shares) | shares 1.1
Options vested and exercisable (in shares) | shares 0.9
Weighted Average Exercise Price  
Options outstanding, beginning (in dollars per share) | $ / shares $ 145.40
Granted (in dollars per share) | $ / shares 348.25
Exercised (in dollars per share) | $ / shares 77.88
Forfeited (in dollars per share) | $ / shares 331.97
Options outstanding, ending (in dollars per share) | $ / shares 176.37
Options vested and expected to vest (in dollars per share) | $ / shares 172.07
Options vested and exercisable (in dollars per share) | $ / shares $ 137.48
XML 107 R90.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation - Nonvested Performance-based Award Activity (Details) - Stock-settled PSU awards - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Units      
Outstanding, beginning (in shares) 98,441    
Granted at target level (in shares) 34,484    
Adjustments above/(below) target (in shares) 2,523    
Vested and converted (in shares) (35,388)    
Forfeited (in shares) (6,686)    
Outstanding, ending (in shares) 93,374 98,441  
Weighted Average Fair Value      
Outstanding, beginning (in dollars per share) $ 334.03    
Granted at target level (in dollars per share) 348.20 $ 306.97 $ 362.40
Adjustments above/(below) target (in dollars per share) 339.07    
Vested and converted (in dollars per share) 350.18    
Forfeited (in dollars per share) 331.62    
Outstanding, ending (in dollars per share) $ 326.56 $ 334.03  
XML 108 R91.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2031
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]        
401 (k) plan contributions   $ 23,200,000 $ 22,700,000 $ 22,800,000
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]       Other Nonoperating Income (Expense)
Fair value of plan assets   29,200,000 32,300,000  
Accumulated benefit obligation   $ 49,500,000 53,700,000  
Assumed healthcare cost trend rate used to determine benefit obligations   6.50%    
Assumed healthcare cost trend rate used to determine net periodic benefit cost   6.75%    
Forecast        
Defined Benefit Plan Disclosure [Line Items]        
Assumed healthcare cost trend rate used to determine benefit obligations 5.00%      
Assumed healthcare cost trend rate used to determine net periodic benefit cost 5.00%      
Other retirement benefits        
Defined Benefit Plan Disclosure [Line Items]        
Settlements   $ 0 0 $ 0
Fair value of plan assets   0 $ 0 $ 0
Expected contribution to the plan   $ 500,000    
Discount rate (as a percent)   5.60% 5.20%  
Rate of compensation increase   0.00% 0.00%  
Expected long-term rate of return on assets (as a percent)   0.00% 0.00% 0.00%
Pension benefits        
Defined Benefit Plan Disclosure [Line Items]        
Settlements   $ 0 $ (100,000) $ (52,200,000)
Fair value of plan assets   29,200,000 $ 32,300,000 $ 29,400,000
Expected contribution to the plan   $ 600,000    
Discount rate (as a percent)   4.38% 3.95%  
Rate of compensation increase   3.07% 3.08%  
Expected long-term rate of return on assets (as a percent)   4.01% 4.22% 4.14%
United States        
Defined Benefit Plan Disclosure [Line Items]        
Employer contribution   $ 0 $ 0 $ 7,100,000
Discount rate (as a percent)   5.60% 5.20%  
Rate of compensation increase   0.00% 0.00%  
Expected long-term rate of return on assets (as a percent)       3.70%
International plans        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 29,200,000 $ 32,300,000  
Accumulated benefit obligation   $ 44,000,000.0 $ 47,700,000  
Discount rate (as a percent)   4.24% 3.80%  
Rate of compensation increase   3.07% 3.08%  
XML 109 R92.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pension benefits      
Net periodic benefit cost:      
Service cost $ 1.2 $ 1.1 $ 1.5
Interest cost 2.1 2.4 4.2
Expected return on plan assets (1.3) (1.2) (6.1)
Amortization of actuarial loss (gain) 0.6 0.6 1.3
Settlement loss 0.0 0.1 52.2
Other 1.0 0.3 1.0
Net periodic benefit cost 3.6 3.3 54.1
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
Net (gain) loss arising during period (0.7) (1.4) 16.0
Amortization of actuarial (loss) gain (0.6) (0.3) (1.3)
Settlement loss 0.0 (0.1) (52.2)
Foreign currency translation (0.2) 0.7 (2.3)
Other 0.0 0.4 0.0
Total recognized in OCI (1.5) (0.7) (39.8)
Total recognized in net periodic benefit cost and OCI 2.1 2.6 14.3
Pension benefits | United States      
Net periodic benefit cost:      
Net periodic benefit cost 1.1 0.8 51.7
Pension benefits | International plans      
Net periodic benefit cost:      
Net periodic benefit cost 2.5 2.5 2.4
Other retirement benefits      
Net periodic benefit cost:      
Service cost 0.0 0.0 0.0
Interest cost 0.2 0.2 0.2
Expected return on plan assets 0.0 0.0 0.0
Amortization of actuarial loss (gain) (1.6) (2.0) (1.9)
Settlement loss 0.0 0.0 0.0
Other 0.0 0.4 0.4
Net periodic benefit cost (1.4) (1.4) (1.3)
Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:      
Net (gain) loss arising during period (0.5) (0.5) (2.0)
Amortization of actuarial (loss) gain 1.6 2.0 1.9
Settlement loss 0.0 0.0 0.0
Foreign currency translation 0.0 0.0 0.0
Other 0.0 0.0 (0.4)
Total recognized in OCI 1.1 1.5 (0.5)
Total recognized in net periodic benefit cost and OCI (0.3) 0.1 (1.8)
Other retirement benefits | United States      
Net periodic benefit cost:      
Net periodic benefit cost (1.4) (1.4) (1.3)
Other retirement benefits | International plans      
Net periodic benefit cost:      
Net periodic benefit cost $ 0.0 $ 0.0 $ 0.0
XML 110 R93.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Change in plan assets:      
Balance $ 32.3    
Balance 29.2 $ 32.3  
Pension benefits      
Change in benefit obligation:      
Balance (57.5) (55.5)  
Service cost (1.2) (1.1) $ (1.5)
Interest cost (2.1) (2.4) (4.2)
Participants’ contributions (0.1) (0.2)  
Actuarial gain 2.2 0.7  
Benefits paid 3.4 2.5  
Settlement loss 0.0 0.5  
Foreign currency translation 2.1 (2.0)  
Balance (53.2) (57.5) (55.5)
Change in plan assets:      
Balance 32.3 29.4  
Actual return on plan assets (0.6) 2.4  
Employer contribution 0.7 1.1  
Participants’ contributions 0.1 0.2  
Benefits paid (2.5) (1.8)  
Settlement loss 0.0 (0.5)  
Foreign currency translation (0.8) 1.5  
Balance 29.2 32.3 29.4
Funded status at end of year (24.0) (25.2)  
Other retirement benefits      
Change in benefit obligation:      
Balance (3.7) (3.9)  
Service cost 0.0 0.0 0.0
Interest cost (0.2) (0.2) (0.2)
Participants’ contributions (0.2) (0.4)  
Actuarial gain 0.6 0.5  
Benefits paid 0.3 0.3  
Settlement loss 0.0 0.0  
Foreign currency translation 0.0 0.0  
Balance (3.2) (3.7) (3.9)
Change in plan assets:      
Balance 0.0 0.0  
Actual return on plan assets 0.0 0.0  
Employer contribution 0.1 (0.1)  
Participants’ contributions 0.2 0.4  
Benefits paid (0.3) (0.3)  
Settlement loss 0.0 0.0  
Foreign currency translation 0.0 0.0  
Balance 0.0 0.0 $ 0.0
Funded status at end of year $ (3.2) $ (3.7)  
XML 111 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Amounts Recognized in Balance Sheet (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
Noncurrent liabilities $ (28.2) $ (29.6)
Pension benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
Noncurrent assets 2.9 2.7
Current liabilities (1.4) (1.4)
Noncurrent liabilities (25.5) (26.5)
Total liabilities (24.0) (25.2)
Other retirement benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
Noncurrent assets 0.0 0.0
Current liabilities (0.5) (0.6)
Noncurrent liabilities (2.7) (3.1)
Total liabilities $ (3.2) $ (3.7)
XML 112 R95.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Pension benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
Net actuarial loss (gain) $ 14.4 $ 15.8
Prior service credit (1.2) (1.1)
Total 13.2 14.7
Other retirement benefits    
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]    
Net actuarial loss (gain) (2.6) (3.6)
Prior service credit 0.0 0.0
Total $ (2.6) $ (3.6)
XML 113 R96.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Expected Benefit Payments (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
2025 $ 3.8
2026 4.2
2027 4.6
2028 4.2
2029 4.9
2030 to 2034 20.8
Total benefit payments expected 42.5
United States  
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
2025 1.3
2026 1.1
2027 1.0
2028 1.0
2029 0.9
2030 to 2034 3.6
Total benefit payments expected 8.9
International plans  
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]  
2025 2.5
2026 3.1
2027 3.6
2028 3.2
2029 4.0
2030 to 2034 17.2
Total benefit payments expected $ 33.6
XML 114 R97.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Assumptions Used (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pension benefits      
Weighted average assumptions used in net periodic benefit cost:      
Discount rate 3.95% 4.35% 2.48%
Rate of compensation increase 3.08% 3.09% 2.79%
Expected long-term rate of return on assets 4.01% 4.22% 4.14%
Weighted average assumptions used in benefit obligations:      
Discount rate 4.38% 3.95%  
Rate of compensation increase 3.07% 3.08%  
Other retirement benefits      
Weighted average assumptions used in net periodic benefit cost:      
Discount rate 5.20% 5.55% 2.75%
Rate of compensation increase 0.00% 0.00% 0.00%
Expected long-term rate of return on assets 0.00% 0.00% 0.00%
Weighted average assumptions used in benefit obligations:      
Discount rate 5.60% 5.20%  
Rate of compensation increase 0.00% 0.00%  
XML 115 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
United States      
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]      
Weighted-average interest crediting rating used to determine net periodic benefit cost 4.00% 4.00% 3.31%
International plans      
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]      
Weighted-average interest crediting rating used to determine net periodic benefit cost 1.13% 1.13% 1.75%
XML 116 R99.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans - Allocation of Plan Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 100.00% 100.00%
Fair value of plan assets $ 29.2 $ 32.3
Pension plan assets in the fair value hierarchy    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 29.2 32.3
Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.6 0.6
Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 28.6 31.7
Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Pension plan assets measured at NAV    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 0.0 0.0
Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Target allocation 19.00%  
Equity securities | Pension plan assets in the fair value hierarchy    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 6.2 5.3
Equity securities | Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Equity securities | Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 6.2 5.3
Equity securities | Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 0.0 $ 0.0
Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Target allocation 79.00%  
Allocation range 75.00% 80.00%
Other    
Defined Benefit Plan Disclosure [Line Items]    
Target allocation 2.00%  
Allocation range 4.00% 4.00%
Cash | Pension plan assets in the fair value hierarchy    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 0.6 $ 0.6
Cash | Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.6 0.6
Cash | Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Cash | Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
International mutual funds | Pension plan assets in the fair value hierarchy    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 21.8 25.9
International mutual funds | Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
International mutual funds | Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 21.8 25.9
International mutual funds | Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Other mutual funds | Pension plan assets in the fair value hierarchy    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.6 0.5
Other mutual funds | Level 1    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.0 0.0
Other mutual funds | Level 2    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets 0.6 0.5
Other mutual funds | Level 3    
Defined Benefit Plan Disclosure [Line Items]    
Fair value of plan assets $ 0.0 $ 0.0
Minimum | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 15.00%  
Minimum | Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 75.00%  
Minimum | Other    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 2.00%  
Maximum | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 20.00%  
Maximum | Debt securities    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 85.00%  
Maximum | Other    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 5.00%  
Weighted Average | Equity securities    
Defined Benefit Plan Disclosure [Line Items]    
Allocation range 21.00% 16.00%
XML 117 R100.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income) - Schedule of Other (Income) Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Income and Expenses [Abstract]      
Severance and benefits $ (2.5) $ (2.8) $ 8.7
Asset-related charges 0.0 0.0 15.3
Other charges 0.0 0.0 (0.2)
Total restructuring and related charges (2.5) (2.8) 23.8
Asset impairments 7.3 9.6 6.2
Foreign exchange transaction losses (gains) 10.2 9.4 (4.1)
Contingent consideration 5.1 2.3 3.0
Loss on disposal of plant 0.0 11.6 0.0
Other items 0.9 1.3 (2.1)
Total other expense (income) $ 21.0 $ 31.4 $ 26.8
XML 118 R101.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income) - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Jun. 30, 2023
facility
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Other Income and Expenses [Abstract]          
Restructuring and related activities, period of implementation (up to) 24 months        
Effect on future earnings, amount $ 17,000,000        
Restructuring and related cost     $ 0    
Foreign exchange transaction (losses) gains     (10,200,000) $ (9,400,000) $ 4,100,000
Loss on disposal of plant     $ 0 $ (11,600,000) $ 0
Number of loss on disposal manufacturing facility | facility   1      
XML 119 R102.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Balance, December 31, 2023 $ 3.8
Balance, December 31, 2024 1.6
2022 Restructuring Plan  
Restructuring Reserve [Roll Forward]  
Balance, December 31, 2023 3.0
(Credits) charges (2.5)
Cash payments (0.5)
Balance, December 31, 2024 0.0
2022 Restructuring Plan | Severance and benefits  
Restructuring Reserve [Roll Forward]  
Balance, December 31, 2023 3.0
(Credits) charges (2.5)
Cash payments (0.5)
Balance, December 31, 2024 0.0
2022 Restructuring Plan | Other charges  
Restructuring Reserve [Roll Forward]  
Balance, December 31, 2023 0.0
(Credits) charges 0.0
Cash payments 0.0
Balance, December 31, 2024 $ 0.0
XML 120 R103.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring and Related Activities [Abstract]      
Cost method investment impairment charges $ 0.3 $ 4.3 $ 3.5
Fixed asset impairment expense 7.0 5.3 2.7
Asset impairments $ 7.3 $ 9.6 $ 6.2
XML 121 R104.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Balance at January 1 $ 38.8 $ 36.5 $ 24.9
Increase due to current year position 5.3 6.4 11.4
Decrease due to prior year position   (1.0)  
Increase due to prior year position 0.7   0.6
Reduction for expiration of statute of limitations/audits (1.2) (3.1) (0.4)
Balance at December 31 $ 43.6 $ 38.8 $ 36.5
XML 122 R105.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2019
Income Tax Contingency [Line Items]          
Accrued liabilities for interest and penalties $ 6.6 $ 3.8      
Total gross unrecognized tax benefits 43.6 38.8 $ 36.5 $ 24.9  
Estimated increase (decrease) in the liability for unrecognized tax benefits 3.3        
Tax benefit from stock-based compensation 19.5 32.0 16.5    
Tax benefit related to a reduction in the liability on the unremitted earnings 2.3 2.8      
Tax benefit from recent court case   3.0      
Tax expense (benefit) from impact of tax law changes enacted     5.7    
Tax expense from recognition of reserves for unrecognized tax benefits     19.8    
Tax benefit from termination of pension plans     20.6    
Deferred tax benefit     $ 8.0    
Operating loss carryforwards, state and local 5.4        
Operating loss carryforwards, foreign 0.7       $ 2.1
Tax on undistributed earnings of subsidiaries 0.4 $ 3.8      
Undistributed earnings of foreign subsidiaries 651.0        
Germany          
Income Tax Contingency [Line Items]          
Tax on undistributed earnings of subsidiaries 0.3        
State and Local Jurisdiction          
Income Tax Contingency [Line Items]          
Operating loss carryforwards 98.8        
State and Local Jurisdiction | Research Tax Credit Carryforward          
Income Tax Contingency [Line Items]          
Tax credit carryforward 0.4       $ 2.7
State and Local Jurisdiction | Year 2025          
Income Tax Contingency [Line Items]          
Operating loss carryforwards, subject to expiration 35.7        
State and Local Jurisdiction | Thereafter          
Income Tax Contingency [Line Items]          
Operating loss carryforwards, subject to expiration 63.1        
Foreign Tax Jurisdiction          
Income Tax Contingency [Line Items]          
Operating loss carryforwards 2.3        
Operating loss carryforwards, not subject to expiration $ 0.2        
XML 123 R106.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Income Before Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. operations $ 243.4 $ 369.4 $ 394.4
International operations 342.1 328.6 285.5
Income before income taxes and equity in net income of affiliated companies $ 585.5 $ 698.0 $ 679.9
XML 124 R107.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Components of Income Tax Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current:      
Federal $ 29.8 $ 30.2 $ 75.7
State 2.1 (4.2) 8.4
International 79.1 58.8 61.4
Current income tax provision 111.0 84.8 145.5
Deferred:      
Federal and state (18.3) (11.6) (20.3)
International 14.8 49.1 (10.5)
Deferred income tax provision (3.5) 37.5 (30.8)
Income tax expense $ 107.5 $ 122.3 $ 114.7
XML 125 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Net operating loss carryforwards $ 6.1 $ 10.0
Tax credit carryforwards 2.1 1.1
Pension and deferred compensation 28.9 22.7
Royalty acceleration 0.0 15.0
Other 17.9 22.4
Capitalized R&D expenses 30.1 23.9
Leases 21.5 18.6
Valuation allowance (12.8) (15.5)
Total deferred tax assets 93.8 98.2
Deferred tax liabilities:    
Property, plant, and equipment 60.9 61.7
Tax on undistributed earnings of subsidiaries 0.4 3.8
Leases 22.0 18.1
Other 5.0 1.6
Total deferred tax liabilities 88.3 85.2
Net deferred tax asset $ 5.5 $ 13.0
XML 126 R109.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Effective Income Tax Reconciliation (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. federal corporate tax rate 21.00% 21.00% 21.00%
Tax on international operations other than U.S. tax rate 1.50% 1.20% (1.50%)
Adjustments to reserves for unrecognized tax benefits 0.80% 0.30% 2.90%
U.S. tax on international earnings, net of foreign tax credits 0.10% 0.50% (0.30%)
Foreign-Derived Intangible Income Deductions (FDII) (1.20%) (1.60%) (2.10%)
State income taxes, net of federal tax effect 0.30% 0.10% 1.00%
U.S. research and development credits (0.60%) (0.70%) (0.60%)
Excess tax benefits on share-based payments (3.30%) (4.60%) (2.40%)
Royalty acceleration 0.00% 0.50% 0.00%
Pension settlement 0.00% 0.00% (1.20%)
Tax on undistributed earnings of subsidiaries (0.50%) 0.30% 0.00%
Other 0.30% 0.50% 0.10%
Effective tax rate 18.40% 17.50% 16.90%
XML 127 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1
Commitments and Contingencies (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
Loss Contingencies [Line Items]  
Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment $ 200.7
Unrecorded Unconditional Purchase Obligation, Term 4 years
Outstanding unconditional contractual commitments due to be paid in 2024 $ 46.7
Insurance Claims  
Loss Contingencies [Line Items]  
Accrual for insurance obligations 1.6
Amount reimbursable by the insurance company 0.4
Letter of Credit | Revolving Credit Facility, Due 2024  
Loss Contingencies [Line Items]  
Letters of credit supporting the reimbursement of workers' compensation and other claims $ 2.4
XML 128 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Narrative (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting, Revenue Reconciling Items [Line Items]      
Number of reportable segments | segment 2    
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Percentage of net sales 100.00% 100.00% 100.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | One Customer      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Percentage of net sales 12.30% 10.90%  
Net sales $ 356.4 $ 322.1  
XML 129 R112.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Sales by Product Group (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting, Revenue Reconciling Items [Line Items]      
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Operating Segments      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Net sales 2,893.2 2,949.8 2,887.2
Operating Segments | Proprietary Products      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Net sales 2,334.5 2,397.3 2,406.8
Operating Segments | Contract-Manufactured Products      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Net sales 558.7 552.5 480.4
Intersegment sales elimination      
Segment Reporting, Revenue Reconciling Items [Line Items]      
Net sales $ 0.0 $ 0.0 $ (0.3)
XML 130 R113.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Sales and Long-lived Assets by Geographic Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Long-Lived Assets 1,715.8 1,512.5  
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 1,230.8 1,238.5 1,286.5
Long-Lived Assets 832.0 757.1  
Germany      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 372.5 406.1 398.7
Long-Lived Assets 191.1 176.0  
Ireland      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 323.2 285.7 240.3
Long-Lived Assets 299.6 207.0  
France      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 242.2 282.9 237.9
Long-Lived Assets 84.7 78.5  
Other European countries      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 385.5 388.1 359.2
Long-Lived Assets 98.1 99.2  
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Net Sales 339.0 348.5 $ 364.3
Long-Lived Assets $ 210.3 $ 194.7  
XML 131 R114.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Segment Financial Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Net sales $ 2,893.2 $ 2,949.8 $ 2,886.9
Cost of goods and services sold 1,894.7 1,820.6 1,750.7
Research and development 69.1 68.4 58.5
Selling, general and administrative expenses 338.5 353.4 316.9
Operating profit 569.9 676.0 734.0
Stock-based compensation expense (18.7) (23.3) (23.7)
Amortization of intangible assets 3.6 3.6 3.7
Loss on disposal of plant 0.0 (11.6) 0.0
Interest (income) expense and other nonoperating expense (income), net (15.6) (22.0) 54.1
Income before income taxes and equity in net income of affiliated companies 585.5 698.0 679.9
Asset-related charges 0.0 0.0 15.3
Assets 3,643.4 3,829.5  
Depreciation and Amortization 155.4 137.3 120.6
Capital Expenditures 377.0 362.0 284.6
Severance related costs (2.5) (2.8) 8.7
Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 2,893.2 2,949.8 2,887.2
Cost of goods and services sold
Research and development
Selling, general and administrative expenses
Other expense (income)
Operating profit 650.1 782.2 844.8
Corporate and Unallocated      
Segment Reporting Information [Line Items]      
Stock-based compensation expense (18.7) (23.3) (23.7)
Corporate general costs (58.6) (68.3) (59.1)
Restructuring and related charges, net 2.1 (2.0) 23.8
Amortization of intangible assets 0.8 0.7 0.7
Cost investment activity 0.0 (4.3) (3.5)
Loss on disposal of plant 0.0 (11.6) 0.0
Asset-related charges     15.3
Assets 410.1 672.9  
Depreciation and Amortization 3.8 4.0 4.7
Capital Expenditures 9.5 12.7 13.3
Severance related costs     8.7
Corporate and Unallocated | Selling, General and Administrative Expenses      
Segment Reporting Information [Line Items]      
Restructuring and related charges, net $ 4.6    
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative expenses    
Corporate and Unallocated | Other expense (income)      
Segment Reporting Information [Line Items]      
Restructuring and related charges, net $ (2.5) $ (2.8)  
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Other expense (income) Other expense (income)  
Corporate and Unallocated | Cost of goods and services sold      
Segment Reporting Information [Line Items]      
Restructuring and related charges, net   $ 0.8  
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of goods and services sold  
Proprietary Products | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales $ 2,334.5 $ 2,397.3 2,406.8
Cost of goods and services sold 1,434.0 1,363.3 1,353.5
Research and development 69.1 68.4 58.5
Selling, general and administrative expenses 231.5 240.6 212.6
Other expense (income) 22.1 14.9 (2.2)
Operating profit 577.8 710.1 784.4
Assets 2,621.1 2,629.1  
Depreciation and Amortization 130.3 112.9 96.9
Capital Expenditures 246.5 259.1 237.3
Contract-Manufactured Products | Operating Segments      
Segment Reporting Information [Line Items]      
Net sales 558.7 552.5 480.4
Cost of goods and services sold 460.7 456.5 397.5
Research and development 0.0 0.0 0.0
Selling, general and administrative expenses 26.2 24.4 20.9
Other expense (income) (0.5) (0.5) 1.6
Operating profit 72.3 72.1 60.4
Assets 612.2 527.5  
Depreciation and Amortization 21.3 20.4 19.0
Capital Expenditures $ 121.0 $ 90.2 $ 34.0
XML 132 R115.htm IDEA: XBRL DOCUMENT v3.25.0.1
Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of period $ 16.3 $ 13.5 $ 12.6
Charged to costs and expenses 0.1 4.5 1.4
Deductions (2.8) (1.7) (0.5)
Balance at end of period 13.6 16.3 13.5
Deferred tax asset valuation allowance      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of period 15.5 13.3 12.2
Charged to costs and expenses 0.0 2.2 1.1
Deductions (2.7) 0.0 0.0
Balance at end of period 12.8 15.5 13.3
Allowance for credit losses      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of period 0.8 0.2 0.4
Charged to costs and expenses 0.1 2.3 0.3
Deductions (0.1) (1.7) (0.5)
Balance at end of period $ 0.8 $ 0.8 $ 0.2
EXCEL 133 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ʭ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�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end XML 134 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 135 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 137 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 540 613 1 false 142 0 false 15 false false R1.htm 0000001 - Document - Cover Sheet http://www.westpharma.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.westpharma.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME CONSOLIDATED STATEMENTS OF INCOME Statements 3 false false R4.htm 9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 4 false false R5.htm 9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 5 false false R6.htm 9952154 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 6 false false R7.htm 9952155 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 7 false false R8.htm 9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 8 false false R9.htm 9952157 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Statements 9 false false R10.htm 9952158 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 10 false false R11.htm 9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 11 false false R12.htm 9952160 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 12 false false R13.htm 9952161 - Disclosure - Revenue Sheet http://www.westpharma.com/role/Revenue Revenue Notes 13 false false R14.htm 9952162 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 14 false false R15.htm 9952163 - Disclosure - Property, Plant and Equipment Sheet http://www.westpharma.com/role/PropertyPlantandEquipment Property, Plant and Equipment Notes 15 false false R16.htm 9952164 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 16 false false R17.htm 9952165 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 17 false false R18.htm 9952166 - Disclosure - Goodwill and Intangible Assets Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 18 false false R19.htm 9952167 - Disclosure - Other Current Liabilities Sheet http://www.westpharma.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 19 false false R20.htm 9952168 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 20 false false R21.htm 9952169 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 21 false false R22.htm 9952170 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 22 false false R23.htm 9952171 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 23 false false R24.htm 9952172 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 24 false false R25.htm 9952173 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 25 false false R26.htm 9952174 - Disclosure - Other Expense (Income) Sheet http://www.westpharma.com/role/OtherExpenseIncome Other Expense (Income) Notes 26 false false R27.htm 9952175 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 27 false false R28.htm 9952176 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 28 false false R29.htm 9952177 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 29 false false R30.htm 9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts Sheet http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Notes 30 false false R31.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 31 false false R32.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 32 false false R33.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 33 false false R34.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 34 false false R35.htm 9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 35 false false R36.htm 9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 36 false false R37.htm 9955513 - Disclosure - Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueTables Revenue (Tables) Tables http://www.westpharma.com/role/Revenue 37 false false R38.htm 9955514 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 38 false false R39.htm 9955515 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentTables Property, Plant and Equipment (Tables) Tables http://www.westpharma.com/role/PropertyPlantandEquipment 39 false false R40.htm 9955516 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 40 false false R41.htm 9955517 - Disclosure - Affiliated Companies (Tables) Sheet http://www.westpharma.com/role/AffiliatedCompaniesTables Affiliated Companies (Tables) Tables http://www.westpharma.com/role/AffiliatedCompanies 41 false false R42.htm 9955518 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.westpharma.com/role/GoodwillandIntangibleAssets 42 false false R43.htm 9955519 - Disclosure - Other Current Liabilities (Tables) Sheet http://www.westpharma.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://www.westpharma.com/role/OtherCurrentLiabilities 43 false false R44.htm 9955520 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 44 false false R45.htm 9955521 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 45 false false R46.htm 9955522 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 46 false false R47.htm 9955523 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 47 false false R48.htm 9955524 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.westpharma.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.westpharma.com/role/StockBasedCompensation 48 false false R49.htm 9955525 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 49 false false R50.htm 9955526 - Disclosure - Other Expense (Income) (Tables) Sheet http://www.westpharma.com/role/OtherExpenseIncomeTables Other Expense (Income) (Tables) Tables http://www.westpharma.com/role/OtherExpenseIncome 50 false false R51.htm 9955527 - Disclosure - Income Taxes (Tables) Sheet http://www.westpharma.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.westpharma.com/role/IncomeTaxes 51 false false R52.htm 9955528 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 52 false false R53.htm 9955529 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 53 false false R54.htm 9955530 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) Details 54 false false R55.htm 9955531 - Disclosure - Revenue - Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue - Revenue Recognition (Details) Details 55 false false R56.htm 9955532 - Disclosure - Revenue - Contracts Assets and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails Revenue - Contracts Assets and Liabilities (Details) Details 56 false false R57.htm 9955533 - Disclosure - Revenue - Narrative (Details) Sheet http://www.westpharma.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 57 false false R58.htm 9955534 - Disclosure - Net Income Per Share - Schedule of Reconciliation of Shares (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails Net Income Per Share - Schedule of Reconciliation of Shares (Details) Details 58 false false R59.htm 9955535 - Disclosure - Net Income Per Share - Narratives (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareNarrativesDetails Net Income Per Share - Narratives (Details) Details 59 false false R60.htm 9955536 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails Net Income Per Share - Schedule of Repurchase of Common Stock (Details) Details 60 false false R61.htm 9955537 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details) Details 61 false false R62.htm 9955538 - Disclosure - Property, Plant and Equipment - Narrative (Details) Sheet http://www.westpharma.com/role/PropertyPlantandEquipmentNarrativeDetails Property, Plant and Equipment - Narrative (Details) Details 62 false false R63.htm 9955539 - Disclosure - Leases - Narrative (Details) Sheet http://www.westpharma.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 63 false false R64.htm 9955540 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 64 false false R65.htm 9955541 - Disclosure - Leases - Assets And Liabilities, Lessee (Details) Sheet http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails Leases - Assets And Liabilities, Lessee (Details) Details 65 false false R66.htm 9955542 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails Leases - Lease Cash Flow and Supplemental Information (Details) Details 66 false false R67.htm 9955543 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 67 false false R68.htm 9955544 - Disclosure - Affiliated Companies - Schedule of Investments (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails Affiliated Companies - Schedule of Investments (Details) Details 68 false false R69.htm 9955545 - Disclosure - Affiliated Companies-Schedule of Aggregate Carrying Amount (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails Affiliated Companies-Schedule of Aggregate Carrying Amount (Details) Details 69 false false R70.htm 9955546 - Disclosure - Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details) Details 70 false false R71.htm 9955547 - Disclosure - Affiliated Companies - Schedule of Company's Affiliate Transactions (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails Affiliated Companies - Schedule of Company's Affiliate Transactions (Details) Details 71 false false R72.htm 9955548 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets - Goodwill (Details) Details 72 false false R73.htm 9955549 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 73 false false R74.htm 9955550 - Disclosure - Goodwill and Intangible Assets - Intangible Assets by Major Class (Details) Sheet http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails Goodwill and Intangible Assets - Intangible Assets by Major Class (Details) Details 74 false false R75.htm 9955551 - Disclosure - Other Current Liabilities (Details) Sheet http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://www.westpharma.com/role/OtherCurrentLiabilitiesTables 75 false false R76.htm 9955552 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.westpharma.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 76 false false R77.htm 9955553 - Disclosure - Debt - Narrative (Details) Sheet http://www.westpharma.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 77 false false R78.htm 9955554 - Disclosure - Derivative Financial Instruments - Narrative (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails Derivative Financial Instruments - Narrative (Details) Details 78 false false R79.htm 9955555 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Details 79 false false R80.htm 9955556 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails Derivative Financial Instruments - Effects of Derivative Instruments (Details) Details 80 false false R81.htm 9955557 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details) Details 81 false false R82.htm 9955558 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details) Details 82 false false R83.htm 9955559 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails Fair Value Measurements - Fair Value of Assets and Liabilities (Details) Details 83 false false R84.htm 9955560 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails Fair Value Measurements - Other Financial Instruments (Details) Details 84 false false R85.htm 9955561 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details) Details 85 false false R86.htm 9955562 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Details 86 false false R87.htm 9955563 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 87 false false R88.htm 9955564 - Disclosure - Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details) Details 88 false false R89.htm 9955565 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails Stock-Based Compensation - Stock Options Activity (Details) Details 89 false false R90.htm 9955566 - Disclosure - Stock-Based Compensation - Nonvested Performance-based Award Activity (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails Stock-Based Compensation - Nonvested Performance-based Award Activity (Details) Details 90 false false R91.htm 9955567 - Disclosure - Benefit Plans - Narrative (Details) Sheet http://www.westpharma.com/role/BenefitPlansNarrativeDetails Benefit Plans - Narrative (Details) Details 91 false false R92.htm 9955568 - Disclosure - Benefit Plans - Components of Net Periodic Benefit Cost (Details) Sheet http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails Benefit Plans - Components of Net Periodic Benefit Cost (Details) Details 92 false false R93.htm 9955569 - Disclosure - Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details) Sheet http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details) Details 93 false false R94.htm 9955570 - Disclosure - Benefit Plans - Amounts Recognized in Balance Sheet (Details) Sheet http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails Benefit Plans - Amounts Recognized in Balance Sheet (Details) Details 94 false false R95.htm 9955571 - Disclosure - Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details) Sheet http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details) Details 95 false false R96.htm 9955572 - Disclosure - Benefit Plans - Expected Benefit Payments (Details) Sheet http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails Benefit Plans - Expected Benefit Payments (Details) Details 96 false false R97.htm 9955573 - Disclosure - Benefit Plans - Assumptions Used (Details) Sheet http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails Benefit Plans - Assumptions Used (Details) Details 97 false false R98.htm 9955574 - Disclosure - Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details) Sheet http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details) Details 98 false false R99.htm 9955575 - Disclosure - Benefit Plans - Allocation of Plan Assets (Details) Sheet http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails Benefit Plans - Allocation of Plan Assets (Details) Details 99 false false R100.htm 9955576 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails Other Expense (Income) - Schedule of Other (Income) Expense (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 100 false false R101.htm 9955577 - Disclosure - Other Expense (Income) - Narrative (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails Other Expense (Income) - Narrative (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 101 false false R102.htm 9955578 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails Other Expense (Income) - Schedule of Restructuring and Related Charges (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 102 false false R103.htm 9955579 - Disclosure - Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 103 false false R104.htm 9955580 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 104 false false R105.htm 9955581 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.westpharma.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 105 false false R106.htm 9955582 - Disclosure - Income Taxes - Income Before Income Taxes (Details) Sheet http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails Income Taxes - Income Before Income Taxes (Details) Details 106 false false R107.htm 9955583 - Disclosure - Income Taxes - Components of Income Tax Expense (Details) Sheet http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails Income Taxes - Components of Income Tax Expense (Details) Details 107 false false R108.htm 9955584 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 108 false false R109.htm 9955585 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails Income Taxes - Effective Income Tax Reconciliation (Details) Details 109 false false R110.htm 9955586 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.westpharma.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.westpharma.com/role/CommitmentsandContingencies 110 false false R111.htm 9955587 - Disclosure - Segment Information - Narrative (Details) Sheet http://www.westpharma.com/role/SegmentInformationNarrativeDetails Segment Information - Narrative (Details) Details 111 false false R112.htm 9955588 - Disclosure - Segment Information - Sales by Product Group (Details) Sheet http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails Segment Information - Sales by Product Group (Details) Details 112 false false R113.htm 9955589 - Disclosure - Segment Information - Sales and Long-lived Assets by Geographic Location (Details) Sheet http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails Segment Information - Sales and Long-lived Assets by Geographic Location (Details) Details 113 false false R114.htm 9955590 - Disclosure - Segment Information - Segment Financial Information (Details) Sheet http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails Segment Information - Segment Financial Information (Details) Details 114 false false R115.htm 9955591 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Details http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccounts 115 false false All Reports Book All Reports wst-20241231.htm wst-20241231.xsd wst-20241231_cal.xml wst-20241231_def.xml wst-20241231_lab.xml wst-20241231_pre.xml wst-20241231_g1.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 139 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "wst-20241231.htm": { "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20241231", "dts": { "inline": { "local": [ "wst-20241231.htm" ] }, "schema": { "local": [ "wst-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "wst-20241231_cal.xml" ] }, "definitionLink": { "local": [ "wst-20241231_def.xml" ] }, "labelLink": { "local": [ "wst-20241231_lab.xml" ] }, "presentationLink": { "local": [ "wst-20241231_pre.xml" ] } }, "keyStandard": 549, "keyCustom": 64, "axisStandard": 42, "axisCustom": 1, "memberStandard": 95, "memberCustom": 40, "hidden": { "total": 12, "http://fasb.org/us-gaap/2024": 8, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 540, "entityCount": 1, "segmentCount": 142, "elementCount": 1056, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1896, "http://xbrl.sec.gov/dei/2024": 38, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 3 }, "report": { "R1": { "role": "http://www.westpharma.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.westpharma.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R4": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R5": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "9952154 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952155 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical", "longName": "9952157 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952158 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R11": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "9952159 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.westpharma.com/role/NewAccountingStandards", "longName": "9952160 - Disclosure - New Accounting Standards", "shortName": "New Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.westpharma.com/role/Revenue", "longName": "9952161 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.westpharma.com/role/NetIncomePerShare", "longName": "9952162 - Disclosure - Net Income Per Share", "shortName": "Net Income Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.westpharma.com/role/PropertyPlantandEquipment", "longName": "9952163 - Disclosure - Property, Plant and Equipment", "shortName": "Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.westpharma.com/role/Leases", "longName": "9952164 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.westpharma.com/role/AffiliatedCompanies", "longName": "9952165 - Disclosure - Affiliated Companies", "shortName": "Affiliated Companies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssets", "longName": "9952166 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.westpharma.com/role/OtherCurrentLiabilities", "longName": "9952167 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.westpharma.com/role/Debt", "longName": "9952168 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "longName": "9952169 - Disclosure - Derivative Financial Instruments", "shortName": "Derivative Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.westpharma.com/role/FairValueMeasurements", "longName": "9952170 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "longName": "9952171 - Disclosure - Accumulated Other Comprehensive Loss", "shortName": "Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.westpharma.com/role/StockBasedCompensation", "longName": "9952172 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.westpharma.com/role/BenefitPlans", "longName": "9952173 - Disclosure - Benefit Plans", "shortName": "Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.westpharma.com/role/OtherExpenseIncome", "longName": "9952174 - Disclosure - Other Expense (Income)", "shortName": "Other Expense (Income)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.westpharma.com/role/IncomeTaxes", "longName": "9952175 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "longName": "9952176 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.westpharma.com/role/SegmentInformation", "longName": "9952177 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccounts", "longName": "9952178 - Disclosure - Schedule II - Valuation and Qualifying Accounts", "shortName": "Schedule II - Valuation and Qualifying Accounts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-526", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-526", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R34": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "longName": "9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.westpharma.com/role/RevenueTables", "longName": "9955513 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "longName": "9955514 - Disclosure - Net Income Per Share (Tables)", "shortName": "Net Income Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentTables", "longName": "9955515 - Disclosure - Property, Plant and Equipment (Tables)", "shortName": "Property, Plant and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.westpharma.com/role/LeasesTables", "longName": "9955516 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesTables", "longName": "9955517 - Disclosure - Affiliated Companies (Tables)", "shortName": "Affiliated Companies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables", "longName": "9955518 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.westpharma.com/role/OtherCurrentLiabilitiesTables", "longName": "9955519 - Disclosure - Other Current Liabilities (Tables)", "shortName": "Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.westpharma.com/role/DebtTables", "longName": "9955520 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "longName": "9955521 - Disclosure - Derivative Financial Instruments (Tables)", "shortName": "Derivative Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "longName": "9955522 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9955523 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.westpharma.com/role/StockBasedCompensationTables", "longName": "9955524 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.westpharma.com/role/BenefitPlansTables", "longName": "9955525 - Disclosure - Benefit Plans (Tables)", "shortName": "Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables", "longName": "9955526 - Disclosure - Other Expense (Income) (Tables)", "shortName": "Other Expense (Income) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.westpharma.com/role/IncomeTaxesTables", "longName": "9955527 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.westpharma.com/role/SegmentInformationTables", "longName": "9955528 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9955529 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails", "longName": "9955530 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "longName": "9955531 - Disclosure - Revenue - Revenue Recognition (Details)", "shortName": "Revenue - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-56", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R56": { "role": "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails", "longName": "9955532 - Disclosure - Revenue - Contracts Assets and Liabilities (Details)", "shortName": "Revenue - Contracts Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.westpharma.com/role/RevenueNarrativeDetails", "longName": "9955533 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "wst:ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails", "longName": "9955534 - Disclosure - Net Income Per Share - Schedule of Reconciliation of Shares (Details)", "shortName": "Net Income Per Share - Schedule of Reconciliation of Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R59": { "role": "http://www.westpharma.com/role/NetIncomePerShareNarrativesDetails", "longName": "9955535 - Disclosure - Net Income Per Share - Narratives (Details)", "shortName": "Net Income Per Share - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails", "longName": "9955536 - Disclosure - Net Income Per Share - Schedule of Repurchase of Common Stock (Details)", "shortName": "Net Income Per Share - Schedule of Repurchase of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R61": { "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "longName": "9955537 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details)", "shortName": "Property, Plant and Equipment - Property, Plant and Equipment, Gross (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R62": { "role": "http://www.westpharma.com/role/PropertyPlantandEquipmentNarrativeDetails", "longName": "9955538 - Disclosure - Property, Plant and Equipment - Narrative (Details)", "shortName": "Property, Plant and Equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R63": { "role": "http://www.westpharma.com/role/LeasesNarrativeDetails", "longName": "9955539 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "wst:LesseeOperatingLeaseOptionToTerminateTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:LesseeOperatingLeaseOptionToTerminateTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "longName": "9955540 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails", "longName": "9955541 - Disclosure - Leases - Assets And Liabilities, Lessee (Details)", "shortName": "Leases - Assets And Liabilities, Lessee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "longName": "9955542 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "longName": "9955543 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails", "longName": "9955544 - Disclosure - Affiliated Companies - Schedule of Investments (Details)", "shortName": "Affiliated Companies - Schedule of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-107", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails", "longName": "9955545 - Disclosure - Affiliated Companies-Schedule of Aggregate Carrying Amount (Details)", "shortName": "Affiliated Companies-Schedule of Aggregate Carrying Amount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsInAndAdvancesToAffiliatesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "longName": "9955546 - Disclosure - Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details)", "shortName": "Affiliated Companies- Schedule of Amounts Due to Affiliates in the Condensed Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-112", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R71": { "role": "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "longName": "9955547 - Disclosure - Affiliated Companies - Schedule of Company's Affiliate Transactions (Details)", "shortName": "Affiliated Companies - Schedule of Company's Affiliate Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:RetainedEarningsUndistributedEarningsFromEquityMethodInvestees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R72": { "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "longName": "9955548 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)", "shortName": "Goodwill and Intangible Assets - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R73": { "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "longName": "9955549 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails", "longName": "9955550 - Disclosure - Goodwill and Intangible Assets - Intangible Assets by Major Class (Details)", "shortName": "Goodwill and Intangible Assets - Intangible Assets by Major Class (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails", "longName": "9955551 - Disclosure - Other Current Liabilities (Details)", "shortName": "Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredRevenueCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredRevenueCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.westpharma.com/role/DebtScheduleofDebtDetails", "longName": "9955552 - Disclosure - Debt - Schedule of Debt (Details)", "shortName": "Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R77": { "role": "http://www.westpharma.com/role/DebtNarrativeDetails", "longName": "9955553 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "wst:DebtInstrumentNumberOfTranches", "unitRef": "tranche", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R78": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails", "longName": "9955554 - Disclosure - Derivative Financial Instruments - Narrative (Details)", "shortName": "Derivative Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-207", "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "longName": "9955555 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-193", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "longName": "9955556 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments (Details)", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "longName": "9955557 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details)", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "longName": "9955558 - Disclosure - Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "shortName": "Derivative Financial Instruments - Derivative Instruments Not Designated as Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-241", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-241", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails", "longName": "9955559 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)", "shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredCompensationPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails", "longName": "9955560 - Disclosure - Fair Value Measurements - Other Financial Instruments (Details)", "shortName": "Fair Value Measurements - Other Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "longName": "9955561 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details)", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R86": { "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "longName": "9955562 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-330", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R87": { "role": "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "longName": "9955563 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "longName": "9955564 - Disclosure - Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details)", "shortName": "Stock-Based Compensation - Allocation of Share-based Compensation Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails", "longName": "9955565 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details)", "shortName": "Stock-Based Compensation - Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "longName": "9955566 - Disclosure - Stock-Based Compensation - Nonvested Performance-based Award Activity (Details)", "shortName": "Stock-Based Compensation - Nonvested Performance-based Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-349", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-350", "name": "wst:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTarget", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R91": { "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "longName": "9955567 - Disclosure - Benefit Plans - Narrative (Details)", "shortName": "Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "longName": "9955568 - Disclosure - Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "shortName": "Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-366", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-366", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R93": { "role": "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "longName": "9955569 - Disclosure - Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details)", "shortName": "Benefit Plans - Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-366", "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R94": { "role": "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "longName": "9955570 - Disclosure - Benefit Plans - Amounts Recognized in Balance Sheet (Details)", "shortName": "Benefit Plans - Amounts Recognized in Balance Sheet (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-391", "name": "wst:AssetsDefinedBenefitPlansNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R95": { "role": "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "longName": "9955571 - Disclosure - Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details)", "shortName": "Benefit Plans - Amounts Recognized in Other Comprehensive In Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-391", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-391", "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "longName": "9955572 - Disclosure - Benefit Plans - Expected Benefit Payments (Details)", "shortName": "Benefit Plans - Expected Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "longName": "9955573 - Disclosure - Benefit Plans - Assumptions Used (Details)", "shortName": "Benefit Plans - Assumptions Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-366", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-366", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails", "longName": "9955574 - Disclosure - Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details)", "shortName": "Benefit Plans - Weighted Average Interest Crediting Rating by Geographic Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-386", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-386", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "longName": "9955575 - Disclosure - Benefit Plans - Allocation of Plan Assets (Details)", "shortName": "Benefit Plans - Allocation of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails", "longName": "9955576 - Disclosure - Other Expense (Income) - Schedule of Other (Income) Expense (Details)", "shortName": "Other Expense (Income) - Schedule of Other (Income) Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherRestructuringCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R101": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "longName": "9955577 - Disclosure - Other Expense (Income) - Narrative (Details)", "shortName": "Other Expense (Income) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-450", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-450", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails", "longName": "9955578 - Disclosure - Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)", "shortName": "Other Expense (Income) - Schedule of Restructuring and Related Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-453", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R103": { "role": "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails", "longName": "9955579 - Disclosure - Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details)", "shortName": "Other Expense (Income) - Schedule of Impairment Expenses related to Fixed Assets Impaired (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "longName": "9955580 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R105": { "role": "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails", "longName": "9955581 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails", "longName": "9955582 - Disclosure - Income Taxes - Income Before Income Taxes (Details)", "shortName": "Income Taxes - Income Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R107": { "role": "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails", "longName": "9955583 - Disclosure - Income Taxes - Components of Income Tax Expense (Details)", "shortName": "Income Taxes - Components of Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "longName": "9955584 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "longName": "9955585 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)", "shortName": "Income Taxes - Effective Income Tax Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "longName": "9955586 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.westpharma.com/role/SegmentInformationNarrativeDetails", "longName": "9955587 - Disclosure - Segment Information - Narrative (Details)", "shortName": "Segment Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true, "unique": true } }, "R112": { "role": "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "longName": "9955588 - Disclosure - Segment Information - Sales by Product Group (Details)", "shortName": "Segment Information - Sales by Product Group (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-476", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R113": { "role": "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails", "longName": "9955589 - Disclosure - Segment Information - Sales and Long-lived Assets by Geographic Location (Details)", "shortName": "Segment Information - Sales and Long-lived Assets by Geographic Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R114": { "role": "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails", "longName": "9955590 - Disclosure - Segment Information - Segment Financial Information (Details)", "shortName": "Segment Information - Segment Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "wst:InterestIncomeExpenseAndOtherNonoperatingExpenseIncomeNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } }, "R115": { "role": "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails", "longName": "9955591 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)", "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "wst-20241231.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r107", "r1237" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1445" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued taxes other than income", "label": "Accrual for Taxes Other than Income Taxes, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r110", "r1166", "r1512" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r110", "r185" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional services", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r110" ] }, "wst_AccruedSalariesWagesAndBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AccruedSalariesWagesAndBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued salaries, wages and benefits", "label": "Accrued Salaries, Wages, and Benefits, Current", "documentation": "Accrued Salaries, Wages, and Benefits, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedSalesCommissionCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalesCommissionCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions, rebates & royalties", "label": "Accrued Sales Commission", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions." } } }, "auth_ref": [ "r110", "r115", "r187" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans:", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r20", "r33", "r133", "r1415", "r1416", "r1417" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r60", "r280", "r1008" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "verboseLabel": "Gains (losses) on derivatives:", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r298", "r308", "r309", "r801", "r1171", "r1415" ] }, "wst_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentAndCumulativeChangesInNetGainLossFromCashFlowHedgesEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentAndCumulativeChangesInNetGainLossFromCashFlowHedgesEffect", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in unrealized (gains) losses of Daikyo's investments & derivatives", "label": "Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect", "documentation": "Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment and Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r308", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r134", "r287", "r1003", "r1049", "r1053" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r307", "r308", "r873", "r874", "r875", "r876", "r877", "r878" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r20", "r33", "r820", "r823", "r912", "r1044", "r1045", "r1415", "r1416", "r1417", "r1432", "r1433", "r1434", "r1436" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r20", "r33", "r131", "r132", "r308", "r309", "r874", "r875", "r876", "r877", "r878", "r1415" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1316" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r122", "r1237", "r1608" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r1062", "r1432", "r1433", "r1434", "r1436", "r1533", "r1609" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1329" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1329" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1329" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1329" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Entity", "label": "Affiliated Entity [Member]", "documentation": "An affiliate is a party that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with the entity." } } }, "auth_ref": [ "r247", "r1102", "r1152", "r1259", "r1506", "r1560", "r1561", "r1563" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1374" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1287", "r1298", "r1308", "r1341" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1290", "r1301", "r1311", "r1344" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1375" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1329" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1336" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1336", "r1345", "r1349", "r1357" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1355" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r717", "r726" ] }, "us-gaap_AllowanceForCreditLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossMember", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r1427", "r1428", "r1429", "r1430", "r1431" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r288", "r411", "r465" ] }, "wst_AluplastSADeCVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AluplastSADeCVMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aluplast S.A. de C.V.", "label": "Aluplast S.A. de C.V. [Member]", "documentation": "Aluplast S.A. de C.V. [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]", "documentation": "Continents of North and South America." } } }, "auth_ref": [ "r1403", "r1404", "r1405", "r1406", "r1611", "r1612", "r1613", "r1614" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r12", "r491", "r497", "r1189" ] }, "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total recognized in net periodic benefit cost and OCI", "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss." } } }, "auth_ref": [ "r1210" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r367" ] }, "us-gaap_AociEquityMethodInvestmentParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociEquityMethodInvestmentParentMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity affiliate investment AOCI", "label": "AOCI, Equity Method Investment, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) (AOCI) from proportionate share of equity method investee's other comprehensive income (loss) (OCI), attributable to parent." } } }, "auth_ref": [ "r298", "r307", "r308", "r309", "r444", "r801" ] }, "wst_ApplicableMarginMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ApplicableMarginMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable Margin", "label": "Applicable Margin [Member]", "documentation": "Applicable Margin" } } }, "auth_ref": [] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific", "label": "Asia Pacific [Member]", "documentation": "Region of Asia Pacific." } } }, "auth_ref": [ "r1403", "r1404", "r1405", "r1406", "r1611", "r1612", "r1613", "r1614" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Asset impairments", "terseLabel": "Asset impairments", "totalLabel": "Asset impairments", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r12", "r58" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "terseLabel": "Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r183", "r199", "r284", "r323", "r372", "r378", "r396", "r400", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r799", "r802", "r866", "r997", "r1095", "r1181", "r1182", "r1237", "r1265", "r1494", "r1495", "r1564" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r275", "r292", "r323", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r799", "r802", "r866", "r1237", "r1494", "r1495", "r1564" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "wst_AssetsDefinedBenefitPlansNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AssetsDefinedBenefitPlansNoncurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent assets", "label": "Assets, Defined Benefit Plans, Noncurrent", "documentation": "Amount of assets, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r841", "r842", "r1224" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "wst_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.westpharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1270", "r1271", "r1294" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.westpharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1270", "r1271", "r1294" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.westpharma.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1270", "r1271", "r1294" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1352" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1353" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1348" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1348" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716" ] }, "wst_AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Types Other than Stock Options and Stock Appreciation Rights", "label": "Award Types Other than Stock Options and Stock Appreciation Rights [Member]", "documentation": "Award Types Other than Stock Options and Stock Appreciation Rights [Member]" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1351" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1350" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1349" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1349" ] }, "us-gaap_BankTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BankTimeDepositsMember", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time deposits", "label": "Bank Time Deposits [Member]", "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest." } } }, "auth_ref": [ "r195" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "wst_BiologicsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "BiologicsCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Biologics", "label": "Biologics Customers [Member]", "documentation": "Biologics Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r792", "r1422" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r83", "r176", "r791", "r843", "r844", "r845" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r39", "r40", "r41" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r278", "r1164" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r278" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1535", "r1536" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, including cash equivalents at beginning of period", "periodEndLabel": "Cash, including cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r150", "r319" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r150" ] }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivative designated as hedging instrument", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r181" ] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Hedged item (intercompany loan)", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r181" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1327" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1324" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1322" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1328" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1328" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 18)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r116", "r190", "r1000", "r1082" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r164", "r521", "r523", "r1147", "r1480", "r1486" ] }, "us-gaap_CommodityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityMember", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Commodity [Member]", "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to commodity prices." } } }, "auth_ref": [ "r97" ] }, "us-gaap_CommodityOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommodityOptionMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Commodity Option [Member]", "documentation": "Option contract in which the underlying asset is a commodity." } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared per share (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r168" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1256", "r1257", "r1258", "r1260", "r1261", "r1262", "r1263", "r1432", "r1433", "r1436", "r1533", "r1605", "r1609" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r121" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r121", "r1083" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r121" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r21", "r121", "r1083", "r1101", "r1609", "r1610" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2024 and 2023; shares outstanding: 72.3 million and 73.5 million in 2024 and 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r121", "r1002", "r1237" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1333" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1332" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1334" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1331" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r303", "r305", "r311", "r993", "r1015", "r1016" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r130", "r310", "r992", "r1013" ] }, "wst_ComputerHardwareAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ComputerHardwareAndSoftwareMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer hardware and software", "label": "Computer Hardware and Software [Member]", "documentation": "Computer Hardware and Software [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r45", "r47", "r103", "r104", "r407", "r1146" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r45", "r47", "r103", "r104", "r407", "r1055", "r1146" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r45", "r47", "r103", "r104", "r407", "r1146", "r1390" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net sales", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r45", "r47", "r103", "r104", "r407" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r45", "r47", "r103", "r104", "r407", "r1146" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r197", "r221", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r327", "r372", "r380", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r1181", "r1182", "r1407", "r1408", "r1494", "r1495" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r197", "r221", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r327", "r372", "r380", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r1181", "r1182", "r1407", "r1408", "r1494", "r1495" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r84", "r1172" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "wst_ContractManufacturedCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractManufacturedCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "label": "Contract-Manufactured Customers [Member]", "documentation": "Contract-Manufactured Customers [Member]" } } }, "auth_ref": [] }, "wst_ContractManufacturedProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractManufacturedProductsMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract-Manufactured Products", "verboseLabel": "Contract-Manufactured Products", "label": "Contract Manufactured Products [Member]", "documentation": "Contract Manufactured Products [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1498" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contract assets, December 31, 2023", "periodEndLabel": "Contract assets, December 31, 2024", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r576", "r578", "r597" ] }, "wst_ContractWithCustomerAssetRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractWithCustomerAssetRollForward", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Asset [Roll Forward]", "label": "Contract With Customer, Asset [Roll Forward]", "documentation": "Contract With Customer, Asset [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Deferred income, December 31, 2023", "negatedPeriodEndLabel": "Deferred income, December 31, 2024", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r576", "r577", "r597" ] }, "wst_ContractWithCustomerLiabilityIncreaseDecreaseDueToAdditionalCashPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractWithCustomerLiabilityIncreaseDecreaseDueToAdditionalCashPayments", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash payments received in advance", "label": "Contract With Customer, Liability, Increase (Decrease) Due To Additional Cash Payments", "documentation": "Contract With Customer, Liability, Increase (Decrease) Due To Additional Cash Payments" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized that was included in the deferred income balance", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r598" ] }, "wst_ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized during the period", "label": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance", "documentation": "Contract with Customer, Liability, Revenue Recognized, Excluding Opening Balance" } } }, "auth_ref": [] }, "wst_ContractWithCustomerLiabilityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ContractWithCustomerLiabilityRollForward", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract With Customer, Liability [Roll Forward]", "label": "Contract With Customer, Liability [Roll Forward]", "documentation": "Contract With Customer, Liability [Roll Forward]" } } }, "auth_ref": [] }, "wst_CorporateAndReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "CorporateAndReconcilingItemsMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate and Unallocated", "label": "Corporate And Reconciling Items [Member]", "documentation": "Corporate And Reconciling Items" } } }, "auth_ref": [] }, "wst_CostInvestmentImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "CostInvestmentImpairment", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost investment activity", "label": "Cost Investment Impairment", "documentation": "Cost Investment Impairment" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods and services sold", "negatedTerseLabel": "Cost of goods and services sold", "verboseLabel": "Cost of goods and services sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r138", "r139", "r951" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods and services sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Shipping and Handling Costs", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1394" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "wst_CreditAvailableForTheIssuanceOfLettersOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "CreditAvailableForTheIssuanceOfLettersOfCredit", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount available for issuance of letters of credit", "label": "Credit Available For The Issuance Of Letters Of Credit", "documentation": "Credit Available For The Issuance Of Letters Of Credit" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r531", "r1492" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r531", "r1492", "r1493" ] }, "wst_CreditFacilityIsAvailableForSwingLineLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "CreditFacilityIsAvailableForSwingLineLoans", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility is available for swing-line loans", "label": "Credit facility is available for swing-line loans", "documentation": "This refers to credit facility is available for swing-line loans" } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross Currency Interest Rate Contract", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1502", "r1531" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": [ "r1553" ] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross-currency swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1392", "r1425", "r1522" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1392", "r1425" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current income tax provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r765", "r1425" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1392", "r1425", "r1522" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r154", "r407" ] }, "us-gaap_CustomerContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerContractsMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts", "label": "Customer Contracts [Member]", "documentation": "Entity's established relationships with its customers through contracts." } } }, "auth_ref": [ "r82", "r1468", "r1469", "r1470", "r1471", "r1473", "r1475", "r1477", "r1478" ] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r82", "r1468", "r1469", "r1470", "r1471", "r1473", "r1475", "r1477", "r1478" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1279", "r1368" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1279", "r1368" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1281", "r1370" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1281", "r1370" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1283", "r1372" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1281", "r1370" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1274", "r1363" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1275", "r1364" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1275", "r1364" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1273", "r1362" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1273", "r1362" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1273", "r1362" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1276", "r1365" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1278", "r1367" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1278", "r1367" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1279", "r1368" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1282", "r1371" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1280", "r1369" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1277", "r1366" ] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "DE", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Germany", "label": "GERMANY" } } }, "auth_ref": [] }, "wst_DaikyoSeikoLtdDaikyoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DaikyoSeikoLtdDaikyoMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Daikyo Seiko, Ltd. (\"Daikyo\")", "label": "Daikyo Seiko, Ltd. (Daikyo) [Member]", "documentation": "Daikyo Seiko, Ltd. (Daikyo) [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/Debt" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r165", "r321", "r506", "r507", "r508", "r509", "r510", "r530", "r531", "r543", "r549", "r550", "r551", "r552", "r553", "r554", "r559", "r566", "r567", "r569", "r880" ] }, "wst_DebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtFairValue", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, fair value", "label": "Debt, Fair Value", "documentation": "Debt, Fair Value" } } }, "auth_ref": [] }, "wst_DebtInstrumentApplicableMarginRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentApplicableMarginRatio", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable margin ratio", "label": "Debt Instrument, Applicable Margin Ratio", "documentation": "Debt Instrument, Applicable Margin Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r30", "r109", "r110", "r184", "r189", "r327", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r1195", "r1196", "r1197", "r1198", "r1199", "r1235", "r1423", "r1481", "r1482", "r1483", "r1554", "r1555" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable interest rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r30", "r189", "r570" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r544", "r880", "r881", "r1196", "r1197", "r1235" ] }, "wst_DebtInstrumentIncreaseInFacilityPrecedingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentIncreaseInFacilityPrecedingPeriod", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preceding period (in months)", "label": "Debt Instrument, Increase In Facility, Preceding Period", "documentation": "Debt Instrument, Increase In Facility, Preceding Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, stated interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r112", "r545" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "verboseLabel": "Line of Credit Facility [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r327", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r1195", "r1196", "r1197", "r1198", "r1199", "r1235", "r1423", "r1554", "r1555" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r327", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r1195", "r1196", "r1197", "r1198", "r1199", "r1235", "r1423", "r1481", "r1482", "r1483", "r1554", "r1555" ] }, "wst_DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentNumberOfFiscalQuartersFollowingAcquisition", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarters following acquisition", "label": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition", "documentation": "Debt Instrument, Number Of Fiscal Quarters Following Acquisition" } } }, "auth_ref": [] }, "wst_DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentNumberOfInstancesRatioOfDebtToEBITDAExceeded", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instances ratio of debt to EBITDA not to exceed threshold", "label": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded", "documentation": "Debt Instrument, Number Of Instances Ratio Of Debt To EBITDA Exceeded" } } }, "auth_ref": [] }, "wst_DebtInstrumentNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentNumberOfTranches", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Debt Instrument, Number Of Tranches", "documentation": "Debt Instrument, Number Of Tranches" } } }, "auth_ref": [] }, "wst_DebtInstrumentRatioOfDebtToEBITDA": { "xbrltype": "pureItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentRatioOfDebtToEBITDA", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ratio of debt to EBITDA", "label": "Debt Instrument, Ratio Of Debt To EBITDA", "documentation": "Debt Instrument, Ratio Of Debt To EBITDA" } } }, "auth_ref": [] }, "wst_DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition": { "xbrltype": "pureItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DebtInstrumentRatioOfDebtToEBITDAAfterAcquisition", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ratio of debt to EBITDA after acquisition", "label": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition", "documentation": "Debt Instrument, Ratio Of Debt To EBITDA After Acquisition" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r30", "r68", "r69", "r105", "r166", "r167", "r327", "r544", "r545", "r546", "r547", "r548", "r550", "r555", "r556", "r557", "r558", "r560", "r561", "r562", "r563", "r564", "r565", "r568", "r1195", "r1196", "r1197", "r1198", "r1199", "r1235", "r1423", "r1554", "r1555" ] }, "wst_DeferredCompensationArrangementWithIndividualConversionUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredCompensationArrangementWithIndividualConversionUnit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation conversion unit (in shares)", "label": "Deferred Compensation Arrangement With Individual, Conversion Unit", "documentation": "Deferred Compensation Arrangement With Individual, Conversion Unit" } } }, "auth_ref": [] }, "wst_DeferredCompensationArrangementWithIndividualNumberOfPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredCompensationArrangementWithIndividualNumberOfPlans", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of deferred compensation plans", "label": "Deferred Compensation Arrangement With Individual, Number Of Plans", "documentation": "Deferred Compensation Arrangement With Individual, Number Of Plans" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Deferred Compensation [Axis]", "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]", "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan." } } }, "auth_ref": [ "r78" ] }, "wst_DeferredCompensationArrangementWithIndividualShareEquivalentsBalance": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredCompensationArrangementWithIndividualShareEquivalentsBalance", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of deferred stock units (in shares)", "label": "Deferred Compensation Arrangement With Individual, Share Equivalents Balance", "documentation": "Deferred Compensation Arrangement With Individual, Share Equivalents Balance" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred compensation benefits", "label": "Deferred Compensation Liability, Classified, Noncurrent", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation assets", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r1412" ] }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationShareBasedPaymentsMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation plans and restricted share awards", "label": "Deferred Compensation, Share-Based Payments [Member]", "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary." } } }, "auth_ref": [] }, "wst_DeferredFederalStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredFederalStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal and state", "label": "Deferred Federal, State and Local Income Tax Expense (Benefit)", "documentation": "Deferred Federal, State and Local Income Tax Expense (Benefit)" } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Adjustment", "documentation": "The amount of any adjustment recognized to the balance of unamortized issuance costs associated with a share-lending arrangement entered into by the entity, in contemplation of a convertible debt offering or other financing, due, for example, to default by the share borrower." } } }, "auth_ref": [ "r67" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1425", "r1521" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r736", "r737" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "totalLabel": "Deferred income tax provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r12", "r216", "r1425" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r117", "r118", "r186", "r757" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r736", "r737", "r998" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income", "label": "Deferred Revenue, Current", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r1414" ] }, "wst_DeferredStockUnitsPayableInCash": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredStockUnitsPayableInCash", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of deferred stock units payable in cash (in shares)", "label": "Deferred Stock Units Payable In Cash", "documentation": "Deferred Stock Units Payable In Cash" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized R&D expenses", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r1519" ] }, "wst_DeferredTaxAssetsLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredTaxAssetsLeasingArrangements", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Deferred Tax Assets, Leasing Arrangements", "documentation": "Deferred Tax Assets, Leasing Arrangements" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax asset", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, foreign", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, not subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, state and local", "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards, subject to expiration", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1519" ] }, "wst_DeferredTaxAssetsRoyaltyAcceleration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DeferredTaxAssetsRoyaltyAcceleration", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty acceleration", "label": "Deferred Tax Assets, Royalty Acceleration", "documentation": "Deferred Tax Assets, Royalty Acceleration" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforwards", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and deferred compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r758" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax on undistributed earnings of subsidiaries", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth_ref": [ "r1519" ] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r635" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r5", "r33", "r133", "r1505" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net actuarial loss (gain)", "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r33", "r647" ] }, "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails": { "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service credit", "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r33", "r647" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r617", "r1210" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gains", "verboseLabel": "Actuarial gain", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r610" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of actuarial loss (gain)", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r604", "r642", "r668", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:", "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Discount rate (as a percent)", "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r649" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r650" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r649" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected long-term rate of return on assets (as a percent)", "terseLabel": "Expected long-term rate of return on assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r651", "r673" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate of compensation increase", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r650" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "presentation": [ "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average interest crediting rating used to determine net periodic benefit cost", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r652" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Balance", "negatedPeriodEndLabel": "Balance", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r605" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefits paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r612", "r676" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Participants\u2019 contributions", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation." } } }, "auth_ref": [ "r609" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r654", "r1208", "r1209", "r1210" ] }, "us-gaap_DefinedBenefitPlanCashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Defined Benefit Plan, Cash [Member]", "documentation": "Cash in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1208", "r1209", "r1210" ] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in benefit obligation:", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in plan assets:", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r619", "r629", "r672", "r1208", "r1209", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanDebtSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDebtSecurityMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities", "label": "Defined Benefit Plan, Debt Security [Member]", "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Defined Benefit Plan, Equity Securities [Member]", "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1208", "r1210" ] }, "wst_DefinedBenefitPlanExpectedFutureBenefitPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DefinedBenefitPlanExpectedFutureBenefitPayments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total benefit payments expected", "label": "Defined Benefit Plan, Expected Future Benefit Payments", "documentation": "Defined Benefit Plan, Expected Future Benefit Payments" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030 to 2034", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails": { "parentTag": "wst_DefinedBenefitPlanExpectedFutureBenefitPayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r636" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected contribution to the plan", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r637", "r1211" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r604", "r641", "r667", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r616", "r627", "r629", "r630", "r1208", "r1209", "r1210" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r611" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Funded status at end of year", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r601", "r625", "r1210" ] }, "wst_DefinedBenefitPlanHealthCareCostTrendAssumptionsUsedCalculatingBenefitObligation": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DefinedBenefitPlanHealthCareCostTrendAssumptionsUsedCalculatingBenefitObligation", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed healthcare cost trend rate used to determine benefit obligations", "label": "Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Benefit Obligation", "documentation": "Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Benefit Obligation" } } }, "auth_ref": [] }, "wst_DefinedBenefitPlanHealthCareCostTrendAssumptionsUsedCalculatingNetPeriodicBenefitCost": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DefinedBenefitPlanHealthCareCostTrendAssumptionsUsedCalculatingNetPeriodicBenefitCost", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed healthcare cost trend rate used to determine net periodic benefit cost", "label": "Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Net Periodic Benefit Cost", "documentation": "Defined Benefit Plan, Health Care Cost Trend, Assumptions Used Calculating Net Periodic Benefit Cost" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "negatedTerseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r604", "r608", "r640", "r666", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r638", "r664", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost:", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Excluding Service Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes components of net periodic benefit cost (credit), excluding service cost component, for defined benefit plan." } } }, "auth_ref": [ "r638", "r664" ] }, "us-gaap_DefinedBenefitPlanOtherCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherCosts", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "terseLabel": "Other", "label": "Defined Benefit Plan, Other Cost (Credit)", "documentation": "Amount of defined benefit plan cost (credit), classified as other." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Benefits paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r621", "r1507" ] }, "wst_DefinedBenefitPlanPlanAssetsContributionsByEmployerNetOfPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DefinedBenefitPlanPlanAssetsContributionsByEmployerNetOfPremiums", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution", "label": "Defined Benefit Plan, Plan Assets, Contributions By Employer, Net Of Premiums", "documentation": "Defined Benefit Plan, Plan Assets, Contributions By Employer, Net Of Premiums" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participants\u2019 contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets." } } }, "auth_ref": [ "r620" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r618" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target allocation", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r626", "r1210" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension settlement charges", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r603", "r645", "r671" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlements", "negatedLabel": "Settlement loss", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": [ "r603", "r645", "r671" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "negatedTerseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r606", "r639", "r665", "r1210", "r1211" ] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement loss", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": [ "r607" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement loss", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r624" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation range", "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage", "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r1501" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average assumptions used in benefit obligations:", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average assumptions used in net periodic benefit cost:", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": [ "r15", "r73", "r74", "r75", "r76" ] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "401 (k) plan contributions", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r677" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/PropertyPlantandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r12", "r59" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r12", "r372", "r383", "r400", "r1181", "r1182" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity call options", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r293", "r294", "r841", "r842", "r855", "r865", "r1064", "r1065", "r1066", "r1067", "r1068", "r1070", "r1071", "r1072", "r1073", "r1074", "r1089", "r1090", "r1133", "r1136", "r1139", "r1140", "r1141", "r1142", "r1170", "r1224", "r1228", "r1258", "r1537", "r1538", "r1539", "r1606" ] }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "xbrltype": "perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, average price risk option strike price", "label": "Derivative, Average Price Risk Option Strike Price", "documentation": "The average strike price on the group of price risk option contracts such as put options or call options." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract Type [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r1072", "r1074", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1098", "r1099", "r1109", "r1110", "r1111", "r1112", "r1115", "r1116", "r1117", "r1118", "r1133", "r1135", "r1139", "r1141", "r1256", "r1258", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1547", "r1548" ] }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "(Loss) gain recognized in earnings", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": [ "r205", "r1529" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument Risk [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r91", "r93", "r96", "r180", "r1072", "r1074", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1098", "r1099", "r1109", "r1110", "r1111", "r1112", "r1115", "r1116", "r1117", "r1118", "r1133", "r1135", "r1139", "r1141", "r1170", "r1256", "r1258", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1547", "r1548" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative Financial Instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r178", "r813", "r827" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r22", "r91", "r93" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r22", "r91", "r93", "r96", "r101", "r102", "r812" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r812" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r95", "r1391" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term derivative instruments", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r293" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r827" ] }, "us-gaap_DerivativeNonmonetaryNotionalAmount": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNonmonetaryNotionalAmount", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, nonmonetary notional amount outstanding", "label": "Derivative, Nonmonetary Notional Amount", "documentation": "Nominal number of units used to calculate payment on derivative." } } }, "auth_ref": [ "r568", "r574", "r827", "r1527", "r1528" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1527", "r1528" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r22", "r85", "r86", "r87", "r90", "r92", "r93", "r98", "r100", "r102", "r827" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative contract term", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r22", "r85", "r86", "r90", "r99", "r326", "r353" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r22" ] }, "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Details of Impairment of Long-Lived Assets Held and Used by Asset", "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]", "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported." } } }, "auth_ref": [ "r61", "r161" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Employee Directors", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r1409", "r1444", "r1607" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r596", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r596", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1499" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r683", "r687", "r718", "r719", "r721", "r1219" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "wst_DistributorshipAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "DistributorshipAgreementMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributorship Agreement", "label": "Distributorship Agreement [Member]", "documentation": "Distributorship Agreement" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r168" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared, not paid", "verboseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r110" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1270", "r1271", "r1294" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1270", "r1271", "r1294", "r1337" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1315" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1268" ] }, "us-gaap_DomesticLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticLineOfCreditMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Line of Credit", "label": "Domestic Line of Credit [Member]", "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, inside the reporting entity's home country." } } }, "auth_ref": [] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1508", "r1509", "r1510" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1326" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East, Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1611", "r1612", "r1613", "r1614" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Net income per share:", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r312", "r345", "r346", "r347", "r348", "r349", "r350", "r357", "r359", "r364", "r365", "r366", "r371", "r786", "r797", "r838", "r839", "r994", "r1017", "r1174" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r312", "r345", "r346", "r347", "r348", "r349", "r350", "r359", "r364", "r365", "r366", "r371", "r786", "r797", "r838", "r839", "r994", "r1017", "r1174" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r43", "r44", "r368" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Income Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r356", "r367", "r369", "r370" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r872" ] }, "us-gaap_EffectOnFutureEarningsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOnFutureEarningsAmount", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect on future earnings, amount", "label": "Effect on Future Earnings, Amount", "documentation": "The quantified amount of the future effect on earnings." } } }, "auth_ref": [ "r162" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r740", "r1222" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal corporate tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r325", "r740", "r771", "r1222" ] }, "wst_EffectiveIncomeTaxRateReconciliationDeferredTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxBenefitAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax benefit", "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Benefit, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Deferred Tax Benefit, Amount" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign-Derived Intangible Income Deductions (FDII)", "label": "Effective Income Tax Rate Reconciliation, FDII, Percent", "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)." } } }, "auth_ref": [ "r1222", "r1513", "r1515" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax on international operations other than U.S. tax rate", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r741", "r744", "r1222", "r1426", "r1513" ] }, "wst_EffectiveIncomeTaxRateReconciliationLitigationSettlementStateAndLocalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationLitigationSettlementStateAndLocalAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit from recent court case", "label": "Effective Income Tax Rate Reconciliation, Litigation Settlement, State and Local, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Litigation Settlement, State and Local, Amount" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1222", "r1426", "r1513", "r1514" ] }, "wst_EffectiveIncomeTaxRateReconciliationPensionSettlementPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationPensionSettlementPercent", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension settlement", "label": "Effective Income Tax Rate Reconciliation, Pension Settlement, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Pension Settlement, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reserves for unrecognized tax benefits", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense." } } }, "auth_ref": [ "r1426", "r1513", "r1514" ] }, "wst_EffectiveIncomeTaxRateReconciliationRecognitionOfReservesForUnrecognizedTaxBenefitsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationRecognitionOfReservesForUnrecognizedTaxBenefitsAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense from recognition of reserves for unrecognized tax benefits", "label": "Effective Income Tax Rate Reconciliation, Recognition Of Reserves For Unrecognized Tax Benefits, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Recognition Of Reserves For Unrecognized Tax Benefits, Amount" } } }, "auth_ref": [] }, "wst_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarningsNetOfForeignTaxCreditsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarningsNetOfForeignTaxCreditsPercent", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. tax on international earnings, net of foreign tax credits", "label": "Effective Income Tax Rate Reconciliation, Repatriation Of Foreign Earnings, Net Of Foreign Tax Credits, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Repatriation Of Foreign Earnings, Net Of Foreign Tax Credits, Percent" } } }, "auth_ref": [] }, "wst_EffectiveIncomeTaxRateReconciliationRoyaltyAccelerationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationRoyaltyAccelerationPercent", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty acceleration", "label": "Effective Income Tax Rate Reconciliation, Royalty Acceleration, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Royalty Acceleration, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess tax benefits on share-based payments", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1386", "r1513", "r1514" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income taxes, net of federal tax effect", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r743", "r1222", "r1426", "r1513" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "U.S. research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1222", "r1426", "r1513", "r1515" ] }, "wst_EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationTerminationOfPensionPlanAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit from termination of pension plans", "label": "Effective Income Tax Rate Reconciliation, Termination Of Pension Plan, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Termination Of Pension Plan, Amount" } } }, "auth_ref": [] }, "wst_EffectiveIncomeTaxRateReconciliationUndistributedEarningsOfSubsidiariesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationUndistributedEarningsOfSubsidiariesPercentage", "calculation": { "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax on undistributed earnings of subsidiaries", "label": "Effective Income Tax Rate Reconciliation, Undistributed Earnings Of Subsidiaries, Percentage", "documentation": "Effective Income Tax Rate Reconciliation, Undistributed Earnings Of Subsidiaries, Percentage" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized compensation expense for all nonvested awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r720" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period for recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r720" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "wst_EmployeeStockPurchasePlanEsppMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "EmployeeStockPurchasePlanEsppMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock Purchase Plan (ESPP) [Member]", "documentation": "Employee Stock Purchase Plan (ESPP) [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1377" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1267" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1267" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1378" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1320" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1373" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1373" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1373" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Deferred Compensation, All Types [Domain]", "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]", "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan." } } }, "auth_ref": [ "r78" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r21", "r269", "r307", "r308", "r309", "r334", "r335", "r336", "r341", "r349", "r351", "r353", "r373", "r456", "r464", "r503", "r575", "r766", "r767", "r781", "r782", "r783", "r787", "r796", "r797", "r818", "r820", "r821", "r822", "r823", "r826", "r837", "r873", "r874", "r875", "r876", "r877", "r878", "r883", "r886", "r912", "r1013", "r1044", "r1045", "r1046", "r1062", "r1122" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investee, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r447", "r448", "r450", "r777", "r1382", "r1383", "r1384", "r1523", "r1524", "r1525", "r1526" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends received from affiliates", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r10", "r12", "r137", "r1010" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r447" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails": { "parentTag": "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method affiliates", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r372", "r388", "r400", "r445", "r1411", "r1453" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliated Companies", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r219", "r449", "r452", "r1384" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r446" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails": { "parentTag": "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-equity method affiliates", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r442" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails": { "parentTag": "us-gaap_AssetImpairmentCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost method investment impairment charges", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r443" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1330" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1287", "r1298", "r1308", "r1341" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1284", "r1295", "r1305", "r1338" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1336" ] }, "wst_ExpirationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ExpirationPeriodAxis", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Axis]", "label": "Expiration Period [Axis]", "documentation": "Expiration Period [Axis]" } } }, "auth_ref": [] }, "wst_ExpirationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ExpirationPeriodDomain", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Period [Domain]", "label": "Expiration Period [Domain]", "documentation": "[Domain] for Expiration Period [Axis]" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "FR", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "France", "label": "FRANCE" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r841", "r842", "r855", "r1224" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r841", "r842", "r855", "r1224" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r557", "r629", "r630", "r631", "r632", "r633", "r634", "r840", "r842", "r843", "r844", "r845", "r854", "r855", "r857", "r920", "r921", "r922", "r1196", "r1197", "r1208", "r1209", "r1210", "r1224", "r1228" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r846", "r847", "r848", "r849", "r850", "r851", "r856" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r850", "r852", "r853", "r854", "r857", "r858", "r859", "r860", "r861", "r990", "r1224", "r1229" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges:", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r88" ] }, "us-gaap_FairValueInputsLevel12And3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel12And3Member", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plan assets in the fair value hierarchy", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)." } } }, "auth_ref": [ "r1224", "r1503", "r1536", "r1547" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r557", "r629", "r634", "r842", "r855", "r920", "r1208", "r1209", "r1210", "r1224" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r557", "r629", "r634", "r842", "r843", "r855", "r921", "r1196", "r1197", "r1208", "r1209", "r1210", "r1224" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r557", "r629", "r630", "r631", "r632", "r633", "r634", "r842", "r843", "r844", "r845", "r855", "r922", "r1196", "r1197", "r1208", "r1209", "r1210", "r1224", "r1228" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r846", "r847", "r848", "r849", "r850", "r851", "r856" ] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plan assets measured at NAV", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r629", "r840", "r857", "r1224" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r557", "r629", "r630", "r631", "r632", "r633", "r634", "r840", "r842", "r843", "r844", "r845", "r854", "r855", "r857", "r920", "r921", "r922", "r1196", "r1197", "r1208", "r1209", "r1210", "r1224", "r1228" ] }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalFundsEffectiveSwapRateMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate", "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg." } } }, "auth_ref": [ "r1532" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease - interest on lease liabilities", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r890", "r896", "r1236" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r892", "r900" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r888", "r904" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (current)", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r888" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r889" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1559" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities (noncurrent)", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r888" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r889" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Finance lease, liability payment due", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finance Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed lease interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r904" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal repayments on finance leases", "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r891", "r900" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets, net", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r887" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease - amortization of right-of-use (ROU) assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r890", "r896", "r1236" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.westpharma.com/role/LeasesAssetsAndLiabilitiesLesseeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r889" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r903", "r1236" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r902", "r1236" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r568", "r574", "r827", "r862", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r1014", "r1187", "r1224", "r1226", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1238", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1449", "r1450", "r1451", "r1452", "r1534", "r1537", "r1538", "r1539", "r1546", "r1549" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life of finite-lived intangible assets (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r282", "r477", "r496", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r498", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r498", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r498", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r498", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r498", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r490", "r492", "r493", "r494", "r495", "r496", "r499", "r500", "r952", "r959", "r1160" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation losses", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r477", "r496", "r959", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r490", "r496", "r499", "r500", "r501", "r952", "r1160", "r1189" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r490", "r492", "r493", "r494", "r495", "r496", "r499", "r500", "r1160" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r952", "r1475" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Jurisdiction", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r740", "r741" ] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": [ "r841", "r842" ] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contracts", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [ "r841", "r842" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign exchange transaction losses (gains)", "terseLabel": "Foreign exchange transaction (losses) gains", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r868", "r869", "r870", "r871", "r1119" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r867" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1170", "r1208", "r1223", "r1224" ] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "verboseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r1089", "r1093", "r1098", "r1111", "r1117", "r1137", "r1138", "r1139", "r1258" ] }, "us-gaap_ForeignLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignLineOfCreditMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Line of Credit", "label": "Foreign Line of Credit [Member]", "documentation": "Contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars, outside the reporting entity's home country." } } }, "auth_ref": [] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International plans", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1508", "r1509", "r1510" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1345" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1345" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1345" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1345" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1345" ] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForwardContractsMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency forwards", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": [ "r1530" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1325" ] }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails": { "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount excluded from effectiveness testing", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings." } } }, "auth_ref": [ "r182", "r807" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on derivative instruments, net, pretax", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r91" ] }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period." } } }, "auth_ref": [ "r94" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 6.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of plant", "negatedLabel": "Loss on disposal of plant", "terseLabel": "Loss on disposal of plant", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r12" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Corporate general costs", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r142", "r1105" ] }, "wst_GenericsCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "GenericsCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Generics", "label": "Generics Customers [Member]", "documentation": "Generics Customers [Member]" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r46", "r1146" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r281", "r478", "r991", "r1182", "r1188", "r1225", "r1237", "r1457", "r1464" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1455", "r1467" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r1455", "r1467" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r485" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated goodwill impairment losses", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r480", "r487", "r1188" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r1188" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r135", "r140", "r198", "r323", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r866", "r1176", "r1181", "r1438", "r1440", "r1441", "r1442", "r1443", "r1494" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22", "r812" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r22" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r22" ] }, "wst_HighValueProductComponentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "HighValueProductComponentsMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product Components", "label": "High-Value Product Components [Member]", "documentation": "High-Value Components [Member]" } } }, "auth_ref": [] }, "wst_HighValueProductDeliveryDevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "HighValueProductDeliveryDevicesMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "High-Value Product Delivery Devices", "label": "High Value Product Delivery Devices [Member]", "documentation": "High Value Product Delivery Devices Member" } } }, "auth_ref": [] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1270", "r1271", "r1294" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r161" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. operations", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r324", "r739" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in net income of affiliated companies", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r136", "r193", "r198", "r995", "r1011", "r1176", "r1181", "r1438", "r1440", "r1441", "r1442", "r1443" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International operations", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r324", "r739" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesIncomeBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes and equity in net income of affiliated companies", "verboseLabel": "Total before tax", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r198", "r1018", "r1176", "r1438", "r1440", "r1441", "r1442", "r1443" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in net income of affiliated companies", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r12", "r137", "r192", "r372", "r385", "r400", "r445", "r1010" ] }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in undistributed earnings of affiliates, net of dividends", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r504", "r511", "r515", "r847", "r851", "r856", "r1039", "r1041", "r1106", "r1160", "r1227", "r1576" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r511", "r515", "r847", "r851", "r856", "r1039", "r1041", "r1106", "r1160", "r1227", "r1576" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r318", "r740", "r741", "r750", "r762", "r1222", "r1518" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r318", "r740", "r741", "r750", "r762", "r1222", "r1518" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1516" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r325", "r730", "r740", "r746", "r747", "r748", "r755", "r760", "r772", "r774", "r775", "r776", "r1061", "r1222" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/IncomeTaxesComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "negatedTerseLabel": "Tax (expense) benefit", "totalLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r206", "r217", "r352", "r353", "r372", "r386", "r400", "r738", "r740", "r773", "r1019", "r1222" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r306", "r734", "r735", "r755", "r756", "r759", "r764", "r1058" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (benefit) from impact of tax law changes enacted", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r733", "r740", "r745", "r1222" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit related to a reduction in the liability on the unremitted earnings", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r741", "r744", "r1222", "r1513" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax benefit from stock-based compensation", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1222", "r1513", "r1515" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid, net", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r38", "r318", "r761", "r762" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Increase) decrease in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract assets - increase (decrease)", "label": "Increase (Decrease) in Contract with Customer, Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r1422" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/RevenueContractsAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in deferred income - decrease (increase)", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r949", "r1422" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease (increase) in inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Increase) decrease in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r1422" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Changes in other assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r360", "r361", "r362", "r366", "r686" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1336", "r1345", "r1349", "r1357" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1355" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1272", "r1361" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1272", "r1361" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1272", "r1361" ] }, "us-gaap_InsuranceClaimsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InsuranceClaimsMember", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Claims", "label": "Insurance Claims [Member]", "documentation": "A demand for payment of a policy benefit because of the occurrence of an insured event, such as the death or disability of the insured; the maturity of an endowment; the incurrence of hospital or medical bills; the destruction or damage of property and related deaths or injuries; defects in, liens on, or challenges to the title to real estate; or the occurrence of a surety loss; and the costs to process claims." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r490", "r1475", "r1476" ] }, "wst_IntercompanyDemandNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "IntercompanyDemandNotesMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany Demand Notes", "label": "Intercompany Demand Notes [Member]", "documentation": "Intercompany Demand Notes" } } }, "auth_ref": [] }, "wst_IntercompanyLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "IntercompanyLoansMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intercompany Loans", "label": "Intercompany Loans [Member]", "documentation": "Intercompany Loans" } } }, "auth_ref": [] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized interest", "label": "Interest Costs Capitalized", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r879" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r145", "r563", "r572", "r1198", "r1199" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r27" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r382", "r1418" ] }, "wst_InterestIncomeExpenseAndOtherNonoperatingExpenseIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "InterestIncomeExpenseAndOtherNonoperatingExpenseIncomeNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest (income) expense and other nonoperating expense (income), net", "label": "Interest Income (Expense) And Other Nonoperating (Expense) Income, Net", "documentation": "Interest Income (Expense) And Other Nonoperating (Expense) Income, Net" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid, net of amounts capitalized", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r314", "r316", "r317" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intersegment sales elimination", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r197", "r372", "r380", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r1181" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r157", "r1167" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r290", "r1165", "r1237" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r207", "r277", "r289", "r474", "r475", "r476", "r950", "r1173" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r157", "r1169" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r157", "r1168" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r143", "r144", "r145" ] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAggregateCarryingAmountDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in affiliated companies", "totalLabel": "Total investments in affiliated companies", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": [ "r1413" ] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAndAdvancesToAffiliatesTextBlock", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments in and Advances to Affiliates", "label": "Investments in and Advances to Affiliates [Table Text Block]", "documentation": "Tabular disclosure of investments in and advances to affiliates. Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities." } } }, "auth_ref": [ "r1615" ] }, "currency_JPY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "JPY", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JPY", "label": "Japan, Yen" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r1500" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r895", "r1236" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1558" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "wst_LegalMattersContingenciesAndLegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "LegalMattersContingenciesAndLegalCostsPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation", "label": "Legal Matters, Contingencies and Legal Costs [Policy Text Block]", "documentation": "Legal Matters, Contingencies and Legal Costs [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.westpharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r885" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r894" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1559" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating lease liability payments due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed lease interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r904" ] }, "wst_LesseeOperatingLeaseOptionToTerminateTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "LesseeOperatingLeaseOptionToTerminateTerm", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, operating lease, terminate term (in years)", "label": "Lessee, Operating Lease, Option To Terminate, Term", "documentation": "Lessee, Operating Lease, Option To Terminate, Term" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, term of contract (in months)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1556" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.westpharma.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r885" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r30", "r109", "r110", "r111", "r114", "r115", "r116", "r119", "r323", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r800", "r802", "r803", "r866", "r1081", "r1175", "r1265", "r1494", "r1564", "r1565" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r126", "r191", "r1005", "r1237", "r1424", "r1454", "r1550" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r111", "r276", "r323", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r800", "r802", "r803", "r866", "r1237", "r1494", "r1564", "r1565" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r842", "r1535" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit supporting the reimbursement of workers' compensation and other claims", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r30", "r189", "r1574" ] }, "wst_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, additional borrowing capacity", "label": "Line Of Credit Facility Additional Borrowing Capacity", "documentation": "Line Of Credit Facility Additional Borrowing Capacity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, current borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r108", "r113" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, unused commitment level", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r108", "r113", "r531" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase", "label": "Long [Member]", "documentation": "Indicates an ownership position in, or purchase of, a security." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.westpharma.com/role/DebtScheduleofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/DebtScheduleofDebtDetails", "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r30", "r189", "r556", "r571", "r1196", "r1197", "r1235", "r1574" ] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate annual maturities of long-term debt [Abstract]", "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r285" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1535", "r1537", "r1538", "r1539" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r327", "r561" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r327", "r561" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r14", "r327", "r561" ] }, "wst_LongTermDebtMaturityYearFourAndAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "LongTermDebtMaturityYearFourAndAfterYearFour", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028 and thereafter", "label": "Long-Term Debt, Maturity, Year Four And After Year Four", "documentation": "Long-Term Debt, Maturity, Year Four And After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/DebtScheduleofDebtDetails", "http://www.westpharma.com/role/FairValueMeasurementsOtherFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r286" ] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, noncurrent", "label": "Long-Term Line of Credit, Noncurrent", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r30", "r64", "r65" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30", "r1481", "r1482", "r1483" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r66", "r1481", "r1482", "r1483" ] }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtWeightedAverageInterestRate", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average of the coupon interest rate (as a percent)", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r524", "r525", "r526", "r529", "r727", "r1054", "r1194", "r1487", "r1488" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r524", "r525", "r526", "r529", "r727", "r1194", "r1487", "r1488" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r524", "r525", "r526", "r529", "r727", "r1194", "r1487", "r1488" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for insurance obligations", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r524", "r1381" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r524", "r525", "r526", "r529", "r727", "r1054", "r1194", "r1487", "r1488" ] }, "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyReceivable", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount reimbursable by the insurance company", "label": "Loss Contingency, Receivable", "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } }, "auth_ref": [ "r1491" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r407", "r1203", "r1248", "r1253", "r1499", "r1575", "r1577", "r1578", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r228", "r230", "r232", "r233", "r235", "r265", "r266", "r525", "r526", "r527", "r528", "r680", "r727", "r845", "r948", "r1038", "r1040", "r1054", "r1073", "r1074", "r1126", "r1128", "r1130", "r1131", "r1143", "r1158", "r1159", "r1186", "r1200", "r1218", "r1228", "r1229", "r1233", "r1234", "r1249", "r1496", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1328" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1328" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r228", "r230", "r232", "r233", "r235", "r265", "r266", "r525", "r526", "r527", "r528", "r680", "r727", "r845", "r948", "r1038", "r1040", "r1054", "r1073", "r1074", "r1126", "r1128", "r1130", "r1131", "r1143", "r1158", "r1159", "r1186", "r1200", "r1218", "r1228", "r1229", "r1233", "r1249", "r1496", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1348" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1502" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1356" ] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MutualFundMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International mutual funds", "label": "Mutual Fund [Member]", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": [ "r1502" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r407", "r1203", "r1248", "r1253", "r1499", "r1575", "r1577", "r1578", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1329" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r315" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r315" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r150", "r151", "r152" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "verboseLabel": "Total reclassifications for the period, net of tax", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r141", "r152", "r194", "r274", "r301", "r304", "r309", "r323", "r340", "r345", "r346", "r347", "r348", "r349", "r352", "r353", "r363", "r451", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r542", "r786", "r797", "r839", "r866", "r1012", "r1103", "r1120", "r1121", "r1264", "r1494" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges:", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r89" ] }, "wst_NetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "NetSalesMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Net Sales [Member]", "documentation": "Net sales member" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Standards", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r218", "r272", "r338", "r339", "r342", "r343", "r354", "r355", "r409", "r457", "r458", "r784", "r785", "r787", "r797", "r824", "r835", "r907", "r913", "r914", "r956", "r957", "r958", "r1048", "r1049", "r1050", "r1051", "r1053" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r337", "r340", "r341", "r342", "r344", "r347", "r354", "r371", "r408", "r409", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r502", "r503", "r512", "r766", "r767", "r768", "r769", "r770", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786", "r787", "r788", "r789", "r790", "r793", "r794", "r795", "r796", "r797", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r825", "r826", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r863", "r864", "r882", "r883", "r884", "r906", "r908", "r909", "r910", "r911", "r912", "r953", "r954", "r955", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1056" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r42", "r267", "r268", "r269", "r270", "r271", "r272", "r337", "r340", "r341", "r342", "r344", "r347", "r354", "r371", "r408", "r409", "r453", "r454", "r455", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r502", "r503", "r512", "r766", "r767", "r768", "r769", "r770", "r778", "r779", "r780", "r781", "r782", "r783", "r785", "r786", "r787", "r788", "r789", "r790", "r793", "r794", "r795", "r796", "r797", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r825", "r826", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r863", "r864", "r882", "r883", "r884", "r906", "r908", "r909", "r910", "r911", "r912", "r953", "r954", "r955", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1056" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Standards and Standards Issued Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1328" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1291", "r1302", "r1312", "r1336", "r1345" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1319" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1318" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1336" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1356" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1356" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r406" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsDerivativeInstrumentsNotDesignatedasHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r22" ] }, "wst_NotesPayableAndOtherDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "NotesPayableAndOtherDebtCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable and other current debt", "label": "Notes Payable and Other Debt, Current", "documentation": "Notes Payable and Other Debt, Current" } } }, "auth_ref": [] }, "wst_NumberOfManufacturingFacilitiesSold": { "xbrltype": "integerItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "NumberOfManufacturingFacilitiesSold", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loss on disposal manufacturing facility", "label": "Number of Manufacturing Facilities Sold", "documentation": "Number of Manufacturing Facilities Sold" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1177", "r1185", "r1439" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r29", "r33" ] }, "us-gaap_OciEquityMethodInvestmentAfterTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciEquityMethodInvestmentAfterTaxParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on equity affiliate accumulated other comprehensive income, net of tax of $0.0, $0.0, and $0.0", "label": "OCI, Equity Method Investment, after Tax, Parent", "documentation": "Amount, after tax, of other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI, attributable to parent." } } }, "auth_ref": [ "r444", "r798", "r801" ] }, "us-gaap_OciEquityMethodInvestmentTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciEquityMethodInvestmentTaxParent", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) on equity affiliate accumulated other comprehensive income, tax", "label": "OCI, Equity Method Investment, Tax, Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) (OCI) for proportionate share of equity method investee's OCI, attributable to parent." } } }, "auth_ref": [ "r444", "r798", "r801" ] }, "wst_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OneCustomerMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One Customer", "label": "One Customer [Member]", "documentation": "One Customer" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating profit", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r198", "r1176", "r1438", "r1440", "r1441", "r1442", "r1443" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r897", "r1236" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r888" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r888" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r888" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r893", "r900" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r887" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r903", "r1236" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.westpharma.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r902", "r1236" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r763" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r394", "r395", "r396", "r397", "r398", "r401", "r1181", "r1182" ] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commodity Call Options", "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": [ "r179", "r1091", "r1096", "r1109", "r1115", "r1133", "r1134", "r1135", "r1256", "r1257" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "verboseLabel": "Receivables due from affiliates", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r291", "r1237" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r283" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net actuarial gain (loss) arising during period, net of tax of $0.3, $0.4, and $(2.4)", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r133", "r134", "r646" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Net actuarial gain (loss) arising during period, tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax", "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net of tax of $3.6, $1.0, and $2.2", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r20", "r177" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r20", "r177" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r295", "r297", "r804", "r805", "r814" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r213", "r297", "r299" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other comprehensive income (loss), cash flow hedge, reclassification for discontinuance, before tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r808" ] }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyExchangeRateChanges", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes", "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Foreign Currency Exchange Rate Changes" } } }, "auth_ref": [] }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlanOtherCostsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanOtherCostsBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Other Costs, before Tax", "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Other Costs, before Tax" } } }, "auth_ref": [] }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement loss", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement Gain (Loss), Before Tax", "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement Gain (Loss), Before Tax" } } }, "auth_ref": [] }, "wst_OtherComprehensiveIncomeLossDefinedBenefitPlansSettlementEffectsArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlansSettlementEffectsArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement effects arising during period, tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax", "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plans, Settlement Effects Arising During Period, Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other comprehensive income (loss), derivative, excluded component, increase (decrease), adjustments, before tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax", "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r296", "r297", "r299", "r807" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) gain on derivatives, tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, Tax", "documentation": "Amount of tax expense (benefit) for adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r296", "r297", "r299" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) gain on derivatives, net of tax of $(0.9), $0.0, and $0.2", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax", "documentation": "Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r296", "r806", "r1013" ] }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax", "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method." } } }, "auth_ref": [ "r296", "r297", "r806", "r811", "r814" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r809" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r810" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income, net of tax", "verboseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r20", "r177", "r302", "r305", "r349" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total recognized in OCI", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax", "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r4", "r5", "r133", "r134", "r1013", "r1210", "r1504" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net (gain) loss arising during period", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r133", "r134", "r169" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of actuarial (loss) gain", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r8", "r134", "r300", "r646" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amortization of actuarial (gain) loss, net of tax of $(0.2), $(0.4), and $(0.1)", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r8", "r134", "r300", "r646" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of actuarial (gain) loss, tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amortization of other, net of tax of $0.0, $(0.1), and $0.1", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, after Tax", "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan." } } }, "auth_ref": [ "r8", "r134", "r300", "r646" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationTax", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of other, tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Transition Asset (Obligation), Reclassification Adjustment from AOCI, Tax", "documentation": "Amount of tax expense (benefit) for reclassification adjustment from accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan." } } }, "auth_ref": [ "r6" ] }, "wst_OtherComprehensiveLossDefinedBenefitPlansSettlementEffectsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherComprehensiveLossDefinedBenefitPlansSettlementEffectsNetOfTax", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Settlement effects arising during period, net of tax of $0.0, $0.0, and $20.3", "label": "Other Comprehensive Loss, Defined Benefit Plans Settlement Effects, Net Of Tax", "documentation": "The adjustment out of other comprehensive income for settlement effects recognized as a component of net periodic benefit cost during the period, net of tax." } } }, "auth_ref": [] }, "wst_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherCountriesMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Countries [Member]", "documentation": "Other Non-European Countries [Member]" } } }, "auth_ref": [] }, "wst_OtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities [Abstract]", "label": "Other Current Liabilities [Abstract]", "documentation": "Other Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDeferredCompensationArrangementsLiabilityClassifiedNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation liabilities", "label": "Other Deferred Compensation Arrangements, Liability, Classified, Noncurrent", "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable after one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "wst_OtherEuropeCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherEuropeCountriesMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other European countries", "label": "Other Europe Countries [Member]", "documentation": "Other Europe Countries [Member]" } } }, "auth_ref": [] }, "wst_OtherExpenseIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherExpenseIncomeMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income)", "label": "Other Expense (Income) [Member]", "documentation": "Other Expense (Income)" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Expense (Income)", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1393", "r1511" ] }, "wst_OtherIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense (income) (Note 16)", "terseLabel": "Other expense (income)", "negatedTotalLabel": "Total other expense (income)", "label": "Other Income (Expense)", "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "verboseLabel": "Payables due to affiliates", "totalLabel": "Total other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r110", "r1237" ] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Liabilities", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r110", "r115", "r1479" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r115" ] }, "wst_OtherMutualFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "OtherMutualFundsMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other mutual funds", "label": "Other Mutual Funds [Member]", "documentation": "Other Mutual Funds" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r152" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other nonoperating expense (income)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r146" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other items", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1328" ] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other retirement benefits", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r651", "r652", "r654", "r657", "r660", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r677", "r678", "r679", "r1210", "r1211", "r1212", "r1213", "r1214" ] }, "us-gaap_OtherPostretirementBenefitsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued retirement plans (excl. pension)", "label": "Liability, Other Retirement Benefits", "documentation": "Amount of liability for retirement benefits, classified as other." } } }, "auth_ref": [ "r188" ] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other charges", "label": "Other Restructuring Costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other charges", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r1190", "r1191", "r1192", "r1193" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r63", "r110" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1289", "r1300", "r1310", "r1343" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1292", "r1303", "r1313", "r1346" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1292", "r1303", "r1313", "r1346" ] }, "wst_PatentsAndLicensingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PatentsAndLicensingMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents and licensing", "label": "Patents and Licensing [Member]", "documentation": "Patents and Licensing [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1317" ] }, "wst_PaymentsForExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PaymentsForExciseTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Excise tax payments", "label": "Payments For Excise Tax", "documentation": "Payments For Excise Tax" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1387", "r1419" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares purchased under share repurchase programs", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r148" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r514", "r1421" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Debt issuance cost", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividend payments", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r148" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares repurchased for employee tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r313" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r147" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1327" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1327" ] }, "wst_PensionAndOtherPostretirementBenefitExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PensionAndOtherPostretirementBenefitExpenseNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other retirement plans, net", "label": "Pension And Other Postretirement Benefit Expense, Net", "documentation": "The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period); net of cash contributed during the reporting period by the entity to fund its benefit plans." } } }, "auth_ref": [] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "lang": { "en-us": { "role": { "verboseLabel": "Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r600", "r626", "r628", "r634", "r653", "r655", "r656", "r657", "r658", "r659", "r674", "r675", "r677", "r1210" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current liabilities", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r110", "r601", "r602", "r625", "r1210" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total liabilities", "label": "Liability, Defined Benefit Plan", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r188", "r602", "r625", "r1573" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails": { "parentTag": "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Pension and other postretirement benefits", "negatedTerseLabel": "Noncurrent liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r115", "r601", "r602", "r625", "r1210" ] }, "us-gaap_PensionAndOtherPostretirementPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementPlansPolicy", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefits", "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } } }, "auth_ref": [ "r15", "r16", "r17", "r23", "r77" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension benefits", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r651", "r652", "r654", "r657", "r660", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r677", "r678", "r682", "r1210", "r1211", "r1215", "r1216", "r1217" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1319" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1336" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1329" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1318" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance share units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "wst_PharmaCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PharmaCustomersMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharma", "label": "Pharma Customers [Member]", "documentation": "Pharma Customers [Member]" } } }, "auth_ref": [] }, "wst_PharmaRubberSADeCVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PharmaRubberSADeCVMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharma Rubber S.A. de C.V.", "label": "Pharma Rubber S.A. de C.V. [Member]", "documentation": "Pharma Rubber S.A. de C.V. [Member]" } } }, "auth_ref": [] }, "wst_PharmaTapSADeCVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "PharmaTapSADeCVMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pharma Tap S.A. de C.V.", "label": "Pharma Tap S.A de C.V. [Member]", "documentation": "Pharma Tap S.A de C.V. [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r654", "r1208", "r1209", "r1210" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1320" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1376" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1319" ] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionAxis", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PositionDomain", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r120", "r1083" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r120", "r573" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r120", "r1083", "r1101", "r1609", "r1610" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2024 and 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r120", "r1001", "r1237" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings of long-term debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1420" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan contributions", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r7", "r26" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock-based compensation awards", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r26" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r155" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r263", "r403", "r951", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1162", "r1201", "r1247", "r1249", "r1250", "r1254", "r1255", "r1410", "r1489", "r1490", "r1499", "r1575", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r263", "r403", "r951", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1162", "r1201", "r1247", "r1249", "r1250", "r1254", "r1255", "r1410", "r1489", "r1490", "r1499", "r1575", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r13", "r905" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r158", "r210", "r214", "r215" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r159", "r279", "r1009" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r905" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r13", "r905", "r996", "r1009", "r1237" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r13", "r210", "r214", "r1007" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r159", "r905" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected useful lives (years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "wst_ProprietaryProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ProprietaryProductsMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proprietary Products", "label": "Proprietary Products [Member]", "documentation": "Proprietary Products [Member]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1317" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1317" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r228", "r230", "r232", "r233", "r235", "r265", "r266", "r525", "r526", "r527", "r528", "r626", "r680", "r713", "r714", "r715", "r727", "r845", "r923", "r932", "r948", "r1038", "r1040", "r1054", "r1073", "r1074", "r1126", "r1128", "r1130", "r1131", "r1143", "r1158", "r1159", "r1186", "r1200", "r1218", "r1228", "r1229", "r1233", "r1234", "r1249", "r1258", "r1484", "r1496", "r1538", "r1567", "r1568", "r1569", "r1570", "r1571" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/LeasesNarrativeDetails", "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r228", "r230", "r232", "r233", "r235", "r265", "r266", "r525", "r526", "r527", "r528", "r626", "r680", "r713", "r714", "r715", "r727", "r845", "r923", "r932", "r948", "r1038", "r1040", "r1054", "r1073", "r1074", "r1126", "r1128", "r1130", "r1131", "r1143", "r1158", "r1159", "r1186", "r1200", "r1218", "r1228", "r1229", "r1233", "r1234", "r1249", "r1258", "r1484", "r1496", "r1538", "r1567", "r1568", "r1569", "r1570", "r1571" ] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified out", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r29", "r33" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.westpharma.com/role/SegmentInformationNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1284", "r1295", "r1305", "r1338" ] }, "wst_ReductionInNumberOfSharesAvailableForGrantForEachAwardGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ReductionInNumberOfSharesAvailableForGrantForEachAwardGranted", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate shares are reduced for each award granted", "label": "Reduction In Number Of Shares Available For Grant For Each Award Granted", "documentation": "Reduction In Number Of Shares Available For Grant For Each Award Granted" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related and Nonrelated Parties [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r410", "r654", "r915", "r916", "r999", "r1006", "r1076", "r1077", "r1078", "r1079", "r1080", "r1100", "r1102", "r1125" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r915", "r916", "r1563" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases from (and payments to) affiliates", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related and Nonrelated Parties [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r410", "r654", "r915", "r916", "r999", "r1006", "r1076", "r1077", "r1078", "r1079", "r1080", "r1100", "r1102", "r1125", "r1563" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r149", "r1059" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of other long-term debt", "label": "Repayments of Other Long-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r149" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r729", "r1160", "r1181", "r1572" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r728" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchMember", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Carryforward", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r1518" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1285", "r1296", "r1306", "r1339" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1286", "r1297", "r1307", "r1340" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1293", "r1304", "r1314", "r1347" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r278" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r43" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "xbrltype": "durationItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related activities, period of implementation (up to)", "label": "Restructuring And Related Activities, Period Of Implementation", "documentation": "Restructuring And Related Activities, Period Of Implementation" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCostRemaining1", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related cost", "label": "Restructuring and Related Cost, Expected Cost Remaining", "documentation": "Amount of expected cost remaining for the specified restructuring cost." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "wst_OtherIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total restructuring and related charges", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r513", "r516", "r518", "r520" ] }, "wst_RestructuringAndRelatedCostsAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "RestructuringAndRelatedCostsAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-related charges", "label": "Restructuring And Related Costs, Asset Impairment Charges", "documentation": "Restructuring And Related Costs, Asset Impairment Charges" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and related charges, net", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r517", "r518", "r1485" ] }, "wst_RestructuringChargesCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "RestructuringChargesCredits", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Credits) charges", "label": "Restructuring (Charges) Credits", "documentation": "Restructuring (Charges) Credits" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r513", "r514", "r518", "r519" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r513", "r514", "r515", "r516", "r518", "r519", "r520" ] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1379", "r1380" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails", "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and severance related charges", "periodStartLabel": "Balance, December 31, 2023", "periodEndLabel": "Balance, December 31, 2024", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r514", "r519" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash restructuring charges", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r514", "r519" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r123", "r168", "r1004", "r1048", "r1053", "r1060", "r1084", "r1237" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r269", "r334", "r335", "r336", "r341", "r349", "r351", "r353", "r456", "r464", "r503", "r766", "r767", "r781", "r782", "r783", "r787", "r796", "r797", "r818", "r821", "r822", "r826", "r837", "r883", "r886", "r1044", "r1046", "r1062", "r1609" ] }, "us-gaap_RetainedEarningsUndistributedEarningsFromEquityMethodInvestees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsUndistributedEarningsFromEquityMethodInvestees", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unremitted income of affiliates", "label": "Retained Earnings, Undistributed Earnings from Equity Method Investees", "documentation": "Amount of consolidated retained earnings that represent undistributed (not yet received) earnings from 50 percent or less owned persons accounted for by the equity method (equity method investees)." } } }, "auth_ref": [ "r322" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r654", "r657", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r1508", "r1509", "r1510" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r650", "r651", "r652", "r654", "r657", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r1508", "r1509", "r1510" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r651", "r652", "r654", "r657", "r660", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r677", "r678", "r679", "r682", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinBalanceSheetDetails", "http://www.westpharma.com/role/BenefitPlansAmountsRecognizedinOtherComprehensiveInLossDetails", "http://www.westpharma.com/role/BenefitPlansAssumptionsUsedDetails", "http://www.westpharma.com/role/BenefitPlansChangesinProjectedBenefitObligationFairValueofPlanAssetsandFundedStatusDetails", "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r651", "r652", "r654", "r657", "r660", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r677", "r678", "r679", "r682", "r1210", "r1211", "r1212", "r1213", "r1214", "r1215", "r1216", "r1217" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net sales", "netLabel": "Net Sales", "terseLabel": "Net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r196", "r197", "r372", "r379", "r380", "r394", "r400", "r403", "r405", "r407", "r595", "r596", "r951" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r407", "r1388" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r220", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r1161" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Product and Service Benchmark", "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r1389" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r220", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r599" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "wst_RevolvingCreditFacilityDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "RevolvingCreditFacilityDue2024Member", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails", "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility, Due 2024", "label": "Revolving Credit Facility, Due 2024 [Member]", "documentation": "Revolving Credit Facility, Due 2024" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r901", "r1236" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r901", "r1236" ] }, "wst_RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "RightOfUseAssetsObtainedInExchangeForNewLeaseLiabilitiesAbstract", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange for new lease liabilities:", "label": "Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]", "documentation": "Right-Of-Use Assets Obtained In Exchange For New Lease Liabilities" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1356" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1356" ] }, "currency_SGD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "SGD", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SGD", "label": "Singapore, Dollars" } } }, "auth_ref": [] }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesAndExciseTaxPayableCurrent", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International value added tax payable", "label": "Sales and Excise Tax Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r107" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r681", "r1402", "r1435" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r264", "r354", "r681", "r1381", "r1435" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r33", "r1551", "r1552" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Plan Assets", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r170" ] }, "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Balance Sheet", "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amounts Recognized in Other Comprehensive Loss", "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost." } } }, "auth_ref": [ "r169" ] }, "wst_ScheduleOfAssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfAssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets And Liabilities, Lessee", "label": "Schedule Of Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Schedule Of Assets And Liabilities, Lessee" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assumptions Used", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r648" ] }, "wst_ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfChangesInFairValueOfPlanAssetsProjectedBenefitObligationsAndNetFundedStatusTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Projected Benefit Obligation, Fair Value of Plan Assets and Funded Status", "label": "Schedule Of Changes In Fair Value Of Plan Assets, Projected Benefit Obligations And Net Funded Status [Table Text Block]", "documentation": "Schedule of Changes in Fair Value of Plan Assets, Projected Benefit Obligations and Net Funded Status [Table Text Block]" } } }, "auth_ref": [] }, "wst_ScheduleOfCommonStockRepurchasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfCommonStockRepurchasesTableTextBlock", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Repurchase of Common Stock", "label": "Schedule Of Common Stock Repurchases [Table Text Block]", "documentation": "Schedule Of Common Stock Repurchases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Share-based Compensation Costs by Plan", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r80" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1520" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r15", "r73", "r74", "r75", "r76" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r91", "r93", "r812" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Currency Contracts", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r22", "r85", "r86", "r87", "r90", "r92", "r93", "r98", "r100" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1437" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r742", "r1222", "r1513" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales by Significant Product Group", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r56" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investee, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r447", "r448", "r450", "r777", "r1382", "r1383", "r1384", "r1523", "r1524", "r1525", "r1526" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r323", "r447", "r448", "r450", "r451", "r866" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofAmountsDuetoAffiliatesintheCondensedConsolidatedBalanceSheetsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofCompanysAffiliateTransactionsDetails", "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": [ "r274", "r323", "r447", "r448", "r450", "r451", "r866" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Expected Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r171" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1535", "r1536" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r490", "r496", "r499", "r500", "r501", "r952", "r1160", "r1189" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1189", "r1474" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r1188" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1188", "r1456", "r1457", "r1458", "r1459", "r1460", "r1461", "r1462", "r1463", "r1464", "r1465", "r1466" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Before Income Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1425" ] }, "wst_ScheduleOfIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets by Major Class [Line Items]", "label": "Schedule Of Intangible Assets By Major Class [Line Items]", "documentation": "[Line Items] for Schedule of Intangible Assets by Major Class [Table]" } } }, "auth_ref": [] }, "wst_ScheduleOfIntangibleAssetsByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfIntangibleAssetsByMajorClassTable", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets by Major Class [Table]", "label": "Schedule Of Intangible Assets By Major Class [Table]", "documentation": "Schedule of Intangible Assets by Major Class [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r31", "r127", "r128", "r129" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r172" ] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Performance-based Share Activity", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r174" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r95", "r1391" ] }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Expense (Income)", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "documentation": "Schedule of Other Income and Expense, by Component [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r13", "r905" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r513", "r514", "r515", "r516", "r518", "r519", "r520" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Obligations", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r62", "r163" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Sales and Long-Lived Assets, by Geographical Areas", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r57", "r135" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r57", "r135" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r684", "r685", "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r24", "r25", "r173" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Beginning and Ending Liability for Unrecognized Tax Benefits", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r751", "r1221" ] }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccounts" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule II - Valuation and Qualifying Accounts", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "documentation": "The entire disclosure for valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r227", "r333" ] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1532" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1266" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1269" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r196", "r197", "r198", "r199", "r372", "r375", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r407", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r501", "r516", "r520", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1178", "r1181", "r1182", "r1188", "r1252", "r1575", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Expenditures", "label": "Segment, Expenditure, Addition to Long-Lived Assets", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r372", "r389", "r400", "r1181", "r1182" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r229", "r231", "r234", "r236", "r243", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r405", "r406", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r1066", "r1069", "r1071", "r1127", "r1129", "r1132", "r1144", "r1145", "r1148", "r1149", "r1150", "r1151", "r1153", "r1154", "r1155", "r1156", "r1157", "r1163", "r1202", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1251", "r1258", "r1499", "r1575", "r1577", "r1578", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r199", "r372", "r374", "r375", "r376", "r377", "r378", "r390", "r392", "r393", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r1177", "r1179", "r1180", "r1181", "r1183", "r1184", "r1185" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense (income)", "label": "Segment Reporting, Other Segment Item, Amount", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r372", "r392", "r393", "r400", "r1181" ] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://www.westpharma.com/role/SegmentInformationNarrativeDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Items [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "verboseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r142" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "wst_SeniorBNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "SeniorBNotesDue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B notes, due July 5, 2024 (3.82%)", "label": "Senior B Notes Due 2024 [Member]", "documentation": "Senior B Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "wst_SeniorCNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "SeniorCNotesDue2027Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series C notes, due July 5, 2027 (4.02%)", "label": "Senior C Notes Due 2027 [Member]", "documentation": "Senior C Notes Due 2027 [Member]" } } }, "auth_ref": [] }, "wst_SeniorNotesDue2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "SeniorNotesDue2022Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A notes, due July 5, 2022 (3.67%)", "label": "Senior A Notes Due 2022 [Member]", "documentation": "Senior A Notes Due 2022 [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails": { "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofOtherIncomeExpenseDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Severance and benefits", "terseLabel": "Severance related costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "negatedTerseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardActualPayoutPercentage", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual payout range", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Actual Payout, Percentage" } } }, "auth_ref": [] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTarget": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTarget", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments above/(below) target (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target" } } }, "auth_ref": [] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTargetWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsAboveBelowTargetWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments above/(below) target (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Adjustments Above (Below) Target, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfSharesIssuableUponVesting": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfSharesIssuableUponVesting", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares to be issued upon conversion (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number of Shares Issuable Upon Vesting" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r705" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r705" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted at target level (in shares)", "terseLabel": "Granted at target level (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted at target level (in dollars per share)", "terseLabel": "Granted at target level (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in shares)", "periodEndLabel": "Outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r700", "r701" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in dollars per share)", "periodEndLabel": "Outstanding, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r700", "r701" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested and converted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r704" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and converted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r704" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r714" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock volatility (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r713" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r715" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r684", "r685", "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limitation on payroll deductions of employee's base salary (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r78" ] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRateAmount", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Limitation on payroll deductions of employee's base salary, amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate, Amount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares per employee (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": [ "r78" ] }, "wst_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeePerYear": { "xbrltype": "sharesItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployeePerYear", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares per employee, per year (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares per Employee per Year" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r694" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r694" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r707" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r698" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r706" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of total options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning (in shares)", "periodEndLabel": "Options outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r692", "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning (in dollars per share)", "periodEndLabel": "Options outstanding, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r692", "r693" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of total options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r709" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r708" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r708" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails", "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r688", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r712", "r713", "r714", "r715", "r716" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r697" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r698" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r683", "r691", "r710", "r711", "r712", "r713", "r716", "r722", "r723", "r724", "r725" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards, expiration period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1220" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r712" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life of options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r78" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life of options outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r175" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value of options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r707" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of current market price for sales to eligible employees (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortMember", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sell", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r898", "r1236" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r153", "r320" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated increase (decrease) in the liability for unrecognized tax benefits", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date." } } }, "auth_ref": [ "r203" ] }, "wst_StandardPackagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "StandardPackagingMember", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Standard Packaging", "label": "Standard Packaging [Member]", "documentation": "Standard Packaging [Member]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and Local Jurisdiction", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r740" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsGoodwillDetails", "http://www.westpharma.com/role/SegmentInformationSalesbyProductGroupDetails", "http://www.westpharma.com/role/SegmentInformationSegmentFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r196", "r197", "r198", "r199", "r273", "r372", "r375", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r407", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r501", "r505", "r516", "r520", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1178", "r1181", "r1182", "r1188", "r1252", "r1575", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r21", "r121", "r124", "r125", "r269", "r307", "r308", "r309", "r334", "r335", "r336", "r341", "r349", "r351", "r353", "r373", "r456", "r464", "r503", "r575", "r766", "r767", "r781", "r782", "r783", "r787", "r796", "r797", "r818", "r820", "r821", "r822", "r823", "r826", "r837", "r873", "r874", "r875", "r876", "r877", "r878", "r883", "r886", "r912", "r1013", "r1044", "r1045", "r1046", "r1062", "r1122" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r229", "r231", "r234", "r236", "r243", "r244", "r245", "r246", "r248", "r249", "r250", "r251", "r252", "r253", "r405", "r406", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r1066", "r1069", "r1071", "r1127", "r1129", "r1132", "r1144", "r1145", "r1148", "r1149", "r1150", "r1151", "r1153", "r1154", "r1155", "r1156", "r1157", "r1163", "r1202", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1251", "r1258", "r1499", "r1575", "r1577", "r1578", "r1580", "r1581", "r1582", "r1583", "r1584", "r1585", "r1586", "r1587", "r1588", "r1589", "r1590", "r1591", "r1592", "r1593", "r1594", "r1595", "r1596", "r1597", "r1598", "r1599", "r1600", "r1601", "r1602", "r1603", "r1604" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r334", "r335", "r336", "r373", "r886", "r951", "r1057", "r1063", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1083", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1104", "r1105", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1122", "r1259" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r264", "r354", "r681", "r1381", "r1385", "r1435" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r334", "r335", "r336", "r373", "r410", "r886", "r951", "r1057", "r1063", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1083", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1096", "r1097", "r1098", "r1099", "r1100", "r1102", "r1104", "r1105", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1122", "r1259" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1288", "r1299", "r1309", "r1342" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of shares (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r21", "r120", "r121", "r168" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r21", "r120", "r121", "r168" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r21", "r120", "r121", "r168", "r697" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Activity related to stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r79", "r120", "r121", "r168" ] }, "wst_StockOptionAndAppreciationRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "StockOptionAndAppreciationRightsMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationAllocationofSharebasedCompensationCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option and appreciation rights", "label": "Stock Option and Appreciation Rights [Member]", "documentation": "Stock Option and Appreciation Rights [Member]" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareNarrativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, shares authorized (in shares)", "label": "Share Repurchase Program, Authorized, Number of Shares", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1497" ] }, "wst_StockSettledPSUAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "StockSettledPSUAwardsMember", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails", "http://www.westpharma.com/role/StockBasedCompensationNonvestedPerformancebasedAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-settled PSU awards", "label": "Stock-Settled PSU Awards [Member]", "documentation": "Stock-Settled PSU Awards" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveLossDetails", "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r121", "r124", "r125", "r156", "r1085", "r1101", "r1123", "r1124", "r1237", "r1265", "r1424", "r1454", "r1550", "r1609" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1335" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails": { "parentTag": "us-gaap_AssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofImpairmentExpensesrelatedtoFixedAssetsImpairedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed asset impairment expense", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r106", "r160" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r763" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r763" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r763" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r28", "r1468", "r1469", "r1470", "r1471", "r1473", "r1475", "r1477", "r1478" ] }, "wst_TermLoanDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "TermLoanDue2024Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan, due December 31, 2024 (6.32%)", "label": "Term Loan Due 2024 [Member]", "documentation": "Term Loan Due 2024" } } }, "auth_ref": [] }, "wst_TermLoanDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "TermLoanDue2027Member", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan, due July 2, 2027 (5.68%)", "label": "Term Loan, Due 2027 [Member]", "documentation": "Term Loan, Due 2027" } } }, "auth_ref": [] }, "wst_The2022RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "The2022RestructuringPlanMember", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Restructuring Plan", "label": "The 2022 Restructuring Plan [Member]", "documentation": "The 2022 Restructuring Plan" } } }, "auth_ref": [] }, "wst_ThereafterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "ThereafterMember", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Thereafter [Member]", "documentation": "Thereafter" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1444", "r1562" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual with Relationship to Entity [Domain]", "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "us-gaap_ToolsDiesAndMoldsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ToolsDiesAndMoldsMember", "presentation": [ "http://www.westpharma.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentGrossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Molds and dies", "label": "Tools, Dies and Molds [Member]", "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1327" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1334" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r200", "r201", "r202", "r1446", "r1447", "r1448" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.westpharma.com/role/GoodwillandIntangibleAssetsIntangibleAssetsbyMajorClassDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r81", "r1189", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473", "r1475", "r1476", "r1477", "r1478" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1355" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1357" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.westpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r568", "r574", "r827", "r862", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r1014", "r1224", "r1226", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1238", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1449", "r1450", "r1451", "r1452", "r1534", "r1537", "r1538", "r1539", "r1546", "r1549" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1358" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1359" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1359" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1357" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1357" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1360" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1358" ] }, "us-gaap_TreasuryLockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryLockMember", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOtherComprehensiveIncomeOCIandEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward treasury locks", "label": "Treasury Lock [Member]", "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Average price per repurchased share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r70" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, at cost (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost (3.0 million and 1.8 million shares in 2024 and 2023)", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r70", "r71", "r124" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares purchased under share repurchase program (in shares)", "verboseLabel": "Shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r21", "r121", "r168" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.westpharma.com/role/NetIncomePerShareScheduleofRepurchaseofCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares purchased under share repurchase program", "verboseLabel": "Total cost of repurchases ($ in millions)", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r21", "r70", "r168" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeScheduleofRestructuringandRelatedChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r513", "r514", "r518", "r519" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.westpharma.com/role/BenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.westpharma.com/role/BenefitPlansExpectedBenefitPaymentsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansWeightedAverageInterestCreditingRatingbyGeographicLocationDetails", "http://www.westpharma.com/role/SegmentInformationSalesandLonglivedAssetsbyGeographicLocationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States of America, Dollars", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails", "http://www.westpharma.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: unamortized debt issuance costs for Term Loan and Series notes", "verboseLabel": "Unamortized debt issuance costs remaining", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsOfForeignSubsidiaries", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed earnings of foreign subsidiaries", "label": "Undistributed Earnings of Foreign Subsidiaries", "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile." } } }, "auth_ref": [ "r18", "r19", "r204", "r731" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1354" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails", "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at January 1", "periodEndLabel": "Balance at December 31", "terseLabel": "Total gross unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r732", "r751", "r1221" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease due to prior year position", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r752", "r1221" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities for interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r749", "r1221" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase due to current year position", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r753", "r1221" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase due to prior year position", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r752", "r1221" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reduction for expiration of statute of limitations/audits", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r754" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding unconditional contractual commitments due to be paid in 2024", "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One", "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Includes, but is not limited to, lease not yet commenced." } } }, "auth_ref": [ "r522", "r1557" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding unconditional contractual commitments for the purchase of raw materials, utilities and equipment", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts." } } }, "auth_ref": [ "r522", "r1557" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationTerm", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecorded Unconditional Purchase Obligation, Term", "label": "Unrecorded Unconditional Purchase Obligation, Term", "documentation": "Term of the unrecognized unconditional purchase obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r521" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r48", "r49", "r50", "r208", "r209", "r211", "r212" ] }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset valuation allowance", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward." } } }, "auth_ref": [ "r1427", "r1428", "r1429", "r1430", "r1431" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r328", "r332" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charged to costs and expenses", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r329" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deductions", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r331" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r332" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r328", "r329", "r330", "r331", "r332" ] }, "srt_ValuationAndQualifyingAccountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "auth_ref": [] }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r328", "r329", "r330", "r331", "r332" ] }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ValuationAndQualifyingAccountsDisclosureTable", "presentation": [ "http://www.westpharma.com/role/ScheduleIIValuationandQualifyingAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r328", "r329", "r330", "r331", "r332" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r899", "r1236" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.westpharma.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1323" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://www.westpharma.com/role/BenefitPlansAllocationofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r845", "r932", "r1158", "r1159", "r1228", "r1566", "r1568", "r1571" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r358", "r366" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME", "http://www.westpharma.com/role/NetIncomePerShareScheduleofReconciliationofSharesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r357", "r366" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.westpharma.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "wst_WestCompanyMexicoSADeCVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "WestCompanyMexicoSADeCVMember", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesScheduleofInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The West Company Mexico, S.A. de C.V.", "label": "The West Company Mexico, S.A. de C.V. [Member]", "documentation": "The West Company Mexico, S.A. de C.V. [Member]" } } }, "auth_ref": [] }, "wst_Year2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.westpharma.com/20241231", "localname": "Year2025Member", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year 2025", "label": "Year 2025 [Member]", "documentation": "Year 2025" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1321" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "60", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "740", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "2C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-2C" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4F", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org/323/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Paragraph": "Column B", "Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Paragraph": "Column C", "Subparagraph": "(1)", "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Paragraph": "Column C", "Subparagraph": "(2)", "Publisher": "SEC" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Paragraph": "Column D", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Paragraph": "Column E", "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "09", "Publisher": "SEC" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(dd)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481725/323-10-35-18" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1095": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1097": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1098": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1099": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1346": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1347": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1348": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1349": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1350": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1351": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1365": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1366": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1367": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1368": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1369": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1370": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1371": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1372": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1373": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1374": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1375": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1376": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1377": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1378": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1379": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1380": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1381": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1382": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1383": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1384": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1385": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Subparagraph": "(ii)", "Footnote": "2", "Publisher": "SEC" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "1", "Publisher": "SEC" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 140 0000105770-25-000013-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-25-000013-xbrl.zip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�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

  •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

  •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

  •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end XML 141 wst-20241231_htm.xml IDEA: XBRL DOCUMENT 0000105770 2024-01-01 2024-12-31 0000105770 2024-06-30 0000105770 2025-02-06 0000105770 2023-01-01 2023-12-31 0000105770 2022-01-01 2022-12-31 0000105770 2024-12-31 0000105770 2023-12-31 0000105770 us-gaap:CommonStockMember 2021-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2021-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000105770 2021-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000105770 us-gaap:CommonStockMember 2022-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2022-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000105770 2022-12-31 0000105770 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000105770 us-gaap:CommonStockMember 2023-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2023-12-31 0000105770 us-gaap:RetainedEarningsMember 2023-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000105770 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000105770 us-gaap:CommonStockMember 2024-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000105770 us-gaap:TreasuryStockCommonMember 2024-12-31 0000105770 us-gaap:RetainedEarningsMember 2024-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000105770 srt:MinimumMember 2024-12-31 0000105770 srt:MaximumMember 2024-12-31 0000105770 wst:BiologicsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:BiologicsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:BiologicsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:GenericsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:GenericsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:GenericsCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:PharmaCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:PharmaCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:PharmaCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:ContractManufacturedCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:ContractManufacturedCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:ContractManufacturedCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:HighValueProductComponentsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:HighValueProductComponentsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:HighValueProductComponentsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:HighValueProductDeliveryDevicesMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:HighValueProductDeliveryDevicesMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:HighValueProductDeliveryDevicesMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:StandardPackagingMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:StandardPackagingMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:StandardPackagingMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 wst:ContractManufacturedProductsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:ContractManufacturedProductsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 wst:ContractManufacturedProductsMember us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 srt:AmericasMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 us-gaap:EMEAMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 srt:AsiaPacificMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000105770 2023-02-28 0000105770 us-gaap:LandMember 2024-12-31 0000105770 us-gaap:LandMember 2023-12-31 0000105770 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000105770 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000105770 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000105770 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000105770 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000105770 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000105770 srt:MinimumMember us-gaap:ToolsDiesAndMoldsMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:ToolsDiesAndMoldsMember 2024-12-31 0000105770 us-gaap:ToolsDiesAndMoldsMember 2024-12-31 0000105770 us-gaap:ToolsDiesAndMoldsMember 2023-12-31 0000105770 srt:MinimumMember wst:ComputerHardwareAndSoftwareMember 2024-12-31 0000105770 srt:MaximumMember wst:ComputerHardwareAndSoftwareMember 2024-12-31 0000105770 wst:ComputerHardwareAndSoftwareMember 2024-12-31 0000105770 wst:ComputerHardwareAndSoftwareMember 2023-12-31 0000105770 us-gaap:ConstructionInProgressMember 2024-12-31 0000105770 us-gaap:ConstructionInProgressMember 2023-12-31 0000105770 wst:WestCompanyMexicoSADeCVMember 2024-12-31 0000105770 wst:AluplastSADeCVMember 2024-12-31 0000105770 wst:PharmaTapSADeCVMember 2024-12-31 0000105770 wst:PharmaRubberSADeCVMember 2024-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2024-12-31 0000105770 srt:AffiliatedEntityMember 2024-12-31 0000105770 srt:AffiliatedEntityMember 2023-12-31 0000105770 wst:DistributorshipAgreementMember 2024-01-01 2024-12-31 0000105770 wst:DistributorshipAgreementMember 2023-01-01 2023-12-31 0000105770 wst:DistributorshipAgreementMember 2022-01-01 2022-12-31 0000105770 srt:AffiliatedEntityMember 2024-01-01 2024-12-31 0000105770 srt:AffiliatedEntityMember 2023-01-01 2023-12-31 0000105770 srt:AffiliatedEntityMember 2022-01-01 2022-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2023-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2022-12-31 0000105770 wst:ProprietaryProductsMember 2022-12-31 0000105770 wst:ContractManufacturedProductsMember 2022-12-31 0000105770 wst:ProprietaryProductsMember 2023-01-01 2023-12-31 0000105770 wst:ContractManufacturedProductsMember 2023-01-01 2023-12-31 0000105770 wst:ProprietaryProductsMember 2023-12-31 0000105770 wst:ContractManufacturedProductsMember 2023-12-31 0000105770 wst:ProprietaryProductsMember 2024-01-01 2024-12-31 0000105770 wst:ContractManufacturedProductsMember 2024-01-01 2024-12-31 0000105770 wst:ProprietaryProductsMember 2024-12-31 0000105770 wst:ContractManufacturedProductsMember 2024-12-31 0000105770 wst:PatentsAndLicensingMember 2024-12-31 0000105770 wst:PatentsAndLicensingMember 2023-12-31 0000105770 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-12-31 0000105770 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000105770 us-gaap:TrademarksMember 2024-12-31 0000105770 us-gaap:TrademarksMember 2023-12-31 0000105770 us-gaap:CustomerRelationshipsMember 2024-12-31 0000105770 us-gaap:CustomerRelationshipsMember 2023-12-31 0000105770 us-gaap:CustomerContractsMember 2024-12-31 0000105770 us-gaap:CustomerContractsMember 2023-12-31 0000105770 wst:TermLoanDue2027Member 2024-12-31 0000105770 wst:TermLoanDue2027Member 2023-12-31 0000105770 wst:TermLoanDue2024Member 2024-12-31 0000105770 wst:TermLoanDue2024Member 2023-12-31 0000105770 wst:SeniorBNotesDue2024Member 2024-12-31 0000105770 wst:SeniorBNotesDue2024Member 2023-12-31 0000105770 wst:SeniorCNotesDue2027Member 2024-12-31 0000105770 wst:SeniorCNotesDue2027Member 2023-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-02-28 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 us-gaap:DomesticLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 us-gaap:ForeignLineOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member wst:ApplicableMarginMember 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member us-gaap:FederalFundsEffectiveSwapRateMember 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrMember 2022-03-01 2022-03-31 0000105770 srt:MinimumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:BaseRateMember 2022-03-01 2022-03-31 0000105770 srt:MaximumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:BaseRateMember 2022-03-01 2022-03-31 0000105770 srt:MinimumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrMember 2022-03-01 2022-03-31 0000105770 srt:MaximumMember wst:RevolvingCreditFacilityDue2024Member us-gaap:SecuredOvernightFinancingRateSofrMember 2022-03-01 2022-03-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2024-01-01 2024-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2023-01-01 2023-12-31 0000105770 wst:RevolvingCreditFacilityDue2024Member 2024-12-31 0000105770 us-gaap:LetterOfCreditMember wst:RevolvingCreditFacilityDue2024Member 2024-12-31 0000105770 wst:TermLoanDue2027Member 2024-07-02 0000105770 wst:TermLoanDue2024Member 2024-07-02 2024-07-02 0000105770 wst:SeniorBNotesDue2024Member 2024-07-02 2024-07-02 0000105770 wst:SeniorBNotesDue2024Member 2012-07-05 0000105770 srt:MinimumMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-02 2024-07-02 0000105770 srt:MaximumMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-02 2024-07-02 0000105770 srt:MinimumMember us-gaap:BaseRateMember 2024-07-02 2024-07-02 0000105770 srt:MaximumMember us-gaap:BaseRateMember 2024-07-02 2024-07-02 0000105770 us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-02 2024-07-02 0000105770 wst:TermLoanDue2024Member 2024-01-01 2024-12-31 0000105770 wst:TermLoanDue2024Member 2023-01-01 2023-12-31 0000105770 us-gaap:SeniorNotesMember 2012-12-31 0000105770 2012-12-31 0000105770 wst:SeniorNotesDue2022Member us-gaap:SeniorNotesMember 2012-12-31 0000105770 wst:SeniorBNotesDue2024Member us-gaap:SeniorNotesMember 2012-12-31 0000105770 wst:SeniorCNotesDue2027Member us-gaap:SeniorNotesMember 2012-12-31 0000105770 us-gaap:SeniorNotesMember 2024-12-31 0000105770 us-gaap:SeniorNotesMember 2023-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember wst:IntercompanyLoansMember 2024-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember wst:IntercompanyLoansMember 2024-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember wst:IntercompanyLoansMember 2023-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember wst:IntercompanyLoansMember 2023-12-31 0000105770 currency:EUR us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember 2024-12-31 0000105770 currency:USD us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember 2024-12-31 0000105770 currency:EUR us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember 2023-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember wst:IntercompanyDemandNotesMember 2023-12-31 0000105770 us-gaap:ForeignExchangeForwardMember 2024-01-01 2024-12-31 0000105770 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-12-31 0000105770 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-12-31 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-12-31 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-12-31 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2024-12-31 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2024-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-01 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2024-07-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2024-12-31 0000105770 us-gaap:OptionMember 2024-12-31 0000105770 wst:OtherExpenseIncomeMember 2024-01-01 2024-12-31 0000105770 wst:OtherExpenseIncomeMember 2023-01-01 2023-12-31 0000105770 wst:OtherExpenseIncomeMember 2022-01-01 2022-12-31 0000105770 us-gaap:FairValueHedgingMember 2024-01-01 2024-12-31 0000105770 us-gaap:FairValueHedgingMember 2023-01-01 2023-12-31 0000105770 us-gaap:FairValueHedgingMember 2022-01-01 2022-12-31 0000105770 srt:ScenarioForecastMember us-gaap:FairValueHedgingMember 2025-01-01 2025-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember 2022-01-01 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember wst:NetSalesMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember wst:NetSalesMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignExchangeContractMember wst:NetSalesMember 2022-01-01 2022-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000105770 us-gaap:TreasuryLockMember 2024-01-01 2024-12-31 0000105770 us-gaap:TreasuryLockMember 2023-01-01 2023-12-31 0000105770 us-gaap:TreasuryLockMember 2022-01-01 2022-12-31 0000105770 us-gaap:CurrencySwapMember 2024-01-01 2024-12-31 0000105770 us-gaap:CurrencySwapMember 2023-01-01 2023-12-31 0000105770 us-gaap:CurrencySwapMember 2022-01-01 2022-12-31 0000105770 wst:NetSalesMember 2024-01-01 2024-12-31 0000105770 wst:NetSalesMember 2023-01-01 2023-12-31 0000105770 wst:NetSalesMember 2022-01-01 2022-12-31 0000105770 us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0000105770 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000105770 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000105770 us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0000105770 us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0000105770 us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember 2024-01-01 2024-12-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember 2023-01-01 2023-12-31 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember 2022-01-01 2022-12-31 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2022-01-01 2022-12-31 0000105770 us-gaap:NondesignatedMember 2024-01-01 2024-12-31 0000105770 us-gaap:NondesignatedMember 2023-01-01 2023-12-31 0000105770 us-gaap:NondesignatedMember 2022-01-01 2022-12-31 0000105770 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:MoneyMarketFundsMember 2024-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:BankTimeDepositsMember 2024-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:CurrencySwapMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CurrencySwapMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CurrencySwapMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CurrencySwapMember 2024-12-31 0000105770 us-gaap:CommodityMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CommodityMember 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2024-12-31 0000105770 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMember 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMember 2023-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CurrencySwapMember 2023-12-31 0000105770 us-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CommodityMember 2023-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2023-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2023-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2021-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2022-01-01 2022-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2022-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2023-01-01 2023-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2023-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2024-01-01 2024-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000105770 us-gaap:AociEquityMethodInvestmentParentMember 2024-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000105770 wst:AwardTypesOtherThanStockOptionsAndStockAppreciationRightsMember 2024-01-01 2024-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2024-01-01 2024-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2023-01-01 2023-12-31 0000105770 wst:StockOptionAndAppreciationRightsMember 2022-01-01 2022-12-31 0000105770 us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000105770 us-gaap:PerformanceSharesMember 2023-01-01 2023-12-31 0000105770 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2024-01-01 2024-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2023-01-01 2023-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2022-01-01 2022-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2022-01-01 2022-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000105770 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000105770 wst:StockSettledPSUAwardsMember 2023-12-31 0000105770 wst:StockSettledPSUAwardsMember 2024-01-01 2024-12-31 0000105770 wst:StockSettledPSUAwardsMember 2024-12-31 0000105770 srt:MinimumMember wst:StockSettledPSUAwardsMember 2024-01-01 2024-12-31 0000105770 srt:MaximumMember wst:StockSettledPSUAwardsMember 2024-01-01 2024-12-31 0000105770 wst:StockSettledPSUAwardsMember 2023-01-01 2023-12-31 0000105770 wst:StockSettledPSUAwardsMember 2022-01-01 2022-12-31 0000105770 wst:EmployeeStockPurchasePlanEsppMember 2024-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-12-31 0000105770 srt:DirectorMember us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-01-01 2024-12-31 0000105770 srt:DirectorMember us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-01-01 2023-12-31 0000105770 srt:DirectorMember us-gaap:DeferredCompensationShareBasedPaymentsMember 2022-01-01 2022-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-12-31 0000105770 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-12-31 0000105770 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0000105770 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000105770 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000105770 country:US 2022-01-01 2022-12-31 0000105770 country:US 2023-01-01 2023-12-31 0000105770 country:US 2024-01-01 2024-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000105770 us-gaap:ForeignPlanMember 2024-12-31 0000105770 us-gaap:ForeignPlanMember 2023-12-31 0000105770 country:US 2024-12-31 0000105770 country:US 2023-12-31 0000105770 srt:ScenarioForecastMember 2031-01-01 2031-12-31 0000105770 us-gaap:ForeignPlanMember 2024-01-01 2024-12-31 0000105770 us-gaap:ForeignPlanMember 2023-01-01 2023-12-31 0000105770 us-gaap:ForeignPlanMember 2022-01-01 2022-12-31 0000105770 srt:WeightedAverageMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2024-12-31 0000105770 srt:WeightedAverageMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanDebtSecurityMember 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanDebtSecurityMember 2023-12-31 0000105770 us-gaap:OtherInvestmentsMember 2024-12-31 0000105770 us-gaap:OtherInvestmentsMember 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2024-12-31 0000105770 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesMember 2024-12-31 0000105770 srt:MinimumMember us-gaap:DefinedBenefitPlanDebtSecurityMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:DefinedBenefitPlanDebtSecurityMember 2024-12-31 0000105770 srt:MinimumMember us-gaap:OtherInvestmentsMember 2024-12-31 0000105770 srt:MaximumMember us-gaap:OtherInvestmentsMember 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel12And3Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel12And3Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel12And3Member 2024-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel12And3Member 2024-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000105770 us-gaap:FairValueInputsLevel12And3Member 2024-12-31 0000105770 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel12And3Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanCashMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel12And3Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:DefinedBenefitPlanEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel12And3Member 2023-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel12And3Member 2023-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0000105770 wst:OtherMutualFundsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0000105770 us-gaap:FairValueInputsLevel12And3Member 2023-12-31 0000105770 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-12-31 0000105770 2022-12-01 2022-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:The2022RestructuringPlanMember 2023-12-31 0000105770 us-gaap:OtherRestructuringMember wst:The2022RestructuringPlanMember 2023-12-31 0000105770 wst:The2022RestructuringPlanMember 2023-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:The2022RestructuringPlanMember 2024-01-01 2024-12-31 0000105770 us-gaap:OtherRestructuringMember wst:The2022RestructuringPlanMember 2024-01-01 2024-12-31 0000105770 wst:The2022RestructuringPlanMember 2024-01-01 2024-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:The2022RestructuringPlanMember 2024-12-31 0000105770 us-gaap:OtherRestructuringMember wst:The2022RestructuringPlanMember 2024-12-31 0000105770 wst:The2022RestructuringPlanMember 2024-12-31 0000105770 2023-04-01 2023-06-30 0000105770 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0000105770 us-gaap:ForeignCountryMember 2024-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember wst:Year2025Member 2024-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember wst:ThereafterMember 2024-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0000105770 2019-12-31 0000105770 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2024-12-31 0000105770 country:DE 2024-12-31 0000105770 us-gaap:InsuranceClaimsMember 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2024-01-01 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2023-01-01 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2022-01-01 2022-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ContractManufacturedProductsMember 2024-01-01 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ContractManufacturedProductsMember 2023-01-01 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ContractManufacturedProductsMember 2022-01-01 2022-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000105770 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0000105770 wst:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000105770 wst:OneCustomerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000105770 country:US 2024-01-01 2024-12-31 0000105770 country:US 2023-01-01 2023-12-31 0000105770 country:US 2022-01-01 2022-12-31 0000105770 country:US 2024-12-31 0000105770 country:US 2023-12-31 0000105770 country:DE 2024-01-01 2024-12-31 0000105770 country:DE 2023-01-01 2023-12-31 0000105770 country:DE 2022-01-01 2022-12-31 0000105770 country:DE 2023-12-31 0000105770 country:IE 2024-01-01 2024-12-31 0000105770 country:IE 2023-01-01 2023-12-31 0000105770 country:IE 2022-01-01 2022-12-31 0000105770 country:IE 2024-12-31 0000105770 country:IE 2023-12-31 0000105770 country:FR 2024-01-01 2024-12-31 0000105770 country:FR 2023-01-01 2023-12-31 0000105770 country:FR 2022-01-01 2022-12-31 0000105770 country:FR 2024-12-31 0000105770 country:FR 2023-12-31 0000105770 wst:OtherEuropeCountriesMember 2024-01-01 2024-12-31 0000105770 wst:OtherEuropeCountriesMember 2023-01-01 2023-12-31 0000105770 wst:OtherEuropeCountriesMember 2022-01-01 2022-12-31 0000105770 wst:OtherEuropeCountriesMember 2024-12-31 0000105770 wst:OtherEuropeCountriesMember 2023-12-31 0000105770 wst:OtherCountriesMember 2024-01-01 2024-12-31 0000105770 wst:OtherCountriesMember 2023-01-01 2023-12-31 0000105770 wst:OtherCountriesMember 2022-01-01 2022-12-31 0000105770 wst:OtherCountriesMember 2024-12-31 0000105770 wst:OtherCountriesMember 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2024-01-01 2024-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2023-01-01 2023-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2022-01-01 2022-12-31 0000105770 wst:CorporateAndReconcilingItemsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0000105770 wst:CorporateAndReconcilingItemsMember wst:OtherExpenseIncomeMember 2024-01-01 2024-12-31 0000105770 wst:CorporateAndReconcilingItemsMember wst:OtherExpenseIncomeMember 2023-01-01 2023-12-31 0000105770 wst:CorporateAndReconcilingItemsMember us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ProprietaryProductsMember 2023-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ContractManufacturedProductsMember 2024-12-31 0000105770 us-gaap:OperatingSegmentsMember wst:ContractManufacturedProductsMember 2023-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2024-12-31 0000105770 wst:CorporateAndReconcilingItemsMember 2023-12-31 0000105770 2024-10-01 2024-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2024-01-01 2024-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2024-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2023-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2024-01-01 2024-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2024-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-01-01 2023-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2022-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2023-01-01 2023-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0000105770 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-01-01 2022-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2021-12-31 0000105770 us-gaap:AllowanceForCreditLossMember 2022-01-01 2022-12-31 iso4217:USD shares iso4217:USD shares pure wst:instance wst:fiscal_quarter wst:tranche iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:plan wst:facility wst:segment 0000105770 2024 FY false http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://www.westpharma.com/20241231#OtherIncomeExpense http://www.westpharma.com/20241231#OtherIncomeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold 10-K true 2024-12-31 --12-31 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-1147 610 594-2900 Common Stock, par value $.25 per share WST NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 23900000000 72303766 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Parts Into Which Incorporated</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proxy Statement for the 2025 Annual Meeting of Shareholders to be filed not later than 120 days after the end of the fiscal year covered by this Form 10-K.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Part III</span></td></tr></table> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks. To safeguard our information assets, we have put various procedures and technologies in place. For example, our Cybersecurity Incident Response Plan clearly defines roles and responsibilities for the investigation of and response to information security incidents to minimize disruption of critical computing services and operations and prevent the loss or theft of sensitive or mission-critical information. Our plan covers various cyber incidents like ransomware attacks, cyber-intrusions, data loss, denial of service, insider threats, malware attacks, and others. In a material cybersecurity incident, our D&amp;T team, inclusive of our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, address the threat via established escalation procedures, roles, responsibilities, and communication. Any cybersecurity incident that is declared as a crisis would follow our global Incident and Crisis Response and Management Procedure, which includes escalation to the West Leadership Team and Board of Directors, as deemed necessary pending the materiality of the incident. We have not encountered cybersecurity challenges that have materially impacted our operations or financial condition. In addition, we retain an external cybersecurity consultancy company to assist when a cybersecurity event arises, as needed and, in addition we maintain appropriate cybersecurity liability insurance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also educates and shares best practices globally with its employees to raise awareness of cybersecurity threats. As part of our onboarding process, we train all new employees on cybersecurity and conduct an annual retraining of all employees on cybersecurity standards. Training also includes how to recognize, report and properly respond to phishing and social engineering schemes. Multiple phishing simulation exercises are conducted throughout the year to increase cybersecurity awareness. Our cybersecurity defenses also utilize technologies such as next generation firewalls, Zero Trust architecture, intrusion detection and prevention measures, anti-malware software, advance threat protection, multifactor authentication, network segmentation and encryption to ensure the security of West intellectual properties, customer and vendor data. In addition, we have a dedicated 24-by-7 Security Operations Center to facilitate the monitoring of the Company's cybersecurity landscape and associated applications.</span></div> The Company has implemented the Committee of Sponsoring Organizations (“COSO”) Enterprise Risk Management (“ERM”) Framework, which outlines the process by which an organization can view any risk by way of governance and culture, integration into strategy, risk assessments, reviewing capabilities and practices, and monitoring and reporting. This process would apply to the cybersecurity risk as it would any of the other enterprise risks. We follow the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“CSF”) with layered security controls to help identify, protect against, detect, respond to, and recover from cyber-attacks. true true false true Our approach to cybersecurity begins with our responsibility for strong governance and controls. Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity. Security begins at the top of our organization, where Company leadership consistently communicates the requirements for vigilance and compliance throughout the organization, and then leads by example. Our diligence and assessment extend beyond West, as the Company performs a cybersecurity assessment when third-party vendors and service providers are onboarded. Throughout the year, we monitor the effectiveness of our third-party vendors' and service providers' control environment, assessing any impact to our Company. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. Security controls and processes are developed and maintained to protect sensitive and confidential information while ensuring availability and integrity. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, who provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Additionally, our ERM program enables a portfolio view of the risks inherent in our business, including cybersecurity. The ERM function monitors and reports on these top risks with periodic updates to the Audit Committee and our Board of Directors, annual updates to the Board of Directors, and regular reporting to the West Leadership Team on risk mitigation and response efforts. The cybersecurity program is led by our Chief Information Officer and our VP of Cybersecurity and Infrastructure Support, true true provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. provide periodic updates to the Audit Committee of our Board of Directors, annual updates to the Board of Directors, and regular reports to the West Leadership Team about the program, including information about cyber risk management governance and the status of ongoing efforts to strengthen cybersecurity effectiveness. Audit Committee 2893200000 2949800000 2886900000 1894700000 1820600000 1750700000 998500000 1129200000 1136200000 69100000 68400000 58500000 338500000 353400000 316900000 -21000000.0 -31400000 -26800000 569900000 676000000.0 734000000.0 3000000.0 9000000.0 7900000 19600000 28000000.0 5100000 -1000000.0 3000000.0 -51300000 585500000 698000000.0 679900000 107500000 122300000 114700000 14700000 17700000 20700000 492700000 593400000 585900000 6.75 7.98 7.87 6.69 7.88 7.73 73000000.0 74300000 74400000 73700000 75300000 75800000 492700000 593400000 585900000 3600000 1000000.0 2200000 -112300000 39400000 -47300000 300000 400000 -2400000 1100000 800000 -9300000 0.0 0.0 20300000 0 -100000 -31900000 200000 400000 100000 800000 1300000 500000 0.0 -100000 100000 0 300000 -300000 0.0 0.0 0.0 200000 700000 100000 -900000 0.0 200000 -2500000 -200000 1400000 -114300000 39200000 -23400000 378400000 632600000 562500000 484600000 853900000 552500000 512000000.0 377000000.0 434700000 124000000.0 135800000 1538100000 1936400000 2985800000 2738000000 1404200000 1324700000 1581600000 1413300000 104500000 99200000 202100000 210000000.0 106000000.0 108500000 10800000 15100000 26000000.0 25700000 74300000 21300000 3643400000 3829500000 0 134000000.0 239300000 242400000 73500000 105900000 31500000 16600000 17900000 17700000 188200000 155200000 550400000 671800000 202600000 72800000 20500000 12700000 28200000 29600000 81800000 84500000 15400000 18600000 62200000 58500000 961100000 948500000 3000000.0 3000000.0 0.0 0.0 0.0 0.0 0 0 0.25 0.25 200000000 200000000 75300000 75300000 72300000 73500000 18800000 18800000 22100000 120200000 3956600000 3523400000 -258100000 -143800000 3000000.0 1800000 1057100000 637600000 2682300000 2881000000 3643400000 3829500000 75300000 18800000 249000000.0 1100000 -229500000 2456700000 -159600000 2335400000 585900000 585900000 -16800000 -500000 61400000 44600000 600000 202800000 202800000 0.74 54800000 54800000 -23400000 -23400000 75300000 18800000 232200000 1200000 -370900000 2987800000 -183000000.0 2684900000 593400000 593400000 -112000000.0 -700000 171600000 59600000 1300000 438300000 438300000 0.78 57800000 57800000 39200000 39200000 75300000 18800000 120200000 1800000 -637600000 3523400000 -143800000 2881000000 492700000 492700000 -98100000 -400000 141400000 43300000 1600000 560900000 560900000 0.82 59500000 59500000 -114300000 -114300000 75300000 18800000 22100000 3000000.0 -1057100000 3956600000 -258100000 2682300000 492700000 593400000 585900000 151800000 133700000 116900000 3600000 3600000 3700000 18700000 23300000 23700000 0 0 15300000 0 -100000 -52200000 0 -11600000 0 7300000 9600000 6200000 -3500000 37500000 -30800000 -2000000.0 -2600000 -14000000.0 13400000 14300000 18100000 4700000 -1000000.0 2000000.0 58800000 -4000000.0 35600000 -42000000.0 13500000 49800000 5800000 21300000 -18500000 2900000 4400000 -2800000 -22600000 -6000000.0 -54700000 653400000 776500000 724000000.0 377000000.0 362000000.0 284600000 1700000 6700000 3600000 -378700000 -368700000 -288200000 164700000 0 0 169000000.0 2300000 44300000 0 0 1200000 23300000 100000 0 59100000 57000000.0 54100000 2000000.0 0 0 25500000 43900000 20900000 7200000 7100000 7300000 560900000 438300000 202800000 5700000 12900000 19400000 -622600000 -459600000 -293600000 -21400000 11400000 -10500000 -369300000 -40400000 131700000 853900000 894300000 762600000 484600000 853900000 894300000 500000 6000000.0 6600000 71400000 90800000 109700000 53000000.0 53300000 33200000 15200000 14800000 14100000 Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. ("West") after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents include money market funds, time deposits and all highly liquid short-term instruments with maturities of three months or less at the time of purchase.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our accounts receivable balance was net of an allowance for credit losses of $0.8 million at both December 31, 2024 and 2023. Under the current expected credit loss model, we utilize a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. The Company provides for cost adjustments for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. The following is a summary of inventories at December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other expense (income). Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for operating leases is recognized on a straight-line basis over the lease term. Conversely, lease expense for finance leases is a front loaded expense recognition pattern over the lease term. Lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. Please refer to Note 6, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Leases</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Goodwill and Other Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates. Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 3 to 25 years and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a more detailed discussion of our pension and other retirement plans. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as a hedge of the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as a hedge of the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as a hedge of the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less. In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less. Please refer to Note 3, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_88" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">,</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling Costs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include salaries and outside services for those directly involved in research and development activities and are primarily expensed as incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. Please refer to Note 17, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other expense (income). The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. Please refer to Note 14, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_121" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a more detailed discussion of our stock-based compensation plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income Per Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The consolidated financial statements include the accounts of West Pharmaceutical Services, Inc. ("West") after the elimination of intercompany transactions. We have no participation or other rights in variable interest entities.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial statements are prepared in conformity with U.S. GAAP. These principles require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingencies in the financial statements. Actual amounts realized may differ from these estimates.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash equivalents include money market funds, time deposits and all highly liquid short-term instruments with maturities of three months or less at the time of purchase.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable:</span> Our accounts receivable balance was net of an allowance for credit losses of $0.8 million at both December 31, 2024 and 2023. Under the current expected credit loss model, we utilize a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. 800000 800000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories:</span> Inventories are valued at the lower of cost (on a first-in, first-out basis) or net realizable value. The following is a summary of inventories at December 31:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 166900000 172300000 65200000 87300000 144900000 175100000 377000000.0 434700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property, plant and equipment assets are carried at cost. Maintenance and minor repairs and renewals are charged to expense as incurred. Costs incurred for computer software developed or obtained for internal use are capitalized for application development activities and immediately expensed for preliminary project activities or post-implementation activities. Upon sale or retirement of depreciable assets, costs and related accumulated depreciation are eliminated, and gains or losses are recognized in other expense (income). Depreciation and amortization are computed principally using the straight-line method over the estimated useful lives of the assets, or the remaining term of the lease, if shorter.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases: </span>Lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. Lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for operating leases is recognized on a straight-line basis over the lease term. Conversely, lease expense for finance leases is a front loaded expense recognition pattern over the lease term. Lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets, including property, plant and equipment, operating lease right-of-use assets and finance lease right-of-use assets, are tested for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. An asset is considered impaired if the carrying value of the asset exceeds the sum of the future expected undiscounted cash flows to be derived from the asset. Once an asset is considered impaired, an impairment loss is recorded within other expense (income) for the difference between the asset’s carrying value and its fair value. For assets held and used in the business, management determines fair value using estimated future cash flows to be derived from the asset, discounted to a net present value using an appropriate discount rate. For assets held for sale or for investment purposes, management determines fair value by estimating the proceeds to be received upon sale of the asset, less disposition costs.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Goodwill and Other Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill is tested for impairment at least annually, following the completion of our annual budget and long-range planning process, or whenever circumstances indicate that the carrying value of these assets may not be recoverable. Goodwill is tested for impairment at the reporting unit level, which is the same as, or one level below, our operating segments. A goodwill impairment charge represents the amount by which a reporting unit’s carrying amount exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. Accounting guidance also allows entities to first assess qualitative factors, including macroeconomic conditions, industry and market considerations, cost factors, and overall financial performance, to determine whether it is necessary to perform the quantitative goodwill impairment test. If, based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount, then it would not be necessary to perform the quantitative goodwill impairment test. We elected to follow this guidance for our annual impairment test. Based upon our assessment, we determined that it was not more likely than not that the fair value of each of our reporting units was less than its carrying amount and determined that it was not necessary to perform the quantitative goodwill impairment test in the current year. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuing identifiable intangible assets requires judgment. For example, for recent identifiable customer relationship intangible asset acquisitions, we applied an excess earnings model, which is a form of the income approach. This approach includes projecting revenues and expenses attributable to the existing customers over the remaining economic life of the customer relationships and then subtracting the required return on net tangible assets and any intangible assets used in the business to estimate any residual excess earnings attributable to the customer relationships. The after-tax excess earnings are then discounted to present value using the respective discount rates. Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives of 3 to 25 years and reviewed for impairment whenever circumstances indicate that the carrying value of these assets may not be recoverable. Factors that could trigger an impairment review include the following: 1) significant under-performance relative to historical or projected future operating results; 2) significant changes in the manner or use of the acquired assets or the strategy of the overall business; 3) significant negative industry or economic trends; and 4) recognition of goodwill impairment charges. If we determine that the carrying value of identifiable intangibles assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an undiscounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets.</span></div> P3Y P25Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefits:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The measurement of the obligations under our defined benefit pension and postretirement medical plans are subject to a number of assumptions. These include the rate of return on plan assets (for funded plans) and the rate at which the future obligations are discounted to present value. For our funded plans, we consider the current and expected asset allocations of our plan assets, as well as historical and expected rates of return, in estimating the long-term rate of return on plan assets. U.S. GAAP requires the recognition of an asset or liability for the funded status of a defined benefit postretirement plan, as measured by the difference between the fair value of plan assets, if any, and the benefit obligation. For a pension plan, the benefit obligation is the projected benefit obligation; for any other postretirement plan, such as a retiree health plan, the benefit obligation is the accumulated postretirement benefit obligation. Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span>, for a more detailed discussion of our pension and other retirement plans. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All derivatives are recognized as either assets or liabilities in the balance sheet and recorded at their fair value. For a derivative designated as a hedge of the exposure to variable cash flows of a forecasted transaction (referred to as a cash flow hedge), the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income (“OCI”), net of tax, and subsequently reclassified into earnings when the forecasted transaction affects earnings. For a derivative designated as a hedge of the exposure to changes in the fair value of a recognized asset or liability or a firm commitment (referred to as a fair value hedge), the derivative’s gain or loss is recognized in earnings in the period of change together with the offsetting loss or gain on the hedged item. For a derivative designated as a hedge of the foreign currency exposure of a net investment in a foreign operation, the gain or loss is reported in OCI, net of tax, as part of the cumulative translation adjustment. The ineffective portion of any derivative used in a hedging transaction is recognized immediately into earnings. Derivative financial instruments that are not designated as hedges are also recorded at fair value, with the change in fair value recognized immediately into earnings. We do not purchase or hold any derivative financial instrument for investment or trading purposes.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foreign currency transaction gains and losses are recognized in the determination of net income. Foreign currency translation adjustments of subsidiaries and affiliates operating outside of the U.S. are accumulated in other comprehensive loss, a separate component of equity.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition:</span> Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with Accounting Standards Codification (“ASC”) 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. We have elected to disregard the effects of a significant financing component, as we expect, at the inception of our contracts, that the period between when we transfer a promised good or service to the customer and when the customer pays for that good or service will be one year or less. In addition, we have elected to omit the disclosure of the majority of our remaining performance obligations, which are satisfied within one year or less.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling Costs:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Shipping and handling costs are included in cost of goods and services sold. Shipping and handling costs billed to customers in connection with the sale are included in net sales.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development:</span> Research and development expenditures are for the creation, engineering and application of new or improved products and processes. Expenditures include salaries and outside services for those directly involved in research and development activities and are primarily expensed as incurred. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, we are involved in legal proceedings, investigations and claims generally incidental to our normal business activities. In accordance with U.S. GAAP, we accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These estimates are based on an analysis made by internal and external legal counsel considering information known at the time. Legal costs in connection with loss contingencies are expensed as incurred.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Deferred income taxes are recognized by applying enacted statutory tax rates to tax loss carryforwards and temporary differences between the tax basis and financial statement carrying values of our assets and liabilities. The enacted statutory tax rate applied is based on the rate expected to be applicable at the time of the forecasted utilization of the loss carryforward or reversal of the temporary difference. Valuation allowances on deferred tax assets are established when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The realizability of deferred tax assets is subject to our estimates of future taxable income, generally at the respective subsidiary company and the country level. Please refer to Note 17, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_130" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information. We recognize interest costs related to income taxes in interest expense and penalties within other expense (income). The tax law ordering approach is used for purposes of determining whether an excess tax benefit has been realized during the year.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation:</span> Under the fair value provisions of U.S. GAAP, stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the vesting period. In order to determine the fair value of stock options on the grant date, we use the Black-Scholes valuation model. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income Per Share:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Basic net income per share is computed by dividing net income attributable to common shareholders by the weighted average number of shares of common stock outstanding during each period. Net income per share assuming dilution considers the dilutive effect of outstanding stock options and other stock awards based on the treasury stock method. The treasury stock method assumes the use of exercise proceeds to repurchase common stock at the average fair market value in the period.</span></div> New Accounting Standards<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU") No. 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company has adopted and implemented the applicable disclosure requirements within this annual report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued guidance that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU") No. 2023-07, Segment Reporting, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and enhancement of interim disclosure requirements. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company has adopted and implemented the applicable disclosure requirements within this annual report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued guidance that seeks to enhance income tax disclosures to provide information to better assess how an entity's operations and related tax risks affect its tax rate and prospects for future cash flows. Within the income tax rate reconciliation, the amendment requires disclosure of additional categories and greater detail about individual reconciling items over a specified threshold. It also requires information pertaining to taxes paid to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions over a specified threshold. This guidance is effective for fiscal years beginning after December 15, 2024. We are currently evaluating the impact of this guidance on our financial statements and disclosures, but we do not expect the adoption to have a material impact on the consolidated financial statements other than the expanded footnote disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued guidance that seeks to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity: (1) disclose the amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each of the Company's relevant expense captions; (2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. This guidance is effective for fiscal years beginning after December 15, 2026. The Company is currently evaluating the impact of this guidance on our financial statements and disclosures.</span></div> Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the majority of our revenue, primarily relating to Proprietary Products product sales, at a point in time, following the transfer of control of our products to our customers, which typically occurs upon shipment or delivery, depending on the terms of the related agreements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue relating to our Contract-Manufactured Products product sales and certain Proprietary Products product sales over time, as our performance does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue relating to our development and tooling agreements over time, as our performance creates or enhances an asset that the customer controls as the asset is created or enhanced.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognized over time, revenue is recognized by applying a method of measuring progress toward complete satisfaction of the related performance obligation. When selecting the method for measuring progress, we select the method that best depicts the transfer of control of goods or services promised to our customers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for our Contract-Manufactured Products product sales, certain Proprietary Products product sales, and our development and tooling agreements is recorded under an input method, which recognizes revenue on the basis of our efforts or inputs to the satisfaction of a performance obligation (for example, resources consumed, labor hours expended, costs incurred, time elapsed, or machine hours used) relative to the total expected inputs to the satisfaction of that performance obligation. The input method that we use is based on costs incurred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year are not material as of December 31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue can be generated from contracts with multiple performance obligations. When a sales agreement involves multiple performance obligations, each obligation is separately identified and the transaction price is allocated based on the amount of consideration we expect to be entitled in exchange for transferring the promised good or service to the customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some customers receive pricing rebates upon attaining established sales volumes. We record rebate costs when sales occur based on our assessment of the likelihood that the required volumes will be attained. We also maintain an allowance for product returns, as we believe that we are able to reasonably estimate the amount of returns based on our substantial historical experience and specific identification of customer claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets and liabilities result from transactions with revenue primarily recorded over time. If the measure of remaining rights exceeds the measure of the remaining performance obligations, we record a contract asset. Contract assets are recorded on the consolidated balance sheet in accounts receivable, net, and other assets (current and noncurrent portions, respectively). Contract assets included in accounts receivable, net, relate to the unbilled amounts of our product sales for which we have recognized revenue over time. Contract assets included in other assets represent the remaining performance obligations of our development and tooling agreements. Conversely, if the measure of the remaining performance obligations exceeds the measure of the remaining rights, we record a contract liability. Contract liabilities are recorded on the consolidated balance sheet within other liabilities (current and noncurrent portions, respectively) and represent cash payments received in advance of our performance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:83.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2024</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2024</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are included within other current assets and deferred income is included within other current liabilities and other long-term liabilities. The decrease in deferred income during 2024 was primarily due to the recognition of current year revenue of $94.8 million and the recognition of $37.7 million of revenue that was included in deferred income at the beginning of the year, offset by additional cash payments of $132.8 million received in advance of satisfying future performance obligations.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by market group:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Generics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by product category: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Components</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High-Value Product Delivery Devices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Packaging </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's reassessment of product categories, beginning in the second quarter of 2023, certain product types have been moved from High-Value Product Components to High-Value Product Delivery Devices. No adjustments were made to the product categorization prior to the second quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Americas</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East, Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.39 0.37 0.41 0.17 0.20 0.18 0.25 0.24 0.24 0.19 0.19 0.17 1 1 1 0.45 0.50 0.55 0.14 0.10 0.05 0.22 0.21 0.23 0.19 0.19 0.17 1 1 1 0.45 0.45 0.48 0.46 0.46 0.43 0.09 0.09 0.09 1 1 1 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract assets and liabilities, excluding amounts included in accounts receivable, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:83.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2023</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets, December 31, 2024</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contract assets - increase (decrease)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income, December 31, 2024</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred income - decrease (increase)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 21500000 23300000 1800000 53900000 53200000 -700000 94800000 37700000 132800000 Net Income Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, there were 0.3 million, 0.2 million and 0.2 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Board of Directors approved a share repurchase program under which we may repurchase up to $1.0 billion in shares of common stock. The share repurchase program did not have an expiration date under which we may repurchase common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions depended on a variety of factors, including market conditions. The below table summarizes share repurchases under this program during the years ended December 31: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583,032 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265,661 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of repurchases ($ in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per repurchased share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock on the open market or in privately-negotiated transactions. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December 31, 2025.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 492700000 593400000 585900000 73000000.0 74300000 74400000 700000 1000000.0 1400000 73700000 75300000 75800000 300000 200000 200000 1000000000 The below table summarizes share repurchases under this program during the years ended December 31: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583,032 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265,661 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost of repurchases ($ in millions)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per repurchased share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1583032 1265661 560900000 438300000 354.30 346.34 550000 Property, Plant and Equipment<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of gross property, plant and equipment at December 31 is presented in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected useful lives (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-35</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds and dies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December 31, 2024, 2023 and 2022 was $151.8 million, $133.7 million and $116.9 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize interest on borrowings during the active construction period of major capital projects. Capitalized interest is added to the cost of the underlying assets and is amortized over the useful lives of the assets. Capitalized interest for the years ended December 31, 2024, 2023 and 2022 was $13.2 million, $5.8 million and $3.7 million, respectively.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of gross property, plant and equipment at December 31 is presented in the following table:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected useful lives (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15-35</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5-12</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds and dies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-10</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,738.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 27900000 33700000 P15Y P35Y 916100000 771500000 P5Y P12Y 1229000000 1136500000 P4Y P7Y 169500000 164500000 P3Y P10Y 232500000 216600000 410800000 415200000 2985800000 2738000000 151800000 133700000 116900000 13200000 5800000 3700000 Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2269. Certain of our leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one year or more. At this time, the Company is not able to assert whether any of these options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - amortization of right-of-use (ROU) assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-610">Other noncurrent assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-612">Other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-614">Other long-term liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.3 years and 9.8 years. As of December 31, 2024, the weighted average remaining lease term for finance leases was 6.3 years. As of December 31, 2023, finance leases were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.99% and 3.55%, respectively. As of December 31, 2024, the weighted average discount rate for finance leases was 4.80%. As of December 31, 2023, finance leases were not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2024 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to adopt practical expedients around the combination of lease and non-lease components and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize lease right-of-use assets and lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.</span></div> Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2269. Certain of our leases provide us with an option, exercisable at our sole discretion, to terminate the lease or extend the lease term for one year or more. At this time, the Company is not able to assert whether any of these options will be exercised.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - amortization of right-of-use (ROU) assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, finance leases were not material. The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-610">Other noncurrent assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-612">Other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-614">Other long-term liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and December 31, 2023, the weighted average remaining lease term for operating leases was 8.3 years and 9.8 years. As of December 31, 2024, the weighted average remaining lease term for finance leases was 6.3 years. As of December 31, 2023, finance leases were not material.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and December 31, 2023, the weighted average discount rate for operating leases was 3.99% and 3.55%, respectively. As of December 31, 2024, the weighted average discount rate for finance leases was 4.80%. As of December 31, 2023, finance leases were not material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2024 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to adopt practical expedients around the combination of lease and non-lease components and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize lease right-of-use assets and lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.</span></div> P1Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - amortization of right-of-use (ROU) assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease - interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets obtained in exchange for new lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 24200000 20300000 15500000 900000 0 0 100000 0 0 2500000 6100000 1300000 9000000.0 5500000 6800000 36700000 31900000 23600000 The following table summarizes the finance lease amounts in the consolidated balance sheets as of December 31, 2024:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.508%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-610">Other noncurrent assets</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-612">Other current liabilities</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (noncurrent)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-614">Other long-term liabilities</span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29700000 900000 2100000 32500000 19100000 13300000 100000 0 0 23300000 100000 0 41200000 10700000 47600000 24600000 0 0 P8Y3M18D P9Y9M18D P6Y3M18D 0.0399 0.0355 0.0480 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2024 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2024 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed lease interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 23400000 900000 20700000 900000 16300000 900000 14900000 500000 11500000 100000 26300000 0 113100000 3300000 13400000 300000 99700000 3000000.0 P12M Affiliated Companies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the following affiliated companies were accounted for under the equity method:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ownership interest</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The West Company Mexico, S.A. de C.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aluplast S.A. de C.V.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Tap S.A. de C.V.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Rubber S.A. de C.V.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daikyo Seiko, Ltd. ("Daikyo")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate carrying value of investments in affiliated companies:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Equity method affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Non-equity method affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total investments in affiliated companies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to record non-equity method investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables due to affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables due from affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's affiliate transactions: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases from (and payments to) affiliates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unremitted income of affiliates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in unrealized (gains) losses of Daikyo's investments &amp; derivatives</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the following affiliated companies were accounted for under the equity method:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ownership interest</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The West Company Mexico, S.A. de C.V.</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aluplast S.A. de C.V.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Tap S.A. de C.V.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharma Rubber S.A. de C.V.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daikyo Seiko, Ltd. ("Daikyo")</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49%</span></td></tr></table></div> 0.49 0.49 0.49 0.49 0.49 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate carrying amounts of our investments in affiliated companies that are accounted for under the equity method and our investments in affiliated companies that are not accounted for under the equity method:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate carrying value of investments in affiliated companies:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Equity method affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Non-equity method affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total investments in affiliated companies</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts due to and from affiliates in the condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables due to affiliates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables due from affiliates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's affiliate transactions: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases from (and payments to) affiliates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unremitted income of affiliates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in unrealized (gains) losses of Daikyo's investments &amp; derivatives</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 194900000 203200000 7200000 6800000 202100000 210000000.0 18700000 25900000 2500000 1600000 110000000.0 142500000 167600000 15300000 11200000 14200000 161400000 148000000.0 133600000 1300000 3400000 2600000 2400000 2200000 1600000 Goodwill and Intangible Assets<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had $0.1 million of accumulated goodwill impairment losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and accumulated amortization as of December 31 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licensing</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The cost basis of intangible assets includes a foreign currency translation loss of $0.7 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. Amortization expense for the years ended December 31, 2024, 2023 and 2022 was $3.6 million, $3.6 million and $3.7 million, respectively. Estimated annual amortization expense for the next five years is as follows: 2025 - $2.8 million, 2026 - $2.5 million, 2027 - $2.3 million, 2028 - $1.7 million and 2029 - $0.9 million. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amount of goodwill by reportable segment were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 77900000 29400000 107300000 1000000.0 200000 1200000 78900000 29600000 108500000 -2100000 -400000 -2500000 76800000 29200000 106000000.0 100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and accumulated amortization as of December 31 were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and licensing</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 24700000 23000000.0 1700000 24800000 21800000 3000000.0 3300000 2700000 600000 3300000 2500000 800000 1200000 1200000 0 1200000 1200000 0 38900000 30800000 8100000 39500000 29000000.0 10500000 8000000.0 7600000 400000 8000000.0 7200000 800000 76100000 65300000 10800000 76800000 61700000 15100000 -700000 -100000 3600000 3600000 3700000 2800000 2500000 2300000 1700000 900000 Other Current Liabilities<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities as of December 31 included the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions, rebates &amp; royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes other than income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement plans (excl. pension)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International value added tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and severance related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities as of December 31 included the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions, rebates &amp; royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term derivative instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes other than income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement plans (excl. pension)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International value added tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and severance related charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 49600000 41700000 24600000 22400000 17400000 2100000 15200000 14800000 12900000 9200000 12600000 10900000 6800000 5100000 6000000.0 5200000 1600000 3800000 1600000 2600000 39900000 37400000 188200000 155200000 Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due July 2, 2027 (5.68%)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (6.32%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs for Term Loan and Series notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multi-Currency Revolving Credit Facility </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we amended and extended the existing multi-currency revolving credit facility (entered into in March 2019), which was scheduled to expire in March 2024, from $300.0 million to a $500.0 million senior unsecured revolving credit facility by entering into a Second Amendment and Joinder and Assumption Agreement (the "Amended Credit Agreement"). The Amended Credit Agreement, which expires March 2027, contains a senior unsecured, multi-currency revolving credit facility of $500.0 million, with sublimits of up to $50.0 million for swing line loans for Domestic Borrowers in U.S. dollars and a $40.0 million swing line loan for West Pharmaceuticals Services Holding GmbH and up to $50.0 million for the issuance of standby letters of credit. The multi-currency revolving credit facility may be increased from time-to-time by the greater of (a) $929.0 million or (b) EBITDA for the preceding twelve-month period in the aggregate through an increase in the multi-currency revolving credit facility, subject to the satisfaction of certain conditions. Borrowings under the credit facility bear interest, at the Company’s option, at either: (a) the Term Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus an applicable margin; or (b) a base rate defined as the highest of: (i) the Bank of America “prime rate”; (ii) the Federal Funds effective rate plus 0.50%; and (iii) Term SOFR plus 1.00%. The applicable margin is based on the ratio of the Company’s Net Consolidated Debt to its modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for Term SOFR loans. The Amended Credit Agreement contains financial covenants providing that the Company shall not permit the ratio of the Company’s Net Consolidated Debt to its Modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Amended Credit Agreement, upon the occurrence of a Qualified Acquisition for each of the four fiscal quarters of the Company immediately following such Qualified Acquisition, the ratio set forth above shall be increased to 4.0 to 1. The Amended Credit Agreement also contains customary limitations on liens securing indebtedness of the Company and its subsidiaries, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of December 31, 2024 and 2023, total unamortized debt issuance costs of $1.0 million and $1.0 million, respectively, were recorded in other current assets and other noncurrent assets and are being amortized as additional interest expense over the term of the multi-currency revolving credit facility. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we had no outstanding borrowings under the multi-currency revolving credit facility. At December 31, 2024, the borrowing capacity available under the multi-currency revolving credit facility, including outstanding letters of credit of $2.4 million, was $497.6 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, the Company entered into the Third Amendment to the Credit Facility Agreement, which amended the Existing Credit Facility Agreement (entered into in December 2019). Among other changes to the existing credit agreement, the Third Amendment established an incremental term loan in the stated principal amount of $130.0 million (the “New Term Loan”), which was fully drawn at closing and matures on July 2, 2027. The entire stated principal amount of the New Term Loan is due at maturity and there is no scheduled amortization prior to such date. Together with cash on hand, proceeds from the New Term Loan were used to repay an outstanding term loan under the Existing Credit Facility Agreement in the principal amount of $79.9 million prior to its December 31, 2024 maturity date and to repay an aggregate principal amount of $53.0 million of the Company’s 3.82% Series B Senior Notes due July 5, 2024 issued under that certain Note Purchase Agreement dated as of July 5, 2012. Interest accrues on the New Term Loan based on a term secured overnight financing rate (“SOFR”) or a base rate, at the Company’s option, plus a margin ranging from 1.250% to 1.625% for SOFR interest rates and 0.250% to 0.625% for base rates according to the Company’s net leverage ratio as defined in the Amended Credit Agreement. Interest rates based on a term SOFR rate is also subject to a credit spread adjustment of 10 basis points. At closing, the Company elected for the New Term Loan to accrue interest at a 3-month term SOFR rate plus a margin of 1.250%. As of December 31, 2024, there were unamortized debt issuance costs remaining of $0.3 million which are being amortized as additional interest expense over the term of the New Term Loan. As of December 31, 2023, there were unamortized debt issuance costs remaining of $0.1 million, which were amortized as additional interest expense over the term of the Term Loan (entered into in December 2019).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we had $130.0 million in borrowings under the New Term Loan which were classified as long-term. Please refer to Note 11, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we concluded a private placement issuance of $168.0 million in senior unsecured notes. The total amount of the private placement issuance was divided into three tranches - $42.0 million 3.67% Series A Notes due July 5, 2022, $53.0 million 3.82% Series B Notes due July 5, 2024, and $73.0 million 4.02% Series C Notes due July 5, 2027 (the “Notes”). The Notes rank pari passu with our other senior unsecured debt. The weighted average of the coupon interest rates on the Notes outstanding as of December 31, 2024 is 3.94%. As of December 31, 2024 and 2023, there were unamortized debt issuance costs remaining of $0.1 million and $0.1 million, respectively, which are being amortized as additional interest expense over the term of the Notes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Covenants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and to not exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At December 31, 2024, we were in compliance with all of our debt covenants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest costs incurred during 2024, 2023 and 2022 were $16.2 million, $14.8 million and $11.6 million, respectively. The aggregate annual maturities of long-term debt, excluding unamortized debt issuance costs, are as follows: $0.0 million in 2025 and 2026, $203.0 million in 2027 and $0.0 million in 2028 and thereafter.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities, at December 31. The interest rates shown in parentheses are as of the corresponding balance sheet date reflected in the table below.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due July 2, 2027 (5.68%)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan, due December 31, 2024 (6.32%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C notes, due July 5, 2027 (4.02%)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs for Term Loan and Series notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0568 130000000.0 0 0.0632 0 81000000.0 0.0382 0 53000000.0 0.0402 73000000.0 73000000.0 203000000.0 207000000.0 400000 200000 202600000 206800000 0 134000000.0 202600000 72800000 300000000 500000000 500000000 50000000 40000000 50000000 929000000 P12M 0.0010 0.0050 0.0100 0 0.00375 0.00875 0.01375 3.5 3 4 4.0 1000000 1000000 0 2400000 497600000 130000000.0 79900000 53000000.0 0.0382 0.01250 0.01625 0.00250 0.00625 0.01250 300000 100000 130000000 168000000.0 3 42000000.0 0.0367 53000000.0 0.0382 73000000.0 0.0402 0.0394 100000 100000 16200000 14800000 11600000 0.0 0.0 203000000.0 0.0 Derivative Financial Instruments<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of December 31, 2024 the total amount of these forward exchange contracts was Singapore Dollar ("SGD") 421.9 million and $13.4 million. As of December 31, 2023 the total amount of these forward exchange contracts was SGD 601.5 million and $13.4 million. We have also entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany demand notes which were executed at various times throughout 2023 and 2024. As of December 31, 2024, the total amount of these forward exchange contracts was Euro ("EUR") 145.3 million and $47.1 million. As of December 31, 2023, the total amount of these forward exchange contracts was EUR 278.6 million and SGD 94.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EUR</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SGD</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPY</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a five-year floating-to-floating forward-starting cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. This cross-currency swap had an original maturity date of December 31, 2024, but was extinguished in July 2024. In July 2024, we entered into a new cross-currency swap for $130 million, which we designated as a hedge of our net investment in Daikyo. As of December 31, 2024, the notional amount of the cross-currency swap is Japanese Yen ("JPY") 17.0 billion ($130.0 million) and the swap termination date is July 2, 2027. Under the current cross-currency swap, we receive fixed USD interest rate payments in return for paying fixed JPY interest rate payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we will periodically enter into forward exchange contracts to mitigate our exposure to fluctuating foreign exchange rates on assets and liabilities, other than the intercompany loans and demand notes referenced above, which are denominated in foreign currencies. The Company has elected not to designate these forward contracts in hedging relationships, and any change in the value of the contracts is recognized in income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly purchase call options on crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases. As of December 31, 2024, we had outstanding contracts to purchase 190,773 barrels of crude oil from December 2024 to June 2026, at a weighted-average strike price of $84.70 per barrel.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 12, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the balance sheet location and fair values of our derivative instruments as of December 31, 2024 and 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The expense recognized in earnings, pre-tax, for forward point components for the years ended December 31, 2024 and 2023 was $5.9 million and $0.2 million, respectively. The income recognized in earnings, pre-tax, for forward point components for the year ended December 31, 2022 was $4.0 million. We expect to recognize an expense of $0.3 million in earnings, pre-tax, for forward point components in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts (hedges of net sales)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts (hedges of cost of goods and services sold)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the above table which summarizes the effects of derivative instruments designated as fair value hedges within the other expense (income) line in our consolidated statements of income for the years ended December 31. The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our consolidated statements of income for the years ended December 31:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022 there was no material ineffectiveness related to our hedges.</span></div> 421900000 13400000 601500000 13400000 145300000 47100000 278600000 94000000.0 P18M <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sell</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">USD</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EUR</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SGD</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JPY</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SGD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 20800000 22900000 0 0 6683700000 28400000 14800000 1800000 39800000 16900000 12200000 0 P5Y 90000000 130000000 17000000000 130000000 190773 84.70 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments designated as fair value hedges in our consolidated statements of income for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hedged item (intercompany loan)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative designated as hedging instrument</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on OCI and earnings, net of tax, for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in OCI</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts (hedges of net sales)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts (hedges of cost of goods and services sold)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Hedges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flow Hedges:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency hedge contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Investment Hedges:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr></table></div>The following table summarizes the effects of derivative instruments designated as cash flow and net investment hedges by line item in our consolidated statements of income for the years ended December 31:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -1600000 300000 28300000 1600000 -300000 -28300000 5900000 1400000 -5200000 5900000 1400000 -5200000 -5900000 -200000 4000000.0 -300000 200000 -2000000.0 1300000 200000 -2000000.0 1300000 1100000 -800000 300000 -6900000 -4000000.0 -1100000 0 0 0 -5800000 -4800000 -800000 6800000 8600000 9100000 6800000 8600000 9100000 700000 -2900000 1600000 700000 -2900000 1600000 500000 -1300000 1200000 -4200000 -2200000 -3500000 -100000 -200000 -200000 -3800000 -3700000 -2500000 0 0 0 0 0 0 -500000 1300000 -1200000 4200000 2200000 3500000 100000 200000 200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effects of derivative instruments not designated as hedges in our consolidated statements of income for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount of Gain (Loss) Recognized in Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency forwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> -700000 -1300000 1500000 -2500000 100000 0 -3200000 -1200000 1500000 Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div> Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. Money market funds are included within cash and cash equivalents and are valued based on quoted market prices in active markets, with no valuation adjustment. Time deposits are included within cash and cash equivalents and are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of the contingent consideration liability, within current and long-term liabilities, related to the SmartDose® technology platform (the “SmartDose® contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other non-current assets as of December 31, 2024 and other current assets as of December 31, 2023, is valued using a market approach. Please refer to Note 11, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_112" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Derivative Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of our derivatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the carrying amounts of our cash and accounts receivable approximate their fair values due to their near-term maturities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At December 31, 2024, the estimated fair value of long-term debt was $200.5 million compared to a carrying amount of $202.6 million. At December 31, 2023, the estimated fair value of short-term and long-term debt was $204.4 million and the carrying amount was $206.8 million. As of December 31, 2024, all debt is long-term.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity call options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11100000 11100000 0 0 117600000 117600000 0 0 71300000 0 71300000 0 17300000 0 17300000 0 23600000 0 23600000 0 300000 0 300000 0 241200000 128700000 112500000 0 3000000.0 0 0 3000000.0 11200000 11200000 0 0 18300000 0 18300000 0 32500000 11200000 18300000 3000000.0 10200000 10200000 0 0 404400000 404400000 0 0 47900000 0 47900000 0 5000000.0 0 5000000.0 0 18400000 0 18400000 0 600000 0 600000 0 496700000 424800000 71900000 0 3600000 0 0 3600000 10400000 10400000 0 0 2200000 0 2200000 0 16200000 10400000 2200000 3600000 200500000 202600000 204400000 206800000 Accumulated Other Comprehensive Loss<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and other postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:34.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the components of accumulated other comprehensive loss, net of tax:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity affiliate investment AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined benefit pension and other postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.4)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.3)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(248.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -1200000 1500000 -31800000 -128100000 -159600000 500000 100000 -9300000 -47300000 -56000000.0 -900000 0 -31700000 0 -32600000 1400000 100000 22400000 -47300000 -23400000 200000 1600000 -9400000 -175400000 -183000000.0 -6800000 700000 800000 39400000 34100000 -6600000 0 1500000 0 -5100000 -200000 700000 -700000 39400000 39200000 0 2300000 -10100000 -136000000.0 -143800000 -5600000 200000 1100000 -112300000 -116600000 -3100000 0 800000 0 -2300000 -2500000 200000 300000 -112300000 -114300000 -2500000 2500000 -9800000 -248300000 -258100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:34.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Detail of components</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gains</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.0)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax (expense) benefit </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div> 500000 -1500000 1400000 5500000 3100000 4100000 1000000.0 -4200000 2400000 100000 300000 300000 -4100000 -9100000 -600000 -1000000.0 -2500000 300000 -3100000 -6600000 -900000 1000000.0 1700000 600000 0 -100000 -52200000 0 -400000 400000 1000000.0 2000000.0 -52000000.0 200000 500000 -20300000 800000 1500000 -31700000 -2300000 -5100000 -32600000 Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At December 31, 2024, there were 1.3 million shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and stock appreciation rights reduce the number of shares available by one share for each award granted. All other awards under the 2016 Plan will reduce the total number of shares available for grant by an amount equal to 2.5 times the number of shares awarded. If awards made under previous plans would entitle a plan participant to an amount of West stock in excess of the target amount, the additional shares (up to a maximum threshold amount) will be distributed under the 2016 Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option and appreciation rights</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plans and restricted share awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company estimates expected forfeitures. The amount of unrecognized compensation expense for all non-vested awards as of December 31, 2024 was $25.8 million, which is expected to be recognized over a weighted average period of 1.6 years.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted to employees vest in equal increments. All awards expire 10 years from the date of grant. Upon the exercise of stock options, shares are issued in exchange for the exercise price of the options.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in outstanding options:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest, December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable, December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the weighted average remaining contractual life of options outstanding and of options exercisable was 4.6 years and 3.7 years, respectively. As of December 31, 2024, the aggregate intrinsic value of total options outstanding was $182.0 million, of which $178.7 million represented vested options.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the options was estimated on the date of grant using a Black-Scholes option valuation model that used the following weighted average assumptions in 2024, 2023 and 2022: a risk-free interest rate of 4.3%, 4.1%, and 1.8%, respectively; stock volatility of 32.0%, 29.8%, and 25.1%, respectively; and dividend yields of 0.3%, 0.3%, and 0.2%, respectively. Stock volatility is estimated based on historical data and the impact from expected future trends. Expected lives, which are based on prior experience, averaged 6.0 years for 2024, 5.7 years for 2023 and 5.6 years for 2022. The weighted average grant date fair value of options granted in 2024, 2023 and 2022 was $134.25, $108.95 and $96.43, respectively. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023 and 2022, the intrinsic value of options exercised was $90.5 million, $151.0 million and $60.1 million, respectively. The grant date fair value of options vested during those same periods was $10.8 million, $8.6 million and $8.8 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to stock options, we grant performance share unit (“PSU”) awards to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock, whereas recipients of cash-settled PSU awards are entitled to receive a payment in cash per unit based on the fair market value of a share of our common stock at the end of the performance period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in our outstanding stock-settled PSU awards:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock-settled PSU awards, January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,441 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334.03 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted at target level</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments above/(below) target</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and converted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock-settled PSU awards, December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.56 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. The weighted average grant date fair value of stock-settled PSU awards granted during the years 2024, 2023 and 2022 was $348.20, $306.97 and $362.40, respectively. Including forfeiture and target achievement expectations, we expect that the stock-settled PSU awards, for which the performance period has completed, will convert to 7,946 shares to be issued during 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, certain eligible employees are entitled to cash-settled PSU awards. The fair value of these cash-settled PSU awards is also based on the market price of our stock at the grant date. These awards are revalued at the end of each quarter based on changes in our stock price. As a result of the cash settlement feature, cash-settled PSU awards are recorded within other long-term liabilities. The amount of cash-settled PSU awards granted during the years 2024, 2023 and 2022 were immaterial. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer an Employee Stock Purchase Plan (“ESPP”), which provides for the sale of our common stock to eligible employees at 85% of the current market price on the last trading day of each quarterly offering period. Payroll deductions are limited to 25% of the employee’s base salary, not to exceed $25,000 in any one calendar year. In addition, employees may not buy more than 2,000 shares during any offering period (8,000 shares per year). Purchases under the ESPP were 25,237 shares, 23,955 shares and 27,894 shares for the years 2024, 2023 and 2022, respectively. At December 31, 2024, there were 3.7 million shares available for issuance under the ESPP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plans and Restricted Share Awards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plans include a Non-Qualified Deferred Compensation Plan for Non-Employee Directors, under which non-employee directors may defer all or part of their annual cash or stock retainers. The deferred fees may be credited to a stock-equivalent account. Amounts credited to this account are converted into deferred stock units based on the fair market value of one share of our common stock on the last day of the quarter. For deferred stock units ultimately paid in cash, a liability is calculated at an amount determined by multiplying the number of units by the fair market value of our common stock at the end of each reporting period. In addition, annual stock awards are granted on the date of our annual meeting and are distributed in shares of common stock at the next annual meeting, unless deferred. In 2024, 2023 and 2022, we granted 6,064, 6,160 and 4,827 deferred stock awards with weighted average grant-date fair values of $386.03, $357.00 and $300.78, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the two deferred compensation plans held a total of 332,897 deferred stock units, including 8,851 units to be paid in cash. As of December 31, 2023, the two deferred compensation plans held a total of 352,541 deferred stock units, including 8,931 units to be paid in cash.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, 2023 and 2022, we granted 9,660, 8,343 and 9,648 stock-settled restricted share unit (“RSU”) awards, respectively, at weighted grant-date fair values of $339.32, $314.06 and $310.52 per share, respectively, to employees under the 2016 Plan. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.</span></div> 1300000 1 2.5 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock-based compensation expense recorded within selling, general and administrative expenses for the years ended December 31:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option and appreciation rights</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance share units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plans and restricted share awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 11000000.0 11300000 5600000 2200000 5900000 15600000 1300000 1300000 1300000 4200000 4800000 1200000 18700000 23300000 23700000 25800000 P1Y7M6D P10Y <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in outstanding options:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest, December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and exercisable, December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1400000 145.40 100000 348.25 300000 77.88 0.0 331.97 1200000 176.37 1100000 172.07 900000 137.48 P4Y7M6D P3Y8M12D 182000000.0 178700000 0.043 0.041 0.018 0.320 0.298 0.251 0.003 0.003 0.002 P6Y P5Y8M12D P5Y7M6D 134.25 108.95 96.43 90500000 151000000.0 60100000 10800000 8600000 8800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes in our outstanding stock-settled PSU awards:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock-settled PSU awards, January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,441 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334.03 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted at target level</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments above/(below) target</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and converted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,686)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock-settled PSU awards, December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.56 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 98441 334.03 34484 348.20 2523 339.07 35388 350.18 6686 331.62 93374 326.56 0 2 348.20 306.97 362.40 7946 0.85 0.25 25000 2000 8000 25237 23955 27894 3700000 1 6064 6160 4827 386.03 357.00 300.78 2 332897 8851 2 352541 8931 9660 8343 9648 339.32 314.06 310.52 Benefit Plans <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our U.S. and international subsidiaries sponsor defined benefit pension plans. In addition, we pay a portion of healthcare costs for retired U.S. salaried employees and their dependents. We also sponsor a defined contribution plan for certain salaried and hourly U.S. employees. Our 401(k) plan contributions were $23.2 million for 2024, $22.7 million for 2023 and $22.8 million for 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pension and Other Retirement Benefits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost and other amounts recognized in OCI were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gain) loss arising during period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial (loss) gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in OCI</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and OCI</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost by geographic location is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The service cost component included within net periodic benefit cost is considered employee compensation and is therefore presented within the selling, general, and administrative and costs of goods and services sold financial statement line items of our consolidated statements of income. The remaining components of net periodic benefit cost are reported separately and are therefore presented within the other nonoperating expense (income) financial statement line item of our consolidated statements of income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company approved the termination of our U.S. qualified defined benefit pension plan (the "U.S. pension plan"). During 2021, a Notice of Intent to Terminate was sent to all interested parties and in 2022 a favorable determination letter was received from the Internal Revenue Service. During 2022, lump sum payments were offered to all current employees and former employees with vested benefits under the U.S. pension plan. A cash contribution of $7.1 million was made by the Company to ensure the U.S. pension plan was fully funded in preparation for the group annuity contract purchase which was executed in August of 2022 to settle the outstanding benefit obligations, as well as to cover any ancillary benefits and expenses remaining. During 2022, we recorded a $52.2 million pension settlement charge within <span style="-sec-ix-hidden:f-1398">other nonoperating expense (income)</span>, which primarily related to the full settlement and relief of the historical balance sheet position, inclusive of accumulated other comprehensive income, of the U.S. pension plan. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024 and 2023, we did not contribute to our U.S. pension plan due to the termination of the plan in 2022. During 2022, we contributed $7.1 million to our U.S. pension plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants’ contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, December 31</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets, January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants’ contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets, December 31</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International pension plan assets, at fair value, included in the preceding table were $29.2 million and $32.3 million at December 31, 2024 and 2023, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the balance sheet were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts in accumulated other comprehensive loss, pre-tax, consisted of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accumulated benefit obligation for all defined benefit pension plans was $49.5 million and $53.7 million at December 31, 2024 and 2023, respectively, including $44.0 million and $47.7 million, respectively, for international pension plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024 and December 31, 2023, our United Kingdom qualified defined benefit pension plan had plan assets in excess of its obligations. As of December 31, 2024 and December 31, 2023, our other defined benefit pension plans had projected benefit obligations and accumulated benefit obligations in excess of plan assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows. The expected benefit payments listed correspond to regular ongoing benefit payments expected to be made by the plans during future years. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 to 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we expect to contribute $0.6 million to pension plans, all of which is in the U.S. In addition, we expect to contribute $0.5 million for other retirement benefits in 2025. We periodically consider additional, voluntary contributions depending on the investment returns generated by pension plan assets, changes in benefit obligation projections and other factors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average assumptions used to determine net periodic benefit cost were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average assumptions used to determine the benefit obligations were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.38 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.60 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine the benefit obligations for U.S. pension plans was 5.60% and 5.20% as of December 31, 2024 and 2023, respectively. The weighted average discount rate used to determine the benefit obligations for all international plans was 4.24% and 3.80% as of December 31, 2024 and 2023, respectively. The weighted average rate of compensation increase for all international plans was 3.07% for 2024 and 3.08% for 2023, while there was no rate increase for the U.S. plans since they are frozen. Other retirement benefits were only available to U.S. employees. The expected long-term rate of return for U.S. plans was not applicable for 2024 and 2023, and 3.70% for 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumed healthcare cost trend rate used to determine benefit obligations was 6.50% for all participants in 2024, decreasing to 5.00% by 2031. The assumed healthcare cost trend rate used to determine net periodic benefit cost was 6.75% for all participants in 2024, decreasing to 5.00% by 2031.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defined benefit pension plan benefit obligation decreased for the year ended December 31, 2024, due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation. The net actuarial losses will be impacted in future periods by actual asset returns, discount rate changes, currency exchange rate fluctuations, actual demographic experience, and certain other factors. The other retirement plan benefit obligation decreased due to actuarial gains and benefit payments during the period, as well as an increase in the discount rate used to calculate the obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balance plans and other plans with promised interest crediting rates. For these plans, the interest crediting rates are set in line with plan rules or country legislation and do not change with market conditions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average interest crediting rating used to determine net periodic benefit cost by geographic location for our pension plans, at December 31, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diversification across and within asset classes is the primary means by which we mitigate risk. We maintain guidelines for all asset and sub-asset categories in order to avoid excessive investment concentrations. Fund assets are monitored on a regular basis. If at any time the fund asset allocation is not within the acceptable allocation range, funds will be reallocated. We also review the fund on a regular basis to ensure that the investment returns received are consistent with the short-term and long-term goals of the fund and with comparable market returns. We are prohibited from pledging fund securities and from investing pension fund assets in our own stock, securities on margin or derivative securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the target asset allocations and acceptable allocation ranges across:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Target allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15% - 20%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75% - 85%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2% - 5%</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets in the fair value hierarchy</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets measured at NAV</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets in the fair value hierarchy</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets measured at NAV</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 23200000 22700000 22800000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost and other amounts recognized in OCI were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net periodic benefit cost:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other changes in plan assets and benefit obligations recognized in OCI, pre-tax:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gain) loss arising during period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of actuarial (loss) gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in OCI</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and OCI</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost by geographic location is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1200000 1100000 1500000 0 0 0 2100000 2400000 4200000 200000 200000 200000 1300000 1200000 6100000 0 0 0 -600000 -600000 -1300000 1600000 2000000.0 1900000 0 -100000 -52200000 0 0 0 1000000.0 300000 1000000.0 0 400000 400000 3600000 3300000 54100000 -1400000 -1400000 -1300000 700000 1400000 -16000000.0 500000 500000 2000000.0 -600000 -300000 -1300000 1600000 2000000.0 1900000 0 100000 52200000 0 0 0 200000 -700000 2300000 0 0 0 0 -400000 0 0 0 400000 -1500000 -700000 -39800000 1100000 1500000 -500000 2100000 2600000 14300000 -300000 100000 -1800000 1100000 800000 51700000 -1400000 -1400000 -1300000 2500000 2500000 2400000 0 0 0 3600000 3300000 54100000 -1400000 -1400000 -1300000 7100000 -52200000 0 0 7100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the benefit obligation and the fair value of plan assets, as well as the funded status of the plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in benefit obligation:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, January 1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants’ contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit obligation, December 31</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets, January 1</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer contribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participants’ contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets, December 31</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 57500000 55500000 3700000 3900000 1200000 1100000 0 0 2100000 2400000 200000 200000 100000 200000 200000 400000 2200000 700000 600000 500000 3400000 2500000 300000 300000 0 500000 0 0 2100000 -2000000.0 0 0 53200000 57500000 3200000 3700000 32300000 29400000 0 0 -600000 2400000 0 0 700000 1100000 100000 -100000 100000 200000 200000 400000 2500000 1800000 300000 300000 0 500000 0 0 800000 -1500000 0 0 29200000 32300000 0 0 -24000000.0 -25200000 -3200000 -3700000 29200000 32300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized in the balance sheet were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2900000 2700000 0 0 1400000 1400000 500000 600000 25500000 26500000 2700000 3100000 24000000.0 25200000 3200000 3700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts in accumulated other comprehensive loss, pre-tax, consisted of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss (gain)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -14400000 -15800000 2600000 3600000 -1200000 -1100000 0 0 13200000 14700000 -2600000 -3600000 49500000 53700000 44000000.0 47700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit payments expected to be paid under our defined benefit pension and other retirement benefit plans in the next ten years are as follows. The expected benefit payments listed correspond to regular ongoing benefit payments expected to be made by the plans during future years. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 to 2034</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1300000 2500000 3800000 1100000 3100000 4200000 1000000.0 3600000 4600000 1000000.0 3200000 4200000 900000 4000000.0 4900000 3600000 17200000 20800000 8900000 33600000 42500000 600000 500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average assumptions used to determine net periodic benefit cost were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.35 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.48 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.55 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average assumptions used to determine the benefit obligations were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other retirement benefits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.38 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.60 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average interest crediting rating used to determine net periodic benefit cost by geographic location for our pension plans, at December 31, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. plans</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.31 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0395 0.0435 0.0248 0.0520 0.0555 0.0275 0.0308 0.0309 0.0279 0 0 0 0.0401 0.0422 0.0414 0 0 0 0.0438 0.0395 0.0560 0.0520 0.0307 0.0308 0 0 0.0560 0.0520 0.0424 0.0380 0.0307 0.0308 0 0 0.0370 0.0650 0.0500 0.0675 0.0500 0.0400 0.0400 0.0331 0.0113 0.0113 0.0175 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average asset allocations by asset category for our pension plans, at December 31, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the target asset allocations and acceptable allocation ranges across:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Target allocation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocation range</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15% - 20%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75% - 85%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2% - 5%</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of our pension plan assets, utilizing the fair value hierarchy discussed in Note 12, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In accordance with U.S. GAAP, certain pension plan assets measured at net asset value (“NAV”) have not been classified in the fair value hierarchy.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets in the fair value hierarchy</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets measured at NAV</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis of Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets in the fair value hierarchy</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets measured at NAV</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 0.21 0.16 0.75 0.80 0.04 0.04 1 1 0.19 0.15 0.20 0.79 0.75 0.85 0.02 0.02 0.05 600000 600000 0 0 6200000 0 6200000 0 21800000 0 21800000 0 600000 0 600000 0 29200000 600000 28600000 0 0 29200000 600000 600000 0 0 5300000 0 5300000 0 25900000 0 25900000 0 500000 0 500000 0 32300000 600000 31700000 0 0 32300000 Other Expense (Income)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consisted of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and related charges</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company approved a restructuring plan to adjust our operating cost base to better respond to the macroeconomic factors influencing our business. These changes were implemented over a period of approximately twenty-four months from the date of the approval. The plan provided annualized savings of approximately $17 million. As of December 31, 2024, the Company does not expect additional expenses or payments associated with our 2022 restructuring plan. The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Impairments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's asset impairment expense includes impairment charges to its cost method investments and expense related to fixed assets impaired or taken out of service. During the periods ended December 31, asset impairments consisted of: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost method investment impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Transaction Losses (Gains)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024 and 2023, the Company recorded a loss on foreign exchange transactions of $10.2 million and $9.4 million, respectively. During 2024, the increase in losses on foreign exchange transactions was the result of increased expense related to exchange rate activity in Europe, partially offset by a decrease in losses related to Argentina's high inflationary environment year over year. During 2023, the loss on foreign exchange transactions was primarily driven by a highly inflationary environment in Argentina. During 2022, the Company recorded a gain on foreign exchange transactions of $4.1 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration represents changes in the fair value of the SmartDose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contingent consideration. Please refer to Note 12, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_115" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss on Disposal of Plant</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company recorded expense of $11.6 million, within other expense (income), as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment during the second quarter of 2023.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income) consisted of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and related charges:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-related charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restructuring and related charges</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of plant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense (income) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -2500000 -2800000 8700000 0 0 15300000 0 0 -200000 -2500000 -2800000 23800000 7300000 9600000 6200000 -10200000 -9400000 4100000 5100000 2300000 3000000.0 0 -11600000 0 -900000 -1300000 2100000 -21000000.0 -31400000 -26800000 P24M 17000000 0 The following table presents activity related to our restructuring obligations related to our 2022 restructuring plan:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and benefits</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Credits) charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000000.0 0 3000000.0 2500000 0 2500000 500000 0 500000 0 0 0 During the periods ended December 31, asset impairments consisted of: <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost method investment impairment charges</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset impairment expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total asset impairments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 300000 4300000 3500000 7000000.0 5300000 2700000 7300000 9600000 6200000 -10200000 -9400000 4100000 -11600000 1 Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global organization, we and our subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. As of December 31, 2024, the statute of limitations for the U.S. federal tax years 2018 through 2024 remain open to examination. For U.S. state and local jurisdictions, tax years 2020 through 2024 are open to examination. We are also subject to examination in various foreign jurisdictions for tax years 2017 through 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) due to prior year position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for expiration of statute of limitations/audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we had balances in accrued liabilities for interest and penalties of $6.6 million and $3.8 million at December 31, 2024 and 2023, respectively. As of December 31, 2024, we had $43.6 million of total gross unrecognized tax benefits, which, if recognized, $43.6 million would favorably impact the effective income tax rate. It is reasonably possible that, due to the expiration of statutes and the closing of tax audits, the amount of gross unrecognized tax benefits may be reduced by approximately $3.3 million during the next twelve months, which would favorably impact our effective tax rate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before income taxes and equity in net income of affiliated companies are:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. operations</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related provision for income taxes consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of our deferred tax assets and liabilities at December 31 are:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and deferred compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty acceleration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes and equity in net income of affiliated companies is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal corporate tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on international operations other than U.S. tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reserves for unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on international earnings, net of foreign tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-Derived Intangible Income Deductions (FDII)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits on share-based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty acceleration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, we recorded a tax benefit of $19.5 million associated with stock-based compensation. The Company recognized a $2.3 million tax benefit related to a reduction in the tax liability on the unremitted earnings of its Germany subsidiaries due to a law change in 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we recorded a tax benefit of $32.0 million associated with stock-based compensation. The Company recognized a $3.0 million state tax benefit based on the outcome of a recent court case. In addition, the Company recorded $2.8 million of tax expense due to a change in the permanent reinvestment assertion of its German subsidiaries.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we recorded tax expense of $5.7 million due to the impact of tax law changes enacted during the year, $19.8 million of tax expense due to the Company's recognition of reserves for unrecognized tax benefits, and a tax benefit of $16.5 million associated with stock-based compensation. A tax benefit of $20.6 million was recognized for the 2022 termination of our U.S. pension plan. The Company did not elect to reclassify to retained earnings the stranded tax effects on items within AOCI related to the Tax Cuts and Jobs Act of 2017, and therefore included within the $20.6 million pension termination benefit is a deferred tax benefit of $8.0 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State operating loss carryforwards of $98.8 million created a deferred tax asset of $5.4 million, while foreign operating loss carryforwards of $2.3 million created a deferred tax asset of $0.7 million. Management estimates that certain state and foreign operating loss carryforwards are unlikely to be utilized and the associated deferred tax assets have been appropriately reserved. State loss carryforwards expire as follows: $35.7 million in 2025 and $63.1 million thereafter. Foreign loss carryforwards will begin to expire in 2028, while $0.2 million of the total $2.3 million will not expire.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we utilized all of our remaining U.S. federal research and development credit carryforwards. State research and development credit carryforwards of $2.7 million created a deferred tax asset of $2.1 million. As of December 31, 2024, $0.4 million of state research and development credits expire in 2025.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2018, West has reasserted indefinite reinvestment related to all post-2017 unremitted earnings in all of our foreign subsidiaries. Beginning in 2023 and consistent with the approved plan mentioned in Note 4, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_91" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net Income Per Share</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company began repurchasing common stock on the open market. To support the funding for this program, West may continue to repatriate earnings from its German affiliates in the future and has recorded a tax liability of $0.3 million. Accordingly, West will continue to not assert permanent reinvestment related to all of the earnings of its wholly owned German affiliates through 2024. West will continue to assert permanent reinvestment of earnings for all other foreign jurisdictions and intends to only repatriate earnings when the tax impact is de minimis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, no deferred taxes have been provided for withholding taxes or other taxes that would result upon repatriation of approximately $651 million of undistributed earnings from foreign subsidiaries (except our German affiliates) to the U.S., as those earnings continue to be permanently reinvested. Further, it is impracticable for us to estimate any future tax costs for any unrecognized deferred tax liabilities associated with our indefinite reinvestment assertion, because the actual tax liability, if any, would be dependent on complex analysis and calculations considering various tax laws, exchange rates, circumstances existing when there is a repatriation, sale or liquidation, or other factors.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of the liability for unrecognized tax benefits is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to current year position</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) due to prior year position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction for expiration of statute of limitations/audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 38800000 36500000 24900000 5300000 6400000 11400000 700000 1000000.0 600000 1200000 3100000 400000 43600000 38800000 36500000 6600000 3800000 43600000 43600000 3300000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income before income taxes and equity in net income of affiliated companies are:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. operations</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income before income taxes and equity in net income of affiliated companies</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 243400000 369400000 394400000 342100000 328600000 285500000 585500000 698000000.0 679900000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The related provision for income taxes consists of:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.8 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29800000 30200000 75700000 2100000 -4200000 8400000 79100000 58800000 61400000 111000000.0 84800000 145500000 -18300000 -11600000 -20300000 14800000 49100000 -10500000 -3500000 37500000 -30800000 107500000 122300000 114700000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of our deferred tax assets and liabilities at December 31 are:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and deferred compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty acceleration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6100000 10000000.0 2100000 1100000 28900000 22700000 0 15000000.0 17900000 22400000 30100000 23900000 21500000 18600000 12800000 15500000 93800000 98200000 60900000 61700000 400000 3800000 22000000.0 18100000 5000000.0 1600000 88300000 85200000 5500000 13000000.0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal corporate tax rate to our effective consolidated tax rate on income before income taxes and equity in net income of affiliated companies is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. federal corporate tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on international operations other than U.S. tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reserves for unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on international earnings, net of foreign tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-Derived Intangible Income Deductions (FDII)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits on share-based payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty acceleration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.015 0.012 -0.015 0.008 0.003 0.029 0.001 0.005 -0.003 0.012 0.016 0.021 0.003 0.001 0.010 0.006 0.007 0.006 -0.033 -0.046 -0.024 0 0.005 0 0 0 -0.012 -0.005 0.003 0 0.003 0.005 0.001 0.184 0.175 0.169 -19500000 -2300000 -32000000 -3000000.0 -2800000 5700000 19800000 -16500000 -20600000 -20600000 -8000000 98800000 5400000 2300000 700000 35700000 63100000 200000 2300000 2700000 2100000 400000 300000 651000000 Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we were obligated under various operating lease agreements. Please refer to Note 6, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_97" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Leases</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we were obligated under debt agreements, net of unamortized debt issuance costs including fixed and variable-rate debt. Please refer to Note 10, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_109" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we were obligated under various tax-qualified and non-qualified defined benefit pension plans in the U.S. and other countries that cover employees and former employees who meet eligibility requirements. Please refer to Note 15, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional details.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, our outstanding unconditional contractual commitments, including for the purchase of raw materials and finished goods, amounted to $200.7 million, the majority of which is to be paid over the next four years, with $46.7 million due to be paid in 2025.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have letters of credit totaling $2.4 million supporting the reimbursement of workers’ compensation and other claims paid on our behalf by insurance carriers. Our accrual for insurance obligations was $1.6 million at December 31, 2024, of which $0.4 million is in excess of our deductible and, therefore, is reimbursable by the insurance company.</span></div> 200700000 P4Y 46700000 2400000 1600000 400000 Segment Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment solutions and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer. The CODM evaluates the performance of our segments based upon, among other things, segment net sales and segment operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The segment operating profit metric is what the CODM uses in evaluating our results of operations and the financial measure that provides a valuable insight into our overall performance and financial position. The CODM considers budget-to-actual variances and variances against prior years within segment operating profit when making decisions about allocating resources to the segments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,397.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, one of our customers individually accounted for more than 10% of consolidated net sales, at 12.3% or $356.4 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. In 2023, one of our customers individually accounted for more than 10% of consolidated net sales, at 10.9% or $322.1 million, contributing to net sales in both the Proprietary and Contract Manufacturing reportable segments. We did not have any customers accounting for greater than 10% of consolidated net sales in 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:25.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Lived Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other European countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,334.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,397.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,406.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,887.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,363.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment expense (income)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">782.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock Based Compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate general costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated items: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and related charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost investment activity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of plant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (income) expense and other nonoperating expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">679.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within <span style="-sec-ix-hidden:f-2004">selling, general and administrative expenses</span> in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within <span style="-sec-ix-hidden:f-2006">other expense (income)</span> related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within <span style="-sec-ix-hidden:f-2009">other expense (income)</span> for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within <span style="-sec-ix-hidden:f-2011">cost of goods and services sold</span>. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During 2024, 2023 and 2022, the company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) During 2023, the Company recorded a cost investment impairment charge of $4.3 million. During 2022, the net cost investment activity was equal to $3.5 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) During 2023, the Company recorded expense of $11.6 million, as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2024, 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 16, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i49e2ff7fe3d645928760b377ff76974e_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other Expense (Income)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of unallocated items. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,621.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,643.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Depreciation and Amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Capital Expenditures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales information about our reportable segments, reconciled to consolidated totals:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,397.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,406.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment sales elimination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated net sales</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2334500000 2397300000 2406800000 558700000 552500000 480400000 0 0 -300000 2893200000 2949800000 2886900000 0.123 356400000 0.109 322100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:25.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Lived Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,230.8 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.0 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other European countries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1230800000 1238500000 1286500000 832000000.0 757100000 372500000 406100000 398700000 191100000 176000000.0 323200000 285700000 240300000 299600000 207000000.0 242200000 282900000 237900000 84700000 78500000 385500000 388100000 359200000 98100000 99200000 339000000.0 348500000 364300000 210300000 194700000 2893200000 2949800000 2886900000 1715800000 1512500000 <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract Manufacturing</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,334.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,893.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,397.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,406.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">480.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,887.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods and services sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,434.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,363.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,353.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment expense (income)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment operating profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">710.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">782.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">784.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of profit or loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock Based Compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate general costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated items: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring and related charges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquisition-related intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost investment activity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of plant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consolidated operating profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest (income) expense and other nonoperating expense (income), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income taxes and equity in net income of affiliated companies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">679.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2) During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within <span style="-sec-ix-hidden:f-2004">selling, general and administrative expenses</span> in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within <span style="-sec-ix-hidden:f-2006">other expense (income)</span> related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within <span style="-sec-ix-hidden:f-2009">other expense (income)</span> for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within <span style="-sec-ix-hidden:f-2011">cost of goods and services sold</span>. During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) During 2024, 2023 and 2022, the company recorded $0.8 million, $0.7 million and $0.7 million, respectively, of amortization expense within operating profit associated with an acquisition of an intangible asset during the second quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) During 2023, the Company recorded a cost investment impairment charge of $4.3 million. During 2022, the net cost investment activity was equal to $3.5 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) During 2023, the Company recorded expense of $11.6 million, as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2024, 2023 and 2022. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,621.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,643.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Depreciation and Amortization</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Capital Expenditures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proprietary Products</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract-Manufactured Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and Unallocated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2334500000 558700000 2893200000 2397300000 552500000 2949800000 2406800000 480400000 2887200000 1434000000 460700000 1363300000 456500000 1353500000 397500000 69100000 0 68400000 0 58500000 0 231500000 26200000 240600000 24400000 212600000 20900000 22100000 -500000 14900000 -500000 -2200000 1600000 577800000 72300000 650100000 710100000 72100000 782200000 784400000 60400000 844800000 18700000 23300000 23700000 58600000 68300000 59100000 2100000 -2000000.0 23800000 800000 700000 700000 0 4300000 3500000 0 -11600000 0 569900000 676000000.0 734000000.0 15600000 22000000.0 -54100000 585500000 698000000.0 679900000 2100000 4600000 -2500000 -2000000 -2800000 800000 23800000 8700000 15300000 800000 700000 700000 4300000 3500000 -11600000 2 2621100000 2629100000 612200000 527500000 410100000 672900000 3643400000 3829500000 130300000 112900000 96900000 21300000 20400000 19000000.0 3800000 4000000.0 4700000 155400000 137300000 120600000 246500000 259100000 237300000 121000000.0 90200000 34000000.0 9500000 12700000 13300000 377000000.0 362000000.0 284600000 12800000 PricewaterhouseCoopers LLP Philadelphia, Pennsylvania false false false false 238 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedule II - Valuation and Qualifying Accounts</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">beginning of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">period</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">end of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances deducted from assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total allowances deducted from assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span>Includes accounts receivable written off, the write-off or write-down of valuation allowances, and translation adjustments. 15500000 0 2700000 12800000 800000 100000 100000 800000 16300000 100000 2800000 13600000 13300000 2200000 0 15500000 200000 2300000 1700000 800000 13500000 4500000 1700000 16300000 12200000 1100000 0 13300000 400000 300000 500000 200000 12600000 1400000 500000 13500000 true